drug_name,section_name,subsection_name,gpt4_output
IMPAVIDO,adverse reactions,6 ADVERSE REACTIONS,"nausea, vomiting, diarrhea, headache, decreased appetite, dizziness, abdominal pain, pruritus, somnolence, elevated transaminases, elevated creatinine"
IMPAVIDO,adverse reactions,6.1 Clinical Trials Experience,"Stevens-Johnson syndrome, melena, thrombocytopenia, arthritis, skin rash, diarrhea, hyperbilirubinemia"
IMPAVIDO,adverse reactions,"Table 2: Treatment Emergent Adverse Reactions Occurring in >=2% of Visceral Leishmaniasis Patients Receiving IMPAVIDO System Organ ClassPreferred Term IMPAVIDON = 299 Amphotericin B DeoxycholateN = 99 Gastrointestinal Disorders Diarrhea 61 (20.4%) 6 (6.1%) Vomiting 113 (37.8%) 20 (20.0%) General Disorders Asthenia 19 (6.3%) 4 (4.0%) Metabolism and Nutrition Disorders Decreased Appetite 69 (23.1%) 22 (22.2%) In this study, creatinine (Cr) elevations >= 1.5 times above baseline occurred in approximately 10% of IMPAVIDO recipients and in 40% of amphotericin B recipients at the end of therapy. Ten percent of subjects in each arm had Cr elevations >=1.5 times above baseline at 6 months follow up. No IMPAVIDO recipient discontinued therapy due to Cr elevation.","Elevations of transaminases, mild, moderate, elevation in transaminases, platelet count < 150,000, platelet count < 50,000"
IMPAVIDO,adverse reactions,"Table 3: Adverse Reactions Occurring in >=2% of IMPAVIDO-Treated Patients >=12 Years of Age with Cutaneous Leishmaniasis in the Placebo-Controlled Trial System Organ ClassPreferred Term IMPAVIDON = 89 PlaceboN = 44 Ear and Labyrinth Disorders Motion Sickness 26 (29.2%) 10 (22.7%) Gastrointestinal Disorders Abdominal Pain 10 (11.2%) 3 (6.8%) Diarrhea 7 (7.9%) 2 (4.5%) Nausea 32 (35.9%) 5 (11.1%) Vomiting 4 (4.5%) 0 General and Administration Site Disorders Malaise 3 (3.4%) 1 (2.3%) Pyrexia 5 (5.6%) 2 (4.5%) Nervous System Disorders Dizziness 4 (4.5%) 0 Headache 25 (28.1%) 10 (22.7%) Somnolence 3 (3.4%) 0 Skin and Subcutaneous Tissue Disorders Pruritus 4 (4.5%) 0 Table 4: Adverse Reactions Occurring in >=2% of IMPAVIDO-Treated Patients >= 12 Years of Age with Cutaneous Leishmaniasis in Two Comparative Trials System Organ ClassPreferred Term IMPAVIDON = 120 MeglumineN = 58 Gastrointestinal Disorders Abdominal Pain 9 (7.5%) 3 (5.2%) Diarrhea 18 (15.0%) 3 (5.2%) Nausea 50 (41.7%) 3 (5.2%) Vomiting 33 (27.5%) 0 Infections and Infestations Lymphangitis 7 (5.8%) 0 Metabolism and Nutrition Disorders Decreased Appetite 13 (10.8%) 4 (5.8%) Nervous System Disorders Dizziness 15 (12.5%) 4 (6.9%) Skin and Subcutaneous Tissue Disorders Pruritus 7 (5.8%) 0 In the placebo controlled trial, 12/89 (13.4%) IMPAVIDO subjects had Cr increases of 1.5-3 times above baseline, compared to 2/44 (4.5%) placebo subjects at end of therapy. In the comparative trial, a similar percentage of subjects who received IMPAVIDO or pentavalent antimony had Cr elevations above baseline at 3 and 6 months after therapy (approximately 5%). Approximately 25% of IMPAVIDO subjects and 11% of pentavalent antimony subjects had Cr elevations 1.5-3 times above baseline at the end of therapy in the two active controlled trials. The frequency of AST and ALT increase above upper limit of normal at end of therapy was similar in IMPAVIDO and placebo recipients (approximately 5%).","anemia, lymphadenopathy, abdominal distension, constipation, dysphagia, flatulence, fatigue, malaise, abscess, cellulitis, ecthyma, paresthesia, testicular pain, testicular swelling, Stevens-Johnson syndrome, urticaria, rash, pyoderma"
IMPAVIDO,adverse reactions,6.2 Postmarketing Experience,"thrombocytopenia, agranulocytosis, melena, generalized edema, peripheral edema, jaundice, seizure, scrotal pain, decreased ejaculate volume, absent ejaculation, epistaxis"
IMPAVIDO,boxed warnings,BOXED WARNING: WARNING: EMBRYO-FETAL TOXICITY,"If the input is ""nan,"" and assuming that ""nan"" refers to 'not applicable' or 'not available' in this context, there is no excerpt to analyze for adverse drug event terms. Therefore, I cannot provide a list of adverse drug event terms without the actual content. Please provide the excerpt from the drug label for analysis."
IMPAVIDO,boxed warnings,WARNING: EMBRYO-FETAL TOXICITY,"fetal harm, Fetal death, teratogenicity"
IMPAVIDO,boxed warnings,EXCERPT: WARNING: EMBRYO-FETAL TOXICITY,"fetal harm, fetal death, teratogenicity"
IMPAVIDO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Embryo-Fetal Toxicity, testicular atrophy, impaired fertility, Renal Effects, Hepatic Effects, Gastrointestinal Effects, Thrombocytopenia, Stevens-Johnson syndrome"
IMPAVIDO,warnings and precautions,5.1 Embryo-Fetal Toxicity,"fetal harm, Embryo-fetal toxicity, death, teratogenicity"
IMPAVIDO,warnings and precautions,5.2 Reproductive Effects,"impaired fertility, follicular atresia, diestrus, reduced viable sperm counts, testicular atrophy, scrotal pain, decreased ejaculation, absent ejaculation"
IMPAVIDO,warnings and precautions,5.3 Renal Effects,"Elevations of serum creatinine, Monitor renal function"
IMPAVIDO,warnings and precautions,5.4 Hepatic Effects,"Elevations in liver transaminases, ALT, AST, bilirubin"
IMPAVIDO,warnings and precautions,5.5 Gastrointestinal Effects,"vomiting, diarrhea, volume depletion"
IMPAVIDO,warnings and precautions,5.6 Thrombocytopenia,"Thrombocytopenia, Monitor platelet count"
IMPAVIDO,warnings and precautions,5.7 Absorption of Oral Contraceptives,"vomiting, diarrhea"
IMPAVIDO,warnings and precautions,5.8 Stevens-Johnson Syndrome,"Stevens-Johnson syndrome, exfoliative rash, bullous rash"
LIVALO,adverse reactions,6 ADVERSE REACTIONS,"Rhabdomyolysis, myoglobinuria, acute renal failure, myopathy, myositis, Liver Enzyme Abnormalities, myalgia, back pain, diarrhea, constipation, pain in extremity"
LIVALO,adverse reactions,6.1 Clinical Studies Experience,"adverse reactions, adverse drug event"
LIVALO,adverse reactions,"Table 1. Adverse Reactions* Reported by >=2.0% of Patients Treated with LIVALO and > Placebo in Short-Term Controlled Studies * Adverse reactions by MedDRA preferred term. AdverseReactions* PlaceboN= 208 LIVALO1 mgN=309 LIVALO2 mgN=951 LIVALO4 mgN=1540 Back Pain 2.9% 3.9% 1.8% 1.4% Constipation 1.9% 3.6% 1.5% 2.2% Diarrhea 1.9% 2.6% 1.5% 1.9% Myalgia 1.4% 1.9% 2.8% 3.1% Pain in extremity 1.9% 2.3% 0.6% 0.9% Other adverse reactions reported from clinical studies were arthralgia, headache, influenza, and nasopharyngitis.","elevated creatine phosphokinase, transaminases, alkaline phosphatase, bilirubin, glucose, myalgia, rash, pruritus, urticaria"
LIVALO,adverse reactions,6.2 Postmarketing Experience,"abdominal discomfort, abdominal pain, dyspepsia, nausea, asthenia, fatigue, malaise, hepatitis, jaundice, hepatic failure, dizziness, hypoesthesia, insomnia, depression, interstitial lung disease, erectile dysfunction, muscle spasms, cognitive impairment, memory loss, forgetfulness, amnesia, memory impairment, confusion, immune-mediated necrotizing myopathy"
LIVALO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"myopathy, rhabdomyolysis, muscle pain, tenderness, weakness, liver enzyme abnormalities, elevations in hepatic transaminases"
LIVALO,warnings and precautions,5.1 Skeletal Muscle Effects,"myopathy, rhabdomyolysis, acute renal failure, myoglobinuria, myopathy, renal impairment, hypothyroidism, immune-mediated necrotizing myopathy (IMNM), proximal muscle weakness, elevated serum creatine kinase, muscle biopsy showing necrotizing myopathy, improvement with immunosuppressive agents, muscle pain, tenderness, weakness, malaise, fever"
LIVALO,warnings and precautions,5.2 Liver Enzyme Abnormalities,"Increases in serum transaminases, aspartate aminotransferase, alanine aminotransferase, elevations, liver enzyme tests, signs or symptoms of liver injury, fatal and non-fatal hepatic failure, serious liver injury, clinical symptoms, hyperbilirubinemia, jaundice, active liver disease, unexplained persistent transaminase elevations"
LIVALO,warnings and precautions,5.3 Endocrine Function,"Increases in HbA1c, fasting serum glucose levels"
XENAZINE,adverse reactions,6 ADVERSE REACTIONS,"Depression, suicidality, Akathisia, restlessness, agitation, Parkinsonism, Dysphagia, Sedation, somnolence, fatigue, insomnia, anxiety, nausea"
XENAZINE,adverse reactions,6.1 Clinical Trials Experience,"adverse reactions, sedation/somnolence, fatigue, insomnia, depression, akathisia, anxiety, nausea"
XENAZINE,adverse reactions,"Table 1. Adverse Reactions in a 12-Week, Double-Blind, Placebo-Controlled Trial in Patients with Huntington's Disease Adverse Reaction XENAZINE n = 54 (%) Placebo n = 30 (%) Sedation/somnolence 31 3 Insomnia 22 0 Depression 19 0 Anxiety/anxiety aggravated 15 3 Irritability 9 3 Decreased appetite 4 0 Obsessive reaction 4 0 Akathisia 19 0 Balance difficulty 9 0 Parkinsonism/bradykinesia 9 0 Dizziness 4 0 Dysarthria 4 0 Unsteady gait 4 0 Headache 4 3 Nausea 13 7 Vomiting 6 3 Fatigue 22 13 Fall 15 13 Laceration (head) 6 0 Ecchymosis 6 0 Upper respiratory tract infection 11 7 Shortness of breath 4 0 Bronchitis 4 0 Dysuria 4 0 Dose escalation was discontinued or dosage of study drug was reduced because of one or more adverse reactions in 28 of 54 (52%) patients randomized to XENAZINE. These adverse reactions consisted of sedation (15), akathisia (7), parkinsonism (4), depression (3), anxiety (2), fatigue (1) and diarrhea (1). Some patients had more than one AR and are, therefore, counted more than once.",extrapyramidal symptoms
XENAZINE,adverse reactions,Table 2 describes the incidence of events considered to be extrapyramidal adverse reactions which occurred at a greater frequency in XENAZINE-treated patients compared to placebo-treated patients.,"As the input provided is simply ""nan"" (not applicable or not available), there are no adverse drug event terms to extract. If you have an actual excerpt from a drug label, please provide it so that I can assist you in identifying any adverse drug event terms."
XENAZINE,adverse reactions,"Table 2. Adverse Reactions Due to Extrapyramidal Symptoms in a 12-Week, Double-Blind, Placebo-Controlled Trial in Patients with Huntington's disease XENAZINE n = 54 % Placebo n = 30 % Akathisia Patients with the following adverse event preferred terms were counted in this category: akathisia, hyperkinesia, restlessness. 19 0 Extrapyramidal event Patients with the following adverse event preferred terms were counted in this category: bradykinesia, parkinsonism, extrapyramidal disorder, hypertonia. 15 0 Any extrapyramidal event 33 0 Patients may have had events in more than one category.","If the input is ""nan"" (which stands for ""not a number"" generally used to signify a missing or undefined value), there is no text provided from which to extract adverse drug event terms. Therefore, I cannot provide a list of terms without the relevant excerpt of a drug label. If you provide the excerpt containing the information about the drug, I can help identify the adverse drug events listed within it."
XENAZINE,adverse reactions,6.2 Postmarketing Experience,"tremor, confusion, worsening aggression, pneumonia, hyperhidrosis, skin rash"
XENAZINE,boxed warnings,BOXED WARNING: WARNING: DEPRESSION AND SUICIDALITY,"As you've provided the input ""nan"" which typically stands for ""not a number,"" this does not seem to be a valid excerpt of a drug label containing any terms related to adverse drug events. Please provide an actual excerpt from a drug label for analysis."
XENAZINE,boxed warnings,WARNING: DEPRESSION AND SUICIDALITY,"depression, suicidal thoughts, suicidality, emergence or worsening of depression, suicidality, unusual changes in behavior"
XENAZINE,boxed warnings,EXCERPT: WARNING: DEPRESSION AND SUICIDALITY,"depression, suicidal thoughts, suicidality, emergence or worsening of depression, worsening of suicidality, unusual changes in behavior"
XENAZINE,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"worsening mood, cognition, rigidity, functional capacity, Neuroleptic Malignant Syndrome (NMS), restlessness, agitation, akathisia, parkinsonism, Dysphagia, aspiration pneumonia, Sedation, Somnolence, QTc prolongation, extrapyramidal disorders"
XENAZINE,warnings and precautions,5.1 Clinical Worsening and Adverse Effects,"worsening in mood, cognitive decline, parkinsonism, dysphagia, sedation/somnolence, akathisia, restlessness, disability, depression"
XENAZINE,warnings and precautions,5.2 Depression and Suicidality,"depression, suicidal ideation, suicidality, worsening depression, suicide, attempted suicide"
XENAZINE,warnings and precautions,5.3 Laboratory Tests,"There are no specific adverse drug event terms mentioned in the provided drug label excerpt. The label discusses pharmacogenetic testing (CYP2D6 genotyping) to adjust dosing in poor metabolizers (PMs), extensive metabolizers (EMs), or intermediate metabolizers (IMs) of XENAZINE, as well as the changes in the levels of drug metabolites in different metabolizers, and the recommended dosing for PMs. It does not specifically list any adverse drug events."
XENAZINE,warnings and precautions,5.4 Neuroleptic Malignant Syndrome (NMS),"Neuroleptic Malignant Syndrome (NMS), hyperpyrexia, muscle rigidity, altered mental status, autonomic instability, irregular pulse, blood pressure changes, tachycardia, diaphoresis, cardiac dysrhythmia, elevated creatinine phosphokinase, myoglobinuria, rhabdomyolysis, acute renal failure, systemic infection, drug fever, central anticholinergic toxicity, heat stroke, primary central nervous system pathology."
XENAZINE,warnings and precautions,"5.5 Akathisia, Restlessness, and Agitation","akathisia, restlessness, agitation"
XENAZINE,warnings and precautions,5.6 Parkinsonism,"parkinsonism, bradykinesia, hypertonia, rigidity, drug-induced parkinsonism"
XENAZINE,warnings and precautions,5.7 Dysphagia,"dysphagia, esophageal dysmotility, aspiration pneumonia"
XENAZINE,warnings and precautions,5.8 Sedation and Somnolence,"sedation, dose-limiting adverse reaction, somnolence"
XENAZINE,warnings and precautions,5.9 QTc Prolongation,"QT prolongation, torsade de pointes-type ventricular tachycardia, cardiac arrhythmias, bradycardia, hypokalemia, hypomagnesemia, sudden death"
XENAZINE,warnings and precautions,5.10 Hypotension and Orthostatic Hypotension,"postural dizziness, syncope, orthostasis, dizziness, hypotension"
XENAZINE,warnings and precautions,5.11 Hyperprolactinemia,"amenorrhea, galactorrhea, gynecomastia, impotence, low levels of estrogen, increased risk of osteoporosis, symptomatic hyperprolactinemia"
XENAZINE,warnings and precautions,5.12 Tardive Dyskinesia (TD),"involuntary, dyskinetic movements, orofacial dyskinesias, vacuous chewing, tardive dyskinesia, supersensitivity to dopamine, extrapyramidal symptoms, parkinsonism, akathisia"
XENAZINE,warnings and precautions,5.13 Binding to Melanin-Containing Tissues,"toxicity, injury, long-term ophthalmologic effects"
LINZESS,adverse reactions,6 ADVERSE REACTIONS,"diarrhea, abdominal pain, flatulence, abdominal distension"
LINZESS,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions"
LINZESS,adverse reactions,"Table 1: Adverse Reactions Reported in at least 2% of LINZESS-treated Patients and at an Incidence Greater than in Placebo Group Patients in the Two Phase 3 Placebo-controlled Trials (1 and 2) in IBS-C a: ""Abdominal pain"" term includes abdominal pain, upper abdominal pain, and lower abdominal pain. Adverse Reactions LINZESS 290 mcg [N=807] % Placebo [N=798] % Gastrointestinal Diarrhea Abdominal pain a Flatulence Abdominal distension 20742 3521 Infections and Infestations Viral Gastroenteritis 3 1 Nervous System Disorders Headache 4 3 Diarrhea","Diarrhea, Severe diarrhea, Fecal incontinence, Dehydration, Abdominal pain, Gastroesophageal reflux disease, Vomiting, Fatigue, Hematochezia, Allergic reactions, Urticaria, Hives"
LINZESS,adverse reactions,"Table 2: Adverse Reactions Reported in at least 2% of 145 mcg LINZESS-treated Patients and at an Incidence Greater than in Placebo Group Patients in the Two Phase 3 Placebo-controlled Trials (3 and 4) in CIC a: ""Abdominal pain"" term includes abdominal pain, upper abdominal pain, and lower abdominal pain. Adverse Reactions LINZESS 145 mcg [N=430] % Placebo [N=423] % Gastrointestinal Diarrhea Abdominal pain a Flatulence Abdominal distension 16763 5652 Infections and Infestations Upper respiratory tract infection Sinusitis 53 42 Diarrhea","diarrhea, severe diarrhea, fecal incontinence, dehydration, abdominal pain, dyspepsia, viral gastroenteritis, rectal hemorrhage, hematochezia, melena, allergic reactions, urticaria, hives"
LINZESS,boxed warnings,BOXED WARNING: WARNING: PEDIATRIC RISK,"If the input text you're providing is simply ""nan"", which typically stands for ""not a number"" or missing data, then there is no content from which I can extract adverse drug event terms. If you can provide the actual excerpt of the drug label, I would be happy to identify the adverse drug event terms for you."
LINZESS,boxed warnings,WARNING: PEDIATRIC RISK,"deaths, dehydration"
LINZESS,boxed warnings,EXCERPT: WARNING: PEDIATRIC RISK,"deaths, dehydration"
LINZESS,warnings and precautions,5 WARNINGS AND PRECAUTIONS,diarrhea
LINZESS,warnings and precautions,5.1 Pediatric Risk,"mortality, dehydration, significant diarrhea"
LINZESS,warnings and precautions,5.2 Diarrhea,"Diarrhea, severe diarrhea, dose suspension, rehydration"
OPSUMIT,adverse reactions,6 ADVERSE REACTIONS,"Embryo-fetal Toxicity, Hepatotoxicity, Decrease in Hemoglobin, anemia, nasopharyngitis/pharyngitis, bronchitis, headache, influenza, urinary tract infection"
OPSUMIT,adverse reactions,6.1 Clinical Trial Experience,"No explicit adverse drug event (ADE) terms are listed in the provided drug label excerpt. The excerpt discusses the structure of clinical trials, the difficulty of comparing adverse reaction rates between trials, and the exposure duration in the SERAPHIN study but does not specify any particular adverse events."
OPSUMIT,adverse reactions,Table 2 presents adverse reactions more frequent on OPSUMIT than on placebo by >=3%.,"If the text input is literally ""nan"" (which usually stands for ""not a number"" and suggests that the data may be missing or undefined), then there are no adverse drug event terms to identify. If ""nan"" is a placeholder for an actual drug label excerpt, I would need the actual text of the label to identify the adverse drug event terms. Please provide the text of the drug label for analysis."
OPSUMIT,adverse reactions,"Table 2 Adverse Reactions Adverse Reaction OPSUMIT 10 mg(N=242)(%) Placebo(N=249)(%) Anemia 13 3 Nasopharyngitis/pharyngitis 20 13 Bronchitis 12 6 Headache 14 9 Influenza 6 2 Urinary tract infection 9 6 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of OPSUMIT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.","hypersensitivity reactions, angioedema, pruritus, rash, nasal congestion"
OPSUMIT,boxed warnings,BOXED WARNING: WARNING: EMBRYO-FETAL TOXICITY,"Your input ""nan"" seems to indicate either a placeholder for non-applicable or non-available information, or it is not the actual content from a drug label. If you have an actual excerpt from a drug label, please provide it, and I can identify the adverse drug event terms for you. Without the proper context or content, I cannot provide a list of terms."
OPSUMIT,boxed warnings,WARNING: EMBRYO-FETAL TOXICITY,fetal harm
OPSUMIT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hepatotoxicity, liver failure, decreases in hemoglobin, pulmonary edema, decreases in sperm count"
OPSUMIT,warnings and precautions,5.1 Embryo-fetal Toxicity,"fetal harm, contraindicated"
OPSUMIT,warnings and precautions,5.2 OPSUMIT REMS Program,embryo-fetal toxicity
OPSUMIT,warnings and precautions,5.3 Hepatotoxicity,"elevations of aminotransferases, hepatotoxicity, liver failure, elevated aminotransferases, hepatic adverse events, nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, itching"
OPSUMIT,warnings and precautions,5.4 Hemoglobin Decrease,"Decreases in hemoglobin concentration, hematocrit, mean decrease in hemoglobin, decrease in hemoglobin to below 10.0 g/dL, severe anemia"
OPSUMIT,warnings and precautions,5.5 Pulmonary Edema with Pulmonary Veno-occlusive Disease (PVOD),"pulmonary edema, PVOD"
OPSUMIT,warnings and precautions,5.6 Decreased Sperm Counts,"adverse effects on spermatogenesis, effects on fertility"
ASCLERA,adverse reactions,6 ADVERSE REACTIONS,mild local reactions at the site of injection
ASCLERA,adverse reactions,6.1 Clinical Study Experience,adverse reaction rates
ASCLERA,adverse reactions,Table 1 shows adverse events more common with Asclera or sodium tetradecyl sulfate (STS) 1% than with placebo by at least 3% in the placebo- controlled EASI study (see Clinical Studies [14] ) . All of these were injection site reactions and most were mild.,"There are no adverse drug event terms provided, as ""nan"" typically stands for ""not applicable"" or ""not available now"". Therefore, there's nothing to return in terms of adverse drug event terms based on the input provided."
ASCLERA,adverse reactions,Table 1: Adverse Reactions in EASI-study ASCLERA (180 patients) STS 1% (105 patients) Placebo (53 patients) Injection site haematoma 42% 65% 19% Injection site irritation 41% 73% 30% Injection site discoloration 38% 74% 4% Injection site pain 24% 31% 9% Injection site pruritus 19% 27% 4% Injection site warmth 16% 21% 6% Neovascularisation 8% 20% 4% Injection site thrombosis 6% 1% 0% Ultrasound examinations at one week (+/-3 days) and 12 weeks (+/-2 weeks) after treatment did not reveal deep vein thrombosis in any treatment group.,"If the input text is ""nan"", it appears to be a placeholder indicating not applicable, not available, or 'not a number'. In this context, it means that there is no text containing adverse drug event terms to analyze. Therefore, no adverse drug event terms can be provided based on the given input."
ASCLERA,adverse reactions,6.2 Post-marketing Safety Experience,"Anaphylactic shock, angioedema, urticaria generalized, asthma, Cerebrovascular accident, migraine, paresthesia (local), loss of consciousness, confusional state, dizziness, Cardiac arrest, palpitations, Deep vein thrombosis, pulmonary embolism, syncope vasovagal, circulatory collapse, vasculitis, Dyspnea, Skin hyperpigmentation, dermatitis allergic, hypertrichosis, Injection site necrosis, pyrexia, hot flush, Nerve injury"
ASCLERA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,anaphylaxis
ASCLERA,warnings and precautions,5.1 Anaphylaxis,"severe allergic reactions, anaphylactic reactions, fatal, severe adverse local effects, tissue necrosis, extravasation"
ASCLERA,warnings and precautions,5.2 Accidental Intra-arterial Injection,"severe necrosis, ischemia, gangrene"
ASCLERA,warnings and precautions,5.3 Inadvertent Perivascular Injection,pain
KYNAMRO,adverse reactions,6 ADVERSE REACTIONS,"hepatotoxicity, injection site reactions, flu-like symptoms, nausea, headache, elevations in serum transaminases, ALT"
KYNAMRO,adverse reactions,6.1 Clinical Trials,"adverse reaction rates, adverse reactions, injection site reactions, alanine aminotransferase increased, flu-like symptoms, aspartate aminotransferase increased, liver function test abnormal"
KYNAMRO,adverse reactions,"Table 2 enumerates adverse reactions that occurred among pooled Phase 3 patients treated with KYNAMRO at an incidence that was at least 2% more than that observed in the placebo-treated patients, listed by system organ class and frequency (MedDRA v.13.0). Similar types and severities of adverse reactions were observed across all populations in this pooled table including the subset of patients with HoFH.","There is no information provided on which to identify adverse drug event terms. The input ""nan"" typically means ""not a number"" or is used to indicate that data is missing or not applicable. Please provide a relevant excerpt of a drug label for analysis."
KYNAMRO,adverse reactions,"Table 2: Summary of Adverse Reactions for Pooled Phase 3 Placebo-Controlled Trials System Organ Class Preferred Term Treatment Group KYNAMRO (%) (N=261) Placebo (%) (N=129) Total Patients with Events 95% 85% Cardiac disorders 9% 6% Angina pectoris 4% 2% Palpitations 3% 0% Gastrointestinal disorders 30% 29% Nausea 14% 8% Vomiting 4% 2% Abdominal pain 3% 1% General disorders and administration site conditions 87% 47% Injection site reactions 84% 33% Fatigue 15% 8% Influenza like illness 13% 3% Pyrexia 8% 3% Chills 6% 1% Edema peripheral 5% 2% Hepatobiliary disorders 9% 5% Hepatic steatosis 7% 2% Investigations 30% 15% Alanine aminotransferase increased 10% 1% Aspartate aminotransferase increased 6% 2% Liver function test abnormal 5% 1% Hepatic enzyme increased 3% 1% Musculoskeletal and connective tissue disorders 26% 26% Pain in extremity 7% 3% Musculoskeletal pain 4% 2% Nervous system disorders 25% 17% Headache 12% 9% Psychiatric disorders 10% 3% Insomnia 3% 1% Vascular disorders 11% 5% Hypertension 7% 3% In the pooled Phase 3 trials, neoplasms (benign and malignant) were reported in 4% of patients receiving KYNAMRO and 0% of patients receiving placebo. In addition, 9% of patients receiving KYNAMRO and 3% of patients receiving placebo developed 1+ or greater proteinuria by dipstick measurement by the end of the trial.","hypersensitivity reaction, angioedema, glomerular nephritis, elevated serum transaminase levels, Elevated ALT levels"
KYNAMRO,adverse reactions,"Table 3: Transaminase Results for Pooled Phase 3 Placebo-Controlled Trials Parameter Statistic Kynamro (%) (N=261) Placebo (%) (N=129) ALT maximum Incidence rate, % >= 3 * ULN and < 5 * ULN 12% 1% >= 5 * ULN and < 10 * ULN 3% 0% >= 10 x ULN 1% 0% ALT >= 3 * ULN, two consecutive results (at least 7 days apart), % 8% 0% AST maximum Incidence rate, % >= 3 * ULN and < 5 * ULN 7% 1% >= 5 * ULN and < 10 * ULN 3% 0% >= 10 x ULN 0% 0% AST >= 3 * ULN, two consecutive results (at least 7 days apart), % 4% 0% Adults: ALT ULN= 41 U/L; AST ULN = 34 U/L","Hepatic Steatosis, increases in liver fat, erythema, pain, hematoma, pruritus, swelling, discoloration, injection site reactions, local erythema, tenderness, influenza-like illness, pyrexia, chills, myalgia, arthralgia, malaise, fatigue, Immunogenicity, anti-KYNAMRO antibodies, severe flu-like symptoms."
KYNAMRO,adverse reactions,6.2 Postmarketing Experience,Idiopathic thrombocytopenic purpura
KYNAMRO,boxed warnings,BOXED WARNING: WARNING: RISK OF HEPATOTOXICITY,"If the input is ""nan"", it indicates that there is no information provided on which to base a response. Therefore, without any text from a drug label, I cannot provide a list of adverse drug event terms. Please provide the excerpt of the drug label for analysis."
KYNAMRO,boxed warnings,WARNING: RISK OF HEPATOTOXICITY,"elevations in transaminases, elevation in alanine aminotransferase (ALT), hepatic fat, hepatic steatosis, steatohepatitis, cirrhosis, hepatotoxicity"
KYNAMRO,boxed warnings,EXCERPT: WARNING: RISK OF HEPATOTOXICITY,"elevations in transaminases, alanine aminotransferase (ALT) increase, aspartate aminotransferase (AST) increase, clinically significant liver toxicity, hepatic fat (hepatic steatosis), progressive liver disease, steatohepatitis, cirrhosis, hepatotoxicity"
KYNAMRO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"erythema, pain, tenderness, pruritus, local swelling, influenza-like illness, pyrexia, chills, myalgia, arthralgia, malaise, fatigue"
KYNAMRO,warnings and precautions,5.1 Risk of Hepatotoxicity,"elevations in transaminases, hepatic steatosis, steatohepatitis, cirrhosis, elevation in ALT >= 3x ULN, elevation in ALT >= 5x ULN, moderate or severe hepatic impairment, active liver disease, unexplained persistent elevations of serum transaminases, clinical symptoms of liver injury, nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms, increases in bilirubin >= 2x ULN, hepatotoxicity"
KYNAMRO,warnings and precautions,5.2 KYNAMRO REMS,hepatotoxicity
KYNAMRO,warnings and precautions,5.3 Injection Site Reactions,"erythema, pain, tenderness, pruritus, local swelling"
KYNAMRO,warnings and precautions,5.4 Flu-Like Symptoms,"influenza-like illness, pyrexia, chills, myalgia, arthralgia, malaise, fatigue"
XARELTO,adverse reactions,6 ADVERSE REACTIONS,"Increased risk of stroke, Bleeding risk, Spinal/epidural hematoma, bleeding"
XARELTO,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, bleeding complications, bleeding events"
XARELTO,adverse reactions,Table 1 shows the number of patients experiencing various types of bleeding events in the ROCKET AF trial.,"If the input text is ""nan"", which commonly denotes 'not a number' or missing data, there is no text provided from which to extract adverse drug event terms. Therefore, there can be no terms extracted. If you have an actual excerpt from a drug label that you would like to analyze, please provide the text."
XARELTO,adverse reactions,"Table 1: Bleeding Events in ROCKET AFFor all sub-types of major bleeding, single events may be represented in more than one row, and individual patients may have more than one event. Parameter XARELTO N = 7111 n (%) Event Rate (per 100 Pt-yrs) Warfarin N = 7125 n (%) Event Rate (per 100 Pt-yrs) Major bleedingDefined as clinically overt bleeding associated with a decrease in hemoglobin of >=2 g/dL, transfusion of >=2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome. Hemorrhagic strokes are counted as both bleeding and efficacy events. Major bleeding rates excluding strokes are 3.3 per 100 Pt-yrs for XARELTO vs. 2.9 per 100 Pt-yrs for warfarin. 395 (5.6) 3.6 386 (5.4) 3.5 Bleeding into a critical organThe majority of the events were intracranial, and also included intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, or retroperitoneal. 91 (1.3) 0.8 133 (1.9) 1.2 Fatal bleeding 27 (0.4) 0.2 55 (0.8) 0.5 Bleeding resulting in transfusion of >=2 units of whole blood or packed red blood cells 183 (2.6) 1.7 149 (2.1) 1.3 Gastrointestinal bleeding 221 (3.1) 2.0 140 (2.0) 1.2 Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and to Reduce the Risk of Recurrence of DVT and of PE",bleeding events
XARELTO,adverse reactions,Table 2 shows the number of patients experiencing major bleeding events in the pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies.,"If the input text meant to be evaluated for adverse drug event terms is ""nan,"" then no terms can be identified from this, as ""nan"" isn't descriptive of or related to any drug events. If ""nan"" stands for ""not applicable"" or ""not available now,"" then there are no terms to extract. Please provide the actual excerpt for analysis."
XARELTO,adverse reactions,"Table 2: Bleeding EventsBleeding event occurred after randomization and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category. in the Pooled Analysis of EINSTEIN DVT and EINSTEIN PE Studies Parameter XARELTO N = 4130 n (%) Enoxaparin/ VKA N = 4116 n (%) Major bleeding event 40 (1.0) 72 (1.7) Fatal bleeding 3 (<0.1) 8 (0.2) Intracranial 2 (<0.1) 4 (<0.1) Non-fatal critical organ bleeding 10 (0.2) 29 (0.7) IntracranialTreatment-emergent major bleeding events with at least >2 subjects in any pooled treatment group 3 (<0.1) 10 (0.2) Retroperitoneal 1 (<0.1) 8 (0.2) Intraocular 3 (<0.1) 2 (<0.1) Intra-articular 0 4 (<0.1) Non-fatal non-critical organ bleedingMajor bleeding which is not fatal or in a critical organ, but resulting in a decrease in Hb >= 2 g/dL and/or transfusion of >=2 units of whole blood or packed red blood cells 27 (0.7) 37 (0.9) Decrease in Hb >= 2g/dL 28 (0.7) 42 (1.0) Transfusion of >=2 units of whole blood or packed red blood cells 18 (0.4) 25 (0.6) Clinically relevant non-major bleeding 357 (8.6) 357 (8.7) Any bleeding 1169 (28.3) 1153 (28.0) EINSTEIN Extension Study",bleeding events
XARELTO,adverse reactions,Table 3 shows the number of patients experiencing bleeding events in the EINSTEIN Extension study.,"I believe there might be some misunderstanding here. If the input text you're referring to is ""nan,"" then it is not possible for me to extract any adverse drug event terms as ""nan"" typically stands for ""not a number"" and does not provide any context or content that would contain drug-related information. If you have an excerpt from a drug label you would like me to analyze, please provide that text, and I will be happy to look for any adverse drug event terms."
XARELTO,adverse reactions,"Table 3: Bleeding EventsBleeding event occurred after the first dose and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category. in EINSTEIN Extension Study Parameter XARELTO 20 mg N = 598 n (%) Placebo N = 590 n (%) Major bleeding eventThere were no fatal or critical organ bleeding events. 4 (0.7) 0 Decrease in Hb >=2 g/dL 4 (0.7) 0 Transfusion of >=2 units of whole blood or packed red blood cells 2 (0.3) 0 Gastrointestinal 3 (0.5) 0 Menorrhagia 1 (0.2) 0 Clinically relevant non-major bleeding 32 (5.4) 7 (1.2) Any bleeding 104 (17.4) 63 (10.7) Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery","adverse reactions, permanent treatment discontinuation, major bleeding events, any bleeding events"
XARELTO,adverse reactions,"Table 4: Bleeding EventsBleeding events occurring any time following the first dose of double-blind study medication (which may have been prior to administration of active drug) until two days after the last dose of double-blind study medication. Patients may have more than one event. in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD 1-3) XARELTO 10 mg Enoxaparin Total treated patients N = 4487n (%) N = 4524n (%) Major bleeding event 14 (0.3) 9 (0.2) Fatal bleeding 1 (<0.1) 0 Bleeding into a critical organ 2 (<0.1) 3 (0.1) Bleeding that required re-operation 7 (0.2) 5 (0.1) Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells 4 (0.1) 1 (<0.1) Any bleeding eventIncludes major bleeding events 261 (5.8) 251 (5.6) Hip Surgery Studies N = 3281n (%) N = 3298n (%) Major bleeding event 7 (0.2) 3 (0.1) Fatal bleeding 1 (<0.1) 0 Bleeding into a critical organ 1 (<0.1) 1 (<0.1) Bleeding that required re-operation 2 (0.1) 1 (<0.1) Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells 3 (0.1) 1 (<0.1) Any bleeding event 201 (6.1) 191 (5.8) Knee Surgery Study N = 1206n (%) N = 1226n (%) Major bleeding event 7 (0.6) 6 (0.5) Fatal bleeding 0 0 Bleeding into a critical organ 1 (0.1) 2 (0.2) Bleeding that required re-operation 5 (0.4) 4 (0.3) Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells 1 (0.1) 0 Any bleeding event 60 (5.0) 60 (4.9) Following XARELTO treatment, the majority of major bleeding complications (>=60%) occurred during the first week after surgery.",Non-hemorrhagic adverse reactions
XARELTO,adverse reactions,"Table 5: Other Adverse ReactionsAdverse reaction (with Relative Risk >1.5 for XARELTO versus placebo) occurred after the first dose and up to 2 days after the last dose of study drug. Incidences are based on the number of patients, not the number of events. Although a patient may have had 2 or more clinical adverse reactions, the patient is counted only once in a category. The same patient may appear in different categories. Reported by >=1% of XARELTO-Treated Patients in EINSTEIN Extension Study System Organ Class Preferred Term XARELTO N = 598 n (%) Placebo N = 590 n (%) Gastrointestinal disorders Abdominal pain upper 10 (1.7) 1 (0.2) Dyspepsia 8 (1.3) 4 (0.7) Toothache 6 (1.0) 0 General disorders and administration site conditions Fatigue 6 (1.0) 3 (0.5) Infections and infestations Sinusitis 7 (1.2) 3 (0.5) Urinary tract infection 7 (1.2) 3 (0.5) Musculoskeletal and connective tissue disorders Back pain 22 (3.7) 7 (1.2) Osteoarthritis 10 (1.7) 5 (0.8) Respiratory, thoracic and mediastinal disorders Oropharyngeal pain 6 (1.0) 2 (0.3) Non-hemorrhagic adverse reactions reported in >=1% of XARELTO-treated patients in RECORD 1-3 studies are shown in Table 6.","If the provided input text is merely ""nan,"" which typically stands for ""not a number"" or indicates missing data, there are no adverse drug event terms to extract. Therefore, based on the given input, my response would be:

No adverse drug event terms provided."
XARELTO,adverse reactions,"Table 6: Other Adverse Drug ReactionsAdverse reaction occurring any time following the first dose of double-blind medication, which may have been prior to administration of active drug, until two days after the last dose of double-blind study medication Reported by >=1% of XARELTO-Treated Patients in RECORD 1-3 Studies System/Organ Class Adverse Reaction XARELTO 10 mg Enoxaparin N = 4487 n (%) N = 4524 n (%) Injury, poisoning and procedural complications Wound secretion 125 (2.8) 89 (2.0) Musculoskeletal and connective tissue disorders Pain in extremity 74 (1.7) 55 (1.2) Muscle spasm 52 (1.2) 32 (0.7) Nervous system disorders Syncope 55 (1.2) 32 (0.7) Skin and subcutaneous tissue disorders Pruritus 96 (2.1) 79 (1.8) Blister 63 (1.4) 40 (0.9) Other clinical trial experience: In an investigational study of acute medically ill patients being treated with XARELTO 10 mg tablets, cases of pulmonary hemorrhage and pulmonary hemorrhage with bronchiectasis were observed.","If the input is ""nan"" which typically means ""not a number"" or is used to indicate a missing value or not applicable data, then there is no excerpt of a drug label to analyze. Therefore, I cannot provide you with a list of adverse drug event terms. If you have an actual excerpt, please provide it so I can assist you further."
XARELTO,adverse reactions,6.2 Postmarketing Experience,"agranulocytosis, thrombocytopenia, retroperitoneal hemorrhage, jaundice, cholestasis, hepatitis, hepatocellular injury, hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema, cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis, Stevens-Johnson syndrome"
XARELTO,boxed warnings,"BOXED WARNING: WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS,(B) SPINAL/EPIDURAL HEMATOMA","As you have provided ""nan"" which stands for 'not a number' and typically indicates a missing value or undefined data, there is no actual drug label text to analyze. Therefore, I cannot extract any adverse drug event terms from it. Could you please provide the actual text excerpt from the drug label?"
XARELTO,boxed warnings,"WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA","thrombotic events, pathological bleeding"
XARELTO,boxed warnings,B. SPINAL/EPIDURAL HEMATOMA,"epidural hematomas, spinal hematomas, long-term or permanent paralysis, neurological impairment"
XARELTO,boxed warnings,(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS,"thrombotic events, pathological bleeding"
XARELTO,boxed warnings,(B) SPINAL/EPIDURAL HEMATOMA,"Epidural hematomas, spinal hematomas, long-term paralysis, permanent paralysis, neurological impairment"
XARELTO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Risk of bleeding, serious and fatal bleeding, blood loss, Pregnancy-related hemorrhage, obstetric hemorrhage, emergent delivery"
XARELTO,warnings and precautions,5.1 Increased Risk of Thrombotic Events after Premature Discontinuation,"thrombotic events, increased rate of stroke, pathological bleeding"
XARELTO,warnings and precautions,5.2 Risk of Bleeding,"bleeding, serious or fatal bleeding, blood loss, pathological hemorrhage, increased bleeding risk."
XARELTO,warnings and precautions,5.3 Spinal/Epidural Anesthesia or Puncture,"epidural or spinal hematoma, long-term or permanent paralysis, bleeding, neurological impairment, midline back pain, sensory and motor deficits, numbness, tingling, weakness in lower limbs, bowel and/or bladder dysfunction"
XARELTO,warnings and precautions,5.4 Use in Patients with Renal Impairment,"acute renal failure, blood loss"
XARELTO,warnings and precautions,5.5 Use in Patients with Hepatic Impairment,"severe hepatic impairment, moderate hepatic impairment, severe hepatic impairment, hepatic disease, coagulopathy, drug exposure, bleeding risk"
XARELTO,warnings and precautions,5.6 Use with P-gp and Strong CYP3A4 Inhibitors or Inducers,"There are no specific adverse drug event terms listed in this text. The text outlines drug-drug interactions and recommendations to avoid concomitant use of the medication XARELTO with certain other drugs, but it does not describe any adverse events directly. Therefore, there are no terms to list."
XARELTO,warnings and precautions,5.7 Risk of Pregnancy-Related Hemorrhage,"potential risk to the mother and fetus, blood loss, drop in hemoglobin and/or hematocrit, hypotension, fetal distress"
XARELTO,warnings and precautions,5.8 Patients with Prosthetic Heart Valves,"There are no specific adverse drug event terms mentioned in the provided text excerpt. The text only states that the safety and efficacy of XARELTO have not been studied in patients with prosthetic heart valves and therefore, its use is not recommended in these patients. It does not list any specific adverse events."
XARELTO,warnings and precautions,5.9 Acute PE in Hemodynamically Unstable Patients or Patients Who Require Thrombolysis or Pulmonary Embolectomy,"hemodynamic instability, thrombolysis, pulmonary embolectomy"
CAPRELSA,adverse reactions,6. ADVERSE REACTIONS,"QT Prolongation, Torsades de Pointes, Skin Reactions, Stevens-Johnson Syndrome, Interstitial Lung Disease, Ischemic Cerebrovascular Events, Hemorrhage, Heart Failure, Diarrhea, Hypothyroidism, Hypertension, Reversible Posterior Leukoencephalopathy Syndrome, Embryofetal Toxicity, diarrhea/colitis, rash, acneiform dermatitis, nausea, headache, upper respiratory tract infections, decreased appetite, abdominal pain"
CAPRELSA,adverse reactions,6.1. Clinical Studies Experience,"diarrhea/colitis, rash, acneiform dermatitis, hypertension, nausea, headache, upper respiratory tract infection, decreased appetite, abdominal pain, asthenia, fatigue, pyrexia, elevated creatinine, QT prolongation"
CAPRELSA,adverse reactions,"Table 1 - Per-Patient Incidence of Selected Adverse Reactions Occurring at a Higher Incidence in CAPRELSA-Treated Patients During Randomized Treatment [Between-Arm Difference of >= 5% (All Grades)CTCAE version 3 was used to grade adverse events.] Preferred Term System Organ Class CAPRELSA 300 mg N=231 Placebo N=99 All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Gastrointestinal Disorders Diarrhea/Colitis 57 11 27 2 Nausea 33 1 16 0 ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7f2967df1578>, 'list': <function print_list at 0x7f2967df1d70>, 'text': <function print_text at 0x7f2967df15f0>, 'caption': <function print_caption at 0x7f2967df19b0>} Abdominal Pain 21 3 11 0 Vomiting 15 1 7 0 Dyspepsia 11 0 4 0 Dry Mouth 9 0 3 0 Skin and Cutaneous Disorders ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7f2967df1578>, 'list': <function print_list at 0x7f2967df1d70>, 'text': <function print_text at 0x7f2967df15f0>, 'caption': <function print_caption at 0x7f2967df19b0>} Rash 53 5 12 0 Dermatitis Acneiform/Acne 35 1 7 0 Dry Skin 15 0 5 0 Photosensitivity Reaction 13 2 0 0 Pruritus 11 1 4 0 ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7f2967df1578>, 'list': <function print_list at 0x7f2967df1d70>, 'text': <function print_text at 0x7f2967df15f0>, 'caption': <function print_caption at 0x7f2967df19b0>} Nail abnormalities 9 0 0 0 Alopecia 8 N/A 0 N/A Vascular Disorders Hypertension/Hypertensive Crisis/Accelerated Hypertension 33 9 5 1 Nervous System Disorders Headache 26 1 9 0 Dysgeusia 8 0 3 0 General Disorders ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7f2967df1578>, 'list': <function print_list at 0x7f2967df1d70>, 'text': <function print_text at 0x7f2967df15f0>, 'caption': <function print_caption at 0x7f2967df19b0>} Fatigue 24 6 23 1 Infections Upper Respiratory Tract InfectionsIncludes laryngitis, nasopharyngitis, pharyngitis, sinusitis, upper respiratory tract infection, acute sinusitis, rhinitis, and tracheitis. 23 0 16 0 Metabolic and Nutritional Disorders Decreased Appetite 21 4 12 0 Hypocalcemia 11 2 3 0 Investigations ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7f2967df1578>, 'list': <function print_list at 0x7f2967df1d70>, 'text': <function print_text at 0x7f2967df15f0>, 'caption': <function print_caption at 0x7f2967df19b0>} ECG QT Prolonged 14 8 1 1 Eye Disorders ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7f2967df1578>, 'list': <function print_list at 0x7f2967df1d70>, 'text': <function print_text at 0x7f2967df15f0>, 'caption': <function print_caption at 0x7f2967df19b0>} Corneal Abnormalities 13 0 1 0 Blurred Vision 9 0 1 0 Renal Disorders Proteinuria 10 0 2 0 Psychiatric Disorders Depression 10 2 3 0 Endocrine Disorders Hypothyroidism 6 0 0 0 Musculoskeletal Disorders Muscle Spasms 6 0 1 0 Clinically important uncommon adverse drug reactions in patients who received CAPRELSA versus patients who received placebo included pancreatitis (0.4% vs. 0%) and heart failure (0.9% vs. 0%).","Blurred vision, corneal opacities, vortex keratopathies, halos, decreased visual acuity, intestinal perforation, Grade 1-2 bleeding events"
CAPRELSA,adverse reactions,Table 2 - Per-Patient Incidence of Selected Laboratory Abnormalities in Patients with MTC Occurring at a Higher Incidence in CAPRELSA-Treated Patients [Between-Arm Difference of >= 5% (All Grades)CTCAE version 3 was used to grade laboratory abnormalities.] Laboratory Abnormalities CAPRELSA 300 mg N=231 Placebo N=99 All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Chemistries Hypocalcemia 57 6 25 3 ALT Increased 51 2 19 0 Hypoglycemia 24 0 7 1 Creatinine Increased 16 0 1 0 Hypomagnesemia 7 <1 2 0 Hematologic Neutropenia 10 <1 5 2 Thrombocytopenia 9 0 3 0 No patient with a Grade 3-4 ALT elevation had a concomitant increase in bilirubin in the MTC study.,"As there is no provided text to analyze (the input is ""nan""), I am unable to extract any adverse drug event terms. Please provide the text from the drug label for analysis."
CAPRELSA,boxed warnings,"BOXED WARNING: WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH","If the input text is ""nan,"" which typically stands for ""not applicable"" or ""not available,"" then there is no text provided to analyze for adverse drug event terms. Therefore, I cannot provide a list of terms. If you provide an excerpt of a drug label, I can assist in identifying any adverse drug event terms within it."
CAPRELSA,boxed warnings,"WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH","QT interval prolongation, Torsades de pointes, sudden death, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome"
CAPRELSA,boxed warnings,"EXCERPT: WARNING: QT PROLONGATION, TORSADES DE POINTES, AND SUDDEN DEATH","QT interval prolongation, Torsades de pointes, sudden death, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome"
CAPRELSA,warnings and precautions,5. WARNINGS AND PRECAUTIONS,"Prolonged QT Interval, Torsades de pointes, sudden death, Severe skin reactions, Stevens-Johnson syndrome, Interstitial lung disease (ILD), Ischemic cerebrovascular events, hemorrhage, heart failure, diarrhea, hypertension, reversible posterior leukoencephalopathy syndrome, Embryofetal toxicity"
CAPRELSA,warnings and precautions,5.1 QT Prolongation and Torsades de Pointes,"QT interval prolongation, Torsades de pointes, ventricular tachycardia, sudden deaths, bradyarrhythmias, uncompensated heart failure, ventricular arrhythmias, myocardial infarction"
CAPRELSA,warnings and precautions,5.2 Skin Reactions and Stevens-Johnson Syndrome,"Severe skin reactions, Stevens-Johnson syndrome, death, Photosensitivity reactions"
CAPRELSA,warnings and precautions,5.3 Interstitial Lung Disease,"Interstitial Lung Disease, pneumonitis, fatalities"
CAPRELSA,warnings and precautions,5.4 Ischemic Cerebrovascular Events,"Ischemic cerebrovascular events, fatalities"
CAPRELSA,warnings and precautions,5.5 Hemorrhage,"Serious hemorrhagic events, fatalities, hemoptysis, severe hemorrhage"
CAPRELSA,warnings and precautions,5.6 Heart Failure,"Heart failure, fatalities"
CAPRELSA,warnings and precautions,5.7 Diarrhea,"Diarrhea, QT prolongation, dehydration, severe diarrhea"
CAPRELSA,warnings and precautions,5.8 Hypothyroidism,"increased dosing of thyroid replacement therapy, hypothyroidism"
CAPRELSA,warnings and precautions,5.9 Hypertension,"Hypertension, hypertensive crisis"
CAPRELSA,warnings and precautions,5.10 Reversible Posterior Leukoencephalopathy Syndrome,"Reversible posterior leukoencephalopathy syndrome (RPLS), seizures, headache, visual disturbances, confusion, altered mental function, hypertension"
CAPRELSA,warnings and precautions,5.11 Drug Interactions,"amiodarone, disopyramide, procainamide, sotalol, dofetilide, chloroquine, clarithromycin, dolasetron, granisetron, haloperidol, methadone, moxifloxacin, pimozide"
CAPRELSA,warnings and precautions,5.12 Renal Impairment,"impaired renal function, moderate to severe renal impairment, QT interval, end-stage renal disease"
CAPRELSA,warnings and precautions,5.13 Hepatic Impairment,moderate and severe hepatic impairment
CAPRELSA,warnings and precautions,5.14 Embryofetal Toxicity,"fetal harm, embryotoxic, fetotoxic, teratogenic, adverse effects on female fertility, embryofetal development, postnatal development"
CAPRELSA,warnings and precautions,5.15 CAPRELSA REMS (Risk Evaluation and Mitigation Strategy) Program,"QT prolongation, Torsades de pointes, sudden death"
KADCYLA,adverse reactions,6 ADVERSE REACTIONS,"Hepatotoxicity, Left Ventricular Dysfunction, Embryo-Fetal Toxicity, Pulmonary Toxicity, Infusion-Related Reactions, Hypersensitivity Reactions, Hemorrhage, Thrombocytopenia, Neurotoxicity, fatigue, nausea, musculoskeletal pain, headache, increased transaminases, constipation, epistaxis"
KADCYLA,adverse reactions,6.1 Clinical Trials Experience,"fatigue, nausea, musculoskeletal pain, hemorrhage, thrombocytopenia, headache, increased transaminases, constipation, epistaxis, neutropenia, leukopenia, peripheral neuropathy, pyrexia"
KADCYLA,adverse reactions,"Table 6 reports the ADRs that occurred in patients in the KADCYLA-treated group (n=490) of the randomized trial (Study 1). Selected laboratory abnormalities are shown in Table 7 . The most common ADRs seen with KADCYLA in the randomized trial (frequency > 25%) were nausea, fatigue, musculoskeletal pain, hemorrhage, thrombocytopenia, increased transaminases, headache, and constipation. The most common NCI-CTCAE (version 3) >= Grade 3 ADRs (frequency >2%) were thrombocytopenia, increased transaminases, anemia, hypokalemia, peripheral neuropathy and fatigue.","The input provided (""nan"") does not contain any drug label information or text from which to extract adverse drug event terms. If the input is meant to imply that the data is ""not a number"" or non-existent, then there are no terms to extract. Please provide the appropriate drug label excerpt for analysis."
KADCYLA,adverse reactions,"Table 6 Summary of Adverse Drug Reactions Occurring in Patients on the KADCYLA Treatment Arm in the Randomized Trial (Study 1) Adverse Drug Reactions (MedDRA)System Organ Class KADCYLA(3.6 mg/kg)n=490Frequency rate % Lapatinib (1250 mg) + Capecitabine (2000 mg/m 2 )n=488Frequency rate % All grades (%) Grade 3 - 4 (%) All grades (%) Grade 3 - 4 (%) ND = Not determined Blood and Lymphatic System Disorders Neutropenia 6.7 2.0 9.0 4.3 Anemia 14.3 4.1 10.5 2.5 Thrombocytopenia 31.2 14.5 3.3 0.4 Cardiac Disorders Left ventricular dysfunction 1.8 0.2 3.3 0.4 Eye Disorders Lacrimation increased 3.3 0 2.5 0 Dry eye 3.9 0 3.1 0 Vision blurred 4.5 0 0.8 0 Conjunctivitis 3.9 0 2.3 0 Gastrointestinal Disorders Dyspepsia 9.2 0 11.5 0.4 Stomatitis 14.1 0.2 32.6 2.5 Dry Mouth 16.7 0 4.9 0.2 Abdominal pain 18.6 0.8 17.6 1.6 Vomiting 19.2 0.8 29.9 4.5 Diarrhea 24.1 1.6 79.7 20.7 Constipation 26.5 0.4 11.1 0 Nausea 39.8 0.8 45.1 2.5 General Disorders and Administration Peripheral edema 7.1 0 8.2 0.2 Chills 7.6 0 3.1 0 Pyrexia 18.6 0.2 8.4 0.4 Asthenia 17.8 0.4 17.6 1.6 Fatigue 36.3 2.5 28.3 3.5 Hepatobiliary Disorders Nodular regenerative hyperplasia 0.4 ND 0 0 Portal hypertension 0.4 0.2 0 0 Immune System Disorders Drug hypersensitivity 2.2 0 0.8 0 Injury, Poisoning, and Procedural Infusion-related reaction 1.4 0 0.2 0 Infections and Infestations Urinary tract infection 9.4 0.6 3.9 0 Investigations Blood alkaline phosphatase increased 4.7 0.4 3.7 0.4 Increased transaminases 28.8 8.0 14.3 2.5 Metabolism and Nutrition Disorders Hypokalemia 10.2 2.7 9.4 4.7 Musculoskeletal and Connective Tissue Disorders Myalgia 14.1 0.6 3.7 0 Arthralgia 19.2 0.6 8.4 0 Musculoskeletal pain 36.1 1.8 30.5 1.4 Nervous System Disorders Dysgeusia 8.0 0 4.1 0.2 Dizziness 10.2 0.4 10.7 0.2 Peripheral neuropathy 21.2 2.2 13.5 0.2 Headache 28.2 0.8 14.5 0.8 Psychiatric Disorders Insomnia 12.0 0.4 8.6 0.2 Respiratory, Thoracic, and Mediastinal Disorders Pneumonitis 1.2 0 0 0 Dyspnea 12.0 0.8 8.0 0.4 Cough 18.2 0.2 13.1 0.2 Epistaxis 22.5 0.2 8.4 0 Skin and Subcutaneous Tissue Disorders Pruritus 5.5 0.2 9.2 0 Rash 11.6 0 27.5 1.8 Vascular Disorders Hemorrhage 32.2 1.8 16.4 0.8 Hypertension 5.1 1.2 2.3 0.4 Table 7 Selected Laboratory Abnormalities Parameter KADCYLA(3.6 mg/kg) Lapatinib (1250 mg) + Capecitabine (2000 mg/m 2 ) All Grade % Grade 3 % Grade 4 % All Grade % Grade 3 % Grade 4 % Increased bilirubin 17 <1 0 57 2 0 Increased AST 98 7 <1 65 3 0 Increased ALT 82 5 <1 54 3 0 Decreased platelet count 83 14 3 21 <1 <1 Decreased hemoglobin 60 4 1 64 3 <1 Decreased neutrophils 39 3 <1 38 6 2 Decreased potassium 33 3 0 31 6 <1 Hepatic failure has been observed in two patients (0.2%) with HER2-positive metastatic breast cancer in clinical trials (n=884) with KADCYLA as single-agent.","Without an actual excerpt of a drug label to analyze, I'm unable to provide the adverse drug event terms you're requesting. If you provide me with the text containing the drug information and potential side effects, I would be able to identify the terms for you."
KADCYLA,adverse reactions,6.2 Immunogenicity,"immune response, anti-therapeutic antibody (ATA) responses, tested positive for anti-KADCYLA antibodies, interference, neutralizing activity, immunogenicity, drug interference, observed incidence of a positive result, clinical significance"
KADCYLA,boxed warnings,BOXED WARNING:,"The input provided does not contain any specific adverse drug event terms. It seems to be a cautionary statement regarding medication substitution, but it does not list any adverse effects. Therefore, there are no adverse drug event terms to return based on the text provided."
KADCYLA,boxed warnings,"WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY","Hepatotoxicity, liver failure, death, reductions in left ventricular ejection fraction, embryo-fetal death, birth defects."
KADCYLA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Pulmonary Toxicity, interstitial lung disease, pneumonitis, Infusion-Related Reactions, Hypersensitivity Reactions, Hemorrhage, thrombocytopenia, Neurotoxicity, peripheral neuropathy"
KADCYLA,warnings and precautions,5.1 Hepatotoxicity,"Hepatotoxicity, asymptomatic, transient increases, serum transaminases, Serious hepatobiliary disorders, fatal cases, severe drug-induced liver injury, hepatic encephalopathy, increased serum transaminases, total bilirubin, nodular regenerative hyperplasia (NRH), non-cirrhotic portal hypertension, portal hypertension, cirrhosis-like pattern"
KADCYLA,warnings and precautions,5.2 Left Ventricular Dysfunction,"left ventricular dysfunction, decrease of LVEF, symptomatic congestive heart failure (CHF), serious cardiac arrhythmia, myocardial infarction, unstable angina"
KADCYLA,warnings and precautions,5.3 Embryo-Fetal Toxicity,"fetal harm, oligohydramnios, fatal pulmonary hypoplasia, skeletal abnormalities, neonatal death, embryo-fetal toxicity, embryo-fetal death, birth defects"
KADCYLA,warnings and precautions,5.4 Pulmonary Toxicity,"interstitial lung disease, pneumonitis, acute respiratory distress syndrome, fatal outcome, grade 3 pneumonitis, dyspnea, cough, fatigue, pulmonary infiltrates, infusion reactions, pulmonary toxicity"
KADCYLA,warnings and precautions,"5.5 Infusion-Related Reactions, Hypersensitivity Reactions","infusion-related reactions, hypersensitivity, flushing, chills, pyrexia, dyspnea, hypotension, wheezing, bronchospasm, tachycardia, severe IRR, life-threatening IRR, allergic/anaphylactic-like reaction"
KADCYLA,warnings and precautions,5.6 Hemorrhage,"hemorrhagic events, central nervous system hemorrhage, respiratory hemorrhage, gastrointestinal hemorrhage, bleeding events, fatal outcomes, hemorrhage, Grade 3 hemorrhage, thrombocytopenia"
KADCYLA,warnings and precautions,5.7 Thrombocytopenia,"Thrombocytopenia, decreased platelet count, Grade 3 thrombocytopenia"
KADCYLA,warnings and precautions,5.8 Neurotoxicity,"Peripheral neuropathy, Grade 1, predominantly sensory, >= Grade 3, any Grade, overall frequency of peripheral neuropathy, incidence of >= Grade 3 peripheral neuropathy, Grade 3 or 4 peripheral neuropathy, neurotoxicity"
KADCYLA,warnings and precautions,5.9 HER2 Testing,"The passage provided does not actually list any adverse drug events; rather, it details the requirements for patient selection for KADCYLA therapy and the importance of HER2 status assessment. It also warns of potential sources of error in the testing process, but it does not mention any adverse effects of the drug itself.

Hence, there are no adverse drug event terms in the text provided."
KADCYLA,warnings and precautions,5.10 Extravasation,"erythema, tenderness, skin irritation, pain, swelling"
RELISTOR,adverse reactions,6 ADVERSE REACTIONS,"Gastrointestinal perforation, severe or persistent diarrhea, opioid withdrawal, abdominal pain, nausea, diarrhea, hyperhidrosis, hot flush, tremor, chills, flatulence, dizziness"
RELISTOR,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, Opioid-Induced Constipation, adverse reactions, symptoms of opioid withdrawal"
RELISTOR,adverse reactions,"Table 2: Adverse Reactions* in 4-Week Double-Blind, Placebo-Controlled Period of Clinical Study of RELISTOR in Adult Patients with Opioid-InducedConstipation and Chronic Non-Cancer Pain Adverse Reaction RELISTOR 12 mg once dailyn = 150 Placebo n = 162 Abdominal Pain 21% 6% Nausea 9% 6% Diarrhea 6% 4% Hyperhidrosis 6% 1% Hot Flush 3% 2% Tremor 1% < 1% Chills 1% 0% *Adverse reactions occuring in >= 1% of patients receiving RELISTOR 12 mg once daily and at an incidence greater than placebo. .","nausea, diarrhea, vomiting, tremor, feeling of body temperature change, piloerection, chills, abdominal pain, myocardial infarctions, stroke, cardiac arrest, sudden death"
RELISTOR,adverse reactions,"Table 3: Adverse Reactions from all Doses in Double-Blind, Placebo-Controlled Clinical Studies of RELISTOR in Adult Patients with Opioid-Induced Constipation and Advanced Illness* Adverse Reaction RELISTORn = 165 Placebon = 123 Abdominal Pain 29% 10% Flatulence 13% 6% Nausea 12% 5% Dizziness 7% 2% Diarrhea 6% 2% * Adverse reactions occuring in >= 5% of patients receiving all doses of RELISTOR (0.075, 0.15, and 0.30 mg/kg/dose) and at an incidence greater than placebo. The rates of discontinuation due to adverse events during the double-blind placebo controlled clinical trials (Study 3 and Study 4) were comparable between RELISTOR (1%) and placebo (2%).","Since the input provided is ""nan"" which stands for 'not a number' and commonly indicates missing or undefined information, there is no drug label excerpt to analyze, hence no adverse drug event terms can be extracted. If you have an actual drug label excerpt, please provide it so I can identify the adverse drug event terms for you."
RELISTOR,adverse reactions,6.2 Postmarketing Experience,"Gastrointestinal Perforation, cramping, vomiting, Diaphoresis, flushing, malaise, pain, opioid withdrawal"
RELISTOR,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Gastrointestinal perforation, severe, persistent or worsening abdominal pain, severe or persistent diarrhea, opioid withdrawal"
RELISTOR,warnings and precautions,5.1 Gastrointestinal Perforation,"gastrointestinal perforation, opioid-induced constipation, peptic ulcer disease, Ogilvie's syndrome, diverticular disease, infiltrative gastrointestinal tract malignancies, peritoneal metastases, impaired integrity of the gastrointestinal tract wall, Crohn's disease, severe persistent or worsening abdominal pain"
RELISTOR,warnings and precautions,5.2 Severe or Persistent Diarrhea,"severe diarrhea, persistent diarrhea"
RELISTOR,warnings and precautions,5.3 Opioid Withdrawal,"opioid withdrawal, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, yawning"
JUXTAPID,adverse reactions,6 ADVERSE REACTIONS,"hepatotoxicity, Reduced absorption of fat-soluble vitamins, serum fatty acids, Gastrointestinal adverse reactions, diarrhea, nausea, vomiting, dyspepsia, abdominal pain"
JUXTAPID,adverse reactions,6.1 Clinical Trials Experience,"diarrhea, abdominal pain, nausea, gastroenteritis, weight loss, headache, difficulty controlling INR on warfarin, vomiting, dyspepsia, abdominal discomfort, abdominal distension, constipation, flatulence, increased ALT, chest pain, influenza, nasopharyngitis, fatigue"
JUXTAPID,adverse reactions,"Table 3: Adverse Reactions Reported in >=10% of Patients in the Clinical Trial in HoFH ADVERSE REACTION N (%) Gastrointestinal Disorders Diarrhea 23 (79) Nausea 19 (65) Dyspepsia 11 (38) Vomiting 10 (34) Abdominal pain 10 (34) Abdominal discomfort 6 (21) Abdominal distension 6 (21) Constipation 6 (21) Flatulence 6 (21) Gastroesophageal reflux disease 3 (10) Defecation urgency 3 (10) Rectal tenesmus 3 (10) Infections Influenza 6 (21) Nasopharyngitis 5 (17) Gastroenteritis 4 (14) Investigations Decreased weight 7 (24) Increased ALT 5 (17) General Disorders Chest pain 7 (24) Fatigue 5 (17) Fever 3 (10) Musculoskeletal Disorders Back pain 4 (14) Nervous System Disorders Headache 3 (10) Dizziness 3 (10) Respiratory Disorders Pharyngolaryngeal pain 4 (14) Nasal congestion 3 (10) Cardiac Disorders Angina pectoris 3 (10) Palpitations 3 (10) Adverse reactions of severe intensity were reported by 8 (28%) of 29 patients, with the most common being diarrhea (4 patients, 14%), vomiting (3 patients, 10%), increased ALT or hepatotoxicity (3 patients, 10%), and abdominal pain, distension, and/or discomfort (2 patients, 7%).","Transaminase Elevations, elevation in ALT, elevation in AST >=3x ULN, elevations in total bilirubin, alkaline phosphatase"
JUXTAPID,adverse reactions,"Table 4: Patient Incidence of Transaminase Elevations During the HoFH Clinical Trial Upper limits of normal (ULN) ranged from 33-41 international units/L for ALT and 36-43 international units/L for AST. N (%) Total Patients 29 Maximum ALT >=3 to <5 x ULN 6 (21%) >=5 to <10 x ULN 3 (10%) >=10 to <20 x ULN 1 (3%) >=20 x ULN 0 Maximum AST >=3 to <5 x ULN 5 (17%) >=5 to <10 x ULN 1 (3%) >=10 to <20 x ULN 0 >=20 x ULN 0 Among the 19 patients who enrolled in an extension study following the HoFH clinical trial, one discontinued because of increased transaminases that persisted despite several dose reductions, and one temporarily discontinued because of markedly elevated transaminases (ALT 24x ULN, AST 13x ULN) that had several possible causes, including a drug-drug interaction between JUXTAPID and the strong CYP3A4 inhibitor clarithromycin [see Drug Interactions (7.1) ] .","Hepatic Steatosis, increase in hepatic fat"
JUXTAPID,boxed warnings,BOXED WARNING: WARNING: RISK OF HEPATOTOXICITY,"If the input provided is ""nan"" which typically stands for ""not a number,"" and this is the entirety of the information given, there are no adverse drug event terms to list. If you meant to provide an actual excerpt of a drug label, please provide the text so I can help find the adverse drug event terms."
JUXTAPID,boxed warnings,WARNING: RISK OF HEPATOTOXICITY,"elevations in transaminases, elevation in alanine aminotransferase (ALT), elevation in aspartate aminotransferase (AST), increases in transaminases, hepatic fat increase, hepatic steatosis, progressive liver disease, steatohepatitis, cirrhosis, clinically significant liver toxicity, hepatotoxicity"
JUXTAPID,boxed warnings,EXCERPT: WARNING: RISK OF HEPATOTOXICITY,"elevations in transaminases, clinically significant liver toxicity, hepatic fat (hepatic steatosis), steatohepatitis, cirrhosis, hepatotoxicity"
JUXTAPID,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Embryo-Fetal Toxicity, Gastrointestinal adverse reactions"
JUXTAPID,warnings and precautions,5.1 Risk of Hepatotoxicity,"elevations in transaminases, hepatic steatosis, hepatic dysfunction, elevated transaminases, increase in bilirubin, INR, hepatic failure, steatohepatitis, cirrhosis, clinical symptoms of liver injury, nausea, vomiting, abdominal pain, fever, jaundice, lethargy, flu-like symptoms, increases in bilirubin >=2x ULN, active liver disease, hepatotoxicity, liver injury"
JUXTAPID,warnings and precautions,5.2 JUXTAPID REMS Program,hepatotoxicity
JUXTAPID,warnings and precautions,5.3 Embryo-Fetal Toxicity,"fetal harm, teratogenicity"
JUXTAPID,warnings and precautions,5.4 Reduced Absorption of Fat-Soluble Vitamins and Serum Fatty Acids,"reduced absorption of fat-soluble nutrients, decrease in serum vitamin E, decrease in ALA, decrease in linoleic acid, decrease in EPA, decrease in DHA, decrease in arachidonic acid, deficiencies in nutrients"
JUXTAPID,warnings and precautions,5.5 Gastrointestinal Adverse Reactions,"diarrhea, nausea, dyspepsia, vomiting, abdominal pain, abdominal discomfort, abdominal distension, constipation, flatulence"
JUXTAPID,warnings and precautions,5.6 Concomitant Use of CYP3A4 Inhibitors,"elevated transaminases, ALT 24x ULN, AST 13x ULN"
JUXTAPID,warnings and precautions,5.7 Risk of Myopathy with Concomitant Use of Simvastatin or Lovastatin,"myopathy, rhabdomyolysis, muscle toxicity"
JUXTAPID,warnings and precautions,5.8 Risk of Supratherapeutic or Subtherapeutic Anticoagulation with Warfarin,"supratherapeutic anticoagulation, subtherapeutic anticoagulation, difficulty controlling INR"
JUXTAPID,warnings and precautions,5.9 Risk of Malabsorption with Rare Hereditary Disorders of Galactose Intolerance,"galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, diarrhea, malabsorption"
SAVELLA,adverse reactions,6 ADVERSE REACTIONS,"nausea, headache, constipation, dizziness, insomnia, hot flush, hyperhidrosis, vomiting, palpitations, heart rate increased, dry mouth, hypertension"
SAVELLA,adverse reactions,6.1 Clinical Trials Experience,"nausea, palpitations, headache, constipation, heart rate increased, hyperhidrosis, vomiting, dizziness, hot flush, dry mouth, hypertension"
SAVELLA,adverse reactions,Table 4 lists all adverse reactions that occurred in at least 2% of patients treated with Savella at either 100 or 200 mg/day and at an incidence greater than that of placebo.,"The input you've provided does not contain any text to identify adverse drug event terms from; it simply reads ""nan"", which typically stands for ""not a number"" and suggests that there may have been an error or that data is missing. Therefore, I cannot provide a list of terms without the appropriate content. If you have an actual drug label excerpt, please share that, and I can identify the adverse drug event terms for you."
SAVELLA,adverse reactions,Table 4: Treatment-Emergent Adverse Reaction Incidence in Placebo Controlled Trials in Fibromyalgia Patients (Events Occurring in at Least 2% of All Savella-Treated Patients and Occurring More Frequently in Either Savella Treatment Group Than in the Placebo Treatment Group) System Organ Class-Preferred Term Savella100 mg/day(n = 623) % Savella200 mg/day(n = 934) % All Savella(n = 1557) % Placebo(n = 652) % Cardiac Disorders Palpitations 8 7 7 2 Tachycardia 3 2 2 1 Eye Disorders Vision blurred 1 2 2 1 Gastrointestinal Disorders Nausea 35 39 37 20 Constipation 16 15 16 4 Vomiting 6 7 7 2 Dry mouth 5 5 5 2 Abdominal pain 3 3 3 2 General Disorders Chest pain 3 2 2 2 Chills 1 2 2 0 Chest discomfort 2 1 1 1 Infections Upper respiratory tract infection 7 6 6 6 Investigations Heart rate increased 5 6 6 1 Blood pressure increased 3 3 3 1 Metabolism and Nutrition Disorders Decreased appetite 1 2 2 0 Nervous System Disorders Headache 19 17 18 14 Dizziness 11 10 10 6 Migraine 6 4 5 3 Paresthesia 2 3 2 2 Tremor 2 2 2 1 Hypoesthesia 1 2 1 1 Tension headache 2 1 1 1 Psychiatric Disorders Insomnia 12 12 12 10 Anxiety 5 3 4 4 Respiratory Disorders Dyspnea 2 2 2 1 Skin Disorders Hyperhidrosis 8 9 9 2 Rash 3 4 3 2 Pruritus 3 2 2 2 Vascular Disorders Hot flush 11 12 12 2 Hypertension 7 4 5 2 Flushing 2 3 3 1 Weight Changes,"weight loss, dysuria, ejaculation disorder, erectile dysfunction, ejaculation failure, libido decreased, prostatitis, scrotal pain, testicular pain, testicular swelling, urinary hesitation, urinary retention, urethral pain, urine flow decreased, diarrhea, dyspepsia, gastroesophageal reflux disease, flatulence, abdominal distension, fatigue, peripheral edema, irritability, pyrexia, urinary tract infection, cystitis, contusion, fall, weight decreased, weight increased, hypercholesterolemia, somnolence, dysgeusia, depression, stress, night sweats"
SAVELLA,adverse reactions,6.2 Postmarketing Experience,"leukopenia, neutropenia, thrombocytopenia, supraventricular tachycardia, accommodation disorder, hyperprolactinemia, hepatitis, anorexia, hyponatremia, rhabdomyolysis, convulsions, loss of consciousness, Parkinsonism, aggression, anger, delirium, hallucination, homicidal ideation, acute renal failure, galactorrhea, erythema multiforme, Stevens Johnson syndrome, hypertensive crisis"
SAVELLA,boxed warnings,BOXED WARNING: WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS,"If the input text is ""nan"" and there is no other information provided, I'm unable to extract any adverse drug event terms. It appears that ""nan"" may simply be a placeholder indicating a non-existent or null value, rather than a drug label excerpt. If you provide an actual drug label excerpt, I can help you identify the adverse drug event terms within it."
SAVELLA,boxed warnings,WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS,"suicidal thinking, behavior (suicidality), clinical worsening, unusual changes in behavior"
SAVELLA,boxed warnings,EXCERPT: WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS,"suicidal ideation, thinking, behavior"
SAVELLA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"suicidality, serotonin syndrome, elevated blood pressure, heart rate elevations, seizures, hepatotoxicity, withdrawal symptoms, abnormal bleeding, genitourinary adverse events"
SAVELLA,warnings and precautions,5.1 Suicide Risk,"worsening of depression, suicidal ideation, suicidality, unusual changes in behavior, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, withdrawal symptoms"
SAVELLA,warnings and precautions,5.2 Serotonin Syndrome,"potentially life-threatening serotonin syndrome, agitation, hallucinations, delirium, coma, autonomic instability, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia, tremor, rigidity, myoclonus, hyperreflexia, incoordination, seizures, nausea, vomiting, diarrhea"
SAVELLA,warnings and precautions,5.3 Elevated Blood Pressure,"hypertensive, hypertension, increases in blood pressure, elevated blood pressure, new onset hypertension, sustained increases in blood pressure, treatment-emergent blood pressure elevations"
SAVELLA,warnings and precautions,5.4 Elevated Heart Rate,"increase in mean 24-hour heart rate, increases in heart rate, tachyarrhythmias, sustained increase in heart rate"
SAVELLA,warnings and precautions,5.5 Seizures,"seizure disorder, seizures/convulsions, seizures"
SAVELLA,warnings and precautions,5.6 Hepatotoxicity,"mild elevations of ALT, mild elevations of AST, increase in ALT, increases in AST, increases of bilirubin, elevated ALT, increase in bilirubin, increased liver enzymes, severe liver injury, fulminant hepatitis, jaundice, liver dysfunction, substantial alcohol use, chronic liver disease"
SAVELLA,warnings and precautions,5.7 Discontinuation of Treatment with Savella,"dysphoric mood, irritability, agitation, dizziness, sensory disturbances, paresthesias, electric shock sensations, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, seizures"
SAVELLA,warnings and precautions,5.8 Hyponatremia,"hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), headache, difficulty concentrating, memory impairment, confusion, weakness, unsteadiness, falls, hallucination, syncope, seizure, coma, respiratory arrest, death"
SAVELLA,warnings and precautions,5.9 Abnormal Bleeding,"bleeding events, gastrointestinal bleeding, ecchymoses, hematomas, epistaxis, petechiae, life-threatening hemorrhages"
SAVELLA,warnings and precautions,5.10 Activation of Mania,"mania, hypomania, major depressive episode"
SAVELLA,warnings and precautions,5.11 Patients with a History of Dysuria,"dysuria, urinary retention, testicular pain, ejaculation disorders"
SAVELLA,warnings and precautions,5.12 Angle Closure Glaucoma,"pupillary dilation, angle closure attack"
SAVELLA,warnings and precautions,5.13 Concomitant Use with Alcohol,"elevated transaminases, aggravate pre-existing liver disease"
SAMSCA,adverse reactions,6 ADVERSE REACTIONS,"thirst, dry mouth, asthenia, constipation, pollakiuria, polyuria, hyperglycemia"
SAMSCA,adverse reactions,6.1 Clinical Trials Experience,"adverse reactions, adverse events, hyponatremia, thirst, dry mouth, asthenia, constipation, pollakiuria, polyuria, hyperglycemia"
SAMSCA,adverse reactions,"Table 1 lists the adverse reactions reported in tolvaptan-treated patients with hyponatremia (serum sodium <135 mEq/L) and at a rate at least 2% greater than placebo-treated patients in two 30-day, double-blind, placebo-controlled trials. In these studies, 223 patients were exposed to tolvaptan (starting dose 15 mg, titrated to 30 and 60 mg as needed to raise serum sodium). Adverse events resulting in death in these trials were 6% in tolvaptan-treated-patients and 6% in placebo-treated patients.","The input you have provided is ""nan,"" which typically stands for ""not a number"" or indicates that data is missing. Without an excerpt of a drug label containing information on adverse drug events, I cannot extract any terms. If you provide an appropriate excerpt, I would be able to help you identify the adverse drug event terms."
SAMSCA,adverse reactions,"Table 1. Adverse Reactions (>2% more than placebo) in Tolvaptan-Treated Patients in Double-Blind, Placebo-Controlled Hyponatremia Trials System Organ ClassMedDRA Preferred Term Tolvaptan15 mg/day-60 mg/day(N = 223)n (%) Placebo (N = 220)n (%) The following terms are subsumed under the referenced ADR in Table 1: Gastrointestinal Disorders Dry mouth 28 (13) 9 (4) Constipation 16 (7) 4 (2) General Disorders and Administration Site Conditions Thirst 35 (16) 11 (5) Asthenia 19 (9) 9 (4) Pyrexia 9 (4) 2 (1) Metabolism and Nutrition Disorders Hyperglycemia 14 (6) 2 (1) Anorexia 8 (4) 2 (1) Renal and Urinary Disorders Pollakiuria or polyuria 25 (11) 7 (3) In a subgroup of patients with hyponatremia (N = 475, serum sodium <135 mEq/L) enrolled in a double-blind, placebo-controlled trial (mean duration of treatment was 9 months) of patients with worsening heart failure, the following adverse reactions occurred in tolvaptan-treated patients at a rate at least 2% greater than placebo: mortality (42% tolvaptan, 38% placebo), nausea (21% tolvaptan, 16% placebo), thirst (12% tolvaptan, 2% placebo), dry mouth (7% tolvaptan, 2% placebo) and polyuria or pollakiuria (4% tolvaptan, 1% placebo).","Gastrointestinal bleeding, Disseminated intravascular coagulation, Intracardiac thrombus, Ventricular fibrillation, Prothrombin time prolonged, Ischemic colitis, Diabetic ketoacidosis, Rhabdomyolysis, Cerebrovascular accident, Urethral hemorrhage, Vaginal hemorrhage, Pulmonary embolism, Respiratory failure, Deep vein thrombosis"
SAMSCA,adverse reactions,6.2 Postmarketing Experience,"osmotic demyelination syndrome, hypernatremia, hypersensitivity reactions, anaphylactic shock, rash generalized"
SAMSCA,boxed warnings,BOXED WARNING: WARNING: INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM,"If the input text for the drug label is ""nan"", which typically stands for ""not applicable"" or ""not available"", then there is no information given on which to identify any adverse drug event terms. Therefore, I cannot provide a list of terms without an actual excerpt of a drug label. If you provide an excerpt containing relevant information, I'd be happy to help identify the adverse drug event terms within it."
SAMSCA,boxed warnings,WARNING: INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM,"osmotic demyelination, dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, death"
SAMSCA,boxed warnings,EXCERPT: WARNING: INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM,"osmotic demyelination, dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, death"
SAMSCA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Liver injury, hepatic injury, Dehydration, hypovolemia"
SAMSCA,warnings and precautions,5.1 Too Rapid Correction of Serum Sodium Can Cause Serious Neurologic Sequelae,"osmotic demyelination syndrome, dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, death"
SAMSCA,warnings and precautions,5.2 Liver Injury,"serious liver injury, fatal liver injury, increased incidence of ALT, fatigue, anorexia, right upper abdominal discomfort, dark urine, jaundice, cirrhosis"
SAMSCA,warnings and precautions,5.3 Dehydration and Hypovolemia,"dehydration, hypovolemia"
SAMSCA,warnings and precautions,5.4 Co-administration with Hypertonic Saline,hypertonic saline
SAMSCA,warnings and precautions,5.5 Drug Interactions,"marked increase in tolvaptan concentrations, reduction in the plasma concentration of tolvaptan, decreased effectiveness of SAMSCA treatment"
SAMSCA,warnings and precautions,5.6 Hyperkalemia or Drugs that Increase Serum Potassium,"acute reduction of the extracellular fluid volume, increased serum potassium"
JETREA,adverse reactions,6 ADVERSE REACTIONS,"Decreased Vision, Intravitreal Injection Procedure Associated Effects, Potential for Lens Subluxation, Retinal Breaks, vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema"
JETREA,adverse reactions,6.1 Clinical Trials Experience,"vitreal floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, retinal edema, macular edema, increased intraocular pressure, anterior chamber cell, photophobia, vitreous detachment, ocular discomfort, iritis, cataract, dry eye, metamorphopsia, conjunctival hyperemia, retinal degeneration, dyschromatopsia"
JETREA,adverse reactions,6.2 Immunogenicity,immunogenicity
JETREA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"decreases in vision, traction, surgical intervention, intravitreal injection procedure associated effects, intraocular inflammation/infection, intraocular hemorrhage, increased IOP, lens subluxation"
JETREA,warnings and precautions,5.1 Decreased Vision,"decrease of >= 3 line of best corrected visual acuity (BCVA), decreases in vision, progression of the condition with traction, required surgical intervention"
JETREA,warnings and precautions,5.2 Intravitreal Injection Procedure Associated Effects,"intraocular inflammation, infection, intraocular hemorrhage, increased intraocular pressure"
JETREA,warnings and precautions,5.3 Potential for Lens Subluxation,lens subluxation
JETREA,warnings and precautions,5.4 Retinal Breaks,"retinal detachment, retinal tear"
JETREA,warnings and precautions,5.5 Dyschromatopsia,"Dyschromatopsia, yellowish vision, electroretinographic changes, a-wave amplitude decrease, b-wave amplitude decrease"
OPDIVO,adverse reactions,6 ADVERSE REACTIONS,"Immune-Mediated Pneumonitis, Immune-Mediated Colitis, Immune-Mediated Hepatitis, Immune-Mediated Nephritis and Renal Dysfunction, Immune-Mediated Hypothyroidism and Hyperthyroidism, Other Immune-Mediated Adverse Reactions, rash, fatigue, dyspnea, musculoskeletal pain, decreased appetite, cough, nausea, constipation"
OPDIVO,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions, Clinically significant adverse reactions, Grade 4 adverse reactions, Grade 3 ipilimumab-related adverse reactions, discontinued for adverse reactions, drug delay for an adverse reaction, Serious adverse reactions, Grade 3 and 4 adverse reactions, frequent Grade 3 and 4 adverse reactions, abdominal pain, hyponatremia, increased aspartate aminotransferase, increased lipase"
OPDIVO,adverse reactions,Table 1 summarizes the adverse reactions that occurred in at least 10% of OPDIVO-treated patients. The most common adverse reaction (reported in at least 20% of patients) was rash.,"If the input provided to me is simply ""nan"" without any actual content from a drug label, there is no information to extract adverse drug event terms from. If ""nan"" stands for ""not applicable"" or indicates that there was supposed to be content but it is missing, then there are no adverse drug event terms to report. If you have the text of a drug label, please provide it so I can assist you in identifying the adverse drug event terms."
OPDIVO,adverse reactions,"Table 1: Selected Adverse Reactions Occurring in >=10% of OPDIVO-Treated Patients and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of >=5% [All Grades] or >=2% [Grades 3-4]) (Trial 1) OPDIVO(n=268) Chemotherapy(n=102) Adverse Reaction AllGrades Grades3-4 AllGrades Grades3-4 Percentage (%) of Patients a Rash is a composite term which includes maculopapular rash, rash erythematous, rash pruritic, rash follicular, rash macular, rash papular, rash pustular, rash vesicular, and dermatitis acneiform. b Upper respiratory tract infection is a composite term which includes rhinitis, pharyngitis, and nasopharyngitis. Skin and Subcutaneous Tissue Disorders Rasha 21 0.4 7 0 Pruritus 19 0 3.9 0 Respiratory, Thoracic, and Mediastinal Disorders Cough 17 0 6 0 Infections and Infestations Upper respiratory tract infectionb 11 0 2.0 0 General Disorders and Administration Site Conditions Peripheral edema 10 0 5 0 Other clinically important adverse reactions in less than 10% of patients treated with OPDIVO in Trial 1 were:","ventricular arrhythmia, iridocyclitis, infusion-related reactions, increased amylase, increased lipase, dizziness, peripheral and sensory neuropathy, exfoliative dermatitis, erythema multiforme, vitiligo, psoriasis"
OPDIVO,adverse reactions,"Table 2: Selected Laboratory Abnormalities Worsening from Baseline Occurring in >=10% of OPDIVO-Treated Patients and at a Higher Incidence than in the Chemotherapy Arm (Between Arm Difference of >=5% [All Grades] or >=2% [Grades 3-4]) (Trial 1) a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: OPDIVO group (range 252 to 256 patients) and chemotherapy group (range 94 to 96 patients). Percentage of Patients with Worsening Laboratory Test from Baselinea Test OPDIVO Chemotherapy All Grades Grades 3-4 All Grades Grades 3-4 Increased AST 28 2.4 12 1.0 Increased alkaline phosphatase 22 2.4 13 1.1 Hyponatremia 25 5 18 1.1 Increased ALT 16 1.6 5 0 Hyperkalemia 15 2.0 6 0 Metastatic Squamous Non-Small Cell Lung Cancer The safety of OPDIVO was evaluated in Trial 3, a single-arm multinational, multicenter trial in 117 patients with metastatic squamous NSCLC and progression on both a prior platinum-based therapy and at least one additional systemic therapy [see Clinical Studies (14.2) ] . Patients received 3 mg/kg of OPDIVO administered intravenously over 60 minutes every 2 weeks. The median duration of therapy was 2.3 months (range: 1 day to 16.1+ months). Patients received a median of 6 doses (range: 1 to 34).","symptomatic interstitial lung disease, dyspnea, pneumonia, chronic obstructive pulmonary disease exacerbation, pneumonitis, hypercalcemia, pleural effusion, hemoptysis, pain"
OPDIVO,adverse reactions,"Table 3 summarizes adverse reactions that occurred in at least 10% of patients. The most common adverse reactions (reported in at least 20% of patients) were fatigue, dyspnea, musculoskeletal pain, decreased appetite, cough, nausea, and constipation.","If the input provided to me is simply ""nan"" and it's meant to represent an excerpt from a drug label, there is no actual content regarding adverse drug events to extract. If ""nan"" stands for 'not applicable' or 'not available,' it means that there is no information given about adverse drug events in the text. Thus, without a proper excerpt or context, it's not possible for me to provide a list of adverse drug event terms. Please provide the actual drug label text for analysis."
OPDIVO,adverse reactions,"Table 3: Adverse Reactions Occurring in >=10% of Patients for All NCI CTCAE* Grades or >=5% for Grades 3-4 (Trial 3) OPDIVO(n=117) Adverse Reaction All Grades Grades3-4 Percentage (%) of Patients * National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. a Includes face edema, peripheral edema, local swelling, localized edema, lymphoedema. b Includes chest discomfort and noncardiac chest pain. c Includes back pain, bone pain, musculoskeletal chest pain, myalgia, neck pain, pain in extremity, spinal pain. d Includes arthritis and osteoarthritis. e Includes abdominal pain lower, abdominal pain upper, gastrointestinal pain. f Includes maculopapular rash, rash erythematous, erythema, dermatitis, dermatitis exfoliative, and dermatitis acneiform. g Includes lung infection and pneumonia aspiration. General Disorders and Administration Site Conditions Fatigue 50 7 Asthenia 19 1.7 Edemaa 17 1.7 Pyrexia 17 0 Chest painb 13 0 Pain 10 2.6 Respiratory, Thoracic, and Mediastinal Disorders Dyspnea 38 9 Cough 32 1.7 Musculoskeletal and Connective Tissue Disorders Musculoskeletal painc 36 6 Arthralgiad 13 0 Metabolism and Nutrition Disorders Decreased appetite 35 2.6 Gastrointestinal Disorders Nausea 29 1.7 Constipation 24 0 Vomiting 19 0.9 Diarrhea 18 2.6 Abdominal paine 16 1.7 Skin and Subcutaneous Tissue Disorders Rashf 16 0.9 Pruritus 11 0.9 Investigations Decreased weight 13 0.9 Infections and Infestations Pneumoniag 10 5 Other clinically important adverse reactions in less than 10% of patients in Trial 3 were:","stomatitis, peripheral neuropathy, bronchitis, upper respiratory tract infection"
OPDIVO,adverse reactions,"Table 4: Laboratory Abnormalities Worsening from Baseline Occurring in >=10% of Patients for all NCI CTCAE Grades or >=2% for Grades 3-4 (Trial 3) a Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available (range 111 to 114 patients). Test Percentage of Patients with Worsening Laboratory Test from Baselinea All Grades Grades 3-4 Chemistry Hyponatremia 38 10 Increased creatinine 22 0 Hypercalcemia 20 2.6 Hypokalemia 20 2.6 Hypomagnesemia 20 0 Hypocalcemia 18 1.8 Hyperkalemia 18 4.4 Increased AST 16 0.9 Increased alkaline phosphatase 14 0 Increased ALT 12 0 Hematology Lymphopenia 47 16 Anemia 28 2.6 Thrombocytopenia 14 0 6.2 Immunogenicity As with all therapeutic proteins, there is a potential for immunogenicity.","treatment-emergent anti-product antibodies, Neutralizing antibodies"
OPDIVO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"pneumonitis, colitis, hepatitis, transaminase elevation, total bilirubin elevation, nephritis, renal dysfunction, serum creatinine elevation, hypothyroidism, hyperthyroidism, embryofetal toxicity"
OPDIVO,warnings and precautions,5.1 Immune-Mediated Pneumonitis,"severe pneumonitis, interstitial lung disease, fatal immune-mediated pneumonitis, Grade 3 pneumonitis, Grade 2 pneumonitis, severe (Grade 3) pneumonitis, life-threatening (Grade 4) pneumonitis, moderate (Grade 2) pneumonitis"
OPDIVO,warnings and precautions,5.2 Immune-Mediated Colitis,"diarrhea, colitis, immune-mediated colitis, Grade 3 colitis, Grade 2 colitis, interruption, permanent discontinuation, immune-mediated adverse reaction, improved to Grade 0, ongoing Grade 2 colitis, severe colitis, life-threatening colitis, moderate colitis, withhold OPDIVO, permanently discontinue OPDIVO, recurrent colitis"
OPDIVO,warnings and precautions,5.3 Immune-Mediated Hepatitis,"liver test abnormalities, increases in AST, alkaline phosphatase, ALT, total bilirubin, Immune-mediated hepatitis, Grade 2 hepatitis, Grade 3 hepatitis, elevated liver test values, abnormal liver tests, Grade 2 or greater transaminase elevations, moderate (Grade 2) immune-mediated hepatitis, severe (Grade 3) immune-mediated hepatitis, life-threatening (Grade 4) immune-mediated hepatitis"
OPDIVO,warnings and precautions,5.4 Immune-Mediated Nephritis and Renal Dysfunction,"elevated creatinine, immune-mediated nephritis, renal dysfunction, Grade 2 increased creatinine, Grade 3 immune-mediated nephritis, Grade 2 immune-mediated renal dysfunction, life-threatening serum creatinine elevation, severe serum creatinine elevation, moderate serum creatinine elevation"
OPDIVO,warnings and precautions,5.5 Immune-Mediated Hypothyroidism and Hyperthyroidism,"hypothyroidism, hyperthyroidism"
OPDIVO,warnings and precautions,5.6 Other Immune-Mediated Adverse Reactions,"adrenal insufficiency, uveitis, pancreatitis, facial nerve paresis, abducens nerve paresis, demyelination, autoimmune neuropathy, motor dysfunction, vasculitis, hypophysitis, diabetic ketoacidosis, hypopituitarism, Guillain-Barre syndrome, myasthenic syndrome"
OPDIVO,warnings and precautions,5.7 Embryofetal Toxicity,"increased abortion, premature infant death"
VICTOZA,adverse reactions,6 ADVERSE REACTIONS,"Thyroid C-cell Tumors, Pancreatitis, Hypoglycemia, Renal Impairment, Hypersensitivity Reactions, headache, nausea, diarrhea, anti-liraglutide antibody formation, Immunogenicity-related events, urticaria"
VICTOZA,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse events, gastrointestinal adverse reactions, nausea, vomiting, withdrawal due to gastrointestinal adverse events"
VICTOZA,adverse reactions,"Tables 1, 2, 3 and 4 summarize common adverse reactions (hypoglycemia is discussed separately) reported in seven of the eight controlled trials of 26 weeks duration or longer. Most of these adverse reactions were gastrointestinal in nature.","gastrointestinal adverse reactions, nausea, vomiting, diarrhea, dyspepsia, constipation"
VICTOZA,adverse reactions,Table 1 Adverse reactions reported in >=5% of Victoza-treated patients in a 52-week monotherapy trial All Victoza N = 497 Glimepiride N = 248 Adverse Reaction (%) (%) Nausea 28.4 8.5 Diarrhea 17.1 8.9 Vomiting 10.9 3.6 Constipation 9.9 4.8 Headache 9.1 9.3 Table 2 Adverse reactions reported in >=5% of Victoza-treated patients and occurring more frequently with Victoza compared to placebo: 26-week combination therapy trials Add-on to Metformin Trial All Victoza + Metformin N = 724 Placebo + Metformin N = 121 Glimepiride + Metformin N = 242 Adverse Reaction (%) (%) (%) Nausea 15.2 4.1 3.3 Diarrhea 10.9 4.1 3.7 Headache 9.0 6.6 9.5 Vomiting 6.5 0.8 0.4 Add-on to Glimepiride Trial All Victoza + Glimepiride N = 695 Placebo + Glimepiride N = 114 Rosiglitazone + Glimepiride N = 231 Adverse Reaction (%) (%) (%) Nausea 7.5 1.8 2.6 Diarrhea 7.2 1.8 2.2 Constipation 5.3 0.9 1.7 Dyspepsia 5.2 0.9 2.6 Add-on to Metformin + Glimepiride Victoza 1.8 + Metformin + Glimepiride N = 230 Placebo + Metformin + Glimepiride N = 114 Glargine + Metformin + Glimepiride N = 232 Adverse Reaction (%) (%) (%) Nausea 13.9 3.5 1.3 Diarrhea 10.0 5.3 1.3 Headache 9.6 7.9 5.6 Dyspepsia 6.5 0.9 1.7 Vomiting 6.5 3.5 0.4 Add-on to Metformin + Rosiglitazone All Victoza + Metformin + Rosiglitazone N = 355 Placebo + Metformin + Rosiglitazone N = 175 Adverse Reaction (%) (%) Nausea 34.6 8.6 Diarrhea 14.1 6.3 Vomiting 12.4 2.9 Headache 8.2 4.6 Constipation 5.1 1.1 Table 3 Adverse Reactions reported in >=5% of Victoza-treated patients in a 26-Week Open-Label Trial versus Exenatide Victoza 1.8 mg once daily + metformin and/or sulfonylurea N = 235 Exenatide 10 mcg twice daily + metformin and/or sulfonylurea N = 232 Adverse Reaction (%) (%) Nausea 25.5 28.0 Diarrhea 12.3 12.1 Headache 8.9 10.3 Dyspepsia 8.9 4.7 Vomiting 6.0 9.9 Constipation 5.1 2.6 Table 4 Adverse Reactions in >=5% of Victoza-treated patients in a 26-Week Open-Label Trial versus Sitagliptin All Victoza + metformin N = 439 Sitagliptin 100 mg/day + metformin N = 219 Adverse Reaction (%) (%) Nausea 23.9 4.6 Headache 10.3 10.0 Diarrhea 9.3 4.6 Vomiting 8.7 4.1 Immunogenicity,"immunogenic, anti-liraglutide antibodies, cross-reacting antibodies, neutralizing effect, infections, upper respiratory tract infections, gastrointestinal events, urticaria, angioedema, injection site reactions, injection site rash, erythema, papillary thyroid carcinoma, hypoglycemia"
VICTOZA,adverse reactions,"Table 5 Incidence (%) and Rate (episodes/patient year) of Hypoglycemia in the 52-Week Monotherapy Trial and in the 26-Week Combination Therapy Trials Victoza Treatment Active Comparator Placebo Comparator Monotherapy Victoza (N = 497) Glimepiride (N = 248) None Patient not able to self-treat 0 0 - Patient able to self-treat 9.7 (0.24) 25.0 (1.66) - Not classified 1.2 (0.03) 2.4 (0.04) - Add-on to Metformin Victoza + Metformin (N = 724) Glimepiride + Metformin (N = 242) Placebo + Metformin (N = 121) Patient not able to self-treat 0.1 (0.001) 0 0 Patient able to self-treat 3.6 (0.05) 22.3 (0.87) 2.5 (0.06) Add-on to Victoza + Metformin Insulin detemir + Victoza + Metformin (N = 163) Continued Victoza + Metformin alone (N = 158One patient is an outlier and was excluded due to 25 hypoglycemic episodes that the patient was able to self-treat. This patient had a history of frequent hypoglycemia prior to the study.) None Patient not able to self-treat 0 0 - Patient able to self-treat 9.2 (0.29) 1.3 (0.03) - Add-on to Glimepiride Victoza + Glimepiride (N = 695) Rosiglitazone + Glimepiride (N = 231) Placebo + Glimepiride (N = 114) Patient not able to self-treat 0.1 (0.003) 0 0 Patient able to self-treat 7.5 (0.38) 4.3 (0.12) 2.6 (0.17) Not classified 0.9 (0.05) 0.9 (0.02) 0 Add-on to Metformin + Rosiglitazone Victoza + Metformin + Rosiglitazone (N = 355) None Placebo + Metformin + Rosiglitazone (N = 175) Patient not able to self-treat 0 - 0 Patient able to self-treat 7.9 (0.49) - 4.6 (0.15) Not classified 0.6 (0.01) - 1.1 (0.03) Add-on to Metformin + Glimepiride Victoza + Metformin + Glimepiride (N = 230) Insulin glargine + Metformin + Glimepiride (N = 232) Placebo + Metformin + Glimepiride (N = 114) Patient not able to self-treat 2.2 (0.06) 0 0 Patient able to self-treat 27.4 (1.16) 28.9 (1.29) 16.7 (0.95) Not classified 0 1.7 (0.04) 0 In a pooled analysis of clinical trials, the incidence rate (per 1,000 patient-years) for malignant neoplasms (based on investigator-reported events, medical history, pathology reports, and surgical reports from both blinded and open-label study periods) was 10.9 for Victoza, 6.3 for placebo, and 7.2 for active comparator. After excluding papillary thyroid carcinoma events [ see Adverse Reactions (6.1) ] , no particular cancer cell type predominated. Seven malignant neoplasm events were reported beyond 1 year of exposure to study medication, six events among Victoza-treated patients (4 colon, 1 prostate and 1 nasopharyngeal), no events with placebo and one event with active comparator (colon). Causality has not been established.","elevated serum bilirubin concentrations, abnormalities in other liver tests, Calcitonin elevations, adverse effects on blood pressure, increases from baseline in heart rate"
VICTOZA,adverse reactions,6.2 Post-Marketing Experience,"Medullary thyroid carcinoma, Dehydration, Nausea, Vomiting, Diarrhea, Increased serum creatinine, Acute renal failure, Worsening of chronic renal failure, Hemodialysis, Angioedema, Anaphylactic reactions, Allergic reactions, Rash, Pruritus, Acute pancreatitis, Hemorrhagic pancreatitis, Necrotizing pancreatitis."
VICTOZA,boxed warnings,BOXED WARNING: WARNING: RISK OF THYROID C-CELL TUMORS,"No excerpt was provided, thus no adverse drug event terms can be identified. Please provide the relevant text for analysis."
VICTOZA,boxed warnings,WARNING: RISK OF THYROID C-CELL TUMORS,"thyroid C-cell tumors, medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), mass in the neck, dysphagia, dyspnea, persistent hoarseness"
VICTOZA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Thyroid C-cell Tumors, Pancreatitis, fatal and non-fatal hemorrhagic pancreatitis, necrotizing pancreatitis, Serious Hypoglycemia, Renal Impairment, nausea, vomiting, diarrhea, dehydration, hypersensitivity reactions, anaphylactic reactions, angioedema"
VICTOZA,warnings and precautions,5.1 Risk of Thyroid C-cell Tumors,"thyroid C-cell tumors, adenomas, carcinomas, Malignant thyroid C-cell carcinomas, medullary thyroid carcinoma (MTC), mass in the neck, dysphagia, dyspnea, persistent hoarseness, unnecessary procedures, thyroid disease, Significantly elevated serum calcitonin, thyroid nodules"
VICTOZA,warnings and precautions,5.2 Pancreatitis,"acute pancreatitis, fatal, non-fatal hemorrhagic pancreatitis, necrotizing pancreatitis, severe abdominal pain, vomiting, chronic pancreatitis, pancreatitis with necrosis"
VICTOZA,warnings and precautions,5.3 Never Share a Victoza Pen Between Patients,blood-borne pathogens
VICTOZA,warnings and precautions,5.4 Use with Medications Known to Cause Hypoglycemia,hypoglycemia
VICTOZA,warnings and precautions,5.5 Renal Impairment,"acute renal failure, worsening of chronic renal failure, nausea, vomiting, diarrhea, dehydration, altered renal function"
VICTOZA,warnings and precautions,5.6 Hypersensitivity Reactions,"hypersensitivity reactions, anaphylactic reactions, angioedema"
VICTOZA,warnings and precautions,5.7 Macrovascular Outcomes,"The text provided does not appear to include any specific adverse drug event terms. It mentions a lack of clinical studies for macrovascular risk reduction with the drug Victoza, but this does not describe an adverse event. Therefore, based on the given excerpt, there are no adverse drug event terms to list."
EFFIENT,adverse reactions,6 ADVERSE REACTIONS,
EFFIENT,adverse reactions,6.1 Clinical Trials Experience,"Bleeding, Thrombotic thrombocytopenic purpura"
EFFIENT,adverse reactions,"Table 1: Non-CABG-Related Bleedinga (TRITON-TIMI 38) a Patients may be counted in more than one row. b See 5.1 for definition. Effient(%)(N=6741) Clopidogrel(%)(N=6716) TIMI Major or Minor bleeding 4.5 3.4 TIMI Major bleedingb 2.2 1.7 Life-threatening 1.3 0.8 Fatal 0.3 0.1 Symptomatic intracranial hemorrhage (ICH) 0.3 0.3 Requiring inotropes 0.3 0.1 Requiring surgical intervention 0.3 0.3 Requiring transfusion (>=4 units) 0.7 0.5 TIMI Minor bleedingb 2.4 1.9 Figure 1 demonstrates non-CABG related TIMI Major or Minor bleeding. The bleeding rate is highest initially, as shown in Figure 1 (inset: Days 0 to 7) [see Warnings and Precautions ( 5.1 )] .","Bleeding, TIMI Major, Minor bleeding"
EFFIENT,adverse reactions,"Table 2: Bleeding Rates for Non-CABG-Related Bleeding by Weight and Age (TRITON-TIMI 38) a 10-mg Effient maintenance dose b 75-mg clopidogrel maintenance dose Major/Minor Fatal Effienta(%) Clopidogrelb(%) Effienta(%) Clopidogrelb(%) Weight <60 kg (N=308 Effient, N=356 clopidogrel) 10.1 6.5 0.0 0.3 Weight >=60 kg (N=6373 Effient, N=6299 clopidogrel) 4.2 3.3 0.3 0.1 Age <75 years (N=5850 Effient, N=5822 clopidogrel) 3.8 2.9 0.2 0.1 Age >=75 years (N=891 Effient, N=894 clopidogrel) 9.0 6.9 1.0 0.1 Bleeding Related to CABG - In TRITON-TIMI 38, 437 patients who received a thienopyridine underwent CABG during the course of the study. The rate of CABG-related TIMI Major or Minor bleeding was 14.1% for the Effient group and 4.5% in the clopidogrel group ( see Table 3 ). The higher risk for bleeding adverse reactions in patients treated with Effient persisted up to 7 days from the most recent dose of study drug.","As no text was provided, I cannot extract any adverse drug event terms. If you provide an excerpt with content, I can assist you with that task."
EFFIENT,adverse reactions,"Table 3: CABG-Related Bleedinga (TRITON-TIMI 38) a Patients may be counted in more than one row. Effient (%)(N=213) Clopidogrel (%)(N=224) TIMI Major or Minor bleeding 14.1 4.5 TIMI Major bleeding 11.3 3.6 Fatal 0.9 0 Reoperation 3.8 0.5 Transfusion of >=5 units 6.6 2.2 Intracranial hemorrhage 0 0 TIMI Minor bleeding 2.8 0.9 Bleeding Reported as Adverse Reactions - Hemorrhagic events reported as adverse reactions in TRITON-TIMI 38 were, for Effient and clopidogrel, respectively: epistaxis (6.2%, 3.3%), gastrointestinal hemorrhage (1.5%, 1.0%), hemoptysis (0.6%, 0.5%), subcutaneous hematoma (0.5%, 0.2%), post-procedural hemorrhage (0.5%, 0.2%), retroperitoneal hemorrhage (0.3%, 0.2%), pericardial effusion/hemorrhage/tamponade (0.3%, 0.2%), and retinal hemorrhage (0.0%, 0.1%).","malignancies, colon and lung malignancies, colorectal malignancies, GI bleed, anemia, severe thrombocytopenia, abnormal hepatic function, allergic reactions, angioedema"
EFFIENT,adverse reactions,"Table 4: Non-Hemorrhagic Treatment Emergent Adverse Events Reported by at Least 2.5% of Patients in Either Group Effient (%)(N=6741) Clopidogrel (%)(N=6716) Hypertension 7.5 7.1 Hypercholesterolemia/Hyperlipidemia 7.0 7.4 Headache 5.5 5.3 Back pain 5.0 4.5 Dyspnea 4.9 4.5 Nausea 4.6 4.3 Dizziness 4.1 4.6 Cough 3.9 4.1 Hypotension 3.9 3.8 Fatigue 3.7 4.8 Non-cardiac chest pain 3.1 3.5 Atrial fibrillation 2.9 3.1 Bradycardia 2.9 2.4 Leukopenia (<4 x 109 WBC/L) 2.8 3.5 Rash 2.8 2.4 Pyrexia 2.7 2.2 Peripheral edema 2.7 3.0 Pain in extremity 2.6 2.6 Diarrhea 2.3 2.6 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of Effient. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.","Thrombocytopenia, Thrombotic thrombocytopenic purpura (TTP), Hypersensitivity reactions, Anaphylaxis"
EFFIENT,boxed warnings,BOXED WARNING: WARNING: BLEEDING RISK,"As an AI language model, I can respond to text-based prompts; however, if the input provided is ""nan"" which typically means ""not a number"" or signifies missing data, I can't extract any adverse drug event terms because there's no actual drug label content provided. If you have the content of a drug label you wish to analyze, please provide the text, and I'd be happy to identify the adverse drug event terms for you."
EFFIENT,boxed warnings,WARNING: BLEEDING RISK,"significant bleeding, fatal bleeding, active pathological bleeding, intracranial bleeding, propensity to bleed"
EFFIENT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"CABG-related bleeding, stent thrombosis, MI, death, Thrombotic thrombocytopenic purpura (TTP), Hypersensitivity, angioedema"
EFFIENT,warnings and precautions,5.1 General Risk of Bleeding,"bleeding, clinically overt bleeding, intracranial hemorrhage, overt bleeding, fatal bleeding, gastrointestinal (GI) bleeding, active peptic ulcer disease, CABG-related bleeding, TIMI Major bleeding, TIMI Minor bleeding"
EFFIENT,warnings and precautions,5.3 Discontinuation of Effient,"active bleeding, elective surgery, stroke, TIA, stent thrombosis, myocardial infarction, death, cardiac events"
EFFIENT,warnings and precautions,5.4 Thrombotic Thrombocytopenic Purpura,"Thrombotic thrombocytopenic purpura, fatal, thrombocytopenia, microangiopathic hemolytic anemia, schistocytes, neurological findings, renal dysfunction, fever"
EFFIENT,warnings and precautions,5.5 Hypersensitivity Including Angioedema,"Hypersensitivity, angioedema"
ENTYVIO,adverse reactions,6 ADVERSE REACTIONS,"Infusion-Related Reactions, Hypersensitivity Reactions, Infections, Progressive Multifocal Leukoencephalopathy, Liver Injury, nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities"
ENTYVIO,adverse reactions,6.1 Clinical Trials Experience,"nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities, infusion-related reactions, hypersensitivity reactions, anaphylaxis, dyspnea, bronchospasm, urticaria, flushing, increased blood pressure, increased heart rate, dizziness, vomiting, infections, urinary tract infection, anal abscess, sepsis, salmonella sepsis, Listeria meningitis, giardiasis, cytomegaloviral colitis, tuberculosis, liver injury, elevations of transaminase, elevations of bilirubin, hepatitis, malignancies, colon cancer, transitional cell carcinoma, breast cancer, carcinoid tumor of the appendix, squamous cell carcinoma, B-cell lymphoma, malignant hepatic neoplasm, malignant lung neoplasm, malignant melanoma, lung cancer, renal cancer"
ENTYVIO,adverse reactions,6.2 Immunogenicity,"immunogenicity, antibodies, anti-vedolizumab antibody, persistently positive, neutralizing antibodies, reduced vedolizumab concentrations, clinical remission"
ENTYVIO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Hypersensitivity Reactions, anaphylaxis, serious allergic reactions, Infections, severe infection, Progressive Multifocal Leukoencephalopathy (PML), JCV infection, death, new or worsening neurological signs or symptoms"
ENTYVIO,warnings and precautions,5.1 Infusion-Related Reactions and Hypersensitivity Reactions,"hypersensitivity reactions, anaphylaxis, allergic reactions, dyspnea, bronchospasm, urticaria, flushing, rash, increased blood pressure, heart rate"
ENTYVIO,warnings and precautions,5.2 Infections,"nasopharyngitis, upper respiratory tract infection, serious infections, anal abscess, sepsis, tuberculosis, salmonella sepsis, Listeria meningitis, giardiasis, cytomegaloviral colitis, severe infections, progressive multifocal leukoencephalopathy (PML)"
ENTYVIO,warnings and precautions,5.3 Progressive Multifocal Leukoencephalopathy,"progressive multifocal leukoencephalopathy (PML), opportunistic infection, immunocompromised, new, unexplained neurological symptoms, progressive weakness, clumsiness of limbs, disturbance of vision, changes in thinking, memory, and orientation, confusion, personality changes, death, severe disability"
ENTYVIO,warnings and precautions,5.4 Liver Injury,"elevations of transaminase, bilirubin, severe liver injury, death, liver transplant, jaundice, significant liver injury"
ENTYVIO,warnings and precautions,5.5 Live and Oral Vaccines,"immunizations, non-live vaccines, live vaccines, secondary transmission of infection"
ADEMPAS,adverse reactions,6 ADVERSE REACTIONS,"Embryo-Fetal Toxicity, Hypotension, Bleeding, headache, dyspepsia/gastritis, dizziness, nausea, diarrhea, vomiting, anemia, gastroesophageal reflux, constipation"
ADEMPAS,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, safety data, adverse drug reactions (ADRs), adverse reactions, overall rates of discontinuation due to an adverse event"
ADEMPAS,adverse reactions,"Table 1: Adverse Reactions Occurring More Frequently (>=3%) on Adempas than Placebo (Pooled from CHEST-1 and PATENT-1) Adverse Reactions Adempas % (n=490) Placebo % (n=214) Headache 27 18 Dyspepsia and Gastritis 21 8 Dizziness 20 13 Nausea 14 11 Diarrhea 12 8 Hypotension 10 4 Vomiting 10 7 Anemia (including laboratory parameters) 7 2 Gastroesophageal reflux disease 5 2 Constipation 5 1 Other events that were seen more frequently in Adempas compared to placebo and potentially related to treatment were: palpitations, nasal congestion, epistaxis, dysphagia, abdominal distension and peripheral edema. With longer observation in uncontrolled long-term extension studies the safety profile was similar to that observed in the placebo controlled phase 3 trials.","If the input text you've provided is simply ""nan"", which typically stands for ""not a number"" and indicates missing data or undefined value, then there is no excerpt of a drug label to analyze and hence no adverse drug event terms can be identified. If you were expecting a drug label excerpt but received ""nan"", it suggests there may have been an error or miscommunication in the provision of the drug label text. Please provide the actual excerpt for analysis."
ADEMPAS,boxed warnings,BOXED WARNING: WARNING: EMBRYO-FETAL TOXICITY,"If the input text is ""nan"" and you are looking for a list of adverse drug event terms from an excerpt of a drug label, there seems to be a misunderstanding because ""nan"" implies that there is no actual excerpt provided. If there is no drug label text included, then it is not possible for me to extract any adverse drug event terms. Could you please provide the actual drug label excerpt?"
ADEMPAS,boxed warnings,WARNING: EMBRYO-FETAL TOXICITY,fetal harm
ADEMPAS,boxed warnings,EXCERPT: WARNING: EMBRYO-FETAL TOXICITY,fetal harm
ADEMPAS,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"symptomatic hypotension, bleeding, pulmonary edema"
ADEMPAS,warnings and precautions,5.1 Embryo-Fetal Toxicity,"fetal harm, contraindicated"
ADEMPAS,warnings and precautions,5.2 Adempas REMS Program,"This excerpt does not explicitly mention any adverse drug events (ADEs). It discusses the risk management program associated with Adempas (also known as riociguat), such as the REMS program, certification requirements for prescribers and pharmacies, and requirements for patient enrollment and contraception. Since no specific ADEs are enumerated, there are no adverse drug event terms to list from this particular text."
ADEMPAS,warnings and precautions,5.3 Hypotension,"symptomatic hypotension, ischemia, hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction"
ADEMPAS,warnings and precautions,5.4 Bleeding,"serious bleeding, hemoptysis, fatal outcome, vaginal hemorrhage, catheter site hemorrhage, subdural hematoma, hematemesis, intra-abdominal hemorrhage"
ADEMPAS,warnings and precautions,5.5 Pulmonary Veno-Occlusive Disease,"pulmonary edema, worsen the cardiovascular status, pulmonary veno-occlusive disease (PVOD)"
MOVANTIK,adverse reactions,6 ADVERSE REACTIONS,"abdominal pain, diarrhea, nausea, flatulence, vomiting, headache"
MOVANTIK,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, Safety data"
MOVANTIK,adverse reactions,Table 1 lists adverse reactions in pooled Studies 1 and 2 occurring in >= 3% of patients receiving MOVANTIK 12.5 mg or 25 mg and at an incidence greater than placebo.,"No input content was provided from which to extract adverse drug event terms. If you provide text from a drug label, I can assist in identifying the terms related to adverse drug events."
MOVANTIK,adverse reactions,Table 1. Adverse ReactionsAdverse reactions occurring in >=3% of patients receiving MOVANTIK 12.5 mg or 25 mg and at an incidence greater than placebo. in Patients with OIC and Non-Cancer Pain (Studies 1 and 2) Adverse Reaction MOVANTIK 25 mg (n=446) MOVANTIK 12.5 mg (n=441) Placebo (n=444) Abdominal Pain 21% 12% 7% Diarrhea 9% 6% 5% Nausea 8% 7% 5% Flatulence 6% 3% 3% Vomiting 5% 3% 4% Headache 4% 4% 3% Hyperhidrosis 3% <1% <1% Opioid Withdrawal,"opioid withdrawal, hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, yawning, gastrointestinal adverse reactions"
MOVANTIK,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Gastrointestinal perforation, severe, persistent or worsening abdominal pain, opioid withdrawal"
MOVANTIK,warnings and precautions,5.1 Gastrointestinal Perforation,"gastrointestinal perforation, peptic ulcer disease, Ogilvie's syndrome, diverticular disease, infiltrative gastrointestinal tract malignancies, peritoneal metastases, impaired integrity of the gastrointestinal tract wall, Crohn's disease, severe persistent or worsening abdominal pain"
MOVANTIK,warnings and precautions,5.2 Opioid Withdrawal,"hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, irritability, yawning, gastrointestinal adverse reactions"
STIVARGA,adverse reactions,6 ADVERSE REACTIONS,"Hepatotoxicity, Hemorrhage, Dermatological Toxicity, Hypertension, Cardiac Ischemia and Infarction, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), Gastrointestinal Perforation or Fistula, asthenia/fatigue, Hand-Foot Skin Reaction (HFSR), diarrhea, decreased appetite/food intake, mucositis, dysphonia, infection, pain, decreased weight, gastrointestinal and abdominal pain, rash, fever, nausea"
STIVARGA,adverse reactions,6.1 Clinical Trials Experience,"hand-foot skin reaction (HFSR), rash, adverse reactions"
STIVARGA,adverse reactions,Table 1 compares the incidence of adverse reactions (>=10%) in patients receiving Stivarga and reported more commonly than in patients receiving placebo (Study 1).,"If the input provided is ""nan"", it appears to be either an error or signifies 'not applicable' or 'not available.' There are no adverse drug event terms to extract from this input. Without a relevant excerpt from a drug label, I cannot provide a list of adverse drug event terms. If you provide the actual text from a drug label, I'd be happy to assist with your request."
STIVARGA,adverse reactions,"Table 1 Adverse drug reactions (>=10%) reported in patients treated with Stivarga in Study 1 and reported more commonly than in patients receiving placebo Adverse Reactions Stivarga (N=500) Placebo (N=253) Grade Grade All % >= 3 % All % >= 3 % Asthenia/fatigue Pain General disorders and administration site conditions Fever 64 29 28 15 3 2 46 21 15 9 2 0 Metabolism and nutrition disorders Decreased appetite and food intake 47 5 28 4 Skin and subcutaneous tissue disorders HFSR/PPE Rash The term rash represents reports of events of drug eruption, rash, erythematous rash, generalized rash, macular rash, maculo-papular rash, papular rash, and pruritic rash. 45 26 17 6 7 4 0 <1 Gastrointestinal disorders Diarrhea Mucositis 43 33 8 4 17 5 2 0 Investigations Weight loss 32 <1 10 0 Infections and infestations Infection 31 9 17 6 Vascular disorders Hypertension Hemorrhage Fatal outcomes observed. 30 21 8 2 8 8 <1 <1 Respiratory, thoracic and mediastinal disorders Dysphonia 30 0 6 0 Nervous system disorders Headache 10 <1 7 0 Laboratory Abnormalities","There are no adverse drug event terms provided in the text snippet given. The excerpt references laboratory abnormalities observed in a study and suggests that these are shown in Table 2, which is not included in the text provided. Therefore, without additional context or the content of Table 2, it is not possible to list any specific adverse drug event terms."
STIVARGA,adverse reactions,"Table 2 Laboratory test abnormalities reported in Study 1 Laboratory Parameter Stivarga (N=500 ) Placebo (N=253 ) Grade Grade All % 3 % 4 % All % 3 % 4 % Blood and lymphatic system disorders Anemia 79 5 1 66 3 0 Thrombocytopenia 41 2 <1 17 <1 0 Neutropenia 3 1 0 0 0 0 Lymphopenia 54 9 0 34 3 0 Metabolism and nutrition disorders Hypocalcemia 59 1 <1 18 1 0 Hypokalemia 26 4 0 8 <1 0 Hyponatremia 30 7 1 22 4 0 Hypophosphatemia 57 31 1 11 4 0 Hepatobiliary disorders Hyperbilirubinemia 45 10 3 17 5 3 Increased AST 65 5 1 46 4 1 Increased ALT 45 5 1 30 3 <1 Renal and urinary disorders Proteinuria 60 <1 0 34 <1 0 Investigations Increased INR International normalized ratio: No Grade 4 denoted in CTCAE, v3.0. 24 4 N/A 17 2 N/A Increased Lipase 46 9 2 19 3 2 Increased Amylase 26 2 <1 17 2 <1 Gastrointestinal Stromal Tumors","adverse events, adverse reactions, treatment discontinuation, dose interruptions, dose reduced"
STIVARGA,adverse reactions,Table 3 compares the incidence of adverse reactions (>=10%) in GIST patients receiving Stivarga and reported more commonly than in patients receiving placebo (Study 2).,"There is no text provided for me to identify adverse drug event terms. The input ""nan"" typically indicates ""not a number"" or that the content is missing. Please provide the text excerpt from the drug label for me to assist you."
STIVARGA,adverse reactions,"Table 3 Adverse reactions (>=10%) reported in patients treated with Stivarga in Study 2 and reported more commonly than in patients receiving placebo Adverse Reactions Stivarga (N=132) Placebo (N=66) Grade Grade All % >= 3 % All % >= 3 % Skin and subcutaneous tissue disorders HFSR/PPE Rash Alopecia 67 30 24 22 7 2 12 3 2 2 0 0 General disorders and administration site conditions Asthenia/Fatigue Fever 52 21 4 0 39 11 2 2 Vascular disorders Hypertension Hemorrhage 59 11 28 4 27 3 5 0 Gastrointestinal disorders Diarrhea Mucositis Nausea Vomiting 47 40 20 17 8 2 2 <1 9 8 12 8 0 2 2 0 Respiratory, thoracic and mediastinal disorders Dysphonia 39 0 9 0 Infections and infestations Infection 32 5 5 0 Metabolism and nutrition disorders Decreased appetite and food intake Hypothyroidism 31 18 <1 0 21 6 3 0 Nervous system disorders Headache 16 0 9 0 Investigations Weight loss 14 0 8 0 Musculoskeletal and connective tissue disorders Musculoskeletal stiffness 14 0 3 0 Laboratory abnormalities observed in Study 2 are shown in Table 4 .","The task cannot be completed because the input provided is ""nan"" which typically stands for ""not a number"" and does not contain any text or information related to a drug label from which to extract adverse drug event terms. If you provide an excerpt of a drug label, I can identify the adverse drug events for you."
STIVARGA,adverse reactions,"Table 4 Laboratory test abnormalities reported in Study 2 Laboratory Parameter Stivarga (N=132 ) Placebo (N=66 ) Grade Grade All % 3 % 4 % All % 3 % 4 % Blood and lymphatic system disorders Thrombocytopenia Neutropenia Lymphopenia 13 16 30 1 2 8 0 0 0 2 12 24 0 3 3 2 0 0 Metabolism and nutrition disorders Hypocalcemia Hypokalemia Hypophosphatemia 17 21 55 2 3 20 0 0 2 5 3 3 0 0 2 0 0 0 Hepatobiliary disorders Hyperbilirubinemia Increased AST Increased ALT 33 58 39 3 3 4 1 1 1 12 47 39 2 3 2 0 0 0 Renal and urinary disorders Proteinuria 33 3 - No Grade 4 denoted in CTCAE, v4.0. 30 3 - Investigations Increased Lipase 14 0 1 5 0 0 6.2 Postmarketing Experience The following adverse reaction has been identified during postapproval use of Stivarga. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:",hypersensitivity reaction
STIVARGA,boxed warnings,BOXED WARNING: WARNING: HEPATOTOXICITY,"If there is no text provided other than ""The input is nan"", then there are no adverse drug event terms to list. If ""nan"" here is intended to mean ""not a number"" or ""not applicable,"" then it can be assumed that the actual drug label or information containing adverse event terms was not provided. Therefore, no terms can be identified or returned as requested. If there is an excerpt that was meant to be included, please provide the text for analysis."
STIVARGA,boxed warnings,WARNING: HEPATOTOXICITY,"hepatotoxicity, fatal hepatotoxicity, elevated liver function tests, hepatocellular necrosis"
STIVARGA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Hemorrhage, Dermatological toxicity, Hypertension, Cardiac ischemia, Infarction, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), Gastrointestinal perforation, Fistulae, Wound healing complications, Embryofetal toxicity"
STIVARGA,warnings and precautions,5.1 Hepatotoxicity,"severe drug induced liver injury, fatal outcome, hepatocyte necrosis, lymphocyte infiltration, fatal hepatic failure, elevated liver function tests, hepatotoxicity"
STIVARGA,warnings and precautions,5.2 Hemorrhage,"increased incidence of hemorrhage, Fatal hemorrhage, severe or life-threatening hemorrhage"
STIVARGA,warnings and precautions,5.3 Dermatological Toxicity,"adverse reactions, skin and subcutaneous tissue reactions, hand-foot skin reaction (HFSR), palmar-plantar erythrodysesthesia (PPE), severe rash, Grade 3 HFSR, Grade 3 rash, serious adverse reactions, erythema multiforme, Stevens Johnson Syndrome, Toxic epidermal necrolysis, dermatologic toxicity"
STIVARGA,warnings and precautions,5.4 Hypertension,"hypertension, hypertensive crisis"
STIVARGA,warnings and precautions,5.5 Cardiac Ischemia and Infarction,"myocardial ischemia, infarction, cardiac ischemia"
STIVARGA,warnings and precautions,5.6 Reversible Posterior Leukoencephalopathy Syndrome (RPLS),"Reversible Posterior Leukoencephalopathy Syndrome (RPLS), seizures, headache, visual disturbances, confusion, altered mental function"
STIVARGA,warnings and precautions,5.7 Gastrointestinal Perforation or Fistula,"Gastrointestinal perforation, fistula, fatal events"
STIVARGA,warnings and precautions,5.8 Wound Healing Complications,"impair wound healing, wound dehiscence"
STIVARGA,warnings and precautions,5.9 Embryo-Fetal Toxicity,"fetal harm, embryolethal, teratogenic, cardiovascular malformations, genitourinary malformations, skeletal malformations"
ANORO,adverse reactions,6 ADVERSE REACTIONS,"asthma-related death, paradoxical bronchospasm, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention, pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain"
ANORO,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions"
ANORO,adverse reactions,"6-Month Trials: The incidence of adverse reactions associated with ANORO ELLIPTA in Table 1 is based on four 6-month trials: 2 placebo-controlled trials (Trials 1 and 2; n = 1,532 and n = 1,489, respectively) and 2 active-controlled trials (Trials 3 and 4; n = 843 and n = 869, respectively). Of the 4,733 subjects, 68% were male and 84% were Caucasian. They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers. At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV1) was 48% (range: 13% to 76%), the mean post-bronchodilator FEV1/forced vital capacity (FVC) ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -45% to 109%).","This excerpt does not list any adverse drug event terms; it only mentions various doses and forms of a medication and a placebo without reporting any negative effects or adverse events. Therefore, there are no adverse drug event terms to list from this text."
ANORO,adverse reactions,Table 1. Adverse Reactions With ANORO ELLIPTA With >=1% Incidence and More Common Than With Placebo in Subjects With Chronic Obstructive Pulmonary Disease,"pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain, productive cough, dry mouth, dyspepsia, abdominal pain, gastroesophageal reflux disease, vomiting, musculoskeletal chest pain, chest discomfort, asthenia, atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, pruritus, rash, conjunctivitis, headache, back pain, cough, urinary tract infection, arthralgia, nausea, vertigo, pleuritic pain, viral respiratory tract infection, toothache, diabetes mellitus."
ANORO,boxed warnings,BOXED WARNING: WARNING: ASTHMA-RELATED DEATH,There is no input provided to identify adverse drug event terms. Please provide an excerpt of a drug label for me to analyze.
ANORO,boxed warnings,WARNING: ASTHMA-RELATED DEATH,"asthma-related death, increase in asthma-related deaths"
ANORO,boxed warnings,EXCERPT: WARNING: ASTHMA-RELATED DEATH,"asthma-related death, increase in asthma-related deaths"
ANORO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"asthma-related death, acutely deteriorating COPD, acute symptoms, overdose, paradoxical bronchospasm, cardiovascular disorders, convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, worsening of narrow-angle glaucoma, worsening of urinary retention, hypokalemia, hyperglycemia"
ANORO,warnings and precautions,5.1 Asthma-Related Death,"asthma-related death, increase in asthma-related deaths, Deterioration of Disease and Acute Episodes, rapidly deteriorating or potentially life-threatening episodes of COPD, acute symptoms, relief of acute symptoms, acute episodes of bronchospasm, deteriorating disease, symptoms of bronchoconstriction, less effective, markers of deterioration of disease"
ANORO,warnings and precautions,5.3 Excessive Use of ANORO ELLIPTA and Use With Other Long-Acting Beta2-Agonists,"overdose, clinically significant cardiovascular effects, fatalities"
ANORO,warnings and precautions,5.4 Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors,increased cardiovascular adverse effects
ANORO,warnings and precautions,5.5 Paradoxical Bronchospasm,"paradoxical bronchospasm, life threatening"
ANORO,warnings and precautions,5.6 Hypersensitivity Reactions,"Hypersensitivity reactions, anaphylactic reactions, severe milk protein allergy."
ANORO,warnings and precautions,5.7 Cardiovascular Effects,"increases in pulse rate, systolic blood pressure, diastolic blood pressure, electrocardiographic changes, flattening of the T wave, prolongation of the QTc interval, ST segment depression"
ANORO,warnings and precautions,5.8 Coexisting Conditions,"convulsive disorders, thyrotoxicosis, aggravate preexisting diabetes mellitus, ketoacidosis"
ANORO,warnings and precautions,5.9 Worsening of Narrow-Angle Glaucoma,"eye pain or discomfort, blurred vision, visual halos, colored images, red eyes, conjunctival congestion, corneal edema"
ANORO,warnings and precautions,5.10 Worsening of Urinary Retention,"urinary retention, difficulty passing urine, painful urination"
ANORO,warnings and precautions,5.11 Hypokalemia and Hyperglycemia,"hypokalemia, adverse cardiovascular effects, transient hyperglycemia"
VIMPAT,adverse reactions,6 ADVERSE REACTIONS,"Suicidal Behavior and Ideation, Dizziness, Ataxia, Cardiac Rhythm and Conduction Abnormalities, Syncope, Multiorgan Hypersensitivity Reactions, diplopia, headache, nausea"
VIMPAT,adverse reactions,6.1 Clinical Trials Experience,"dizziness, insomnia, headache, nausea, somnolence, fatigue, ataxia, vomiting, diplopia, vertigo, blurred vision, diarrhea, gait disturbance, asthenia, contusion, skin laceration, tremor, nystagmus, balance disorder, memory impairment, depression, pruritus, liver function tests abnormalities, ALT elevations, hepatitis, nephritis, neutropenia, anemia, palpitations, tinnitus, constipation, dyspepsia, dry mouth, oral hypoaesthesia, irritability, pyrexia, feeling drunk, fall, muscle spasms, paresthesia, cognitive disorder, hypoaesthesia, dysarthria, disturbance in attention, cerebellar syndrome, confusional state, mood altered, depressed mood, injection site pain, irritation, erythema, profound bradycardia."
VIMPAT,adverse reactions,"Table 3: Adverse Reactions in a 15-minute Infusion Study in Patients with Partial-Onset Seizures System Organ Class/Preferred Term VIMPAT 200 mgN=25% VIMPAT 300 mgN=50% VIMPAT 400 mgN=25% VIMPAT TotalN=100% Eye disorders Diplopia 4 6 20 9 Blurred Vision 0 4 12 5 Gastrointestinal disorders Nausea 0 16 24 14 Dry mouth 0 6 12 6 Vomiting 0 4 12 5 Oral Paresthesia 4 4 8 5 Oral Hypoesthesia 0 6 8 5 Diarrhea 0 8 0 4 General disorders/administration site conditions Fatigue 0 18 12 12 Gait disturbance 8 2 0 3 Chest pain 0 0 12 3 Nervous system disorders Dizziness 20 46 60 43 Somnolence 0 34 36 26 Headache 8 4 16 8 Paresthesia 8 6 4 6 Tremor 0 6 4 4 Abnormal Coordination 0 6 0 3 Skin & subcutaneous tissue disorders Pruritus 0 6 4 4 Hyperhidrosis 0 0 8 2 Adverse reactions that occurred with infusion of VIMPAT 200 mg over 15-minutes followed by VIMPAT 100 mg administered orally twice per day were similar in frequency to those that occurred in 3-month adjunctive therapy controlled trials. Considering the difference in period of observations (1 week vs. 3 months), the incidence of CNS adverse reactions, such as dizziness, somnolence, and paresthesia may be higher with 15-minute administration of VIMPAT Injection than with administration over a 30-to 60-minute period.",nan
VIMPAT,adverse reactions,6.2 Postmarketing Experience,"agranulocytosis, aggression, agitation, hallucination, insomnia, psychotic disorder, angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis"
VIMPAT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"suicidal behavior, ideation, dizziness, ataxia, Cardiac Rhythm and Conduction Abnormalities, syncope, increased seizure frequency, Multiorgan Hypersensitivity Reactions"
VIMPAT,warnings and precautions,5.1 Suicidal Behavior and Ideation,"suicidal thoughts, behavior, depression, mood changes, suicidal behavior, ideation, suicides, worsening of depression, unusual changes in mood or behavior, signs and symptoms of depression, emergence of suicidal thoughts, thoughts about self-harm"
VIMPAT,warnings and precautions,5.2 Dizziness and Ataxia,"dizziness, ataxia"
VIMPAT,warnings and precautions,5.3 Cardiac Rhythm and Conduction Abnormalities,"PR interval prolongation, first-degree atrioventricular (AV) block, second degree AV block, complete AV block, profound bradycardia, third degree AV block, Atrial fibrillation, Atrial flutter"
VIMPAT,warnings and precautions,5.4 Syncope,"syncope, loss of consciousness, changes in orthostatic blood pressure, atrial flutter, fibrillation, tachycardia, bradycardia"
VIMPAT,warnings and precautions,5.5 Withdrawal of Antiepileptic Drugs (AEDs),increased seizure frequency
VIMPAT,warnings and precautions,5.6 Multiorgan Hypersensitivity Reactions,"symptomatic hepatitis, nephritis, rash, elevated liver enzymes, myocarditis, multiorgan hypersensitivity reaction, fever, eosinophilia, lymphadenopathy, organ system involvement"
VIMPAT,warnings and precautions,5.7 Phenylketonurics,"aspartame, phenylalanine"
BANZEL,adverse reactions,6 ADVERSE REACTIONS,"Suicidal Behavior and Ideation, Central Nervous System Reactions, QT Shortening, Multi-Organ Hypersensitivity/Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Leukopenia, headache, dizziness, fatigue, somnolence, nausea"
BANZEL,adverse reactions,6.1 Clinical Trials Experience,"headache, dizziness, fatigue, somnolence, nausea"
BANZEL,adverse reactions,Table 2 lists adverse reactions that occurred in at least 3% of pediatric patients (ages 3 to less than 17 years) with epilepsy treated with BANZEL in controlled adjunctive studies and were numerically more common in patients treated with BANZEL than in patients on placebo.,"somnolence, vomiting, headache"
BANZEL,adverse reactions,"Table 2: Adverse Reactions in Pediatric Patients (Ages 3 to less than 17 years) in Pooled Double-Blind Adjunctive Trials Adverse Reaction BANZEL (N=187) % Placebo (N=182) % Somnolence 17 9 Vomiting 17 7 Headache 16 8 Fatigue 9 8 Dizziness 8 6 Nausea 7 3 Influenza 5 4 Nasopharyngitis 5 3 Decreased Appetite 5 2 Rash 4 2 Ataxia 4 1 Diplopia 4 1 Bronchitis 3 2 Sinusitis 3 2 Psychomotor Hyperactivity 3 1 Upper Abdominal Pain 3 2 Aggression 3 2 Ear Infection 3 1 Disturbance in Attention 3 1 Pruritis 3 0 Table 3 lists adverse reactions that occurred in at least 3% of adult patients with epilepsy treated with BANZEL (up to 3200 mg per day) in adjunctive controlled studies and were numerically more common in patients treated with BANZEL than in patients on placebo. In these studies, either BANZEL or placebo was added to the current AED therapy.","dizziness, fatigue, nausea, diplopia, vision blurred, ataxia"
BANZEL,adverse reactions,Table 3: Adverse Reactions in Adults in Pooled Double-Blind Adjunctive Trials Adverse Reaction BANZEL (N=823) % Placebo (N=376) % Headache 27 26 Dizziness 19 12 Fatigue 16 10 Nausea 12 9 Somnolence 11 9 Diplopia 9 3 Tremor 6 5 Nystagmus 6 5 Blurred Vision 6 2 Vomiting 5 4 Ataxia 4 0 Upper Abdominal Pain 3 2 Anxiety 3 2 Constipation 3 2 Dyspepsia 3 2 Back Pain 3 1 Gait Disturbance 3 1 Vertigo 3 1 Discontinuation in Controlled Clinical Studies,"adverse drug event, adverse reaction, discontinued, discontinuation"
BANZEL,adverse reactions,"Table 4: Most Common Adverse Reactions Leading to Discontinuation in Pediatric Patients (Ages 4 to less than 17 years) in Pooled Double-Blind Adjunctive Trials Adverse Reaction BANZEL (N=187) % Placebo (N=182) % Convulsion 2 1 Rash 2 1 Fatigue 2 0 Vomiting 1 0 In adult double-blind, adjunctive clinical studies, 10% of patients receiving BANZEL as adjunctive therapy (at doses up to 3200 mg per day) and 6% receiving placebo discontinued as a result of an adverse reaction. The adverse reactions most commonly leading to discontinuation of BANZEL (>1%) used as adjunctive therapy are presented in Table 5.","As no input text has been provided from a drug label, I'm unable to extract adverse drug event terms. Please provide the text from a drug label for me to assist you with this task.
"
BANZEL,adverse reactions,Table 5: Most Common Adverse Reactions Leading to Discontinuation in Adult Patients in Pooled Double-Blind Adjunctive Trials Adverse Reaction BANZEL (N=823) % Placebo (N=376) % Dizziness 3 1 Fatigue 2 1 Headache 2 1 Nausea 1 0 Ataxia 1 0 Pediatric Patients age s 1 to less than 4 years,"vomiting, somnolence, bronchitis, constipation, cough, decreased appetite, rash, otitis media, pneumonia, decreased weight, gastroenteritis, nasal congestion, pneumonia aspiration, anemia, lymphadenopathy, leukopenia, neutropenia, iron deficiency anemia, thrombocytopenia, bundle branch block right, atrioventricular block first degree, increased appetite, pollakiuria, urinary incontinence, dysuria, hematuria, nephrolithiasis, polyuria, enuresis, nocturia, incontinence"
BANZEL,adverse reactions,6.2 Post m arketing Experience,"Stevens-Johnson syndrome, serious skin rashes with mucosal involvement"
BANZEL,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"depression, suicidal thoughts/behavior, unusual changes in mood or behavior, Central nervous system reactions, multi-organ hypersensitivity reaction, precipitating seizures, seizure exacerbation, status epilepticus"
BANZEL,warnings and precautions,5.1 Suicidal Behavior and Ideation,"suicidal thoughts, suicidal behavior, depression, unusual changes in mood or behavior, suicidal thinking, suicidal ideation, emergence of suicidal thoughts, worsening of depression, emergence of suicidal behavior, signs and symptoms of depression, thoughts about self-harm."
BANZEL,warnings and precautions,5.2 C entral Nervous System Reactions,"somnolence, fatigue, coordination abnormalities, dizziness, gait disturbances, ataxia"
BANZEL,warnings and precautions,5.3 QT Shortening,"shortening of the QT interval, QT shortening, sudden death, ventricular arrhythmias, ventricular fibrillation"
BANZEL,warnings and precautions,5.4 Multi-organ Hypersensitivity /Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS),"DRESS, multi-organ hypersensitivity, fatal, life-threatening, fever, rash, lymphadenopathy, hepatitis, nephritis, hematological abnormalities, myocarditis, myositis, acute viral infection, Eosinophilia, hypersensitivity"
BANZEL,warnings and precautions,5.5 Withdrawal of AEDs,"precipitating seizures, seizure exacerbation, status epilepticus"
BANZEL,warnings and precautions,5.6 Status Epilepticus,"treatment emergent status epilepticus, episodes that could be described as status epilepticus"
BANZEL,warnings and precautions,5.7 Leukopenia,"reduce white cell count, Leukopenia"
XELJANZ,adverse reactions,6 ADVERSE REACTIONS,"upper respiratory tract infections, headache, diarrhea, nasopharyngitis"
XELJANZ,adverse reactions,6.1 Clinical Trial Experience,"serious infections, upper respiratory tract infections, nasopharyngitis, urinary tract infections, pneumonia, cellulitis, herpes zoster, tuberculosis, opportunistic infections, malignancies, lymphopenia, neutropenia, liver enzyme elevations, lipid elevations, serum creatinine elevations"
XELJANZ,adverse reactions,Table 4: Adverse Reactions Occurring in at Least 2% or More of Patients on 5 or 10 mg Twice Daily XELJANZ With or Without DMARD (0-3 months) and at Least 1% Greater Than That Observed in Patients on Placebo XELJANZ5 mg Twice Daily XELJANZ10 mg Twice Daily Placebo Preferred Term N = 1336(%) N = 1349(%) N = 809(%) N reflects randomized and treated patients from the seven clinical trials Diarrhea 4.0 2.9 2.3 Nasopharyngitis 3.8 2.8 2.8 Upper respiratory tract infection 4.5 3.8 3.3 Headache 4.3 3.4 2.1 Hypertension 1.6 2.3 1.1 Other adverse reactions occurring in controlled and open-label extension studies included:,"Anemia, Diverticulitis, Dehydration, Insomnia, Paresthesia, Dyspnea, Cough, Sinus congestion, Abdominal pain, Dyspepsia, Vomiting, Gastritis, Nausea, Hepatic steatosis, Rash, Erythema, Pruritus, Musculoskeletal pain, Arthralgia, Tendonitis, Joint swelling, Non-melanoma skin cancers, Pyrexia, Fatigue, Peripheral edema"
XELJANZ,boxed warnings,BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY,"The input provided is ""nan,"" which usually stands for ""not a number"" or is used to indicate that no information is present. It appears there is no excerpt of a drug label to extract adverse drug event terms from. Therefore, I cannot provide a list of terms without the actual content. If you have a drug label excerpt, please provide it so I can assist you further."
XELJANZ,boxed warnings,WARNING: SERIOUS INFECTIONS AND MALIGNANCY,"If the input is ""nan"" which typically stands for ""not applicable"" or ""not available,"" and no actual drug label text has been provided, then there is no information to extract adverse drug event terms from.

If ""nan"" is a mistake and you have an excerpt you'd like analyzed, please provide the excerpt for review."
XELJANZ,boxed warnings,EXCERPT: WARNING: SERIOUS INFECTIONS AND MALIGNANCY,"serious infections, hospitalization, death, tuberculosis, bacterial infections, invasive fungal infections, viral infections, opportunistic infections, lymphoma, malignancies, Epstein Barr Virus-associated post-transplant lymphoproliferative disorder"
XELJANZ,boxed warnings,SERIOUS INFECTIONS,"serious infections, hospitalization, death, Active tuberculosis, pulmonary disease, extrapulmonary disease, Invasive fungal infections, cryptococcosis, pneumocystosis, Bacterial infections, viral infections, opportunistic pathogens, chronic infection, recurrent infection, tuberculosis"
XELJANZ,boxed warnings,MALIGNANCIES,"Lymphoma, malignancies, Epstein Barr Virus-associated post-transplant lymphoproliferative disorder"
XELJANZ,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"active serious infection, localized infections, Gastrointestinal Perforations, changes in lymphocytes, changes in neutrophils, changes in hemoglobin, changes in liver enzymes, changes in lipids"
XELJANZ,warnings and precautions,5.1 Serious Infections,"fatal infections, bacterial infections, mycobacterial infections, invasive fungal infections, viral infections, opportunistic pathogens, pneumonia, cellulitis, herpes zoster, urinary tract infection, diverticulitis, tuberculosis, cryptococcosis, esophageal candidiasis, pneumocystosis, multidermatomal herpes zoster, cytomegalovirus, BK virus, disseminated disease, localized disease, histoplasmosis, coccidioidomycosis, listeriosis, chronic infection, recurrent infection, serious infection, opportunistic infection, sepsis, latent tuberculosis, active tuberculosis, viral reactivation, herpes virus reactivation, chronic viral hepatitis reactivation, hepatitis B, hepatitis C."
XELJANZ,warnings and precautions,5.2 Malignancy and Lymphoproliferative Disorders,"malignancy, solid cancers, lymphoma, Epstein Barr Virus-associated post-transplant lymphoproliferative disorder, Non-Melanoma Skin Cancer"
XELJANZ,warnings and precautions,5.3 Gastrointestinal Perforations,"gastrointestinal perforation, diverticulitis, new onset abdominal symptoms"
XELJANZ,warnings and precautions,5.4 Laboratory Abnormalities,"lymphocytosis, lymphocyte abnormalities, decreased mean absolute lymphocyte counts, lymphocyte counts less than 500 cells/mm^3, increased incidence of treated and serious infections, neutropenia, neutrophil count less than 2000 cells/mm^3, ANC less than 1000 cells/mm^3, persistent ANC of 500-1000 cells/mm^3, ANC less than 500 cells/mm^3, anemia, low hemoglobin level, hemoglobin levels less than 8 g/dL, liver enzyme elevation, drug-induced liver injury, lipid elevations, increases in total cholesterol, increased low-density lipoprotein (LDL) cholesterol, increased high-density lipoprotein (HDL) cholesterol."
XELJANZ,warnings and precautions,5.5 Vaccinations,"secondary transmission of infection, Avoid use of live vaccines"
GATTEX,adverse reactions,6 ADVERSE REACTIONS,"abdominal pain, injection site reactions, nausea, headaches, abdominal distension, upper respiratory tract infection, vomiting, fluid overload"
GATTEX,adverse reactions,6.1 Clinical Trials Experience,"abdominal pain, injection site reactions, nausea, headaches, abdominal distension, upper respiratory tract infection"
GATTEX,adverse reactions,"Table 1: Adverse reactions in >=5% of GATTEX-treated SBS subjects and more frequent than placebo: Studies 1 and 3 Adverse Reaction Placebo(N=59)n (%) GATTEX0.05mg/kg/day(N=77)n (%) Abdominal Pain 16 ( 27.1) 29 ( 37.7) Upper Respiratory Tract Infection 8 ( 13.6) 20 ( 26.0) Nausea 12 ( 20.3) 19 ( 24.7) Abdominal Distension 1 ( 1.7) 15 ( 19.5) Vomiting 6 ( 10.2) 9 ( 11.7) Fluid Overload 4 ( 6.8) 9 ( 11.7) Flatulence 4 ( 6.8) 7 ( 9.1) Hypersensitivity 3 ( 5.1) 6 ( 7.8) Appetite Disorders 2 ( 3.4) 5 ( 6.5) Sleep Disturbances 0 4 ( 5.2) Cough 0 4 ( 5.2) Skin Hemorrhage 1 ( 1.7) 4 ( 5.2) Subjects with Stoma Gastrointestinal Stoma Complication 3 (13.6) 13 (41.9) In placebo-controlled Studies 1 and 3, 12% of patients in each of the placebo and GATTEX study groups experienced an injection site reaction.","malignancy, metastatic adenocarcinoma, lung cancers, polyps, colorectal villous adenomas, hyperplastic polyp, small duodenal polyp, intestinal obstruction/stenosis, cholecystitis, gallbladder perforation, cholelithiasis, cholestasis, pancreatic pseudocyst, chronic pancreatitis, acute pancreatitis, fluid overload, congestive heart failure, cognition and attention disturbances, coma"
GATTEX,adverse reactions,6.2 Immunogenicity,"immunogenic properties, antibodies, anti-GATTEX antibody, cross-reactive, neutralizing antibodies, immunogenicity incidence rate, false negatives, Immunogenicity assay results"
GATTEX,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"neoplastic growth, intestinal malignancy, intestinal obstruction, biliary and pancreatic disease, fluid overload"
GATTEX,warnings and precautions,5.1 Acceleration of Neoplastic Growth,"hyperplastic changes, neoplasia, colorectal polyps, small bowel neoplasia, colorectal cancer, small bowel cancer"
GATTEX,warnings and precautions,5.2 Intestinal Obstruction,"intestinal obstruction, stomal obstruction"
GATTEX,warnings and precautions,5.3 Biliary and Pancreatic Disease,"Cholecystitis, cholangitis, cholelithiasis, Pancreatitis"
GATTEX,warnings and precautions,5.4 Fluid Overload,"Fluid overload, congestive heart failure, significant cardiac deterioration"
GATTEX,warnings and precautions,5.5 Increased Absorption of Concomitant Oral Medication,"Altered mental status, Adverse Reactions"
XOFIGO,adverse reactions,6 ADVERSE REACTIONS,"nausea, diarrhea, vomiting, peripheral edema, anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia"
XOFIGO,adverse reactions,6.1 Clinical Trials Experience,"nausea, diarrhea, vomiting, peripheral edema, Grade 3 and 4 adverse events, anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia"
XOFIGO,adverse reactions,Table 3 shows adverse reactions occurring in >= 2% of patients and for which the incidence for Xofigo exceeds the incidence for placebo.,"If the input is ""nan"" (which typically indicates ""not a number"" or a missing value in data), then there is no text provided to extract adverse drug event terms from. Therefore, there are no terms to return. If this was not the intended input and there is supposed to be text from a drug label provided, please provide the actual excerpt for analysis."
XOFIGO,adverse reactions,Table 3: Adverse Reactions in the Randomized Trial System/Organ ClassPreferred Term Xofigo (n=600) Placebo (n=301) Grades 1-4% Grades 3-4% Grades 1-4% Grades 3-4% Blood and lymphatic system disorders Pancytopenia 2 1 0 0 Gastrointestinal disorders Nausea 36 2 35 2 Diarrhea 25 2 15 2 Vomiting 19 2 14 2 General disorders and administration site conditions Peripheral edema 13 2 10 1 Renal and urinary disorders Renal failure and impairment 3 1 1 1 Laboratory Abnormalities Table 4 shows hematologic laboratory abnormalities occurring in > 10% of patients and for which the incidence for Xofigo exceeds the incidence for placebo.,"The input you provided is ""nan,"" which stands for 'not a number'. This term is often used to indicate that a value is undefined or not representable, especially in data processing. As no actual drug label text was provided, I cannot extract any adverse drug event terms. If you provide an excerpt from a drug label, I can then identify any adverse drug event terms within the text."
XOFIGO,adverse reactions,Table 4: Hematologic Laboratory Abnormalities,"anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia, dehydration, erythema, pain, edema, secondary malignant neoplasms"
XOFIGO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Bone Marrow Suppression, hematologic values do not recover, life-threatening complications"
XOFIGO,warnings and precautions,5.1 Bone Marrow Suppression,"bone marrow failure, pancytopenia, deaths, bone marrow suppression, vascular hemorrhage, myelosuppression, infection-related deaths, serious infections, febrile neutropenia, thrombocytopenia, neutropenia, leukopenia, life-threatening complications"
SYNRIBO,adverse reactions,6 ADVERSE REACTIONS,"myelosuppression, bleeding, hyperglycemia, thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, lymphopenia"
SYNRIBO,adverse reactions,6.1 Clinical Trials Experience,"pancytopenia, thrombocytopenia, increased alanine aminotransferase"
SYNRIBO,adverse reactions,"Table 2: Adverse Reactions OccurringOccurred in the period between the first dose and 30 days after the last dose. in at Least 10% of Patients (Chronic Myeloid Leukemia - Chronic Phase) Number (%) of Patients(N=108) Adverse reactions All reactions Grade 3 or 4 reactions Patients with at least 1 commonly occurring adverse reaction 107 (99) 94 (87) Blood and Lymphatic System Disorders Thrombocytopenia 82 (76) 73 (68) Anemia 66 (61) 39 (36) Neutropenia 57 (53) 51 (47) Lymphopenia 18 (17) 17 (16) Bone Marrow Failure 11 (10) 11 (10) Febrile Neutropenia 11 (10) 11 (10) Gastrointestinal Disorders Diarrhea 44 (41) 1 (1) Nausea 38 (35) 1 (1) Constipation 15 (14) 0 Abdominal Pain/Upper Abdominal Pain 25 (23) 0 Vomiting 13 (12) 0 General Disorders and Administration Site Conditions Fatigue 31 (29) 5 (5) Pyrexia 27 (25) 1 (1) Asthenia 25 (23) 1 (1) Edema Peripheral 17 (16) 0 ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7fe5e1c95578>, 'list': <function print_list at 0x7fe5e1c95d70>, 'text': <function print_text at 0x7fe5e1c955f0>, 'caption': <function print_caption at 0x7fe5e1c959b0>} Infusion and injection site related reactions 38 (35) 0 Infections and InfestationsInfection includes bacterial, viral, fungal, and non-specified. 52 (48) 12 (11) Metabolism and Nutrition Disorders Anorexia 11 (10) 1 (1) Musculoskeletal and Connective Tissue Disorders Arthralgia 20 (19) 1 (1) Pain in Extremity 14 (13) 1 (1) Back Pain 13 (12) 2 (2) Myalgia 12 (11) 1 (1) Nervous System Disorders Headache 22 (20) 1 (1) Psychiatric Disorders Insomnia 13 (12) 1 (1) Respiratory, Thoracic and Mediastinal Disorders Cough 17 (16) 1 (1) Epistaxis 18 (17) 1 (1) Skin and Subcutaneous Tissue Disorders Alopecia 16 (15) 0 Rash 12 (11) 0 Serious adverse reactions were reported for 51% of patients. Serious adverse reactions reported for at least 5% of patients were bone marrow failure and thrombocytopenia (each 10%), and febrile neutropenia (6%). Serious adverse reactions of infections were reported for 8% of patients.","deaths, cerebral hemorrhage, multi-organ failure, progression of disease, cycle delay, adverse reactions, withdrawal, leukocytosis, thrombocytopenia, Grade 3 or Grade 4 treatment emergent adverse reaction"
SYNRIBO,adverse reactions,"Table 3: Adverse Reactions OccurringOccurred in the period between the first dose and 30 days after the last dose. in at Least 10% of Patients (Chronic Myeloid Leukemia - Accelerated Phase) Number (%) of Patients(N=55) Adverse reactions All reactions Grade 3 or 4 reactions Patients with at least 1 commonly occurring adverse reaction 55 (100) 47 (86) Blood and Lymphatic System Disorders Anemia 28 (51) 21 (38) Febrile Neutropenia 11 (20) 9 (16) Neutropenia 11 (20) 10 (18) Thrombocytopenia 32 (58) 27 (49) Gastrointestinal Disorders Diarrhea 19 (35) 4 (7) Nausea 16 (29) 2 (4) Vomiting 9 (16) 1 (2) Abdominal Pain/Upper Abdominal Pain 9 (16) 0 General Disorders and Administration Site Conditions Fatigue 17 (31) 5 (9) Pyrexia 16 (29) 1 (2) Asthenia 13 (24) 1 (2) Chills 7 (13) 0 ast_print:dispatch: unexpected key: ""footnote"" in dispatch table: {'*item_func*': <function ignore_element at 0x7fe5e1c95578>, 'list': <function print_list at 0x7fe5e1c95d70>, 'text': <function print_text at 0x7fe5e1c955f0>, 'caption': <function print_caption at 0x7fe5e1c959b0>} Infusion and injection site related reactions 12 (22) 0 Infections and InfestationsInfection includes bacterial, viral, fungal, and non-specified. 31 (56) 11 (20) Metabolism and Nutrition Disorders Anorexia 7 (13) 1 (2) Musculoskeletal and Connective Tissue Disorders Pain in Extremity 6 (11) 1 (2) Nervous System Disorders Headache 7 (13) 0 Respiratory, Thoracic and Mediastinal Disorders Cough 8 (15) 0 Dyspnea 6 (11) 1 (2) Epistaxis 6 (11) 1 (2) Serious adverse reactions were reported for 60% of patients. Serious adverse reactions reported for at least 5% of patients were febrile neutropenia (18%), thrombocytopenia (9%), anemia (7%), and diarrhea (6%). Serious adverse reactions of infections were reported for 11% of patients.","cerebral hemorrhage, progression of disease, laboratory abnormalities, myelosuppression, pancytopenia, thrombocytopenia, febrile neutropenia, bone marrow necrosis, hyperosmolar non-ketotic hyperglycemia, elevated transaminases"
SYNRIBO,adverse reactions,"Table 4: Grade 3/4 Laboratory Abnormalities in Clinical Studies in Patients with Chronic Phase and Accelerated Phase CML Chronic Phase Accelerated Phase % % Hematology Parameters Hemoglobin Decreased 62 72 80 Leukocytes Decreased 61 Neutrophils Decreased 81 85 71 Platelets Decreased 88 Biochemistry Parameters Alanine aminotransferase (ALT) Increased 6 2 Bilirubin Increased Creatinine Increased 9 9 6 16 Glucose Increased 10 15 Uric Acid Increased 56 57 Glucose Decreased 8 6 6.2 Additional Data From Safety Population The following adverse reactions were reported in patients in the SYNRIBO clinical studies of patients with chronic phase and accelerated phase CML at a frequency of 1% to less than 10%. Within each category, adverse reactions are ranked on the basis of frequency.","tachycardia, palpitations, acute coronary syndrome, angina pectoris, arrhythmia, bradycardia, ventricular extrasystoles, ear pain, ear hemorrhage, tinnitus, cataract, vision blurred, conjunctival hemorrhage, dry eye, lacrimation increased, conjunctivitis, diplopia, eye pain, eyelid edema, stomatitis, mouth ulceration, abdominal distension, dyspepsia, gastroesophageal reflux disease, gingival bleeding, aphthous stomatitis, dry mouth, hemorrhoids, gastritis, gastrointestinal hemorrhage, melena, mouth hemorrhage, oral pain, anal fissure, dysphagia, gingival pain, gingivitis, mucosal inflammation, pain, chest pain, hyperthermia, influenza-like illness, catheter site pain, general edema, malaise, hypersensitivity, contusion, transfusion reaction, decreased appetite, diabetes mellitus, gout, dehydration, bone pain, myalgia, muscular weakness, muscle spasms, musculoskeletal chest pain, musculoskeletal pain, musculoskeletal stiffness, musculoskeletal discomfort, dizziness, cerebral hemorrhage, paresthesia, convulsion, hypoesthesia, lethargy, sciatica, burning sensation, dysgeusia, tremor, anxiety, depression, agitation, confusional state, mental status change, dysuria, pharyngolaryngeal pain, nasal congestion, dysphonia, productive cough, rales, rhinorrhea, hemoptysis, sinus congestion, erythema, pruritus, dry skin, petechiae, hyperhidrosis, night sweats, ecchymosis, purpura, skin lesion, skin ulcer, rash erythematous, rash papular, skin exfoliation, skin hyperpigmentation, hematoma, hypertension, hot flush, hypotension."
SYNRIBO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"myelosuppression, thrombocytopenia, neutropenia, anemia, bleeding, hemorrhage, fatal cerebral hemorrhage, gastrointestinal hemorrhage, hyperglycemia, glucose intolerance, hyperosmolar non-ketotic hyperglycemia, embryo-fetal toxicity, fetal harm"
SYNRIBO,warnings and precautions,5.1 Myelosuppression,"thrombocytopenia, neutropenia, anemia, myelosuppression, infections, fever"
SYNRIBO,warnings and precautions,5.2 Bleeding,"severe thrombocytopenia, hemorrhage, Grade 3 and 4 thrombocytopenia, fatalities from cerebral hemorrhage, severe, non-fatal, gastrointestinal hemorrhages, bleeding events"
SYNRIBO,warnings and precautions,5.3 Hyperglycemia,"glucose intolerance, Grade 3 or 4 hyperglycemia, Hyperosmolar non-ketotic hyperglycemia"
SYNRIBO,warnings and precautions,5.4 Embryo-Fetal Toxicity,"fetal harm, embryo-fetal death, potential hazard to the fetus"
ICLUSIG,adverse reactions,6 ADVERSE REACTIONS,"Vascular Occlusion, Heart Failure, Hepatotoxicity, Hypertension, Pancreatitis, Neuropathy, Ocular Toxicity, Hemorrhage, Fluid Retention, Cardiac Arrhythmias, Myelosuppression, arterial ischemia, cardiac failure, peripheral neuropathy, hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, pyrexia, thrombocytopenia, infections, neutropenia, lipase increased, ALT increased, AST increased, GGT increased"
ICLUSIG,adverse reactions,"Table 5: Adverse Reactions Occurring in >10% of Patients, Any Group CP-CML(N=270) AP-CML(N=85) BP-CML(N=62) Ph+ ALL(N=32) System Organ Class Any Grade(%) CTCAE Grade3 / 4(%) Any Grade(%) CTCAE Grade3 / 4(%) Any Grade(%) CTCAE Grade3 / 4(%) Any Grade(%) CTCAE Grade3 / 4(%) Adverse drug reactions, reported using MedDRA and graded using NCI-CTC-AE v 4.0 (NCI Common Terminology Criteria for Adverse Events) for assessment of toxicity. Treatment-emergent, all causality events Cardiac or Vascular disorders Hypertension 68 39 71 36 65 26 53 31 Arterial ischemia 20 11 19 9 10 5 3 0 Cardiac Failure 7 4 6 4 15 8 6 3 Gastrointestinal disorders Abdominal pain 49 10 40 8 34 6 44 6 Constipation 37 2 24 2 26 0 47 3 Nausea 23 1 27 0 32 2 22 0 Diarrhea 16 1 26 0 18 3 13 3 Vomiting 13 2 24 0 23 2 22 0 Oral mucositis 10 1 15 1 23 0 9 3 GI hemorrhage 2 <1 8 1 11 5 9 6 Blood and lymphatic system disorders Febrile neutropenia 1 <1 4 4 11 11 25 25 Infections and infestations Sepsis 1 1 5 5 8 8 22 22 Pneumonia 3 2 11 9 13 11 9 3 Urinary tract infection 7 1 12 1 0 0 9 0 Upper respiratory tract infection 11 1 8 0 11 2 0 0 Nasopharyngitis 9 0 12 0 3 0 3 0 Cellulitis 2 1 4 2 11 3 0 0 Nervous system disorders Headache 39 3 28 0 31 3 25 0 Peripheral neuropathy 16 2 11 1 8 0 6 0 Dizziness 11 0 5 0 5 0 3 0 Respiratory, thoracic, and mediastinal disorders Pleural effusion 3 1 11 2 13 0 19 3 Cough 12 0 17 0 18 0 6 0 Dyspnea 11 2 15 2 21 7 6 0 Skin and subcutaneous tissue disorders Rash and related conditions 54 5 48 8 39 5 34 6 Dry skin 39 2 27 1 24 2 25 0 Musculoskeletal and connective tissue disorders Arthralgia 26 2 31 1 19 0 13 0 Myalgia 22 1 20 0 16 0 6 0 Pain in extremity 17 2 17 0 13 0 9 0 Back pain 15 1 11 2 16 2 13 0 Muscle spasms 12 0 5 0 5 0 13 0 Bone pain 12 <1 12 1 11 3 9 3 General disorders and administration site conditions Fatigue or asthenia 39 3 36 6 35 5 31 3 Pyrexia 23 1 31 5 32 3 25 0 Edema, peripheral 13 <1 19 0 13 0 22 0 Pain 8 <1 7 0 16 3 6 3 Chills 7 0 11 0 13 2 9 0 Metabolism and nutrition disorders Decreased appetite 8 <1 12 1 8 0 31 0 Investigations Weight decreased 6 <1 7 0 5 0 13 0 Psychiatric disorders Insomnia 7 0 12 0 8 0 9 0 Table 6: Serious Adverse Reactions (SAR) N (%) Cardiovascular disorders Arterial ischemic event 53 (11.8%) Cardiovascular 28 (6.2%) Cerebrovascular 18 (4.0%) Peripheral vascular 16 (3.6%) Hemorrhage 22 (4.9%) CNS hemorrhage 10 (2.2%) Gastrointestinal hemorrhage 10 (2.2%) Cardiac failure 22 (4.9%) Effusions 13 (2.9%) Atrial fibrillation 11 (2.4%) Venous thromboembolism 10 (2.2%) Hypertension 8 (1.8%) Gastrointestinal disorders Pancreatitis 23 (5.1%) Abdominal pain 17 (3.8%) Blood and lymphatic system disorders Febrile neutropenia 13 (2.9%) Thrombocytopenia 13 (2.9%) Anemia 12 (2.7%) Infections Pneumonia 24 (5.3%) Sepsis 11 (2.4%) General Pyrexia 14 (3.1%) EXCERPT: The most common non-hematologic adverse reactions (>= 20%) were hypertension, rash, abdominal pain, fatigue, headache, dry skin, constipation, arthralgia, nausea, and pyrexia. Hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia ( 6 ).","SUSPECTED ADVERSE REACTIONS, Myelosuppression, thrombocytopenia, neutropenia, anemia"
ICLUSIG,adverse reactions,"Table 7: Incidence of Clinically Relevant Grade 3/4Reported using NCI-CTC-AE v 4.0 Hematologic Abnormalities Laboratory Test CP-CML(N=270)(%) AP-CML(N=85)(%) BP-CML(N=62)(%) Ph+ ALL(N=32)(%) ANC=absolute neutrophil count, Hgb=hemoglobin, WBC=white blood cell count Hematology Thrombocytopenia (platelet count decreased) 36 47 57 47 Neutropenia (ANC decreased) 24 51 55 63 Leukopenia (WBC decreased) 14 35 53 63 Anemia (Hgb decreased) 9 26 55 34 Lymphopenia 10 26 37 22 Table 8: Incidence of Clinically Relevant Non-Hematologic Laboratory Abnormalities Laboratory Test Safety PopulationN=449 Any Grade(%) CTCAE Grade 3/4(%) ALT=alanine aminotransferase, AST=aspartate aminotransferase. Liver function tests ALT increased 53 8 AST increased 41 4 Alkaline phosphatase increased 37 2 Albumin decreased 28 1 Bilirubin increased 19 1 Pancreatic enzymes Lipase increased 41 15 Amylase increased 3 <1 Chemistry Glucose increased 58 6 Phosphorus decreased 57 8 Calcium decreased 52 1 Sodium decreased 29 5 Glucose decreased 24 0 Potassium decreased 16 2 Potassium increased 15 2 Sodium increased 10 <1 Bicarbonate decreased 11 <1 Creatinine increased 7 <1 Calcium increased 5 0 Triglycerides increased 3 <1","If the input is ""nan,"" it likely means that it's not applicable or simply a placeholder indicating that there is no data provided. Without a proper excerpt of a drug label, I cannot identify any adverse drug event terms. Thus, no terms can be returned from the given input."
ICLUSIG,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hypertension, pancreatitis, neuropathy, ocular toxicity, hemorrhage, fluid retention, cardiac arrhythmias, myelosuppression, tumor lysis syndrome, compromised wound healing, gastrointestinal perforation, embryo-fetal toxicity"
ICLUSIG,warnings and precautions,5.1 Vascular Occlusion,"arterial thrombosis, venous thrombosis, occlusions, fatal myocardial infarction, stroke, stenosis, severe peripheral vascular disease, urgent revascularization procedures, vascular occlusion, recurrent or multi-site vascular occlusion, vascular occlusive events, heart failure, myocardial ischemic event, cerebrovascular occlusion, stenosis of large arterial vessels of the brain, peripheral arterial occlusive events, fatal mesenteric artery occlusion, life-threatening peripheral arterial disease, digital or distal extremity necrosis, amputations, venous thromboembolism, deep venous thrombosis, pulmonary embolism, superficial thrombophlebitis, retinal vein thrombosis"
ICLUSIG,warnings and precautions,5.2 Heart Failure,"fatal heart failure, serious heart failure, left ventricular dysfunction, any grade of heart failure"
ICLUSIG,warnings and precautions,5.3 Hepatotoxicity,"hepatotoxicity, liver failure, death, Fulminant hepatic failure, acute liver failure, Severe hepatotoxicity, aspartate aminotransferase (ALT) elevation, alanine aminotransferase (AST) elevation"
ICLUSIG,warnings and precautions,5.4 Hypertension,"treatment-emergent hypertension, hypertensive crisis, confusion, headache, chest pain, shortness of breath, Stage 1 hypertension, Stage 2 hypertension"
ICLUSIG,warnings and precautions,5.5 Pancreatitis,"Clinical pancreatitis, grade 3, discontinuation, treatment interruption, lipase elevation, abdominal symptoms"
ICLUSIG,warnings and precautions,5.6 Neuropathy,"peripheral neuropathy, paresthesia, hypoesthesia, hyperesthesia, cranial neuropathy, neuropathic pain, weakness"
ICLUSIG,warnings and precautions,5.7 Ocular Toxicity,"blindness, blurred vision, retinal toxicities, macular edema, retinal vein occlusion, retinal hemorrhage, conjunctival irritation, corneal irritation, dry eye, eye pain, visual blurring, cataracts, glaucoma, iritis, iridocyclitis, ulcerative keratitis"
ICLUSIG,warnings and precautions,5.8 Hemorrhage,"Serious bleeding events, fatalities, Hemorrhage, serious bleeding events, Cerebral hemorrhage, gastrointestinal hemorrhage, hemorrhagic events, grade 4 thrombocytopenia, severe hemorrhage"
ICLUSIG,warnings and precautions,5.9 Fluid Retention,"fluid retention, brain edema, pericardial effusion, pleural effusion, ascites, peripheral edema"
ICLUSIG,warnings and precautions,5.10 Cardiac Arrhythmias,"Symptomatic bradyarrhythmias, pacemaker implantation, complete heart block, sick sinus syndrome, atrial fibrillation with bradycardia and pauses, fainting, dizziness, chest pain, Supraventricular tachyarrhythmias, Atrial fibrillation, atrial flutter, supraventricular tachycardia, atrial tachycardia, palpitations"
ICLUSIG,warnings and precautions,5.11 Myelosuppression,"Severe myelosuppression, AP-CML, BP-CML, Ph+ALL, CP-CML"
ICLUSIG,warnings and precautions,5.12 Tumor Lysis Syndrome,"tumor lysis syndrome, hyperuricemia"
ICLUSIG,warnings and precautions,5.13 Compromised Wound Healing and Gastrointestinal Perforation,"gastrointestinal perforation, fistula"
ICLUSIG,warnings and precautions,5.14 Embryo-Fetal Toxicity,"fetal harm, embryo-fetal toxicity, potential hazard to the fetus"
SABRIL,adverse reactions,6 ADVERSE REACTIONS,"Vision Loss, Magnetic Resonance Imaging (MRI) Abnormalities in Infants, Neurotoxicity, Suicidal Behavior and Ideation, Withdrawal of Antiepileptic Drugs (AEDs), Anemia, Somnolence and Fatigue, Peripheral Neuropathy, Weight Gain, Edema, fatigue, somnolence, nystagmus, tremor, vision blurred, memory impairment, arthralgia, abnormal coordination, confusional state, increased weight, upper respiratory tract infection, aggression, diplopia, bronchitis, ear infection, otitis media acute"
SABRIL,adverse reactions,6.1 Clinical Trial Experience,"headache, somnolence, fatigue, dizziness, convulsion, nasopharyngitis, weight increased, upper respiratory tract infection, visual field defect, depression, tremor, nystagmus, nausea, diarrhea, memory impairment, insomnia, irritability, coordination abnormal, vision blurred, diplopia, vomiting, influenza, pyrexia, rash, infections, status epilepticus, developmental coordination disorder, dystonia, hypotonia, hypertonia"
SABRIL,adverse reactions,"Table 5. Treatment Emergent Adverse Reactions Occurring in >=2% and More than One Patient per SABRIL-Treated Group and More Frequently than in Placebo Patients (Studies 024 and 025) SABRIL dosage(mg/day) Body System Adverse Reaction 3000[N=134]% 6000[N=43]% Placebo[N=135]% Ear Disorders Tinnitus 2 0 1 Vertigo 2 5 1 Eye Disorders Vision blurred 13 16 5 Diplopia 7 16 3 Asthenopia 2 2 0 Eye pain 0 5 0 Gastrointestinal Disorders Diarrhoea 10 16 7 Nausea 10 2 8 Vomiting 7 9 6 Constipation 8 5 3 Abdominal pain upper 5 5 1 Dyspepsia 4 5 3 Stomach discomfort 4 2 1 Abdominal pain 3 2 1 Toothache 2 5 2 Abdominal distension 2 0 1 General Disorders Fatigue 23 40 16 Gait disturbance 6 12 7 Asthenia 5 7 1 Oedema peripheral 5 7 1 Fever 4 7 3 Chest pain 1 5 1 Thirst 2 0 0 Malaise 0 5 0 Infections Nasopharyngitis 14 9 10 Upper respiratory tract infection 7 9 6 Influenza 5 7 4 Urinary tract infection 4 5 0 Bronchitis 0 5 1 Injury Contusion 3 5 2 Joint sprain 1 2 1 Muscle strain 1 2 1 Wound secretion 0 2 0 Metabolism and Nutrition Disorders Increased appetite 1 5 1 Weight increased 6 14 3 Musculoskeletal Disorders Arthralgia 10 5 3 Back pain 4 7 2 Pain in extremity 6 2 4 Myalgia 3 5 1 Muscle twitching 1 9 1 Muscle spasms 3 0 1 Nervous System Disorders Headache 33 26 31 Somnolence 22 26 13 Dizziness 24 26 17 Nystagmus 13 19 9 Tremor 15 16 8 Memory impairment 7 16 3 Coordination abnormal 7 16 2 Disturbance in attention 9 0 1 Sensory disturbance 4 7 2 Hyporeflexia 4 5 1 Paraesthesia 7 2 1 Lethargy 4 7 2 Hyperreflexia 4 2 3 Hypoaesthesia 4 5 1 Sedation 4 0 0 Status epilepticus 2 5 0 Dysarthria 2 2 1 Postictal state 2 0 1 Sensory loss 0 5 0 Psychiatric Disorders Irritability 7 23 7 Depression 6 14 3 Confusional state 4 14 1 Anxiety 4 0 3 Depressed mood 5 0 1 Thinking abnormal 3 7 0 Abnormal behaviour 3 5 1 Expressive language disorder 1 7 1 Nervousness 2 5 2 Abnormal dreams 1 5 1 Reproductive System Dysmenorrhoea 9 5 3 Erectile dysfunction 0 5 0 Respiratory and Thoracic Disorders Pharyngolaryngeal pain 7 14 5 Cough 2 14 7 Pulmonary congestion 0 5 1 Sinus headache 6 2 1 Skin and Subcutaneous Tissue Disorders Rash 4 5 4 Pediatrics 10 to 16 years of age Table 6 lists adverse reactions from controlled clinical studies of pediatric patients receiving SABRIL or placebo as add-on therapy for refractory complex partial seizures. Adverse reactions that are listed occurred in at least 2% of SABRIL treated patients and more frequently than placebo. The median SABRIL dose was 49.4 mg/kg, (range of 8.0 - 105.9 mg/kg).","As you've provided the input as ""nan"" which stands for ""not a number"" and typically indicates a missing or non-applicable value, there is no text excerpt to analyze for adverse drug event terms. Therefore, I cannot return any terms. If you provide an actual excerpt of a drug label, I could then assist in identifying any adverse drug event terms within it."
SABRIL,adverse reactions,"Table 6. Treatment-Emergent Adverse Reactions Reported by >=2% of Pediatric CPS Patients (10 to 16 years of age) Treated with SABRIL and Higher than Placebo Body System Adverse Reaction All SABRIL[N=109]% Placebo[N=46]% Eye Disorders Diplopia 5 0 Vision blurred 3 0 Gastrointestinal Disorders Diarrhoea 6 2 Abdominal pain upper 3 0 Constipation 3 2 General Disorders Fatigue 9 4 Infections and Infestations Upper respiratory tract infection 10 4 Influenza 6 2 Otitis media 6 2 Investigations Weight increased 17 2 Nervous System Disorders Somnolence 6 2 Tremor 6 0 Nystagmus 5 2 Psychomotor hyperactivity 4 2 Psychiatric Disorders Abnormal behavior 6 2 Aggression 5 0 Disorientation 4 0 Reproduction and Breast Disorders Dysmenorrhea 3 0 Skin and Subcutaneous Tissue Disorders Acne 3 0 Infantile Spasms In a randomized, placebo-controlled IS study with a 5 day double-blind treatment phase (n=40), the adverse events reported by >5% of patients receiving SABRIL and that occurred more frequently than in placebo patients, were somnolence (SABRIL 45%, placebo 30%), bronchitis (SABRIL 30%, placebo 15%), ear infection (SABRIL 10%, placebo 5%), and otitis media acute SABRIL 10%, placebo 0%).","adverse events, treatment emergent adverse reactions"
SABRIL,adverse reactions,"Table 7. Treatment Emergent Adverse Reactions Occurring in >=5% of Infantile Spasms Patients SABRILLow Dose SABRIL High Dose Body System Adverse Reaction [N=114]% [N=108]% Eye Disorders (other than field or acuity changes) Strabismus 5 5 Conjunctivitis 5 2 Gastrointestinal Disorders Vomiting 14 20 Constipation 14 12 Diarrhea 13 12 General Disorders Fever 29 19 Infections Upper respiratory tract infection 51 46 Otitis media 44 30 Viral infection 20 19 Pneumonia 13 11 Candidiasis 8 3 Ear infection 7 14 Gastroenteritis viral 6 5 Sinusitis 5 9 Urinary tract infection 5 6 Influenza 5 3 Croup infectious 5 1 Metabolism & Nutrition Disorders Decreased appetite 9 7 Nervous System Disorders Sedation 19 17 Somnolence 17 19 Status epilepticus 6 4 Lethargy 5 7 Convulsion 4 7 Hypotonia 4 6 Psychiatric Disorders Irritability 16 23 Insomnia 10 12 Respiratory Disorders Nasal congestion 13 4 Cough 3 8 Skin and Subcutaneous Tissue Disorders Rash 8 11 6.2 Post Marketing Experience The following adverse reactions have been reported during post approval use of SABRIL worldwide. All adverse reactions that are not listed above as adverse reactions reported in clinical trials, that are not relatively common in the population and are not too vague to be useful are listed in this section. These reactions are reported voluntarily from a population of uncertain size; therefore, it is not possible to estimate their frequency or establish a causal relationship to drug exposure. Adverse reactions are categorized by system organ class.","Congenital cardiac defects, congenital external ear anomaly, congenital hemangioma, congenital hydronephrosis, congenital male genital malformation, congenital oral malformation, congenital vesicoureteric reflux, dentofacial anomaly, dysmorphism, fetal anticonvulsant syndrome, hamartomas, hip dysplasia, limb malformation, limb reduction defect, low set ears, renal aplasia, retinitis pigmentosa, supernumerary nipple, talipes, Deafness, Delayed puberty, Gastrointestinal hemorrhage, esophagitis, Developmental delay, facial edema, malignant hyperthermia, multi-organ failure, Cholestasis, Dystonia, encephalopathy, hypertonia, hypotonia, muscle spasticity, myoclonus, optic neuritis, dyskinesia, Acute psychosis, apathy, delirium, hypomania, neonatal agitation, psychotic disorder, Laryngeal edema, pulmonary embolism, respiratory failure, stridor, Angioedema, maculo-papular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis"
SABRIL,boxed warnings,BOXED WARNING: WARNING: VISION LOSS,"If the input is 'nan', which typically stands for 'not a number' or indicates that the information is not available or is missing, then it means there are no adverse drug event terms provided in the text for analysis. Therefore, no terms can be returned."
SABRIL,boxed warnings,WARNING: VISION LOSS,"permanent bilateral concentric visual field constriction, tunnel vision, decrease visual acuity, vision loss, severe vision loss, retinopathy, glaucoma"
SABRIL,boxed warnings,EXCERPT: WARNING: VISION LOSS,"progressive and permanent bilateral concentric visual field constriction, reduce visual acuity, vision loss, new and worsening vision loss, vision damage, permanent vision loss"
SABRIL,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Permanent vision loss, Abnormal MRI signal changes, Suicidal behavior and ideation, Withdrawal seizures, Anemia, Somnolence and fatigue"
SABRIL,warnings and precautions,5.1 Vision Loss,"vision loss, treatment failure"
SABRIL,warnings and precautions,5.2 SABRIL SHARE Program,"vision loss, abnormal MRI signal changes, increased T2 signal, restricted diffusion, motor abnormalities, neurotoxicity, brain histopathology, neurobehavioral abnormalities"
SABRIL,warnings and precautions,5.4 Neurotoxicity,"Vacuolation, intramyelinic edema (IME), swollen or degenerating axons, mineralization, gliosis, alterations in MRI, changes in visual and somatosensory evoked potentials (EP), decreased myelination, oligodendrocyte injury, increase in apoptosis, neurobehavioral abnormalities (convulsions, neuromotor impairment, learning deficits), hippocampal vacuolation, convulsions (in mature offspring), abnormal MRI signal changes, increased T2 signal, restricted diffusion"
SABRIL,warnings and precautions,5.5 Suicidal Behavior and Ideation,"suicidal thoughts, behavior, depression, unusual changes in mood, worsening of depression, suicidal ideation, suicidal behavior, emergence of suicidal thoughts, behavior, or thoughts about self-harm"
SABRIL,warnings and precautions,5.6 Withdrawal of Antiepileptic Drugs (AEDs),"complex partial seizures, infantile spasms"
SABRIL,warnings and precautions,5.7 Anemia,"anemia, declines in hemoglobin, decrease in hematocrit"
SABRIL,warnings and precautions,5.8 Somnolence and Fatigue,"somnolence, fatigue"
SABRIL,warnings and precautions,5.9 Peripheral Neuropathy,"peripheral neuropathy, numbness or tingling in the toes or feet, reduced distal lower limb vibration or position sensation, progressive loss of reflexes"
SABRIL,warnings and precautions,5.10 Weight Gain,"weight gain, edema"
SABRIL,warnings and precautions,5.11 Edema,"edema, peripheral edema"
VPRIV,adverse reactions,6 ADVERSE REACTIONS,"hypersensitivity reactions, headache, dizziness, abdominal pain, nausea, back pain, joint pain, prolonged activated PTT, fatigue/asthenia, pyrexia"
VPRIV,adverse reactions,6.1 Clinical Trials Experience,hypersensitivity reactions
VPRIV,adverse reactions,"Table 1: Adverse Reactions Observed in >= 10% of Adult and Pediatric Patients with Type 1 Gaucher Disease Treated with VPRIV in the Pooled 5 Clinical Studies Naive to ERTN = 54 Switched from imiglucerase to VPRIVN = 40 Number of Patients (% ) Hypersensitivity reaction 28 (52) 9 (23) Headache 19 (35) 12 (30) Dizziness 12 (22) 3 (8) Pyrexia 12 (22) 5 (13) Abdominal pain 10 (19) 6 (15) Back pain 9 (17) 7 (18) Joint pain (knee) 8 (15) 3 (8) Asthenia/Fatigue 8 (15) 5 (13) Activated partial thromboplastin time prolonged 6 (11) 2 (5) Nausea 3 (6) 4 (10) Less common adverse reactions affecting more than one patient (>2% in the treatment-naive group and > 3% in patients switched from imiglucerase to VPRIV treatment) were bone pain, tachycardia, rash, urticaria, flushing, hypertension, and hypotension.","rash, aPTT prolonged, pyrexia"
VPRIV,adverse reactions,6.2 Immunogenicity,"immunogenicity, hypersensitivity reactions, infusion reactions"
VPRIV,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hypersensitivity reactions, anaphylaxis"
VPRIV,warnings and precautions,5.1 Hypersensitivity Reactions Including Anaphylaxis,"hypersensitivity reactions, anaphylaxis, headache, dizziness, hypotension, hypertension, nausea, fatigue, asthenia, pyrexia, body temperature increased, chest discomfort, dyspnea, pruritus"
DALIRESP,adverse reactions,6 ADVERSE REACTIONS,"diarrhea, weight decrease, nausea, headache, back pain, influenza, insomnia, dizziness, decreased appetite"
DALIRESP,adverse reactions,6.1 Adverse Reactions in Clinical Studies,"diarrhea, nausea, serious adverse reactions, atrial fibrillation, lung cancer, prostate cancer, acute pancreatitis, acute renal failure"
DALIRESP,adverse reactions,Table 1 summarizes the adverse reactions reported by >= 2% of patients in the DALIRESP group in 8 controlled COPD clinical trials.,"As an AI, I need a valid drug label excerpt to identify adverse drug event terms. The input you provided is ""nan,"" which typically stands for ""not a number"" and doesn't contain any information I can use to fulfill your request. If you provide me with a snippet from a drug label or a description of side effects, I can help identify the terms related to adverse drug events."
DALIRESP,adverse reactions,Table 1: Adverse Reactions Reported by >= 2% of Patients Treated with DALIRESP 500 mcg daily and Greater Than Placebo Treatment Adverse Reactions DALIRESP Placebo (Preferred Term) (N=4438) (N=4192) n (%) n (%) Diarrhea 420 (9.5) 113 (2.7) Weight decreased 331 (7.5) 89 (2.1) Nausea 209 (4.7) 60 (1.4) Headache 195 (4.4) 87 (2.1) Back pain 142 (3.2) 92 (2.2) Influenza 124 (2.8) 112 (2.7) Insomnia 105 (2.4) 41 (1.0) Dizziness 92 (2.1) 45 (1.1) Decreased appetite 91 (2.1) 15 (0.4) Adverse reactions that occurred in the DALIRESP group at a frequency of 1 to 2% where rates exceeded that in the placebo group include:,"abdominal pain, dyspepsia, gastritis, vomiting, rhinitis, sinusitis, urinary tract infection, muscle spasms, tremor, anxiety, depression"
DALIRESP,adverse reactions,6.2 Postmarketing Experience,"hypersensitivity reactions, angioedema, urticaria, rash"
DALIRESP,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Acute bronchospasm, Psychiatric Events, Suicidality, Insomnia, Anxiety, Depression, Suicidal thoughts, Mood changes, Weight Decrease, Drug Interactions"
DALIRESP,warnings and precautions,5.1 Treatment of Acute Bronchospasm,acute bronchospasm
DALIRESP,warnings and precautions,5.2 Psychiatric Events including Suicidality,"psychiatric adverse reactions, insomnia, anxiety, depression, suicidal ideation, behavior, completed suicide, suicide attempts, suicidal thoughts, mood changes"
DALIRESP,warnings and precautions,5.3 Weight Decrease,"Weight loss, adverse reaction, moderate weight loss, severe weight loss, clinically significant weight loss, unexplained weight loss"
DALIRESP,warnings and precautions,5.4 Drug Interactions,"reduction in exposure, decrease in the therapeutic effectiveness"
SYLVANT,adverse reactions,6 ADVERSE REACTIONS,"pruritus, increased weight, rash, hyperuricemia, upper respiratory tract infection"
SYLVANT,adverse reactions,6.1 Clinical Trials Experience,"pruritus, increased weight, rash, hyperuricemia, upper respiratory tract infection"
SYLVANT,adverse reactions,"Table 3: Per Patient Incidence of Common Adverse Reactions in Study 1 During Initial 8 Infusions SYLVANT+BSCn=53 Placebo+BSCn=26 All Grades Grades 3-4 All Grades Grades 3-4 Skin disorders Rash (rash, rash generalized, rash maculo-papular, rash popular and rash pruritic) 15 (28%) 1 (2%) 3 (12%) 0 Pruritis 15 (28%) 0 2 (8%) 0 Skin hyperpigmentation 2 (4%) 0 0 0 Eczema 2 (4%) 0 0 0 Psoriasis 2 (4%) 0 0 0 Dry skin 2 (4%) 0 0 0 Infections Lower respiratory tract 4 (8%) 2 (4%) 1 (4%) 1 (4%) Upper respiratory tract 14 (26%) 1 (2%) 4 (15%) 1 (4%) Blood and lymphatic system disorders Thrombocytopenia 5 (9%) 2 (4%) 1 (4%) 1 (4%) General disorders Edema (general and localized) 14 (26%) 4 (8%) 7 (27%) 0 Gastrointestinal disorders Constipation 4 (8%) 0 1 (4%) 0 Metabolism Hypertriglyceridemia 4 (8%) 0 0 0 Hypercholesterolemia 2 (4%) 0 0 0 Hyperuricemia 6 (11%) 1 (2%) 0 0 Respiratory, thoracic and mediastinal disorders Oropharyngeal pain 4 (8%) 0 1 (4%) 0 Renal and urinary disorders Renal impairment 4 (8%) 0 0 0 Nervous system disorders Headache 4 (8%) 0 1 (4%) 0 Investigations Weight increased 10 (19%) 1 (2%) 0 0 Vascular disorders Hypotension 2 (4%) 1 (2%) 0 0 SYLVANT was also evaluated as a single agent in another hematologic disease in Study 2. Study 2 was an international, multicenter, randomized Phase 2 study of every 4 week infusions comparing SYLVANT and BSC to placebo and BSC. There were 50 patients randomized to the SYLVANT arm at a dose of 15 mg/kg (unapproved dose) and 26 patients randomized to the placebo arm. The median age was 72 years (range 50 to 85), 58% male, 96% White, 1% Asian, 1% Black, and 1% other. The median number of infusions in both arms was 3 (range 1 to 4). The study was stopped early due to a lack of efficacy. Adverse reactions that occurred > 3% in the SYLVANT arm are presented in Table 4 .","If the provided input is ""nan"" and I am to interpret that literally as ""not a number"" or ""non-applicable"", then there is no excerpt of a drug label to analyze, and consequently, no adverse drug event terms to extract. If ""nan"" was a placeholder for an actual text excerpt that was not provided, please provide the relevant excerpt to analyze for adverse drug event terms."
SYLVANT,adverse reactions,Table 4: Per Patient Incidence of Common Adverse Reactions in Study 2 SYLVANT+BSCn=50 Placebo+BSCn=26 All Grades Grades 3-4 All Grades Grades 3-4 Infections Lower respiratory tract 4 (8%) 4 (8%) 0 0 General disorders Edema(peripheral) 8 (16%) 0 2 (8%) 0 Gastrointestinal disorders Abdominal pain/abdominal distension 6 (12%) 0 0 0 Metabolism Decreased appetite 2 (4%) 0 0 0 Dehydration 2 (4%) 1 (2%) 0 0 Vascular disorders Hypotension 3 (6%) 0 0 0 Long Term Exposure,"upper respiratory tract infection, diarrhea, pain in extremities, arthralgia, fatigue, anaphylactic reaction, infusion related reactions, back pain, chest pain or discomfort, nausea and vomiting, flushing, erythema, palpitations"
SYLVANT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"severe infections, infections, Infusion Related Reactions, Gastrointestinal (GI) perforation"
SYLVANT,warnings and precautions,5.1 Concurrent Active Severe Infections,"severe infections, mask signs and symptoms of acute inflammation, suppression of fever, suppression of acute Phase reactants, infections"
SYLVANT,warnings and precautions,5.2 Vaccinations,"live vaccines, IL-6 inhibition, normal immune response"
SYLVANT,warnings and precautions,5.3 Infusion Related Reactions and Hypersensitivity,"anaphylaxis, infusion reaction"
SYLVANT,warnings and precautions,5.4 Gastrointestinal Perforation,"Gastrointestinal (GI) perforation, increased risk for GI perforation, symptoms that may be associated or suggestive of GI perforation"
LASTACAFT,adverse reactions,6 ADVERSE REACTIONS,"eye irritation, burning and/or stinging on instillation, eye redness, eye pruritus"
LASTACAFT,adverse reactions,6.1 Clinical Studies Experience,"eye irritation, burning and/or stinging upon instillation, eye redness, eye pruritus"
LASTACAFT,adverse reactions,6.2 Non-ocular Adverse Reactions,"nasopharyngitis, headache"
LASTACAFT,adverse reactions,6.3 Postmarketing Experience,"eye discharge, eye swelling, erythema of eyelid, eyelid edema, hypersensitivity, somnolence"
LASTACAFT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"eye injury, contamination"
LASTACAFT,warnings and precautions,5.1 Potential for Eye Injury and Contamination,"eye injury, contamination"
LASTACAFT,warnings and precautions,5.2 Contact Lens Use,"eye is red, contact lens-related irritation"
LASTACAFT,warnings and precautions,5.3 Topical Ophthalmic Use Only,"Based on the provided text, there are no adverse drug event terms; the text merely states that ""LASTACAFT (r) is for topical ophthalmic use only"". This indicates the route of administration, not any adverse events. Therefore, there are no adverse drug event terms to list from the given excerpt."
GAZYVA,adverse reactions,6 ADVERSE REACTIONS,"Hepatitis B reactivation, Progressive multifocal leukoencephalopathy, Infusion reactions, Tumor lysis syndrome, Infections, Neutropenia, Thrombocytopenia, Anemia, Pyrexia, Cough, Nausea, Diarrhea"
GAZYVA,adverse reactions,6.1 Clinical Trial Experience,"adverse reaction rates, safety population, untreated patients, treated, Stage 1 analysis, Stage 2, received, dose, split, enrolled, Dosage and Administration."
GAZYVA,adverse reactions,"Table 3 Summary of Adverse Reactions Reported in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 1) Adverse Reactions(MedDRA)System Organ Class GAZYVA + Chlorambuciln = 241 Chlorambuciln = 116 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Injury, poisoning, and procedural complications Infusion reactions 69 21 0 0 Blood and lymphatic system disorders Neutropenia 41 35 18 16 Thrombocytopenia 15 11 8 4 Anemia 12 5 10 4 Leukopenia 7 5 0 0 General disorders and administration site conditions Pyrexia 10 < 1 7 0 Respiratory, thoracic, and mediastinal disorders Cough 10 0 7 < 1 Infections and infestations Urinary tract infection 6 2 3 < 1 Musculoskeletal and connective tissue disorder Back pain 5 < 1 2 0 Table 4 Summary of Adverse Reactions Reported in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 2) Adverse Reactions(MedDRA)System Organ Class GAZYVA + Chlorambuciln = 336 Rituximab + Chlorambuciln = 321 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Injury, poisoning and procedural complications Infusion reactions 66 20 38 4 Blood and lymphatic system disorders Neutropenia 38 33 32 28 Thrombocytopenia 14 10 7 3 Leukopenia 6 4 2 < 1 General disorders and administration site conditions Pyrexia 9 < 1 7 < 1 Gastrointestinal disorders Diarrhea 10 2 8 < 1 Constipation 8 0 5 0 Infections and infestations Nasopharyngitis 6 < 1 3 0 Urinary tract infection 5 1 2 < 1 Table 5 Post-Baseline Laboratory Abnormalities by CTCAE Grade in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 1) Investigations GAZYVA + Chlorambuciln = 241 Chlorambuciln = 116 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Hematology Neutropenia 78 48 53 27 Lymphopenia 80 40 9 3 Leukopenia 84 37 12 < 1 Chemistry Hypocalcemia 38 3 33 2 Hyperkalemia 33 5 18 3 Hyponatremia 30 8 12 3 AST (SGOT increased) 29 1 16 0 Creatinine increased 30 <1 20 2 ALT (SGPT increased) 27 2 16 0 Hypoalbuminemia 23 <1 15 <1 Alkaline phosphatase increased 18 0 11 0 Hypokalemia 15 1 5 <1 Table 6 Post-Baseline Laboratory Abnormalities by CTCAE Grade in >= 5% of Patients and at Least 2% Greater in the GAZYVA Treated Arm (Stage 2) Investigations GAZYVA + Chlorambuciln = 336 Rituximab + Chlorambuciln = 321 All Grades % Grades 3-4 % All Grades % Grades 3-4 % Hematology Neutropenia 76 46 69 41 Lymphopenia 80 39 50 16 Leukopenia 84 35 62 16 Thrombocytopenia 48 13 40 8 Anemia 39 10 37 10 Chemistry Hypocalcemia 37 3 32 <1 Hyperkalemia 14 1 10 <1 Hyponatremia 26 7 18 2 AST (SGOT increased) 27 2 21 <1 ALT (SGPT increased) 28 2 21 1 Hypoalbuminemia 23 <1 16 <1 Infusion Reactions: The incidence of infusion reactions was 65% with the first infusion of GAZYVA. The incidence of Grade 3 or 4 infusion reactions was 20% with 7% of patients discontinuing therapy. The incidence of reactions with subsequent infusions was 3% with the second 1000 mg and < 1% thereafter. No Grade 3 or 4 infusion reactions were reported beyond the first 1000 mg infused.","infusion reaction, Neutropenia, Infection, Thrombocytopenia, hemorrhagic events, fatal hemorrhagic events, Tumor Lysis Syndrome, Musculoskeletal Disorders, Liver Enzyme Elevations, hepatotoxicity"
GAZYVA,adverse reactions,6.2 Immunogenicity,anti-GAZYVA antibodies
GAZYVA,adverse reactions,6.3 Additional Clinical Trial Experience,"Worsening of Pre-existing Cardiac Conditions, Fatal cardiac events"
GAZYVA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Infusion reactions, Tumor Lysis Syndrome, Neutropenia, Thrombocytopenia, Immunization"
GAZYVA,warnings and precautions,5.1 Hepatitis B Virus Reactivation,"Hepatitis B virus reactivation, fulminant hepatitis, hepatic failure, death, increase in transaminase levels, increase in bilirubin levels, liver failure"
GAZYVA,warnings and precautions,5.2 Progressive Multifocal Leukoencephalopathy,"JC virus infection, progressive multifocal leukoencephalopathy (PML), fatal"
GAZYVA,warnings and precautions,5.3 Infusion Reactions,"severe and life-threatening infusion reactions, hypotension, tachycardia, dyspnea, respiratory symptoms, bronchospasm, larynx and throat irritation, wheezing, laryngeal edema, nausea, vomiting, diarrhea, hypertension, flushing, headache, pyrexia, chills, anaphylaxis, acute life-threatening respiratory symptoms, other life-threatening infusion reaction, hypertensive crisis"
GAZYVA,warnings and precautions,5.4 Tumor Lysis Syndrome,"Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, hyperphosphatemia, Tumor Lysis Syndrome (TLS)."
GAZYVA,warnings and precautions,5.5 Infections,"Serious bacterial infections, fungal infections, viral infections, Fatal infections, active infection, recurring infections, chronic infections, increased risk of infection"
GAZYVA,warnings and precautions,5.6 Neutropenia,"Grade 3 or 4 neutropenia, infection, late onset neutropenia, prolonged neutropenia"
GAZYVA,warnings and precautions,5.7 Thrombocytopenia,"Grade 3 or 4 thrombocytopenia, acute thrombocytopenia, Fatal hemorrhagic events, thrombocytopenia, hemorrhagic events"
GAZYVA,warnings and precautions,5.8 Immunization,"live or attenuated viral vaccines, adverse drug event, Immunization with live virus vaccines"
ONGLYZA,adverse reactions,6 ADVERSE REACTIONS,"upper respiratory tract infection, urinary tract infection, headache, peripheral edema"
ONGLYZA,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse events, discontinuation of therapy due to adverse events, lymphopenia, rash, blood creatinine increased, blood creatine phosphokinase increased, adverse reactions"
ONGLYZA,adverse reactions,"Table 1: Adverse Reactions in Placebo-Controlled TrialsThe 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue. Reported in >=5% of Patients Treated with ONGLYZA 5 mg and More Commonly than in Patients Treated with Placebo Number (%) of Patients ONGLYZA 5 mg N=882 Placebo N=799 Upper respiratory tract infection 68 (7.7) 61 (7.6) Urinary tract infection 60 (6.8) 49 (6.1) Headache 57 (6.5) 47 (5.9) In patients treated with ONGLYZA 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate >=5% and more commonly than in patients treated with placebo.","sinusitis, abdominal pain, gastroenteritis, vomiting, peripheral edema, fractures, thrombocytopenia, hypoglycemia"
ONGLYZA,adverse reactions,"Table 2 shows the adverse reactions reported (regardless of investigator assessment of causality) in >=5% of patients participating in an additional 24-week, active-controlled trial of coadministered ONGLYZA and metformin in treatment-naive patients.","The input ""nan"" typically means ""not a number"" or is used as a placeholder for missing data. In this context, it suggests there is no drug label text provided for analyzing. Therefore, there are no adverse drug event terms to list. If you provide a drug label excerpt, I would be able to assist in identifying any adverse drug event terms within it."
ONGLYZA,adverse reactions,"Table 2: Initial Therapy with Combination of ONGLYZA and Metformin in Treatment-Naive Patients: Adverse Reactions Reported in >=5% of Patients Treated with Combination Therapy of ONGLYZA 5 mg Plus Metformin (and More Commonly than in Patients Treated with Metformin Alone) Number (%) of Patients ONGLYZA 5 mg + Metformin N=320 Metformin N=328 Headache 24 (7.5) 17 (5.2) Nasopharyngitis 22 (6.9) 13 (4.0) Hypoglycemia Adverse reactions of hypoglycemia were based on all reports of hypoglycemia. A concurrent glucose measurement was not required or was normal in some patients. Therefore, it is not possible to conclusively determine that all these reports reflect true hypoglycemia.","hypoglycemia, confirmed hypoglycemia, symptomatic hypoglycemia, hypersensitivity reactions, urticaria, facial edema, tuberculosis, lymphopenia, foodborne fatal salmonella sepsis"
ONGLYZA,adverse reactions,6.2 Postmarketing Experience,"hypersensitivity reactions, anaphylaxis, angioedema, exfoliative skin conditions, acute pancreatitis, severe and disabling arthralgia"
ONGLYZA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Acute Pancreatitis, Hypoglycemia, Hypersensitivity-Related Events, urticaria, facial edema, anaphylaxis, angioedema, exfoliative skin conditions, Arthralgia"
ONGLYZA,warnings and precautions,5.1 Pancreatitis,"acute pancreatitis, pancreatitis"
ONGLYZA,warnings and precautions,5.2 Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin,hypoglycemia
ONGLYZA,warnings and precautions,5.3 Hypersensitivity Reactions,"serious hypersensitivity reactions, anaphylaxis, angioedema, exfoliative skin conditions"
ONGLYZA,warnings and precautions,5.4 Severe and Disabling Arthralgia,"severe and disabling arthralgia, severe joint pain"
ONGLYZA,warnings and precautions,5.5 Macrovascular Outcomes,There are no specific adverse drug event terms in the provided text excerpt to list. The statement does not mention any side effects or negative outcomes associated with the use of ONGLYZA or any other antidiabetic drug. It simply states that no clinical studies have conclusively shown a reduction in macrovascular risk with these medications.
SIVEXTRO,adverse reactions,6 ADVERSE REACTIONS,"nausea, headache, diarrhea, vomiting, dizziness"
SIVEXTRO,adverse reactions,6.1 Adverse Reactions in Clinical Trials,"adverse reaction rates, Adverse reactions, Serious Adverse Reactions, Adverse Reactions Leading to Discontinuation, adverse reaction, Most Common Adverse Reactions, nausea, headache, diarrhea, vomiting, dizziness"
SIVEXTRO,adverse reactions,Table 2 lists selected adverse reactions occurring in at least 2% of patients treated with SIVEXTRO in clinical trials.,nan
SIVEXTRO,adverse reactions,Table 2: Selected Adverse Reactions Occurring in >=2% of Patients Receiving SIVEXTRO in the Pooled Phase 3 ABSSSI Clinical Trials Adverse Reactions Pooled Phase 3 ABSSSI Clinical Trials SIVEXTRO(200 mg oral/intravenous once daily for 6 days)(N=662) Linezolid(600 mg oral/intravenous twice daily for 10 days)(N=662) Gastrointestinal Disorders Nausea 8% 12% Diarrhea 4% 5% Vomiting 3% 6% Nervous System Disorder Headache 6% 6% Dizziness 2% 2% The following selected adverse reactions were reported in SIVEXTRO-treated patients at a rate of less than 2% in these clinical trials:,"anemia, palpitations, tachycardia, asthenopia, vision blurred, visual impairment, vitreous floaters, infusion-related reactions, drug hypersensitivity, Clostridium difficile colitis, oral candidiasis, vulvovaginal mycotic infection, hepatic transaminases increased, white blood cell count decreased, hypoesthesia, paresthesia, VII th nerve paralysis, insomnia, pruritus, urticaria, dermatitis, flushing, hypertension"
SIVEXTRO,adverse reactions,Table 3: Potentially Clinically Significant Lowest Laboratory Values in the Pooled Phase 3 ABSSSI Clinical Trials Laboratory Assay Potentially Clinically Significant Values SIVEXTRO(200 mg oral/intravenous once daily for 6 days)(N=618) Linezolid(600 mg oral/intravenous twice daily for 10 days)(N=617) M = male; F = female Hemoglobin (<10.1 g/dL [M]) (<9 g/dL [F]) 3.1% 3.7% Platelet count (<112 * 10 3 /mm 3 ) 2.3% 4.9% Absolute neutrophil count (<0.8 * 10 3 /mm 3 ) 0.5% 0.6% Myelosuppression,"hematologic parameters, Peripheral Neuropathy, Optic Neuropathy, peripheral neuropathy, optic nerve disorders"
SIVEXTRO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"neutropenia, diarrhea"
SIVEXTRO,warnings and precautions,5.1 Patients with Neutropenia,"neutropenia, reduced antibacterial activity"
SIVEXTRO,warnings and precautions,5.2 Clostridium difficile -Associated Diarrhea,"Clostridium difficile-associated diarrhea (CDAD), mild diarrhea, fatal colitis, increased morbidity, mortality, diarrhea"
SIVEXTRO,warnings and precautions,5.3 Development of Drug-Resistant Bacteria,"The excerpt provided does not specifically list any adverse drug events. It discusses the potential risk associated with inappropriate use of the drug, but does not mention specific adverse effects on the patient. Therefore, there are no adverse drug event terms to list from the given text."
PREPOPIK,adverse reactions,6 ADVERSE REACTIONS,"nausea, headache, vomiting, abdominal bloating, distension, pain/cramping, watery diarrhea"
PREPOPIK,adverse reactions,6.1 Clinical Trials Experience,"nausea, headache, vomiting, abdominal bloating, distension, pain/cramping, watery diarrhea"
PREPOPIK,adverse reactions,"Table 1: Treatment-Emergent Adverse Reactions observed in at Least (>1%) of Patients using the Split-Dose Regimen and Day-Before Regimen abdominal bloating, distension, pain/cramping, and watery diarrhea not requiring an intervention were not collected Adverse Reaction Study 1: Split-Dose Regimen Study 2: Day-Before Regimen PREPOPIK (r) (N=305)n (% = n/N) 2L PEG+Ewith 2 * 5-mg bisacodyl tablets(N=298)n (% = n/N) PREPOPIK (r) (N=296)n (% = n/N) 2L PEG+Ewith 2 * 5-mg bisacodyl tablets(N=302)n (% = n/N) Nausea 8 (2.6) 11 (3.7) 9 (3.0) 13 (4.3) Headache 5 (1.6) 5 (1.7) 8 (2.7) 5 (1.7) Vomiting 3 (1.0) 10 (3.4) 4 (1.4) 6 (2.0) Electrolyte Abnormalities",abnormal electrolyte shifts
PREPOPIK,adverse reactions,"Table 2: Shifts from Normal Baseline to Outside the Normal Range at Day 7 and Day 30 Laboratory Parameter (direction of change) Visit Study 1: Split-Dose Regimen Study 2: Day-Before Regimen PREPOPIK (r) 2L PEG+E with 2* 5 mg bisacodyl tablets PREPOPIK (r) 2L PEG+E with 2* 5 mg bisacodyl tablets n/N (%) n/N (%) Potassium (low) Day of Colonoscopy 19/260 (7.3) 11/268 ( 4.1 ) 13/274 (4.7) 13/271 (4.8) 24-48 hours 3/302 (1.0) 2/294 (0.7) 3/287 (1.0) 5/292 (1.7) Day 7 11/285 (3.9) 8/279 (2.9) 6/276 (2.2) 14/278 (5.0) Day 30 11/284 (3.9) 8/278 (2.9) 7/275 (2.5) 8/284 (2.8) Sodium (low) Day of Colonoscopy 11/298 (3.7) 3/295 (1.0) 3/286 (1.0) 3/295 (1.0) 24-48 hours 1/303 (0.3) 1/295 (0.3) 1/288 (0.3) 1/293 (0.3) Day 7 2/300 (0.7) 1/292 (0.3) 1/285 (0.4) 1/291 (0.3) Day 30 2/299( 0.7) 3/291 (1.0) 1/284( 0.4) 1/296 (0.3) Chloride (low) Day of Colonoscopy 11/301 (3.7) 1/298 (0.3) 3/287 (1.0) 0/297 (0.0) 24-48 hours 1/303 (0.3) 0/295 (0.0) 2/288 (0.7) 0/293 (0.0) Day 7 1/303 (0.3) 3/295 (1.0) 0/285 (0.0) 0/293 (0.0) Day 30 2/302 (0.7) 3/294 (1.0) 0/285 (0.0) 0/298 (0.0) Magnesium (high) Day of Colonoscopy 34/294 (11.6) 0/294 (0.0) 25/288 (8.7) 1/289 (0.3) 24-48 hours 0/303 (0.0) 0/295 (0.0) 0/288 (0.0) 0/293 (0.0) Day 7 0/297 (0.0) 1/291 (0.3) 1/286 (0.3) 1/285 (0.4) Day 30 1/296 (0.3) 2/290 (0.7) 0/286 (0.0) 0/290 (0.0) Calcium (low) Day of Colonoscopy 2/292 (0.7) 1/286 (0.3) 0/276 (0.0) 2/282 (0.7) 24-48 hours 0/303 (0.0) 0/295 (0.0) 0/288 (0.0) 0/293 (0.0) Day 7 0/293 (0.0) 1/283 (0.4) 0/274 (0.0) 0/278 (0.0) Day 30 0/292 (0.0) 1/282 (0.4) 0/274 (0.0) 1/283 (0.4) Creatinine (high) Day of Colonoscopy 5/260 (1.9) 13/268 (4.9) 12/266 (4.5) 16/270 (5.9) 24-48 hours 1/303 (0.3) 0/295 (0.0) 0/288 (0.0) 0/293 (0.0) Day 7 10/264 (0.4) 13/267 (4.8) 10/264 (3.8) 10/265 (3.8) Day 30 11/264 (4.2) 14/265(5.3) 18/264 (6.8) 10/272 (3.7) eGFR (low) Day of Colonoscopy 22/221 (10.0) 17/214 (7.9) 26/199 (13.1) 25/224 (11.2) 24-48 hours 76/303 (25.1) 72/295 (24.4) 82/288 (28.5) 62/293 (21.2) Day 7 22/223 (10.0) 17/213 (8.0) 11/198 (5.6) 28/219 (12.8) Day 30 24/223(10.8) 21/211 (10.0) 21/199 (10.6) 24/224 (10.7) 6.2 Postmarketing Experience The following foreign spontaneous reports have been identified during use of formulations similar to Prepopik (r) . Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.","allergic reactions, hypersensitivity reactions, rash, urticaria, purpura, hypokalemia, hyponatremia, hypermagnesemia, abdominal pain, diarrhea, fecal incontinence, proctalgia, aphthoid ileal ulcers, ischemic colitis, generalized tonic-clonic seizures"
PREPOPIK,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"fluid and electrolyte abnormalities, arrhythmia, seizures, renal impairment, mucosal ulcerations, GI obstruction, perforation, aspiration"
PREPOPIK,warnings and precautions,5.1 Serious Fluid and Serum Chemistry Abnormalities,"vomiting, dehydration, orthostatic hypotension, cardiac arrhythmias, seizures, renal impairment"
PREPOPIK,warnings and precautions,5.2 Seizures,"generalized tonic-clonic seizures, hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia, neurologic abnormalities"
PREPOPIK,warnings and precautions,5.3 Use in Patients with Renal Impairment,"impaired renal function, renal injury, accumulation of magnesium in plasma"
PREPOPIK,warnings and precautions,5.4 Cardiac Arrhythmias,"serious arrhythmias, prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy"
PREPOPIK,warnings and precautions,"5.5 Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis","colonic mucosal aphthous ulcerations, ischemic colitis, hospitalization"
PREPOPIK,warnings and precautions,5.6 Use in Patients with Significant Gastrointestinal Disease,"gastrointestinal obstruction, perforation, severe active ulcerative colitis"
PREPOPIK,warnings and precautions,5.7 Aspiration,"impaired gag reflex, regurgitation, aspiration"
PREPOPIK,warnings and precautions,5.8 Not for Direct Ingestion,"nausea, vomiting, dehydration, electrolyte disturbances"
OFEV,adverse reactions,6 ADVERSE REACTIONS,"Liver Enzyme and Bilirubin Elevations, Gastrointestinal Disorders, Embryofetal Toxicity, Arterial Thromboembolic Events, Risk of Bleeding, Gastrointestinal Perforation, diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased, hypertension"
OFEV,adverse reactions,6.1 Clinical Trials Experience,"adverse reactions, bronchitis, myocardial infarction, pneumonia, lung neoplasm malignant, major adverse cardiovascular events (MACE), MI, fatal events, permanent dose reductions, diarrhea, discontinuation, nausea, decreased appetite"
OFEV,adverse reactions,"Table 1 Adverse Reactions Occurring in >=5% of OFEV-treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3 a Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain and abdominal tenderness. b Includes gamma-glutamyltransferase increased, hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic function abnormal, liver function test abnormal, transaminase increased, blood alkaline phosphatase-increased, alanine aminotransferase abnormal, aspartate aminotransferase abnormal, and gamma-glutamyltransferase abnormal. c Includes hypertension, blood pressure increased, hypertensive crisis, and hypertensive cardiomyopathy. Adverse Reaction OFEV, 150 mgn=723 Placebon=508 Gastrointestinal disorders Diarrhea 62% 18% Nausea 24% 7% Abdominal pain a 15% 6% Vomiting 12% 3% Hepatobiliary disorders Liver enzyme elevation b 14% 3% Metabolism and nutrition disorders Decreased appetite 11% 5% Nervous systemic disorders Headache 8% 5% Investigations Weight decreased 10% 3% Vascular disorders Hypertension c 5% 4% In addition, hypothyroidism was reported in patients treated with OFEV, more than placebo (1.1% vs. 0.6%).","Without an actual excerpt of a drug label provided in the input, there is no text to find the adverse drug event terms. If you provide a specific drug label text, I can help identify the adverse drug event terms within it. Since the input is ""nan"" (presumably meaning 'not a number' or indicating a null value), there are no terms to return."
OFEV,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"elevated liver enzymes, ALT elevations, AST elevations, bilirubin elevations, diarrhea, nausea, vomiting, embryofetal toxicity, arterial thromboembolic events, bleeding events, gastrointestinal perforation"
OFEV,warnings and precautions,5.1 Elevated Liver Enzymes,"elevations of liver enzymes, Liver enzyme increases, ALT and/or AST elevations, elevations of bilirubin, liver function tests, liver enzyme elevations, dosage modifications, interruption"
OFEV,warnings and precautions,5.2 Gastrointestinal Disorders,"Diarrhea, Nausea, Vomiting"
OFEV,warnings and precautions,5.3 Embryofetal Toxicity,"fetal harm, teratogenic, embryofetocidal"
OFEV,warnings and precautions,5.4 Arterial Thromboembolic Events,"arterial thromboembolic events, myocardial infarction, acute myocardial ischemia"
OFEV,warnings and precautions,5.5 Risk of Bleeding,"bleeding events, risk of bleeding"
OFEV,warnings and precautions,5.6 Gastrointestinal Perforation,gastrointestinal perforation
ZONTIVITY,adverse reactions,6 ADVERSE REACTIONS,
ZONTIVITY,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse events, bleeding, GUSTO severe bleeding, intracranial, hemodynamic compromise, GUSTO moderate bleeding, transfusion of whole blood or packed red blood cells, increased GUSTO moderate or severe bleeding"
ZONTIVITY,adverse reactions,"Table 1: Non-CABG-Related Bleeds in Post-MI or PAD Patients without a History of Stroke or TIA (First Dose to Last Dose + 30 Days) in the TRA 2 degrees P Study Placebo(n=10,049) ZONTIVITY(n=10,059) Endpoints Patients with events(%) K-M % Patients with events(%) K-M % Hazard Ratio , (95% CI) GUSTO Bleeding Categories Severe 82 (0.8%) 1.0% 100 (1.0%) 1.3% 1.24 (0.92 - 1.66) Moderate or Severe 199 (2.0%) 2.4% 303 (3.0%) 3.7% 1.55 (1.30 - 1.86) Any GUSTO Bleeding (Severe/Moderate/Mild) 1769 (17.6%) 19.8% 2518 (25.0%) 27.7% 1.52 (1.43 - 1.61) Fatal Bleeding 14 (0.1%) 0.2% 16 (0.2%) 0.2% 1.15 (0.56 - 2.36) Intracranial Hemorrhage (ICH) 31 (0.3%) 0.4% 45 (0.4%) 0.6% 1.46 (0.92-2.31) Clinically Significant Bleeding 950 (9.5%) 10.9% 1349 (13.4%) 15.5% 1.47 (1.35 - 1.60) Gastrointestinal Bleeding 297 (3.0%) 3.5% 400 (4.0%) 4.7% 1.37 (1.18-1.59) The effects of ZONTIVITY on bleeding were examined in a number of subsets based on demographic and other baseline characteristics. Many of these are shown in Figure 1. Such analyses must be interpreted cautiously, as differences can reflect the play of chance among a large number of analyses.","moderate or severe bleeding, discontinued, bleeding events, ischemic stroke, ICH, adverse reactions, adverse events"
ZONTIVITY,adverse reactions,"Table 2: TRA 2 degrees P / TRACER - Percentage of Patients Reporting Non-hemorrhagic Adverse Reactions at a Rate at Least 2% in the ZONTIVITY Group and at Least 10% Greater than Placebo ZONTIVITYN=19,632 PlaceboN=19,607 n (%) n (%) Anemia 982 (5.0) 783 (4.0) Depression 477 (2.4) 405 (2.1) Rashes, Eruptions, and Exanthemas 439 (2.2) 395 (2.0) The following adverse reactions occurred at a rate less than 2% in the ZONTIVITY group but at least 40% greater than placebo. In descending order of rate in the ZONTIVITY group: iron deficiency, retinopathy or retinal disorder, and diplopia/oculomotor disturbances.","diplopia, oculomotor disturbances"
ZONTIVITY,boxed warnings,BOXED WARNING: WARNING: BLEEDING RISK,"As there is no actual text excerpt provided (the input is ""nan"") and without any context to infer from, I cannot provide a list of adverse drug event terms. If you provide an actual drug label or text excerpt, I would be happy to identify any adverse drug event terms contained within it."
ZONTIVITY,boxed warnings,WARNING: BLEEDING RISK,"stroke, transient ischemic attack (TIA), intracranial hemorrhage (ICH), active pathological bleeding, bleeding, fatal bleeding"
ZONTIVITY,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"bleeding, risk of bleeding"
ZONTIVITY,warnings and precautions,5.1 General Risk of Bleeding,"bleeding, ICH (intracranial hemorrhage), fatal bleeding, hypotensive"
ZONTIVITY,warnings and precautions,5.2 Strong CYP3A Inhibitors or Inducers,"Strong CYP3A inhibitors increase, inducers decrease ZONTIVITY exposure, Avoid concomitant use"
BELVIQ,adverse reactions,6 ADVERSE REACTIONS,"Serotonin Syndrome, NMS-like Reactions, Valvular Heart Disease, Cognitive Impairment, Psychiatric Disorders, Hypoglycemia, Heart Rate Decreases, Hematological Changes, Prolactin Elevation, headache, dizziness, fatigue, nausea, dry mouth, constipation, back pain, cough"
BELVIQ,adverse reactions,6.1 Clinical Trials Experience,"headache, depression, dizziness, fatigue, nausea, dry mouth, constipation, hypoglycemia, back pain, cough"
BELVIQ,adverse reactions,"Table 2. Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients without Diabetes Mellitus Adverse Reaction Number of patients (%) BELVIQ 10 mg BID N=3195 Placebo N=3185 Gastrointestinal Disorders Nausea 264 (8.3) 170 (5.3) Diarrhea 207 (6.5) 179 (5.6) Constipation 186 (5.8) 125 (3.9) Dry mouth 169 (5.3) 74 (2.3) Vomiting 122 (3.8) 83 (2.6) General Disorders And Administration Site Conditions Fatigue 229 (7.2) 114 (3.6) Infections And Infestations Upper respiratory tract infection 439 (13.7) 391 (12.3) Nasopharyngitis 414 (13.0) 381 (12.0) Urinary tract infection 207 (6.5) 171 (5.4) Musculoskeletal And Connective Tissue Disorders Back pain 201 (6.3) 178 (5.6) Musculoskeletal pain 65 (2.0) 43 (1.4) Nervous System Disorders Headache 537 (16.8) 321 (10.1) Dizziness 270 (8.5) 122 (3.8) Respiratory, Thoracic And Mediastinal Disorders Cough 136 (4.3) 109 (3.4) Oropharyngeal pain 111 (3.5) 80 (2.5) Sinus congestion 93 (2.9) 78 (2.4) Skin And Subcutaneous Tissue Disorders Rash 67 (2.1) 58 (1.8) Table 3. Adverse Reactions Reported by Greater Than or Equal to 2% of BELVIQ Patients and More Commonly than with Placebo in Patients with Type 2 Diabetes Mellitus Number of patients (%) Adverse Reaction BELVIQ 10 mg BID N=256 Placebo N=252 Gastrointestinal Disorders Nausea 24 (9.4) 20 (7.9) Toothache 7 (2.7) 0 General Disorders And Administration Site Conditions Fatigue 19 (7.4) 10 (4.0) Peripheral edema 12 (4.7) 6 (2.4) Immune System Disorders Seasonal allergy 8 (3.1) 2 (0.8) Infections And Infestations Nasopharyngitis 29 (11.3) 25 (9.9) Urinary tract infection 23 (9.0) 15 (6.0) Gastroenteritis 8 (3.1) 5 (2.0) Metabolism And Nutrition Disorders Hypoglycemia 75 (29.3) 53 (21.0) Worsening of diabetes mellitus 7 (2.7) 2 (0.8) Decreased appetite 6 (2.3) 1 (0.4) Musculoskeletal And Connective Tissue Disorders Back pain 30 (11.7) 20 (7.9) Muscle spasms 12 (4.7) 9 (3.6) Nervous System Disorders Headache 37 (14.5) 18 (7.1) Dizziness 18 (7.0) 16 (6.3) Psychiatric Disorders Anxiety 9 (3.5) 8 (3.2) Insomnia 9 (3.5) 6 (2.4) Stress 7 (2.7) 3 (1.2) Depression 6 (2.3) 5 (2.0) Respiratory, Thoracic And Mediastinal Disorders Cough 21 (8.2) 11 (4.4) Vascular Disorders Hypertension 13 (5.1) 8 (3.2) Other Adverse Reactions","serotonergic excess, serotonin syndrome, chills, tremor, confusional state, disorientation, hyperhidrosis, hypoglycemia, cognitive impairment, difficulty with concentration/attention, difficulty with memory, confusion, psychiatric disorders, euphoria, depression, mood problems, suicidal ideation, lymphocyte counts below the lower limit of normal, neutrophil counts low, hemoglobin below the lower limit of normal, elevations of prolactin, eye disorders, blurred vision, dry eye, visual impairment, visual disorders, conjunctival infections, irritations, inflammations, ocular sensation disorders, cataract conditions, regurgitant cardiac valve disease, valvular regurgitation, valvulopathy"
BELVIQ,adverse reactions,"Table 4. Incidence of FDA-Defined Valvulopathy at Week 52 by Treatment Group1 1 Patients without valvulopathy at baseline who received study medication and had a post-baseline echocardiogram; ITT-intention-to-treat; LOCF-last observation carried forward Study 1 Study 2 Study 3 BELVIQ N=1278 Placebo N=1191 BELVIQ N=1208 Placebo N=1153 BELVIQ N=210 Placebo N=209 FDA-defined Valvulopathy, n (%) 34 (2.7) 28 (2.4) 24 (2.0) 23 (2.0) 6 (2.9) 1 (0.5) Relative Risk (95% CI) 1.13 (0.69, 1.85) 1.00 (0.57, 1.75) 5.97 (0.73, 49.17) Pooled RR (95% CI) 1.16 (0.81, 1.67)","If the input text is ""nan,"" which typically means ""not a number"" or may indicate the absence of text, then there are no adverse drug event terms to extract. Therefore, there is nothing to return in this case."
BELVIQ,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Serotonin Syndrome, Neuroleptic Malignant Syndrome (NMS)-like Reactions, Valvular heart disease, Cognitive Impairment, Psychiatric Disorders, depression, suicidal thoughts, hypoglycemia, Priapism"
BELVIQ,warnings and precautions,5.1 Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions,"serotonin syndrome, Neuroleptic Malignant Syndrome (NMS)-like reactions, mental status changes, agitation, hallucinations, coma, autonomic instability, tachycardia, labile blood pressure, hyperthermia, neuromuscular aberrations, hyperreflexia, incoordination, gastrointestinal symptoms, nausea, vomiting, diarrhea, neuroleptic malignant syndrome, hyperthermia, muscle rigidity, autonomic instability, mental status changes"
BELVIQ,warnings and precautions,5.2 Valvular Heart Disease,"Regurgitant cardiac valvular disease, mitral regurgitation, aortic regurgitation, valvular regurgitation, congestive heart failure, cardiac valvulopathy, dyspnea, dependent edema, cardiac murmur"
BELVIQ,warnings and precautions,5.3 Cognitive Impairment,"impairments in attention, memory, confusion, somnolence, fatigue"
BELVIQ,warnings and precautions,5.4 Psychiatric Disorders,"euphoria, hallucination, dissociation, depression, suicidal ideation, suicidal thoughts, behaviors"
BELVIQ,warnings and precautions,5.5 Potential Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus on Anti-diabetic Therapy,hypoglycemia
BELVIQ,warnings and precautions,5.6 Priapism,"Priapism, painful erections, irreversible damage to the erectile tissue, angulation, cavernosal fibrosis, Peyronie's disease"
BELVIQ,warnings and precautions,5.7 Heart Rate Decreases,bradycardia
BELVIQ,warnings and precautions,5.8 Hematological Changes,"decreases in white blood cell count, leukopenia, lymphopenia, neutropenia, decreased white cell count, decreases in red blood cell count, anemia, decreases in hemoglobin, decreases in hematocrit"
BELVIQ,warnings and precautions,5.9 Prolactin Elevation,"elevates prolactin levels, galactorrhea, gynecomastia, prolactinoma"
BELVIQ,warnings and precautions,5.10 Pulmonary Hypertension,pulmonary hypertension
STELARA,adverse reactions,6 ADVERSE REACTIONS,"infections, malignancies, Reversible Posterior Leukoencephalopathy Syndrome, nasopharyngitis, upper respiratory tract infection, headache, fatigue"
STELARA,adverse reactions,6.1 Clinical Studies Experience,"adverse reaction rates, safety data"
STELARA,adverse reactions,Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the STELARA (r) groups than the placebo group during the placebo-controlled period of Ps STUDY 1 and Ps STUDY 2 [see Clinical Studies (14) ] .,"As the input provided is ""nan,"" which signifies that there is no information given or it's not applicable, I'm unable to extract any adverse drug event terms. If you provide an excerpt from a drug label, I would be able to identify the adverse event terms within that text."
STELARA,adverse reactions,"Table 1. Adverse reactions reported by >=1% of subjects through Week 12 in Ps STUDY 1 and Ps STUDY 2 STELARA (r) Placebo 45 mg 90 mg Subjects treated 665 664 666 Nasopharyngitis 51 (8%) 56 (8%) 49 (7%) Upper respiratory tract infection 30 (5%) 36 (5%) 28 (4%) Headache 23 (3%) 33 (5%) 32 (5%) Fatigue 14 (2%) 18 (3%) 17 (3%) Diarrhea 12 (2%) 13 (2%) 13 (2%) Back pain 8 (1%) 9 (1%) 14 (2%) Dizziness 8 (1%) 8 (1%) 14 (2%) Pharyngolaryngeal pain 7 (1%) 9 (1%) 12 (2%) Pruritus 9 (1%) 10 (2%) 9 (1%) Injection site erythema 3 (<1%) 6 (1%) 13 (2%) Myalgia 4 (1%) 7 (1%) 8 (1%) Depression 3 (<1%) 8 (1%) 4 (1%) Adverse reactions that occurred at rates less than 1% in the controlled period of Ps STUDIES 1 and 2 through week 12 included: cellulitis, herpes zoster, diverticulitis and certain injection site reactions (pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation).","RPLS, infections, serious infections, malignancies, non-melanoma skin cancer, prostate cancer, melanoma, colorectal cancer, breast cancer, arthralgia, nausea, dental infections"
STELARA,adverse reactions,6.2 Immunogenicity,"antibodies to ustekinumab, injection site reactions, serious hypersensitivity reactions"
STELARA,adverse reactions,6.3 Post-marketing Experience,"serious hypersensitivity reactions, anaphylaxis, angioedema, other hypersensitivity reactions, rash, urticaria, pustular psoriasis, erythrodermic psoriasis"
STELARA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"serious infections, mycobacteria infections, salmonella infections, Bacillus Calmette-Guerin (BCG) infections, tuberculosis (TB), malignancy, anaphylaxis, hypersensitivity reactions, Reversible Posterior Leukoencephalopathy Syndrome (RPLS)"
STELARA,warnings and precautions,5.1 Infections,"infections, reactivation of latent infections, serious bacterial infections, fungal infections, viral infections, diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, gastroenteritis, urinary tract infections"
STELARA,warnings and precautions,5.2 Theoretical Risk for Vulnerability to Particular Infections,"disseminated infections, mycobacteria, salmonella, Bacillus Calmette-Guerin (BCG) vaccinations, Serious infections, fatal outcomes"
STELARA,warnings and precautions,5.3 Pre-treatment Evaluation for Tuberculosis,"active tuberculosis, latent tuberculosis"
STELARA,warnings and precautions,5.4 Malignancies,"immunosuppressant, risk of malignancy, Malignancies, inhibition of IL-12/IL-23p40, non-melanoma skin cancer, rapid appearance of multiple cutaneous squamous cell carcinomas"
STELARA,warnings and precautions,5.5 Hypersensitivity Reactions,"Hypersensitivity reactions, anaphylaxis, angioedema"
STELARA,warnings and precautions,5.6 Reversible Posterior Leukoencephalopathy Syndrome,"reversible posterior leukoencephalopathy syndrome, headache, seizures, confusion, visual disturbances, acute hypertension, fatal outcomes"
STELARA,warnings and precautions,5.7 Immunizations,"live vaccines, BCG vaccines, transmission to patient, Non-live vaccinations, immune response sufficient to prevent disease"
STELARA,warnings and precautions,5.8 Concomitant Therapies,adverse drug event terms: Ultraviolet-induced skin cancers
NATROBA,adverse reactions,6 ADVERSE REACTIONS,"application site erythema, ocular erythema"
NATROBA,adverse reactions,6.1 Clinical Studies Experience,"adverse reaction rates, adverse drug event terms"
NATROBA,adverse reactions,"Table 1: Selected Adverse Events Occurring in at least 1% of Subjects Signs Spinosad(N=552) Permethrin 1%(N=457) Application site erythema 17 (3%) 31 (7%) Ocular erythema 12 (2%) 15 (3%) Application site irritation 5 (1%) 7 (2%) Other less common reactions (less than 1% but more than 0.1%) were application site dryness, application site exfoliation, alopecia, and dry skin.Systemic safety was not assessed in pediatric subjects under 6 months of age as laboratory parameters were not monitored in these controlled studies.","Given the input ""nan"" (typically meaning ""not a number"" or representing missing data), there are no adverse drug event terms to identify. Therefore, I cannot provide you with any terms.
"
NATROBA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Benzyl alcohol toxicity, Not recommended in infants below the age of 6 months, potential for increased systemic absorption"
NATROBA,warnings and precautions,5.1 Benzyl Alcohol Toxicity,"serious adverse reactions, death"
ELELYSO,adverse reactions,6 ADVERSE REACTIONS,"pruritus, flushing, headache, arthralgia, pain in extremity, abdominal pain, vomiting, fatigue, back pain, dizziness, nausea, rash"
ELELYSO,adverse reactions,6.1 Clinical Trials Experience,"pruritus, flushing, headache, arthralgia, pain in extremity, abdominal pain, vomiting, fatigue, back pain, dizziness, nausea, rash"
ELELYSO,adverse reactions,Table 1: Adverse Reactions in >=5% of Treatment-Naive Adult Patients Treated with ELELYSO Preferred Term Treatment-Naive Adults (N=32)n (%) Headache 6 (19%) Arthralgia 4 (13%) Fatigue 3 (9%) Nausea 3 (9%) Dizziness 3 (9%) Abdominal pain 2 (6%) Pruritus 2 (6%) Flushing 2 (6%) Vomiting 2 (6%) Urticaria 2 (6%) Similar adverse reactions were observed in patients who continued ELELYSO treatment during the extension trial for up to 24 months. One patient experienced a mild and intermittent Type III immune-mediated fixed drug eruption and continued in the study.,"vomiting, hypersensitivity reactions, severe vomiting, gastrointestinal inflammation, throat irritation, chest discomfort"
ELELYSO,adverse reactions,"Table 2: Adverse Reactions in >=10% of Patients Switched from Imiglucerase to ELELYSO Preferred Term Patients Switched from Imiglucerase (N=31; 26 adults and 5 children)n (%) Arthralgia 4 (13%) Headache 4 (13%) Pain in extremity 3 (10%) 6.2 Immunogenicity As with all therapeutic proteins, patients may develop anti-drug antibodies (ADA) to ELELYSO.","hypersensitivity reactions, anaphylaxis"
ELELYSO,adverse reactions,6.3 Postmarketing Experience,Anaphylaxis
ELELYSO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hypersensitivity reactions, anaphylaxis"
ELELYSO,warnings and precautions,5.1 Hypersensitivity Reactions Including Anaphylaxis,"hypersensitivity reactions, anaphylaxis, urticaria, hypotension, flushing, wheezing, chest tightness, nausea, vomiting, dizziness, pruritus, angioedema, erythema, rash, cough, throat irritation"
STRIVERDI,adverse reactions,6 ADVERSE REACTIONS,"nasopharyngitis, upper respiratory tract infection, bronchitis, urinary tract infection, cough, dizziness, rash, diarrhea, back pain, arthralgia"
STRIVERDI,adverse reactions,6.1 Clinical Trials Experience in Chronic Obstructive Pulmonary Disease,"adverse reaction rates, Adverse reactions, primary safety database, mean percent predicted FEV1, adverse reaction, discontinued due to an adverse reaction, adverse reaction most commonly leading to discontinuation, most common serious adverse reactions, COPD exacerbation, pneumonia, atrial fibrillation"
STRIVERDI,adverse reactions,Table 1 shows all adverse drug reactions reported by at least 2% of patients (and higher than placebo) who received STRIVERDI RESPIMAT 5 mcg during the 48-week trials.,"If the input is ""nan,"" there is no information provided from which I can extract adverse drug event terms. ""Nan"" typically stands for ""not a number"" or could signify that the expected content is missing or not applicable. If you have an actual excerpt of a drug label, please provide it for analysis."
STRIVERDI,adverse reactions,"Table 1: Number and frequency of adverse drug reactions greater than 2% (and higher than placebo) in COPD patients exposed to STRIVERDI RESPIMAT 5 mcg: Pooled data from the four 48-week, double-blind, active- and placebo-controlled clinical trials in COPD patients 40 years of age and older","Nasopharyngitis, Upper Respiratory Tract Infection, Bronchitis, Urinary Tract Infection, Cough, Dizziness, Rash, Diarrhea, Back Pain, Arthralgia, Pneumonia, Constipation, Pyrexia, Lung cancers"
STRIVERDI,boxed warnings,BOXED WARNING: WARNING: ASTHMA-RELATED DEATH,"As no input text was provided, I'm unable to extract adverse drug event terms. Please provide the drug label excerpt for analysis."
STRIVERDI,boxed warnings,WARNING: ASTHMA-RELATED DEATH,"asthma-related death, increase in asthma-related deaths"
STRIVERDI,boxed warnings,EXCERPT: WARNING: ASTHMA-RELATED DEATH,"asthma-related death, increase in asthma-related deaths"
STRIVERDI,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"acutely deteriorating COPD, excessive use, clinically significant cardiovascular effects, fatal, life-threatening paradoxical bronchospasm, cardiovascular disorders, convulsive disorders, thyrotoxicosis, sensitivity to sympathomimetic drugs"
STRIVERDI,warnings and precautions,5.1 Asthma-Related Death [ see Boxed Warning ],"asthma-related death, deterioration of Disease, acute Episodes, acutely deteriorating COPD"
STRIVERDI,warnings and precautions,5.3 Excessive Use of STRIVERDI RESPIMAT and Use with Long-Acting Beta2-Agonists,"cardiovascular effects, fatalities"
STRIVERDI,warnings and precautions,5.4 Paradoxical Bronchospasm,"paradoxical bronchospasm, life-threatening"
STRIVERDI,warnings and precautions,5.5 Cardiovascular Effects,"increases in pulse rate, systolic blood pressure, diastolic blood pressure, ECG changes, flattening of the T wave, prolongation of the QTc interval, ST segment depression, cardiovascular disorders, coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, hypertension"
STRIVERDI,warnings and precautions,5.6 Co-existing Conditions,"convulsive disorders, thyrotoxicosis, prolongation of the QT interval, diabetes mellitus, ketoacidosis"
STRIVERDI,warnings and precautions,5.7 Hypokalemia and Hyperglycemia,"hypokalemia, adverse cardiovascular effects, increases in plasma glucose, cardiac arrhythmias"
STRIVERDI,warnings and precautions,5.8 Hypersensitivity Reactions,"Immediate hypersensitivity reactions, angioedema"
BELSOMRA,adverse reactions,6 ADVERSE REACTIONS,"CNS depressant effects, daytime impairment, abnormal thinking, behavioral changes, worsening of Depression, Suicidal ideation, Sleep paralysis, hypnagogic/hypnopompic hallucinations, cataplexy-like symptoms, somnolence"
BELSOMRA,adverse reactions,6.1 Clinical Trials Experience,"clinical trials, adverse reaction rates, long-term study, higher than recommended doses"
BELSOMRA,adverse reactions,Table 1: Patient Exposure to BELSOMRA 15 mg or 20 mg in Study 1 and Study 2 Patients Treated BELSOMRA15 mg BELSOMRA20 mg For >= 1 Day (n) 202 291 Men (n) 69 105 Women (n) 133 186 Mean Age (years) 70 45 For >= 3 Months (n) 118 172 The pooled safety data described below (see Table 2 ) reflect the adverse reaction profile during the first 3 months of treatment.,somnolence
BELSOMRA,adverse reactions,"Table 2 shows the percentage of patients with adverse reactions during the first three months of treatment, based on the pooled data from 3-month controlled efficacy trials (Study 1 and Study 2).","somnolence, headache, abnormal dreams, dry mouth, cough, upper respiratory tract infection"
BELSOMRA,adverse reactions,"Table 2: Percentage of Patients with Adverse Reactions Incidence >=2% and Greater than Placebo in 3-Month Controlled Efficacy Trials (Study 1 and Study 2) Placebo BELSOMRA(20 mg in non-elderly or 15 mg in elderly patients) n=767 n=493 Gastrointestinal Disorders Diarrhea 1 2 Dry mouth 1 2 Infections and Infestations Upper respiratory tract infection 1 2 Nervous System Disorders Headache 6 7 Somnolence 3 7 Dizziness 2 3 Psychiatric Disorders Abnormal dreams 1 2 Respiratory, Thoracic and Mediastinal Disorders Cough 1 2 Dose Relationship for Adverse Reactions","adverse reactions, CNS adverse reactions, somnolence, serum cholesterol increase"
BELSOMRA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Daytime somnolence, impaired alertness, motor coordination impairment, impaired driving, insomnia, ""sleep-driving"", complex behaviors while out of bed, depression, suicidal thinking, compromised respiratory function, sleep paralysis, hypnagogic/hypnopompic hallucinations, cataplexy-like symptoms"
BELSOMRA,warnings and precautions,5.1 CNS Depressant Effects and Daytime Impairment,"somnolence, CNS depressant effects, impairment, impaired driving, risk of falling asleep while driving, daytime somnolence, driving impairment, CNS depression"
BELSOMRA,warnings and precautions,5.2 Need to Evaluate for Co-morbid Diagnoses,"sleep disturbances, failure of insomnia to remit, worsening of insomnia, emergence of new cognitive or behavioral abnormalities"
BELSOMRA,warnings and precautions,5.3 Abnormal Thinking and Behavioral Changes,"amnesia, anxiety, hallucinations, neuro-psychiatric symptoms, sleep-driving, preparing and eating food, making phone calls, having sex"
BELSOMRA,warnings and precautions,5.4 Worsening of Depression/Suicidal Ideation,"suicidal ideation, worsening of depression, suicidal thoughts, completed suicides, suicidal tendencies, intentional overdose, new behavioral sign or symptom"
BELSOMRA,warnings and precautions,5.5 Patients with Compromised Respiratory Function,"compromised respiratory function, severe obstructive sleep apnea (OSA), severe chronic obstructive pulmonary disease (COPD)"
BELSOMRA,warnings and precautions,"5.6 Sleep Paralysis, Hypnagogic/Hypnopompic Hallucinations, Cataplexy-like Symptoms","Sleep paralysis, hypnagogic/hypnopompic hallucinations, mild cataplexy, leg weakness"
NPLATE,adverse reactions,6 ADVERSE REACTIONS,"arthralgia, dizziness, insomnia, myalgia, pain in extremity, abdominal pain, shoulder pain, dyspepsia, paresthesia, headache"
NPLATE,adverse reactions,6.1 Clinical Trials Experience,"bone marrow reticulin deposition, worsening thrombocytopenia, headache"
NPLATE,adverse reactions,"Table 2. Adverse Drug Reactions Identified in Two Placebo-Controlled Studies Preferred Term Nplate (n = 84) Placebo (n = 41) Arthralgia 26% 20% Dizziness 17% 0% Insomnia 16% 7% Myalgia 14% 2% Pain in Extremity 13% 5% Abdominal Pain 11% 0% Shoulder Pain 8% 0% Dyspepsia 7% 0% Paresthesia 6% 0% Among 142 patients with chronic ITP who received Nplate in the single-arm extension study, the incidence rates of the adverse reactions occurred in a pattern similar to those reported in the placebo-controlled clinical studies.","Since the input provided is ""nan"" which typically means ""not a number"" or is used to indicate that data is not available or not applicable, there is no text to extract adverse drug event terms from. Therefore, I cannot provide a list of terms without the appropriate content to analyze. If you have an actual excerpt from a drug label, please provide it, and I can assist with finding the adverse drug event terms."
NPLATE,adverse reactions,6.2 Postmarketing Experience,"Erythromelalgia, Hypersensitivity, Angioedema"
NPLATE,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"increases blast cell counts, progression to acute myelogenous leukemia, Thrombotic/thromboembolic complications, Portal vein thrombosis, worsened thrombocytopenia, severe thrombocytopenia"
NPLATE,warnings and precautions,5.1 Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia,"acute myelogenous leukemia (AML), thrombocytopenia, increased peripheral blood blast cell counts"
NPLATE,warnings and precautions,5.2 Thrombotic/Thromboembolic Complications,"Thrombotic/thromboembolic complications, Portal vein thrombosis"
NPLATE,warnings and precautions,5.3 Bone Marrow Reticulin Formation and Risk for Bone Marrow Fibrosis,"risk for development or progression of reticulin fiber formation, marrow fibrosis with collagen, bone marrow fibrosis, cytopenias, new or worsening morphological abnormalities, cytopenia(s)"
NPLATE,warnings and precautions,5.4 Worsened Thrombocytopenia after Cessation of Nplate,"thrombocytopenia, worsened thrombocytopenia"
NPLATE,warnings and precautions,5.5 Lack or Loss of Response to Nplate,"Hyporesponsiveness, failure to maintain a platelet response, neutralizing antibodies, clinically important bleeding"
NPLATE,warnings and precautions,5.6 Laboratory Monitoring,"CBCs, platelet counts, dose-adjustment phase, stable Nplate dose, discontinuation of Nplate"
ORBACTIV,adverse reactions,6 ADVERSE REACTIONS,"Hypersensitivity Reactions, Infusion related reactions, Clostridium difficile-associated diarrhea, Osteomyelitis, headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea"
ORBACTIV,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, serious adverse reactions, cellulitis, headache, nausea, vomiting, limb and subcutaneous abscesses, diarrhea, adverse reactions, osteomyelitis"
ORBACTIV,adverse reactions,"Table 1 provides selected adverse reactions occurring in >= 1.5% of patients receiving ORBACTIV in the pooled ABSSSI clinical trials. There were 540 (55.3%) patients in the ORBACTIV arm and 559 (56.9%) patients in the vancomycin arm, who reported >=1 adverse reaction.","There is no text provided for me to extract adverse drug event terms from. If ""The input is nan"" is part of the excerpt, it suggests that there may be a mistake since ""nan"" stands for ""not a number"". It could be that the text was intended to be provided but was not included in your request. Please provide the necessary text so I can assist you with identifying the adverse drug event terms."
ORBACTIV,adverse reactions,Table 1: Incidence of Selected Adverse Reactions Occurring in >= 1.5% of Patients Receiving ORBACTIV in the Pooled ABSSSI Clinical Trials Adverse Reactions ORBACTIVN=976 (%) VancomycinN=983 (%) Gastrointestinal disorders Diarrhea 36 (3.7) 32 (3.4) Nausea 97 (9.9) 103 (10.5) Vomiting 45 (4.6) 46 (4.7) Nervous system disorders Dizziness 26 (2.7) 26 (2.6) Headache 69 (7.1) 66 (6.7) General disorders and administration Infusion site phlebitis 24 (2.5) 15 (1.5) Infusion site reaction 19 (1.9) 34 (3.5) Infections and infestations Abscess (limb and subcutaneous) 37 (3.8) 23 (2.3) Investigations Alanine aminotransferase increased 27 (2.8) 15 (1.5) Aspartate aminotransferase increased 18 (1.8) 15 (1.5) Cardiac disorders Tachycardia 24 (2.5) 11 (1.1) The following selected adverse reactions were reported in ORBACTIV-treated patients at a rate of less than 1.5%:,"anemia, eosinophilia, infusion site erythema, extravasation, induration, pruritis, rash, edema peripheral, hypersensitivity, osteomyelitis, total bilirubin increased, hyperuricemia, hypoglycemia, tenosynovitis, myalgia, bronchospasm, wheezing, urticaria, angioedema, erythema multiforme, leucocytoclastic vasculitis."
ORBACTIV,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"bleeding, artificially prolong aPTT, prolong PT, prolong INR, Hypersensitivity reactions, acute hypersensitivity, Infusion-related reactions, Clostridium difficile-associated colitis, Osteomyelitis"
ORBACTIV,warnings and precautions,5.1 Potential Risk of Bleeding with Concomitant Use of Warfarin,"higher exposure of warfarin, increase the risk of bleeding, signs of bleeding, artificially prolong PT, prolong INR, anticoagulation effect, unreliable"
ORBACTIV,warnings and precautions,5.2 Coagulation Test Interference,"prolonged aPTT, prolonged PT, prolonged INR, effects on activated clotting time (ACT)"
ORBACTIV,warnings and precautions,5.3 Hypersensitivity,"Serious hypersensitivity reactions, acute hypersensitivity reaction, allergy, hypersensitivity reactions"
ORBACTIV,warnings and precautions,5.4 Infusion Related Reactions,"pruritus, urticaria, flushing"
ORBACTIV,warnings and precautions,5.5 Clostridium difficile -associated Diarrhea,"Clostridium difficile-associated diarrhea (CDAD), mild diarrhea, fatal colitis, increased morbidity, mortality, refractory to antibacterial therapy"
ORBACTIV,warnings and precautions,5.6 Osteomyelitis,osteomyelitis
ORBACTIV,warnings and precautions,5.7 Development of Drug Resistant Bacteria,"proven or strongly suspected bacterial infection, increases the risk, development of drug-resistant bacteria"
MEKINIST,adverse reactions,6 ADVERSE REACTIONS,"New Primary Malignancies, Hemorrhage, Venous Thromboembolism, Cardiomyopathy, Ocular Toxicities, Interstitial Lung Disease, Serious Febrile Reactions, Serious Skin Toxicity, Hyperglycemia, rash, diarrhea, lymphedema, pyrexia, chills, fatigue, nausea, vomiting, abdominal pain, peripheral edema, cough, headache, arthralgia, night sweats, decreased appetite, constipation, myalgia"
MEKINIST,adverse reactions,6.1 Clinical Trials Experience,"RPED, RVO"
MEKINIST,adverse reactions,"Table 3 presents adverse reactions identified from analyses of Trial 1, a randomized, open-label trial of patients with BRAF V600E or V600K mutation-positive melanoma receiving MEKINIST (N = 211) 2 mg orally once daily or chemotherapy (N = 99) (either dacarbazine 1,000 mg/m 2 every 3 weeks or paclitaxel 175 mg/m 2 every 3 weeks) [see Clinical Studies (14.1)] . Patients with abnormal LVEF, history of acute coronary syndrome within 6 months, or current evidence of Class II or greater congestive heart failure (New York Heart Association) were excluded from Trial 1. The median duration of treatment with MEKINIST was 4.3 months. In Trial 1, 9% of patients receiving MEKINIST experienced adverse reactions resulting in permanent discontinuation of trial medication. The most common adverse reactions resulting in permanent discontinuation of MEKINIST were decreased left ventricular ejection fraction (LVEF), pneumonitis, renal failure, diarrhea, and rash. Adverse reactions led to dose reductions in 27% of patients treated with MEKINIST. Rash and decreased LVEF were the most common reasons cited for dose reductions of MEKINIST.","If the input is ""nan"", which typically stands for ""not applicable"" or ""not available,"" and there is no provided text excerpt from a drug label, I cannot provide a list of adverse drug event terms. For accurate assistance, please provide the drug label excerpt in question."
MEKINIST,adverse reactions,Table 3. Selected Adverse Reactions Occurring in >=10% of Patients Receiving MEKINIST and at a Higher Incidence (>=5%) Than in the Chemotherapy Arm or >=2% (Grades 3 or 4) Adverse Reactions,"Rash, Dermatitis acneiform, Dry skin, Pruritus, Paronychia, Diarrhea, Stomatitis, Abdominal pain, Lymphedema, Hypertension, Hemorrhage, Bradycardia, Xerostomia, Folliculitis, Rash pustular, Cellulitis, Rhabdomyolysis, Dizziness, Dysgeusia, Vision blurred, Dry eye"
MEKINIST,adverse reactions,Table 4. Percent-Patient Incidence of Laboratory Abnormalities Occurring at a Higher Incidence in Patients Treated With MEKINIST in Trial 1 (Between-Arm Difference of >=5% [All Grades] or >=2% [Grades 3 or 4] a ),"Increased aspartate aminotransferase (AST), Increased alanine aminotransferase (ALT), Hypoalbuminemia, Anemia, Increased alkaline phosphatase, Pyrexia, Chills, Nausea, Decreased ejection fraction"
MEKINIST,adverse reactions,Table 5. Common Adverse Drug Reactions Occurring in >10% (All Grades) or >=5% (Grades 3 or 4) of Patients Treated With MEKINIST in Combination With Dabrafenib in Trial 2,"Pyrexia, Chills, Fatigue, Edema peripheral, Rash, Night sweats, Dry skin, Dermatitis acneiform, Actinic keratosis, Erythema, Pruritus, Nausea, Vomiting, Diarrhea, Abdominal pain, Constipation, Dry mouth, Headache, Dizziness, Cough, Oropharyngeal pain, Arthralgia, Myalgia, Back pain, Muscle spasms, Pain in extremity, Decreased appetite, Dehydration, Insomnia, Hemorrhage, Urinary tract infection, Renal failure, Vision blurred, Transient blindness, Stomatitis, Pancreatitis, Asthenia, Cellulitis, Folliculitis, Paronychia, Rash pustular, Skin papilloma, Palmar-plantar erythrodysesthesia syndrome, Hyperkeratosis, Hyperhidrosis, Hypertension"
MEKINIST,adverse reactions,Table 6. Treatment-Emergent Laboratory Abnormalities Occurring at >=10% (All Grades) or >=2% (Grades 3 or 4) of Patients Treated With MEKINIST in Combination With Dabrafenib in Trial 2,"Leukopenia, Lymphopenia, Neutropenia, Anemia, Thrombocytopenia, Increased AST, Increased alkaline phosphatase, Increased ALT, Hyperbilirubinemia, Hyperglycemia, Increased GGT, Hyponatremia, Hypoalbuminemia, Hypophosphatemia, Hypokalemia, Increased creatinine, Hypomagnesemia, Hyperkalemia, Hypercalcemia, Hypocalcemia, QT Prolongation"
MEKINIST,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Tumor promotion, Hemolytic anemia, New primary malignancies, Hemorrhage, Venous Thromboembolism, Cardiomyopathy, Ocular Toxicities, Interstitial Lung Disease (ILD), Serious Febrile Reactions, Serious Skin Toxicity, Hyperglycemia, Embryofetal Toxicity"
MEKINIST,warnings and precautions,5.1 New Primary Malignancies,"new primary malignancies, basal cell carcinoma, cutaneous squamous cell carcinomas, keratoacanthoma, new primary melanoma, non-cutaneous malignancies, KRAS mutation-positive pancreatic adenocarcinoma, recurrent NRAS mutation-positive colorectal carcinoma, head and neck carcinoma, glioblastoma"
MEKINIST,warnings and precautions,5.2 Hemorrhage,"Hemorrhages, major hemorrhages, symptomatic bleeding, critical area or organ bleeding, increased incidence and severity of hemorrhagic event, intracranial hemorrhage, gastric hemorrhage, Grade 4 hemorrhagic events, Grade 3 hemorrhagic events"
MEKINIST,warnings and precautions,5.3 Venous Thromboembolism,"Venous thromboembolism, deep venous thrombosis (DVT), pulmonary embolism (PE)"
MEKINIST,warnings and precautions,5.4 Cardiomyopathy,"cardiomyopathy, cardiac failure, left ventricular dysfunction, decreased left ventricular ejection fraction (LVEF)"
MEKINIST,warnings and precautions,5.5 Ocular Toxicities,"Retinal Vein Occlusion, macular edema, decreased visual function, neovascularization, glaucoma, loss of vision, other visual disturbances, Retinal Pigment Epithelial Detachment, reduction in visual acuity, Ocular Coherence Tomography abnormalities, Uveitis, Iritis, visual signs and symptoms of uveitis, change in vision, photophobia, eye pain"
MEKINIST,warnings and precautions,5.6 Interstitial Lung Disease,"ILD, pneumonitis, cough, dyspnea, hypoxia, pleural effusion, infiltrates"
MEKINIST,warnings and precautions,5.7 Serious Febrile Reactions,"febrile reactions, fever, hypotension, rigors, chills, dehydration, renal failure, pyrexia, syncope"
MEKINIST,warnings and precautions,5.8 Serious Skin Toxicity,"Serious skin toxicity, rash, dermatitis acneiform rash, palmar-plantar erythrodysesthesia syndrome, erythema, severe skin toxicity, secondary infections of the skin, infections of the skin"
MEKINIST,warnings and precautions,5.9 Hyperglycemia,"Hyperglycemia, increase in the dose of insulin, initiation of oral hypoglycemic agent therapy, Grade 3 hyperglycemia, severe hyperglycemia"
MEKINIST,warnings and precautions,5.10 Embryofetal Toxicity,"fetal harm, embryotoxic, abortifacient"
CYRAMZA,adverse reactions,6 ADVERSE REACTIONS,"Hemorrhage, Arterial Thromboembolic Events, Hypertension, Infusion-Related Reactions, Gastrointestinal Perforation, Impaired Wound Healing, Reversible Posterior Leukoencephalopathy Syndrome, Proteinuria Including Nephrotic Syndrome, Thyroid Dysfunction, diarrhea, hypertension, fatigue, neutropenia, epistaxis, asthenia, stomatitis/mucosal inflammation, decreased appetite"
CYRAMZA,adverse reactions,6.1 Clinical Trials Experience,"hypertension, diarrhea, anemia, intestinal obstruction, red blood cell transfusions"
CYRAMZA,adverse reactions,Table 2 provides the frequency and severity of adverse reactions in Study 1.,"If the input to analyze is ""nan"", and assuming ""nan"" is meant to indicate a non-applicable or not available content, it's not possible to provide a list of adverse drug event terms. I would need an actual excerpt of a drug label to identify and list any adverse drug event terms."
CYRAMZA,adverse reactions,"Table 2: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA in Study 1 Adverse Reactions (MedDRA) System Organ Class CYRAMZA (8 mg/kg) N=236 Placebo N=115 All Grades (Frequency %) Grade 3-4 (Frequency %) All Grades (Frequency %) Grade 3-4 (Frequency %) Gastrointestinal Disorders Diarrhea 14 1 9 2 Metabolism and Nutrition Disorders Hyponatremia 6 3 2 1 Nervous System Disorders Headache 9 0 3 0 Vascular Disorders Hypertension 16 8 8 3 Clinically relevant adverse reactions reported in >=1% and <5% of CYRAMZA-treated patients in Study 1 were: neutropenia (4.7% CYRAMZA versus 0.9% placebo), epistaxis (4.7% CYRAMZA versus 0.9% placebo), rash (4.2% CYRAMZA versus 1.7% placebo), intestinal obstruction (2.1% CYRAMZA versus 0% placebo), and arterial thromboembolic events (1.7% CYRAMZA versus 0% placebo) [see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.1 , 5.2 )] .","proteinuria, gastrointestinal perforation, infusion-related reactions, fatigue, neutropenia, diarrhea, epistaxis, febrile neutropenia, thrombocytopenia"
CYRAMZA,adverse reactions,Table 3 provides the frequency and severity of adverse reactions in Study 2.,"As no text is provided, I cannot extract any adverse drug event terms. If you provide the text from a drug label, I can then identify the adverse event terms for you."
CYRAMZA,adverse reactions,"Table 3: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA plus Paclitaxel in Study 2 Adverse Reactions (MedDRA) System Organ Class CYRAMZA plus Paclitaxel (N=327) Placebo plus Paclitaxel (N=329) All Grades (Frequency %) Grade >=3 (Frequency %) All Grades (Frequency %) Grade >=3 (Frequency %) Blood and Lymphatic System Disorders Neutropenia 54 41 31 19 Thrombocytopenia 13 2 6 2 Gastrointestinal Disorders Diarrhea 32 4 23 2 Gastrointestinal hemorrhage events 10 4 6 2 Stomatitis 20 1 7 1 General Disorders and Administration Site Disorders Fatigue/Asthenia 57 12 44 6 Peripheral edema 25 2 14 1 Metabolism and Nutrition Disorders Hypoalbuminemia 11 1 5 1 Renal and Urinary Disorders Proteinuria 17 1 6 0 Respiratory, Thoracic, and Mediastinal Disorders Epistaxis 31 0 7 0 Vascular Disorder Hypertension 25 15 6 3 Clinically relevant adverse reactions reported in >=1% and <5% of the CYRAMZA plus paclitaxel treated patients in Study 2 were sepsis (3.1% CYRAMZA plus paclitaxel versus 1.8% placebo plus paclitaxel) and gastrointestinal perforations (1.2% CYRAMZA plus paclitaxel versus 0.3% for placebo plus paclitaxel).","neutropenia, febrile neutropenia, fatigue/asthenia, stomatitis/mucosal inflammation, infusion-related reaction, epistaxis, pulmonary hemorrhage, pneumonia, serious adverse events"
CYRAMZA,adverse reactions,Table 4 provides the frequency and severity of adverse reactions in Study 3.,"The input provided is ""nan"" which likely signifies ""not a number"" or ""not applicable."" Without actual content from a drug label, it is impossible to extract any adverse drug event terms. Please provide the excerpt of the drug label containing the relevant information."
CYRAMZA,adverse reactions,"Table 4: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA in Study 3 Adverse Reactions (MedDRA) System Organ Class CYRAMZA plus docetaxel (N=627) Placebo plus docetaxel (N=618) All Grades (Frequency %) Grade 3-4 (Frequency %) All Grades (Frequency %) Grade 3-4 (Frequency %) Blood and Lymphatic System Disorders Febrile neutropenia 16 16 10 10 Neutropenia 55 49 46 40 Thrombocytopenia 13 3 5 <1 Gastrointestinal Disorders Stomatitis/Mucosal inflammation 37 7 19 2 Eye Disorders Lacrimation increased 13 <1 5 0 General Disorders and Administration Site Disorders Fatigue/Asthenia 55 14 50 11 Peripheral edema 16 0 9 <1 Respiratory, Thoracic, and Mediastinal Disorders Epistaxis 19 <1 7 <1 Vascular Disorders Hypertension 11 6 5 2 Clinically relevant adverse drug reactions reported in >=1% and <5% of the CYRAMZA plus docetaxel-treated patients in Study 3 were hyponatremia (4.8% CYRAMZA plus docetaxel versus 2.4% for placebo plus docetaxel) and proteinuria (3.3% CYRAMZA plus docetaxel versus 0.8% placebo plus docetaxel).","uncontrolled hypertension, Grade 4 hypertension, Grade 3 proteinuria, Grade 3-4 bleeding event, bowel perforation, diarrhea, neutropenia, decreased appetite, epistaxis, stomatitis, thrombocytopenia, proteinuria, gastrointestinal perforation, intestinal obstruction, febrile neutropenia"
CYRAMZA,adverse reactions,Table 5 provides the frequency and severity of adverse reactions in Study 4.,"If the input is ""nan"", this usually indicates that the provided data is 'not a number' or nonexistent. In this context, it suggests that there is no excerpt to analyze or that there has been an error in providing the excerpt. Since there is no drug label information given, it's not possible to list any adverse drug event terms. If you provide the excerpt or clarify the input, I could assist you with identifying the adverse drug event terms."
CYRAMZA,adverse reactions,"Table 5: Adverse Reactions Occurring at Incidence Rate >=5% and a >=2% Difference Between Arms in Patients Receiving CYRAMZA in Study 4 a Includes 3 patients with nephrotic syndrome in the CYRAMZA plus FOLFIRI treatment group. Adverse Reactions (MedDRA) System Organ Class CYRAMZA plus FOLFIRI N=529 Placebo plus FOLFIRI N=528 All Grades (Frequency %) Grade >=3 (Frequency %) All Grades (Frequency %) Grade >=3 (Frequency %) Blood and Lymphatic System Disorders Neutropenia 59 38 46 23 Thrombocytopenia 28 3 14 <1 Gastrointestinal Disorders Decreased appetite 37 2 27 2 Diarrhea 60 11 51 10 Gastrointestinal hemorrhage events 12 2 7 1 Stomatitis 31 4 21 2 General Disorders and Administration Site Disorders Peripheral edema 20 <1 9 0 Metabolism and Nutrition Disorders Hypoalbuminemia 6 1 2 0 Renal and Urinary Disorders Proteinuria a 17 3 5 <1 Respiratory, Thoracic, and Mediastinal Disorders Epistaxis 33 0 15 0 Skin and Subcutaneous Tissue Disorders Palmar-plantar erythrodysesthesia syndrome 13 1 5 <1 Vascular Disorders Hypertension 26 11 9 3 Clinically relevant adverse reactions reported in >=1% and <5% of CYRAMZA plus FOLFIRI-treated patients in Study 4 consisted of gastrointestinal perforation (1.7% CYRAMZA plus FOLFIRI versus 0.6% for placebo plus FOLFIRI).",Increased TSH levels
CYRAMZA,adverse reactions,6.2 Immunogenicity,"immunogenicity, treatment-emergent anti-ramucirumab antibodies, Neutralizing antibodies"
CYRAMZA,boxed warnings,"BOXED WARNING: WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING","If the input provided is ""nan,"" which typically stands for ""not a number"" or indicates a missing value or a placeholder for an undefined result, it means there is no text provided to extract adverse drug event terms from. Without the actual text of a drug label, I cannot provide a list of adverse drug event terms. If you can provide the text, I'd be happy to assist with identifying the adverse drug events."
CYRAMZA,boxed warnings,"WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING","Hemorrhage, gastrointestinal hemorrhage, severe hemorrhagic events, fatal hemorrhagic events, severe bleeding, gastrointestinal perforation, impaired wound healing, wound healing complications"
CYRAMZA,boxed warnings,"EXCERPT: WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, AND IMPAIRED WOUND HEALING","Hemorrhage, gastrointestinal hemorrhage, fatal hemorrhagic events, severe bleeding, Gastrointestinal Perforation, Impaired Wound Healing, wound healing complications"
CYRAMZA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Arterial Thromboembolic Events, Hypertension, Infusion-Related Reactions, Impaired Wound Healing, Clinical Deterioration in Patients with Cirrhosis, Reversible Posterior Leukoencephalopathy Syndrome, Proteinuria, Nephrotic Syndrome, Thyroid Dysfunction, Embryofetal Risk"
CYRAMZA,warnings and precautions,5.1 Hemorrhage,"hemorrhage, gastrointestinal hemorrhage, fatal hemorrhagic events, severe bleeding, gastric hemorrhage, pulmonary hemorrhage"
CYRAMZA,warnings and precautions,5.2 Arterial Thromboembolic Events,"arterial thromboembolic events, myocardial infarction, cardiac arrest, cerebrovascular accident, cerebral ischemia"
CYRAMZA,warnings and precautions,5.3 Hypertension,"severe hypertension, hypertensive crisis, hypertensive encephalopathy"
CYRAMZA,warnings and precautions,5.4 Infusion-Related Reactions,"infusion-related reactions, severe events, rigors/tremors, back pain/spasms, chest pain, tightness, chills, flushing, dyspnea, wheezing, hypoxia, paresthesia, bronchospasm, supraventricular tachycardia, hypotension"
CYRAMZA,warnings and precautions,5.5 Gastrointestinal Perforations,gastrointestinal perforation
CYRAMZA,warnings and precautions,5.6 Impaired Wound Healing,"Impaired wound healing, serious or non-healing wounds, wound healing complications"
CYRAMZA,warnings and precautions,5.7 Clinical Deterioration in Patients with Child-Pugh B or C Cirrhosis,"clinical deterioration, new onset encephalopathy, worsening encephalopathy, ascites, hepatorenal syndrome"
CYRAMZA,warnings and precautions,5.8 Reversible Posterior Leukoencephalopathy Syndrome,"Reversible Posterior Leukoencephalopathy Syndrome (RPLS), ongoing neurologic sequelae, death"
CYRAMZA,warnings and precautions,5.9 Proteinuria Including Nephrotic Syndrome,"severe proteinuria, nephrotic syndrome"
CYRAMZA,warnings and precautions,5.10 Thyroid Dysfunction,hypothyroidism
CYRAMZA,warnings and precautions,5.11 Embryofetal Toxicity,"fetal harm, embryofetal development issues, postnatal development issues"
RAXIBACUMAB,adverse reactions,6 ADVERSE REACTIONS,"rash, pain in extremity, pruritus, somnolence"
RAXIBACUMAB,adverse reactions,6.1 Clinical Trials Experience,"urticaria, clonus, dyspnea, rash, pain in extremity, pruritus, somnolence"
RAXIBACUMAB,adverse reactions,Table 3. Adverse Reactions Reported in >=1.5% of Healthy Adult Subjects Exposed to Raxibacumab 40 mg/kg IV Preferred Term Placebo N = 80 (%) Single-dose Raxibacumab N = 283 (%) Double-dose Raxibacumab >=4 Months Apart N = 20 (%) Double-dose Raxibacumab 2 Weeks Apart N = 23 (%) Total Raxibacumab Subjects N = 326 (%) Rash/Rash erythematous/Rash papular 1 (1.3) 9 (3.2) 0 0 9 (2.8) Pain in extremity 1 (1.3) 7 (2.5) 0 0 7 (2.1) Pruritus 0 7 (2.5) 0 0 7 (2.1) Somnolence 0 4 (1.4) 0 1 (4.3) 5 (1.5) Rashes,"rash, anemia, leukopenia, lymphadenopathy, palpitations, vertigo, fatigue, infusion site pain, peripheral edema, blood amylase increased, blood creatine phosphokinase increased, prothrombin time prolonged, back pain, muscle spasms, syncope vasovagal, insomnia, flushing, hypertension"
RAXIBACUMAB,warnings and precautions,5 WARNINGS AND PRECAUTIONS,Infusion reactions
RAXIBACUMAB,warnings and precautions,5.1 Infusion Reactions,"infusion-related reactions, rash, urticaria, pruritus"
ARCALYST,adverse reactions,6 ADVERSE REACTIONS,"Mycobacterium intracellulare infection, gastrointestinal bleeding, colitis, sinusitis, bronchitis, Streptococcus pneumoniae meningitis, injection-site reaction, upper respiratory infection"
ARCALYST,adverse reactions,6.1 Clinical Trial Experience,"adverse drug event terms, adverse events"
ARCALYST,adverse reactions,"Table 1: Most Frequent Adverse Reactions (Part A, Reported by at Least Two Patients) Adverse Event ARCALYST160 mg(n = 23) Placebo(n= 24) Any AE 17 (74%) 13 (54%) Injection-site reactions 11 (48%) 3 (13%) Upper respiratory tract infection 6 (26%) 1 (4%) Nausea 1 (4%) 3 (13%) Diarrhea 1 (4%) 3 (13%) Sinusitis 2 (9%) 1 (4%) Abdominal pain upper 0 2 (8%) Cough 2 (9%) 0 Hypoesthesia 2 (9%) 0 Stomach discomfort 1 (4%) 1 (4%) Urinary tract infection 1 (4%) 1 (4%) 6.2 Injection-Site Reactions In patients with CAPS, the most common and consistently reported adverse event associated with ARCALYST was injection-site reaction (ISR). The ISRs included erythema, swelling, pruritis, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth and hemorrhage. Most injection-site reactions lasted for one to two days. No ISRs were assessed as severe, and no patient discontinued study participation due to an ISR.","The input ""nan"" usually stands for ""not a number"" and appears to indicate that there is no drug label text provided to analyze. Without any text, it is impossible to list any adverse drug event terms. If you have a drug label or text excerpt you'd like me to analyze, please provide it, and I'll happily identify the adverse drug event terms for you."
ARCALYST,adverse reactions,6.3 Infections,"infections, Serious Infections, infection in his olecranon bursa, bronchitis/sinusitis, Streptococcus pneumoniae meningitis"
ARCALYST,adverse reactions,6.4 Malignancies,"There is no specific adverse drug event term provided in the given text excerpt. It merely refers to the section where such information might be found. The text ""[see Warnings and Precautions (5.2)]"" is an instruction to consult section 5.2 of the drug label for potential warnings and precautions associated with the drug, which might include adverse drug event information. However, since no specific adverse events are listed within the provided excerpt, none can be provided in response."
ARCALYST,adverse reactions,6.5 Hematologic Events,transient neutropenia
ARCALYST,adverse reactions,6.6 Immunogenicity,"treatment-emergent binding antibodies, neutralizing antibodies"
ARCALYST,adverse reactions,6.7 Lipid profiles,"increases in total cholesterol, increases in HDL cholesterol, increases in LDL cholesterol, increases in triglycerides"
ARCALYST,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"interfere with immune response, Serious, life-threatening infections, hypersensitivity reactions, Live vaccines should not be given concurrently"
ARCALYST,warnings and precautions,5.1 Infections,"increased risk of serious infections, bronchitis, bacterial meningitis, serious infection, active or chronic infection, reactivation of latent tuberculosis (TB), atypical or opportunistic infections"
ARCALYST,warnings and precautions,5.2 Immunosuppression,"active infections, chronic infections, development of malignancies, increase in the risk of malignancies"
ARCALYST,warnings and precautions,5.3 Immunizations,"risks of secondary transmission of infection, interfere with normal immune response, may not be effective, IL-1 blockade may interfere with immune response to infections"
ARCALYST,warnings and precautions,5.4 Lipid Profile Changes,changes in their lipid profiles
ARCALYST,warnings and precautions,5.5 Hypersensitivity,Hypersensitivity reactions
RAPIVAB,adverse reactions,6 ADVERSE REACTIONS,"Serious skin and hypersensitivity reactions, Neuropsychiatric Events, diarrhea"
RAPIVAB,adverse reactions,6.1 Clinical Trials Experience,"diarrhea, serious adverse event, clinically significant laboratory abnormalities"
RAPIVAB,adverse reactions,"Table 2: Laboratory Abnormalities Occurring in >=2% of Subjects Treated with RAPIVAB 600 mg Laboratory Parameter Abnormality RAPIVAB 600 mg Placebo Alanine Aminotransferase (> 2.5 * ULN) (N=654)3% (N=430)2% Serum Glucose (> 160 mg/dL) (N=660)5% (N=433)3% Creatine Phosphokinase (>= 6.0 * ULN) (N=654)4% (N=431)2% Neutrophils (< 1.000 *10 9 /L) (N=654)8% (N=430)6% In a subset of subjects with serious influenza requiring hospitalization treated with RAPIVAB 600 mg as monotherapy (N=101) the following adverse reactions were also reported more frequently with RAPIVAB as compared to placebo: constipation (4% versus 2%), insomnia (3% versus 0%), AST increased (3% versus 2%), and hypertension (2% versus 0%).","If the input is ""nan,"" which typically stands for ""not a number"" or simply means that there is no valid text provided, I cannot extract any adverse drug event terms. Please provide the actual drug label excerpt for analysis."
RAPIVAB,adverse reactions,6.2 Postmarketing Experience,"Stevens-Johnson Syndrome, exfoliative dermatitis, rash, abnormal behavior, hallucination"
RAPIVAB,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Stevens-Johnson syndrome, erythema multiforme, hallucinations, delirium, abnormal behavior"
RAPIVAB,warnings and precautions,5.1 Serious Skin/Hypersensitivity Reactions,"serious skin reactions, erythema multiforme, Stevens-Johnson syndrome"
RAPIVAB,warnings and precautions,5.2 Neuropsychiatric Events,"hallucinations, delirium, abnormal behavior, fatal outcomes, encephalitis, encephalopathy, injury"
RAPIVAB,warnings and precautions,5.3 Risk of Bacterial Infections,"serious bacterial infections, secondary bacterial infections"
FOLOTYN,adverse reactions,6 ADVERSE REACTIONS,"Bone Marrow Suppression, Mucositis, Dermatologic Reactions, Tumor Lysis Syndrome, Hepatic Toxicity, thrombocytopenia, nausea, fatigue, pyrexia, sepsis, febrile neutropenia, dehydration, dyspnea."
FOLOTYN,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, safety, Adverse Reactions"
FOLOTYN,adverse reactions,"Table 4 summarizes the most frequent adverse reactions, regardless of causality, using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0).","Without an actual excerpt of a drug label provided, I cannot identify any adverse drug event terms. For this task, I would need a text sample that lists specific side effects or adverse events associated with a medication. If you provide a drug label excerpt, I would then be able to extract the relevant terms for you."
FOLOTYN,adverse reactions,"Table 4 Adverse Reactions Occurring in PTCL Patients (Incidence >= 10% of patients) N=111 Total Grade 3 Grade 4 Preferred Term N % N % N % aStomatitis or mucosal inflammation of the gastrointestinal and genitourinary tracts. bFive patients with platelets < 10,000/mcL cAlanine aminotransferase, aspartate aminotransferase, and transaminases increased Any Adverse Event 111 100 48 43 34 31 Mucositis a 78 70 19 17 4 4 Thrombocytopenia b 45 41 15 14 21 19 b Nausea 44 40 4 4 0 0 Fatigue 40 36 5 5 2 2 Anemia 38 34 17 15 2 2 Constipation 37 33 0 0 0 0 Pyrexia 36 32 1 1 1 1 Edema 33 30 1 1 0 0 Cough 31 28 1 1 0 0 Epistaxis 29 26 0 0 0 0 Vomiting 28 25 2 2 0 0 Neutropenia 27 24 14 13 8 7 Diarrhea 23 21 2 2 0 0 Dyspnea 21 19 8 7 0 0 Anorexia 17 15 3 3 0 0 Hypokalemia 17 15 4 4 1 1 Rash 17 15 0 0 0 0 Pruritus 16 14 2 2 0 0 Pharyngolaryngeal pain 15 14 1 1 0 0 Liver function test abnormal c 14 13 6 5 0 0 Abdominal pain 13 12 4 4 0 0 Pain in extremity 13 12 0 0 0 0 Back pain 12 11 3 3 0 0 Leukopenia 12 11 3 3 4 4 Night sweats 12 11 0 0 0 0 Asthenia 11 10 1 1 0 0 Tachycardia 11 10 0 0 0 0 Upper respiratory tract infection 11 10 1 1 0 0 Serious Adverse Events","pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea, thrombocytopenia, cardiopulmonary arrest, pancytopenia"
FOLOTYN,adverse reactions,6.2 Post Marketing Experience,
FOLOTYN,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Thrombocytopenia, neutropenia, anemia, mucositis, Dermatologic reactions, Tumor lysis syndrome, Hepatic toxicity, Embryo-Fetal toxicity"
FOLOTYN,warnings and precautions,5.1 Bone Marrow Suppression,"bone marrow suppression, thrombocytopenia, neutropenia, anemia, hematological toxicity"
FOLOTYN,warnings and precautions,5.2 Mucositis,mucositis
FOLOTYN,warnings and precautions,5.3 Dermatologic Reactions,"severe dermatologic reactions, death, skin exfoliation, ulceration, toxic epidermal necrolysis (TEN)"
FOLOTYN,warnings and precautions,5.4 Tumor Lysis Syndrome,tumor lysis syndrome (TLS)
FOLOTYN,warnings and precautions,5.5 Hepatic Toxicity,"hepatic toxicity, liver function test abnormalities, Persistent liver function test abnormalities"
FOLOTYN,warnings and precautions,5.6 Risk of Increased Toxicity in the Presence of Impaired Renal Function,"increased exposure, toxicity, renal function, systemic toxicity, Serious adverse drug reactions, toxic epidermal necrolysis, mucositis, end stage renal disease (ESRD)"
FOLOTYN,warnings and precautions,5.7 Embryo-Fetal Toxicity,"fetal harm, embryotoxic, fetotoxic, potential hazard to the fetus"
KRYSTEXXA,adverse reactions,6 ADVERSE REACTIONS,"anaphylaxis, infusion reactions, gout flares, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, vomiting"
KRYSTEXXA,adverse reactions,6.1 Clinical Trials Experience,"anaphylaxis, infusion reactions, urticaria, dyspnea, chest discomfort, chest pain, erythema, pruritus, gout flares, congestive heart failure exacerbation"
KRYSTEXXA,adverse reactions,"Table 1. Adverse Reactions Occurring in 5% or More of Patients Treated with KRYSTEXXA Compared to Placebo Adverse Reaction (Preferred Term) KRYSTEXXA 8 mg e very 2 weeks (N=85) N a (%) Placebo (N=43) N (%) Gout flare 65 (77%) 35 (81%) Infusion reaction 22 (26%) 2 (5%) Nausea 10 (12%) 1 (2%) Contusion b or Ecchymosis b 9 (11%) 2 (5%) Nasopharyngitis 6 (7%) 1 (2%) Constipation 5 (6%) 2 (5%) Chest Pain 5 (6%) 1 (2%) Anaphylaxis 4 (5%) 0 (0%) Vomiting 4 (5%) 1 (2%) a If the same subject in a given group had more than one occurrence in the same preferred term event category, the subject was counted only once.","contusion, ecchymosis"
KRYSTEXXA,adverse reactions,6.2 Immunogenicity,"Anti-pegloticase antibodies, failure to maintain pegloticase-induced normalization of uric acid, infusion reactions, immunogenicity"
KRYSTEXXA,boxed warnings,BOXED WARNING: WARNING: ANAPHYLAXIS AND INFUSION REACTIONS,"If the input text you've provided is ""nan"", which usually stands for 'not a number' or indicates missing data, there is no information to extract adverse drug event terms from. Therefore, I cannot provide a list of adverse drug event terms without an appropriate excerpt from a drug label. Please provide the text containing the adverse drug events you wish to identify."
KRYSTEXXA,boxed warnings,WARNING: ANAPHYLAXIS AND INFUSION REACTIONS,"Anaphylaxis, infusion reactions, delayed-type hypersensitivity reactions"
KRYSTEXXA,boxed warnings,EXCERPT: WARNING: ANAPHYLAXIS AND INFUSION REACTIONS,"anaphylaxis, infusion reactions, delayed-type hypersensitivity reactions"
KRYSTEXXA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Anaphylaxis, Infusion Reactions, Gout Flares, Congestive Heart Failure Exacerbation"
KRYSTEXXA,warnings and precautions,5.1 Anaphylaxis,"anaphylaxis, wheezing, peri-oral or lingual edema, hemodynamic instability, rash, urticaria, delayed type hypersensitivity reactions"
KRYSTEXXA,warnings and precautions,5.2 Infusion Reactions,infusion reactions
KRYSTEXXA,warnings and precautions,5. 3 Gout Flares,"Gout flares, adverse reactions"
KRYSTEXXA,warnings and precautions,5. 4 Congestive Heart Failure,"congestive heart failure, exacerbation, adverse reactions"
KRYSTEXXA,warnings and precautions,5. 5 Re-treatment with KRYSTEXXA,"anaphylaxis, infusion reactions"
NUCYNTA,adverse reactions,6 ADVERSE REACTIONS,"Respiratory Depression, Interaction with Alcohol, Chronic Pulmonary Disease, Hypotensive Effects, Interactions with Other CNS Depressants, Drug abuse, addiction, and dependence, Gastrointestinal Effects, Seizures, Serotonin Syndrome, nausea, dizziness, vomiting, somnolence"
NUCYNTA,adverse reactions,6.1 Clinical Studies Experience,"nausea, dizziness, vomiting, somnolence, headache"
NUCYNTA,adverse reactions,"Table 1 Adverse Reactions Reported by >=1% of NUCYNTA(r)-Treated Patients In Seven Phase 2/3 Placebo- and/or Oxycodone-Controlled, One Non-controlled, and One Phase 3 Oxycodone-Controlled Safety, Multiple-Dose Clinical Studies System/Organ Class MedDRA Preferred Term NUCYNTA (r) 21 mg - 120 mg(n=2178)% Placebo(n=619)% Gastrointestinal disorders Nausea 30 13 Vomiting 18 4 Constipation 8 3 Dry mouth 4 <1 Dyspepsia 2 <1 General disorders and administration site conditions Fatigue 3 <1 Feeling hot 1 <1 Infections and infestations Nasopharyngitis 1 <1 Upper respiratory tract infection 1 <1 Urinary tract infection 1 <1 Metabolism and nutrition disorders Decreased appetite 2 0 Nervous system disorders Dizziness 24 8 Somnolence 15 3 Tremor 1 <1 Lethargy 1 <1 Psychiatric disorders Insomnia 2 <1 Confusional state 1 0 Abnormal dreams 1 <1 Anxiety 1 <1 Skin and subcutaneous tissue disorders Pruritus 5 1 Hyperhidrosis 3 <1 Pruritus generalized 3 <1 Rash 1 <1 Vascular disorders Hot flush 1 <1 The following adverse drug reactions occurred in less than 1% of NUCYNTA (r) -treated patients in the pooled safety data from nine Phase 2/3 clinical studies:","heart rate increased, heart rate decreased, visual disturbance, abdominal discomfort, impaired gastric emptying, irritability, edema, drug withdrawal syndrome, feeling drunk, hypersensitivity, gamma-glutamyltransferase increased, alanine aminotransferase increased, aspartate aminotransferase increased, involuntary muscle contractions, sensation of heaviness, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, depressed level of consciousness, memory impairment, ataxia, presyncope, syncope, coordination abnormal, seizure, euphoric mood, disorientation, restlessness, agitation, nervousness, thinking abnormal, urinary hesitation, pollakiuria, oxygen saturation decreased, cough, dyspnea, respiratory depression, urticaria, blood pressure decreased, nausea, dizziness, vomiting, somnolence, pruritus"
NUCYNTA,adverse reactions,6.2 Post-marketing Experience,"diarrhea, headache, hallucination, suicidal ideation, panic attack, palpitations, anaphylaxis, angioedema, anaphylactic shock"
NUCYNTA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"misuse, abuse, addiction, respiratory depression, hypotension, sedation, respiratory depression, coma, CO2 retention, seizures, Serotonin Syndrome, withdrawal symptoms, impaired mental/physical abilities"
NUCYNTA,warnings and precautions,5.1 Abuse Potential,"abuse, addiction, misuse, diversion, overdose, death"
NUCYNTA,warnings and precautions,5.2 Life Threatening Respiratory Depression,"respiratory depression, respiratory arrest, death, reduced urge to breathe, decreased rate of respiration, carbon dioxide (CO2) retention, sedating effects, hypoxia, hypercarbia, decreased respiratory reserve, increased airway resistance, decreased respiratory drive, apnea"
NUCYNTA,warnings and precautions,5.3 Accidental Exposure,"accidental ingestion, fatal overdose"
NUCYNTA,warnings and precautions,"5.4 Interactions with Alcohol, Other Opioids, and Drugs of Abuse","central nervous system depression, respiratory depression, hypotension, profound sedation, coma, death"
NUCYNTA,warnings and precautions,"5.5 Elderly, Cachectic, and Debilitated Patients",Respiratory depression
NUCYNTA,warnings and precautions,5.6 Use in Patients with Chronic Pulmonary Disease,"respiratory depression, chronic obstructive pulmonary disease, cor pulmonale, decreased respiratory reserve, hypoxia, hypercarbia, pre-existing respiratory depression, apnea"
NUCYNTA,warnings and precautions,5.7 Interactions with CNS Depressants and Illicit Drugs,"hypotension, profound sedation, coma, respiratory depression"
NUCYNTA,warnings and precautions,5.8 Hypotensive Effect,"severe hypotension, signs of hypotension, vasodilation, reduce cardiac output, blood pressure"
NUCYNTA,warnings and precautions,5.9 Use in Patients with Head Injury or Increased Intracranial Pressure,"sedation, respiratory depression, increased intracranial pressure, impaired consciousness, coma"
NUCYNTA,warnings and precautions,5.10 Seizures,"predisposition to a seizure disorder, aggravate convulsions, induce or aggravate seizures, worsened seizure control"
NUCYNTA,warnings and precautions,5.11 Serotonin Syndrome Risk,"life-threatening serotonin syndrome, agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting, diarrhea"
NUCYNTA,warnings and precautions,5.12 Use in Patients with Gastrointestinal Conditions,"GI obstruction, paralytic ileus, spasm of the sphincter of Oddi, biliary tract disease, acute pancreatitis, worsening symptoms"
NUCYNTA,warnings and precautions,5.13 Withdrawal,"anxiety, sweating, insomnia, rigors, pain, nausea, tremors, diarrhea, upper respiratory symptoms, piloerection, hallucinations"
NUCYNTA,warnings and precautions,5.14 Driving and Operating Heavy Machinery,"impaired mental abilities, impaired physical abilities, potentially hazardous activities"
NUCYNTA,warnings and precautions,5.15 Hepatic Impairment,"hepatic impairment, higher serum concentrations, severe hepatic impairment, moderate hepatic impairment, respiratory depression, central nervous system depression"
NUCYNTA,warnings and precautions,5.16 Renal Impairment,"severe renal impairment, accumulation, elevated metabolite"
ACTEMRA,adverse reactions,6 ADVERSE REACTIONS,"upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions"
ACTEMRA,adverse reactions,6.1 Clinical Trials Experience in Rheumatoid Arthritis Patients Treated with Intravenous ACTEMRA (ACTEMRA-IV),"serious infections, upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, hepatic transaminase values, pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis, gastrointestinal perforation, purulent peritonitis, lower GI perforation, fistula, abscess, infusion reactions, rash, pruritus, urticaria, anaphylaxis, hypersensitivity reactions, neutropenia, thrombocytopenia, elevated liver enzymes"
ACTEMRA,adverse reactions,"Table 1 Incidence of Liver Enzyme Abnormalities in the 24 Week Controlled Period of Studies I to VFor a description of these studies, see Section 14, Clinical Studies. ACTEMRA8 mg per kg MONOTHERAPY Methotrexate ACTEMRA4 mg per kg + DMARDs ACTEMRA8 mg per kg + DMARDs Placebo + DMARDs N = 288(%) N = 284(%) N = 774(%) N = 1582(%) N = 1170(%) ULN = Upper Limit of Normal AST (U/L) > ULN to 3* ULN 22 26 34 41 17 > 3* ULN to 5* ULN 0.3 2 1 2 0.3 > 5* ULN 0.7 0.4 0.1 0.2 < 0.1 ALT (U/L) > ULN to 3* ULN 36 33 45 48 23 > 3* ULN to 5* ULN 1 4 5 5 1 > 5* ULN 0.7 1 1.3 1.5 0.3 In the all-exposure population, the elevations in ALT and AST remained consistent with what was seen in the 24 week, controlled clinical trials","elevations, increases, elevated lipids, hypersensitivity reaction, malignancies"
ACTEMRA,adverse reactions,Table 2 Adverse Reactions Occurring in at Least 2% or More of Patients on 4 or 8 mg per kg ACTEMRA plus DMARD and at Least 1% Greater Than That Observed in Patients on Placebo plus DMARD 24 Week Phase 3 Controlled Study Population ACTEMRA8 mg per kg MONOTHERAPY Methotrexate ACTEMRA4 mg per kg + DMARDs ACTEMRA8 mg per kg + DMARDs Placebo + DMARDs Preferred Term N = 288(%) N = 284(%) N = 774(%) N = 1582(%) N = 1170(%) Upper Respiratory Tract Infection 7 5 6 8 6 Nasopharyngitis 7 6 4 6 4 Headache 7 2 6 5 3 Hypertension 6 2 4 4 3 ALT increased 6 4 3 3 1 Dizziness 3 1 2 3 2 Bronchitis 3 2 4 3 3 Rash 2 1 4 3 1 Mouth Ulceration 2 2 1 2 1 Abdominal Pain Upper 2 2 3 3 2 Gastritis 1 2 1 2 1 Transaminase increased 1 5 2 2 1 Other infrequent and medically relevant adverse reactions occurring at an incidence less than 2% in rheumatoid arthritis patients treated with ACTEMRA-IV in controlled trials were:,"oral herpes simplex, stomatitis, gastric ulcer, weight increased, total bilirubin increased, leukopenia, edema peripheral, dyspnea, cough, conjunctivitis, nephrolithiasis, hypothyroidism"
ACTEMRA,adverse reactions,6.2 Clinical Trials Experience in Rheumatoid Arthritis Patients Treated with Subcutaneous ACTEMRA (ACTEMRA-SC),"injection site reactions, erythema, pruritus, pain, hematoma, Immunogenicity, anti-tocilizumab antibodies, neutralizing antibodies, Laboratory Abnormalities, Neutropenia, Thrombocytopenia, Elevated Liver Enzymes, ALT or AST elevation, Lipids, total cholesterol elevation, LDL increase"
ACTEMRA,adverse reactions,6.3 Clinical Trials Experience in Polyarticular Juvenile Idiopathic Arthritis Patients Treated With Intravenous ACTEMRA (ACTEMRA-IV),"infections, nasopharyngitis, upper respiratory tract infections, serious infections, infusion reactions, headache, nausea, hypotension, dizziness, hypersensitivity reactions, immunogenicity, neutropenia, thrombocytopenia, elevated liver enzymes, lipids"
ACTEMRA,adverse reactions,6.4 Clinical Trials Experience in Systemic Juvenile Idiopathic Arthritis Patients Treated with Intravenous ACTEMRA (ACTEMRA-IV),"upper respiratory tract infection, headache, nasopharyngitis, diarrhea, infections, serious infections, pneumonia, gastroenteritis, varicella, otitis media, macrophage activation syndrome, infusion reactions, angioedema, rash, urticaria, arthralgia, anaphylaxis, neutropenia, thrombocytopenia, elevated liver enzymes, elevation in ALT, elevation in AST, lipids, elevation in total cholesterol, elevation in LDL"
ACTEMRA,adverse reactions,6.5 Postmarketing Experience,"fatal anaphylaxis, Stevens-Johnson Syndrome"
ACTEMRA,boxed warnings,BOXED WARNING: WARNING: RISK OF SERIOUS INFECTIONS,"If the input text is ""nan"", this suggests there is no text provided for analysis. Therefore, I cannot extract any adverse drug event terms without an actual excerpt from a drug label. If you can provide the excerpt, I would be happy to assist you in identifying the adverse drug event terms."
ACTEMRA,boxed warnings,WARNING: RISK OF SERIOUS INFECTIONS,"serious infections, hospitalization, death, Active tuberculosis, pulmonary disease, extrapulmonary disease, latent tuberculosis, Invasive fungal infections, candidiasis, aspergillosis, pneumocystis, Bacterial infections, viral infections, opportunistic pathogens"
ACTEMRA,boxed warnings,EXCERPT: WARNING: RISK OF SERIOUS INFECTIONS,"serious infections, hospitalization, death, tuberculosis (TB), bacterial infections, invasive fungal infections, viral infections, other opportunistic infections"
ACTEMRA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Serious Infections, localized infections, Gastrointestinal (GI) perforation, treatment-related changes in neutrophils, platelets, lipids, liver function tests, Hypersensitivity reactions, anaphylaxis, death"
ACTEMRA,warnings and precautions,5.1 Serious Infections,"pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis, bacterial arthritis, tuberculosis, cryptococcus, aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis, listeriosis, viral reactivation, hepatitis B reactivation."
ACTEMRA,warnings and precautions,5.2 Gastrointestinal Perforations,"gastrointestinal perforation, complications of diverticulitis, new onset abdominal symptoms"
ACTEMRA,warnings and precautions,5.3 Laboratory Parameters,"Rheumatoid Arthritis Neutropenia, infections, neutropenia, Thrombocytopenia, reduction in platelets, serious bleeding events, Elevated Liver Enzymes, transaminase elevations, hepatic injury, Lipid Abnormalities, increases in lipid parameters, total cholesterol, triglycerides, LDL cholesterol, HDL cholesterol."
ACTEMRA,warnings and precautions,5.4 Immunosuppression,"malignancies, increased risk of malignancies"
ACTEMRA,warnings and precautions,"5.5 Hypersensitivity Reactions, Including Anaphylaxis","hypersensitivity reactions, anaphylaxis, anaphylactic events, fatal outcome, treatment discontinuation, generalized erythema, rash, uticaria, injection site reactions"
ACTEMRA,warnings and precautions,5.6 Demyelinating Disorders,"multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, demyelinating disorders"
ACTEMRA,warnings and precautions,5.7 Active Hepatic Disease and Hepatic Impairment,"active hepatic disease, hepatic impairment"
ACTEMRA,warnings and precautions,5.8 Vaccinations,"live vaccines, secondary transmission of infection, IL-6 inhibition, immunosuppressive agents"
VIIBRYD,adverse reactions,6 ADVERSE REACTIONS,"Suicidal Thoughts and Behaviors in Children, Adolescents, and Young Adults, Serotonin Syndrome, Increased Risk of Bleeding, Activation of Mania or Hypomania, Discontinuation Syndrome, Seizures, Angle-Closure Glaucoma, Hyponatremia, diarrhea, nausea, vomiting, insomnia"
VIIBRYD,adverse reactions,6.1 Clinical Trials Experience,"diarrhea, nausea, vomiting, insomnia"
VIIBRYD,adverse reactions,Table 2 shows the incidence of common adverse reactions occuring in >= 2% of VIIBRYD-treated patients and greater than the rate of placebo-treated patients in MDD Studies. There were no dose-related adverse reactions between 20 mg and 40 mg reported.,"Your input seems to be ""nan"", typically standing for ""not a number"" or indicating missing information. Without a provided excerpt of a drug label to analyze, I cannot extract any adverse drug event terms. Please provide the actual text for analysis."
VIIBRYD,adverse reactions,"Table 2: Common Adverse Reactions Occurring in >= 2% of VIIBRYD-treated Patients and Greater than the Rate of Placebo-Treated Patients System Organ Class Preferred Term Placebo N=967 VIIBRYD 20 mg/day N=288 VIIBRYD 40 mg/day N=978 1 Includes abdominal discomfort, abdominal pain upper, and abdominal pain. 2 Includes headache and tension headache 3 Includes restlessness, akathisia, and restless legs syndrome Sexual adverse reactions are presented in Table 3 Gastrointestinal disorders Diarrhea 10% 26% 29% Nausea 7% 22% 24% Dry mouth 5% 8% 7% Vomiting 2% 4% 5% Abdominal pain 1 3% 7% 4% Dyspepsia 2% 2% 3% Flatulence 1% 3% 3% Gastroenteritis 1% 1% 2% Abdominal distension 1% 2% 1% Nervous system disorders Headache 2 14% 15% 14% Dizziness 5% 6% 8% Somnolence 2% 4% 5% Paresthesia 1% 1% 2% Psychiatric disorders Insomnia 2% 7% 6% Abnormal dreams 2% 2% 3% Restlessness 3 1% 2% 3% General disorders Fatigue 3% 4% 3% Cardiac disorders Palpitations <1% 1% 2% Metabolism and nutrition disorders Increased appetite 1% 1% 3% Musculoskeletal and connective tissue disorders Arthralgia 1% 2% 1% Investigations Increased weight 1% 1% 2% Sexual adverse reactions","As there is no actual text provided from which to extract adverse drug event terms, the task cannot be performed. If you provide a drug label excerpt, I can help identify any adverse drug event terms listed within it."
VIIBRYD,adverse reactions,Table 3 displays the most common sexual adverse reactions in the placebo-controlled MDD studies.,"If the input text is ""nan"", which generally indicates ""not a number"" or missing data, then there are no adverse drug event terms to extract. Therefore, there is no list to provide. If this is an error and the actual text was not provided, please provide the excerpt for analysis."
VIIBRYD,adverse reactions,Table 3: Common Sexual Adverse Reactions Occurring in >= 2% of VIIBRYD-treated Patients and Greater than the Rate of Placebo-Treated Patients - Not applicable*Includes abnormal orgasm and anorgasmia Preferred Term Males Females Placebo N=416 VIIBRYD 20 mg/day N=122 VIIBRYD 40 mg/day N=417 Placebo N=551 VIIBRYD 20 mg/day N=166 VIIBRYD 40 mg/day N=561 Abnormal Orgasm* <1% 2% 2% 0% 1% 1% Erectile dysfunction 1% 0% 3% - - - Libido decreased <1% 3% 4% <1% 2% 2% Ejaculation disorder 0% 1% 2% - - - Other adverse reactions observed in clinical studies,"ventricular extrasystoles, dry eye, vision blurred, cataracts, sedation, tremor, migraine, panic attack, hyperhidrosis, night sweats, irritability, hallucinations, suicide attempt, suicidal ideation, rash, generalized rash, urticaria, drug eruption"
VIIBRYD,boxed warnings,BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS,"The input provided is ""nan"" which stands for 'not applicable' or 'not available'. This indicates that there is no text provided to extract adverse drug event terms from. If you need assistance with a different task or have another excerpt to analyze, please provide the relevant text."
VIIBRYD,boxed warnings,WARNING: SUICIDAL THOUGHTS AND BEHAVIORS,"suicidal thoughts, behaviors, clinical worsening"
VIIBRYD,boxed warnings,EXCERPT: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS,"suicidal thoughts, behaviors, clinical worsening"
VIIBRYD,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Serotonin Syndrome, Increased Risk of Bleeding, Activation of Mania/Hypomania, Seizures, Angle Closure Glaucoma"
VIIBRYD,warnings and precautions,"5.1 Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults","suicidal thoughts, behaviors, clinical worsening, emergent suicidal thoughts, emergent suicidal behaviors"
VIIBRYD,warnings and precautions,5.2 Serotonin Syndrome,"serotonin syndrome, agitation, hallucinations, delirium, coma, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia, tremor, rigidity, myoclonus, hyperreflexia, incoordination, seizures, nausea, vomiting, diarrhea"
VIIBRYD,warnings and precautions,5.3 Increased Risk of Bleeding,"bleeding events, gastrointestinal bleeding, ecchymosis, hematoma, epistaxis, petechiae, life-threatening hemorrhages"
VIIBRYD,warnings and precautions,5.4 Activation of Mania or Hypomania,"mixed/manic episode, mania, hypomania"
VIIBRYD,warnings and precautions,5.5 Discontinuation Syndrome,"nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances, paresthesia, electric shock sensations, tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, seizures"
VIIBRYD,warnings and precautions,5.6 Seizures,"seizure disorder, seizures"
VIIBRYD,warnings and precautions,5.7 Angle-Closure Glaucoma,"pupillary dilation, angle closure attack"
VIIBRYD,warnings and precautions,5.8 Hyponatremia,"hyponatremia, headache, difficulty concentrating, memory impairment, confusion, weakness, unsteadiness, falls, hallucination, syncope, seizure, coma, respiratory arrest, death"
LUZU,adverse reactions,6 ADVERSE REACTIONS,application site reactions
LUZU,adverse reactions,6.1 Clinical Trials Experience,application site reactions
LUZU,adverse reactions,6.2 Post-Marketing Experience,"contact dermatitis, cellulitis"
LUMASON,adverse reactions,6 ADVERSE REACTIONS,"severe cardiopulmonary reactions, hypersensitivity reactions, headache, nausea"
LUMASON,adverse reactions,6.1 Clinical Trials Experience,"hypersensitivity-type rash, near syncope symptoms, anaphylactic shock, Headache, Nausea, Dysgeusia, Injection site pain, Chest discomfort, Feeling Hot, Chest pain, Injection Site Warmth, fatalities, arrhythmias, hypertensive episodes"
LUMASON,boxed warnings,BOXED WARNING: WARNING: SERIOUS CARDIOPULMONARY REACTIONS,"If the input provided is ""nan,"" which typically means ""not a number"" or could stand for ""not applicable"" or ""no available data,"" then I cannot extract any adverse drug event terms from the text, as no relevant text has been provided. Please provide the actual excerpt for analysis."
LUMASON,boxed warnings,WARNING: SERIOUS CARDIOPULMONARY REACTIONS,"Serious cardiopulmonary reactions, fatalities"
LUMASON,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Cardiopulmonary reactions, fatalities, Anaphylactoid reactions"
LUMASON,warnings and precautions,5.1 Cardiopulmonary Reactions,"Serious cardiopulmonary reactions, fatalities, fatal cardiac arrest, respiratory arrest, shock, syncope, symptomatic arrhythmias, atrial fibrillation, tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia, hypertension, hypotension, dyspnea, hypoxia, chest pain, respiratory distress, stridor, wheezing, loss of consciousness, convulsions"
LUMASON,warnings and precautions,5.2 Anaphylactoid Reactions,"anaphylactoid reactions, skin erythema, rash, urticaria, flushing, throat tightness, dyspnea, anaphylactic shock"
LUMASON,warnings and precautions,5.3 Systemic Embolization,"right-to-left cardiac shunts, bypass filtering by the lung, arterial circulation, occlusion of the microcirculation, tissue ischemia, intra-arterial injection"
LUMASON,warnings and precautions,5.4 High Mechanical Index,"microsphere cavitation, rupture, ventricular arrhythmias"
LYNPARZA,adverse reactions,6 ADVERSE REACTIONS,"Myelodysplastic syndrome, Acute Myeloid Leukemia, Pneumonitis, anemia, nausea, fatigue, asthenia, vomiting, diarrhea, dysgeusia, dyspepsia, headache, decreased appetite, nasopharyngitis, pharyngitis, URI, cough, arthralgia, musculoskeletal pain, myalgia, back pain, dermatitis, rash, abdominal pain, discomfort, increase in creatinine, mean corpuscular volume elevation, decrease in hemoglobin, decrease in lymphocytes, decrease in absolute neutrophil count, decrease in platelets."
LYNPARZA,adverse reactions,6.1 Clinical Trial Experience,"adverse reactions, dose interruption, dose reduction, discontinuation, death, acute leukemia, COPD, cerebrovascular accident, intestinal perforation, pulmonary embolism, sepsis, suture rupture"
LYNPARZA,adverse reactions,Table 1 Adverse Reactions Reported in >=20% of Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza 3 or more lines of prior chemotherapy Adverse Reaction Grades 1-4 N=223 % Grades 3-4 N=223 % Blood and Lymphatic disorders Anemia 34 18 Gastrointestinal disorders Abdominal pain/discomfort 43 8 Decreased appetite 22 1 Nausea 64 3 Vomiting 43 4 Diarrhea 31 1 Dyspepsia 25 0 General disorders Fatigue/asthenia 66 8 Infections and infestations Nasopharyngitis/URI 26 0 Musculoskeletal and Connective Tissue disorders Arthralgia/musculoskeletal pain 21 0 Myalgia 22 0 Table 2 presents the frequency of abnormal laboratory findings in the 223 patients with g BRCA -mutated advanced ovarian cancer who had received three or more prior lines of chemotherapy receiving Lynparza 400 mg twice daily.,"Since the input is ""nan"" and no drug label excerpt is provided, it's not possible to extract any adverse drug event terms. If you have an actual drug label excerpt, please provide it so I can identify the adverse drug event terms for you."
LYNPARZA,adverse reactions,"Table 2 Laboratory Abnormalities Reported in Patients with gBRCA-Mutated Advanced Ovarian Cancer Receiving Lynparza Laboratory Parameter1 3 or more lines of prior chemotherapy Grades 1-4 N=223 % Grades 3-4 N=223 % Decrease in hemoglobin (anemia) 90 15 Decrease in absolute neutrophil count (neutropenia) 25 7 Decrease in platelets (thrombocytopenia) 30 3 Decrease in lymphocytes (lymphopenia) 56 17 Mean corpuscular volume elevation 57 - Increase in creatinine 30 2 The following adverse reactions and laboratory abnormalities have been identified in >=10 to <20% of the 223 patients receiving Lynparza and not included in the table: cough, constipation, dysgeusia, peripheral edema, back pain, dizziness, headache, urinary tract infection, dyspnea, and rash. The following adverse reactions and laboratory abnormalities have been identified in >=1 to <10% of the 223 patients receiving Lynparza and not included in the table: leukopenia, stomatitis, peripheral neuropathy, pyrexia, hypomagnesemia, hyperglycemia, anxiety, depression, insomnia, dysuria, urinary incontinence, vulvovaginal disorder, dry skin/ eczema, pruritis, hypertension, venous thrombosis (including pulmonary embolism), and hot flush.","If the input provided is ""nan"" and this refers to an actual excerpt of a drug label that meant to be provided but was not, then no adverse drug event terms can be extracted from non-existent text. If the term ""nan"" itself is to be considered as the text for drug label excerpt, it contains no information on adverse drug events. Therefore, no terms can be listed. Please provide the actual excerpt from the drug label for analysis."
LYNPARZA,adverse reactions,"Table 3 presents adverse reactions reported in >=20% of patients from a randomized trial of Lynparza 400 mg twice daily as maintenance monotherapy compared to placebo in patients with platinum sensitive, relapsed, high-grade serous ovarian cancer following treatment with 2 or more platinum-containing regimens. Table 4 presents the laboratory abnormalities in patients from this randomized trial. Of the 96 patients with g BRCA -mutation, 53 received Lynparza, and 43 received placebo. The median duration on treatment with Lynparza was 11.1 months for patients with a g BRCA mutation compared to 4.4 months for patients with g BRCA mutation on placebo.","dose interruptions, dose reductions, discontinuation, died as a result of an adverse reaction"
LYNPARZA,adverse reactions,"Table 3 Adverse Reactions Reported in >=20% of Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial Adverse Reactions Lynparza N=53 Placebo N=43 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Blood and Lymphatic disorders Anemia 25 4 7 2 Gastrointestinal disorders Abdominal pain/discomfort 47 0 58 2 Decreased appetite 25 0 14 0 Nausea 75 2 37 0 Vomiting 32 4 9 0 Diarrhea 28 4 21 2 Dyspepsia 25 0 14 0 Dysgeusia 21 0 9 0 General disorders Fatigue (including asthenia, lethargy) 68 6 53 2 Infections and infestations Nasopharyngitis/Pharyngitis/URI 43 0 16 0 Musculoskeletal and Connective tissue disorders Arthralgia/Musculoskeletal pain 32 4 21 0 Myalgia 25 2 12 0 Back pain 25 6 21 0 Nervous system disorder Headache 25 0 19 2 Respiratory, Thoracic, Mediastinal disorders Cough 21 0 14 0 Skin and Subcutaneous Tissue Dermatitis/Rash 25 0 14 0 Table 4 Laboratory Abnormalities in Patients with gBRCA-Mutated Ovarian Cancer in the Randomized Trial Laboratory parameter1 Lynparza N=53 Placebo N=43 Grades 1-4 % Grades 3-4 % Grades 1-4 % Grades 3-4 % Decrease in hemoglobin 85 8 58 2 Decrease in absolute neutrophil count 32 8 23 0 Decrease in platelets 26 6 19 0 Mean corpuscular volume elevation 85 - 44 - Increase in creatininePatients were allowed to enter clinical studies with laboratory values of CTCAE Grade 1. 26 0 5 0","If the input text is ""nan,"" indicating that the content is not available or not applicable, then there are no adverse drug event terms to extract. Therefore, I am unable to provide a list of terms without an actual excerpt of a drug label. Please provide the text from which the adverse drug event terms need to be identified."
LYNPARZA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Myelodysplastic syndrome, Acute Myeloid Leukemia, hematological toxicity, Pneumonitis, Embryo-Fetal toxicity"
LYNPARZA,warnings and precautions,5.1 Myelodysplastic syndrome/Acute Myeloid Leukemia,"Myelodysplastic syndrome, Acute Myeloid Leukemia, fatal, hematological toxicity"
LYNPARZA,warnings and precautions,5.2 Pneumonitis,"Pneumonitis, fatal cases, dyspnea, fever, cough, wheezing, radiological abnormality"
LYNPARZA,warnings and precautions,5.3 Embryo-Fetal Toxicity,"fetal harm, teratogenic, embryo-fetal toxicity"
EGRIFTA,adverse reactions,6 ADVERSE REACTIONS,"hypersensitivity, rash, urticaria, arthralgia, extremity pain, peripheral edema, hyperglycemia, carpal tunnel syndrome, injection site erythema, pruritus, pain, irritation, swelling, hemorrhage, myalgia"
EGRIFTA,adverse reactions,6.1 Clinical Trial Experience,"adverse reaction rates, Adverse reactions"
EGRIFTA,adverse reactions,"Table 1. Adverse Reactions Reported in >= 1% and More Frequent in EGRIFTA(r) -treated than Placebo Patients during the 26-Week Main Phase (Combined Studies) Incidence of patients (%) with adverse drug reactions System Organ Class Preferred Term EGRIFTA (r) (N=543) Placebo(N=263) Musculoskeletal and connective tissue disorders Arthralgia Pain in extremity Myalgia Musculoskeletal pain Musculoskeletal stiffness Joint stiffness Muscle spasms Joint swelling 13.36.15.51.81.71.51.11.1 11.04.61.90.80.40.80.80.0 General disorders and administration site conditions Injection site erythema Injection site pruritus Edema peripheral Injection site pain Injection site irritation Pain Injection site hemorrhage Injection site urticaria Injection site swelling Injection site reaction Chest pain Injection site rash 8.57.66.14.12.91.71.71.71.51.31.11.1 2.70.82.33.01.11.10.40.40.40.80.80.0 Nervous system disorders Paresthesia Hypoesthesia Carpal tunnel syndrome 4.84.21.5 2.31.50.0 Gastrointestinal disorders Nausea Vomiting Dyspepsia Abdominal pain upper 4.42.61.71.1 3.80.00.80.8 Cardiac disorders Palpitations 1.1 0.4 Psychiatric disorders Depression 2.0 1.5 Skin and subcutaneous tissue disorders Rash Pruritus Night sweats 3.72.41.1 1.51.10.4 Vascular disorders Hypertension 1.3 0.8 Injury, poisoning and procedural complications Muscle strain 1.1 0.0 Investigations Blood creatine phosphokinase increased 1.5 0.4 Mean levels of fasting blood glucose and fasting insulin were not significantly different between EGRIFTA (r) -treated and placebo-treated patients after 26 weeks of treatment.",increased risk of developing diabetes
EGRIFTA,adverse reactions,"Table 2. Adverse Reactions Reported in >= 1% and More Frequent in EGRIFTA(r)-treated than Placebo Patients during the 26-Week Extension Phase of the Combined Studies (Week 26 to Week 52 of the studies) 1T-T = tesamorelin for Week 0-26 and tesamorelin for Week 26-52 2T-P = tesamorelin for Week 0-26 and placebo for Week 26-52 For patients who continued from Week 26-52, mean levels of fasting blood glucose, fasting insulin, and HbA1c were not different between the T-T and T-P groups. Incidence of patients (%) with adverse drug reactions System Organ Class Preferred Term T-T 1 (Week 26-52)(N=246) T-P 2 (Week 26-52)(N=135) Musculoskeletal and connective tissue disorders Pain in extremity Myalgia 3.31.2 0.70.0 General disorders and administration site conditions Injection site pruritus Edema peripheral Injection site erythema 2.02.01.2 0.00.00.0 Nervous system disorders Paresthesia Hypoesthesia Neuropathy peripheral 1.61.61.6 1.50.71.5 Gastrointestinal disorders Vomiting 2.0 0.7 Psychiatric disorders Depression Insomnia 1.61.2 0.70.0 Skin and subcutaneous tissue disorders Pruritus Urticaria Night sweats 1.21.21.2 0.70.00.0 Vascular disorders Hypertension Hot flush 1.61.2 1.50.7 6.2 Immunogenicity As with all therapeutic proteins and peptides, there is a potential for in vivo development of anti- EGRIFTA (r) antibodies. In the combined Phase 3 clinical trials anti-tesamorelin IgG antibodies were detected in 49.5% of patients treated with EGRIFTA (r) for 26 weeks and 47.4% of patients who received EGRIFTA (r) for 52 weeks. In the subset of patients with hypersensitivity reactions, anti-tesamorelin IgG antibodies were detected in 85.2%. Cross-reactivity to endogenous growth hormone-releasing hormone (GHRH) was observed in approximately 60% of patients who developed anti-tesamorelin antibodies. Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue (VAT) and IGF-1 response suggesting that the presence of antibodies did not alter the efficacy of EGRIFTA (r) . In a group of patients who had antibodies to tesamorelin after 26 weeks of treatment (56%) and were re-assessed 6 months later, after stopping EGRIFTA (r) treatment, 18% were still antibody positive.",Neutralizing antibodies
EGRIFTA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"edema, arthralgia, carpal tunnel syndrome, glucose intolerance, rash, urticaria, injection site reactions, acute critical illness"
EGRIFTA,warnings and precautions,5.1 Neoplasms,"active malignancy, non-malignant neoplasms, re-activation of the underlying malignancy"
EGRIFTA,warnings and precautions,5.2 Elevated IGF-1,"development or progression of malignancies, persistent elevations of IGF-1 levels"
EGRIFTA,warnings and precautions,5.3 Fluid Retention,"fluid retention, increased tissue turgor, musculoskeletal discomfort, edema, arthralgia, carpal tunnel syndrome"
EGRIFTA,warnings and precautions,5.4 Glucose Intolerance,"glucose intolerance, elevated HbA1c, increased risk of developing diabetes, impaired glucose tolerance, diabetes, glucose intolerance, worsening of retinopathy"
EGRIFTA,warnings and precautions,5.5 Hypersensitivity Reactions,"hypersensitivity reactions, pruritus, erythema, flushing, urticaria, rash"
EGRIFTA,warnings and precautions,5.6 Injection Site Reactions,"injection site reactions, injection site erythema, pruritus, pain, irritation, bruising"
EGRIFTA,warnings and precautions,5.7 Acute Critical Illness,"increased mortality, complications, acute respiratory failure"
ELLA,adverse reactions,6 ADVERSE REACTIONS,"headache, abdominal pain, nausea, dysmenorrhea, fatigue, dizziness"
ELLA,adverse reactions,6.1 Clinical Trials Experience,"headache, nausea, abdominal pain, upper abdominal pain"
ELLA,adverse reactions,"Table 1: Adverse Reactions in >= 5% of Women (%) Receiving a Single Dose of ella (30 mg Ulipristal Acetate) Most Common Adverse Reactions Open-Label Study Single-Blind Comparative Study N = 1,533 N = 1,104 Headache 18 19 Nausea 12 13 Abdominal and upper abdominal pain 15 8 Dysmenorrhea 7 13 Fatigue 6 6 Dizziness 5 5 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ella: Skin and Subcutaneous Tissue Disorders: AcneBecause these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.","If you are indicating that the content to analyze is ""nan,"" typically representing ""not a number"" or indicating that there is no content provided, then there are no adverse drug event terms to extract. Without an actual excerpt from a drug label, I cannot provide a list of terms.

If this is a misunderstanding and you have a drug label excerpt youd like me to analyze for adverse drug event terms, please provide the text."
ELLA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"ectopic pregnancy, lower abdominal pain, alter the next expected menses, menses is delayed"
ELLA,warnings and precautions,5.1 Existing Pregnancy,"The provided text is about the indications, precautions, and recommendations for the administration of a drug called ""ella."" However, it does not explicitly list any adverse drug events or side effects. Therefore, there are no adverse drug event terms present in the given excerpt."
ELLA,warnings and precautions,5.2 Ectopic Pregnancy,"ectopic pregnancy, lower abdominal pain"
ELLA,warnings and precautions,5.3 Repeated Use,"Based on the provided excerpt, there are no specific adverse drug event terms mentioned. The text discusses the recommended usage of ""ella"" as an emergency contraceptive, precautions about not using it as a regular form of contraception, and the recommendation against repeated use within the same menstrual cycle due to a lack of evaluation for safety and efficacy. However, specific adverse events are not listed in the provided text snippet."
ELLA,warnings and precautions,5.4 CYP3A4 Inducers,"There are no specific adverse drug event terms mentioned in this excerpt. The text describes a drug-drug interaction that leads to decreased plasma concentration of the drug ""ella"" when administered with the CYP3A4 inducer ""rifampin."" However, to be clear, the text implies that this interaction may reduce the effectiveness of ""ella,"" but does not directly list any adverse events."
ELLA,warnings and precautions,5.5 Fertility Following Use,There are no specific adverse drug event terms provided in the given text. The text discusses efficacy and mechanisms rather than adverse effects.
ELLA,warnings and precautions,5.6 Effect on Menstrual Cycle,"menses occurring more than 7 days earlier, delay of menses more than 7 days, intermenstrual bleeding"
ELLA,warnings and precautions,5.7 Sexually Transmitted Infections/HIV,"This text does not mention specific adverse drug events (ADEs). Therefore, there is nothing to list in terms of adverse events. The text only states that ""ella"" does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs), which are potential risks associated with unprotected sex but not adverse events caused by the drug itself."
ZALTRAP,adverse reactions,6 ADVERSE REACTIONS,"Hemorrhage, Gastrointestinal Perforation, Compromised Wound Healing, Fistula Formation, Hypertension, Arterial Thromboembolic Events, Proteinuria, Neutropenia, Neutropenic Complications, Diarrhea, Dehydration, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), leukopenia, neutropenia, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, headache."
ZALTRAP,adverse reactions,6.1 Clinical Trial Experience,"leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, headache, asthenia, infections, dehydration, venous thromboembolic events."
ZALTRAP,adverse reactions,"Table 1 - Selected Adverse Reactions and Laboratory Findings in Study 1: Primary System Organ Class Preferred Term (%) Placebo/FOLFIRI(N=605) ZALTRAP/FOLFIRI(N=611) All grades Grades 3-4 All grades Grades 3-4 Note: Adverse Reactions are reported using MedDRA version MEDDRA13.1 and graded using NCI CTC version 3.0 Infections and infestations Urinary Tract Infection 6% 0.8% 9% 0.8% Blood and lymphatic system disorders Leukopenia 72% 12% 78% 16% Neutropenia 57% 30% 67% 37% Thrombocytopenia 35% 2% 48% 3% Metabolism and nutrition disorders Decreased Appetite 24% 2% 32% 3% Dehydration 3% 1% 9% 4% Nervous system disorders Headache 9% 0.3% 22% 2% Vascular disorders Hypertension 11% 1.5% 41% 19% Respiratory, thoracic and mediastinal disorders Epistaxis 7% 0 28% 0.2% Dysphonia 3% 0 25% 0.5% Dyspnea 9% 0.8% 12% 0.8% Oropharyngeal Pain 3% 0 8% 0.2% Rhinorrhea 2% 0 6% 0 Gastrointestinal disorders Diarrhea 57% 8% 69% 19% Stomatitis 33% 5% 50% 13% Abdominal Pain 24% 2% 27% 4% Abdominal Pain Upper 8% 1% 11% 1% Hemorrhoids 2% 0 6% 0 Rectal Hemorrhage 2% 0.5% 5% 0.7% Proctalgia 2% 0.3% 5% 0.3% Skin and subcutaneous tissue disorders Palmar-Plantar Erythrodysesthesia Syndrome 4% 0.5% 11% 3% Skin Hyperpigmentation 3% 0 8% 0 Renal and urinary disorders Proteinuria 41% 1% 62% 8% Serum creatinine increased 19% 0.5% 23% 0 General disorders and administration site conditions Fatigue 39% 8% 48% 13% Asthenia 13% 3% 18% 5% Investigations AST increased 54% 2% 62% 3% ALT increased 39% 2% 50% 3% Weight decreased 14% 0.8% 32% 3% Infections occurred at a higher frequency in patients receiving ZALTRAP/FOLFIRI (46%, all grades; 12%, Grade 3-4) than in patients receiving placebo/FOLFIRI (33%, all grades; 7%, Grade 3-4), including urinary tract infection, nasopharyngitis, upper respiratory tract infection, pneumonia, catheter site infection, and tooth infection.","severe hypersensitivity reactions, venous thromboembolic events, deep venous thrombosis, pulmonary embolism, Grade 3-4 VTE"
ZALTRAP,adverse reactions,6.2 Immunogenicity,"immunogenicity, anti-product antibody (APA), APA development, neutralizing antibodies, lower mean free ziv-aflibercept trough concentrations"
ZALTRAP,boxed warnings,"BOXED WARNING: WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING","If you're indicating that the input you've provided is ""nan"" (not a number), which typically represents a missing or undefined value, then there's no actual text excerpt from a drug label to analyze for adverse drug event terms. Therefore, I cannot provide you with a list of adverse drug event terms without an appropriate excerpt of a drug label to review."
ZALTRAP,boxed warnings,"WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING","hemorrhage, gastrointestinal hemorrhage, GI bleeding, severe bleeding, gastrointestinal perforation, fatal GI perforation, compromised wound healing"
ZALTRAP,boxed warnings,"EXCERPT: WARNING: HEMORRHAGE, GASTROINTESTINAL PERFORATION, COMPROMISED WOUND HEALING","Hemorrhage, Severe hemorrhage, Fatal hemorrhage, Gastrointestinal hemorrhage, Gastrointestinal Perforation, Compromised Wound Healing"
ZALTRAP,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Adverse reactions, Fistula Formation, Hypertension, Hypertensive crisis, Arterial Thromboembolic Events, Transient ischemic attacks, Cerebrovascular accident, Angina pectoris, Proteinuria, Nephrotic syndrome, Thrombotic microangiopathy, Neutropenia, Neutropenic Complications, Diarrhea, Dehydration, Reversible Posterior Leukoencephalopathy Syndrome"
ZALTRAP,warnings and precautions,5.1 Hemorrhage,"hemorrhage, severe hemorrhagic events, fatal hemorrhagic events, bleeding, Grade 3-4 hemorrhagic events, gastrointestinal hemorrhage, hematuria, post-procedural hemorrhage, severe intracranial hemorrhage, pulmonary hemorrhage/hemoptysis, fatal events"
ZALTRAP,warnings and precautions,5.2 Gastrointestinal Perforation,"GI perforation, fatal GI perforation"
ZALTRAP,warnings and precautions,5.3 Compromised Wound Healing,"compromised wound healing, Grade 3 compromised wound healing"
ZALTRAP,warnings and precautions,5.4 Fistula Formation,"Fistula formation, gastrointestinal and non-gastrointestinal sites, mCRC, fistulas (anal, enterovesical, enterocutaneous, colovaginal, intestinal sites), Grade 3 GI fistula formation"
ZALTRAP,warnings and precautions,5.5 Hypertension,"hypertension, Grade 3-4 hypertension, Grade 3 hypertension, hypertensive crisis, Grade 4 hypertension, uncontrolled hypertension, hypertensive encephalopathy"
ZALTRAP,warnings and precautions,5.6 Arterial Thromboembolic Events,"Arterial thromboembolic events, transient ischemic attack, cerebrovascular accident, angina pectoris"
ZALTRAP,warnings and precautions,5.7 Proteinuria,"Severe proteinuria, nephrotic syndrome, thrombotic microangiopathy (TMA), Grade 3-4 proteinuria"
ZALTRAP,warnings and precautions,5.8 Neutropenia and Neutropenic Complications,"neutropenic complications, febrile neutropenia, neutropenic infection, Grade 3-4 neutropenia, Grade 3-4 febrile neutropenia, Grade 3-4 neutropenic infection/sepsis"
ZALTRAP,warnings and precautions,5.9 Diarrhea and Dehydration,"severe diarrhea, Grade 3-4 diarrhea, Grade 3-4 dehydration"
ZALTRAP,warnings and precautions,5.10 Reversible Posterior Leukoencephalopathy Syndrome (RPLS),"RPLS, posterior reversible encephalopathy syndrome, neurologic sequelae, death"
MYRBETRIQ,adverse reactions,6 ADVERSE REACTIONS,"hypertension, nasopharyngitis, urinary tract infection, headache"
MYRBETRIQ,adverse reactions,6.1 Clinical Trials Experience,"nausea, headache, hypertension, diarrhea, constipation, dizziness, tachycardia, atrial fibrillation, prostate cancer"
MYRBETRIQ,adverse reactions,"Table 1 lists adverse reactions, derived from all adverse events, that were reported in Studies 1, 2 and 3 at an incidence greater than placebo and in 1% or more of patients treated with MYRBETRIQ (r) 25 mg or 50 mg once daily for up to 12 weeks. The most commonly reported adverse reactions (greater than 2% of MYRBETRIQ (r) patients and greater than placebo) were hypertension, nasopharyngitis, urinary tract infection and headache.","If the input text is ""nan,"" indicating that there is no text provided or that it may be a placeholder for ""not applicable"" or ""not available,"" then I cannot extract any adverse drug event terms. Therefore, there is no information to generate a list from."
MYRBETRIQ,adverse reactions,"Table 1: Percentages of Patients with Adverse Reactions, Derived from All Adverse Events, Exceeding Placebo Rate and Reported by 1% or More Patients Treated With MYRBETRIQ(r) 25 mg or 50 mg Once Daily in Studies 1, 2, and 3 Placebo (%) MYRBETRIQ(r) 25 mg (%) MYRBETRIQ(r) 50 mg (%) Number of Patients 1380 432 1375 HypertensionIncludes reports of blood pressure above the normal range, and BP increased from baseline, occurring predominantly in subjects with baseline hypertension. 7.6 11.3 7.5 Nasopharyngitis 2.5 3.5 3.9 Urinary Tract Infection 1.8 4.2 2.9 Headache 3.0 2.1 3.2 Constipation 1.4 1.6 1.6 Upper Respiratory Tract Infection 1.7 2.1 1.5 Arthralgia 1.1 1.6 1.3 Diarrhea 1.3 1.2 1.5 Tachycardia 0.6 1.6 1.2 Abdominal Pain 0.7 1.4 0.6 Fatigue 1.0 1.4 1.2 Other adverse reactions reported by less than 1% of patients treated with MYRBETRIQ (r) in Studies 1, 2, or 3 included:","palpitations, blood pressure increased, glaucoma, dyspepsia, gastritis, abdominal distension, sinusitis, rhinitis, GGT increased, AST increased, ALT increased, LDH increased, nephrolithiasis, bladder pain, vulvovaginal pruritus, vaginal infection, urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema"
MYRBETRIQ,adverse reactions,"Table 2 lists the rates of the most commonly reported adverse reactions, derived from all adverse events in patients treated with MYRBETRIQ (r) 50 mg for up to 52 weeks in Study 4. The most commonly reported adverse reactions (>3% of MYRBETRIQ (r) patients) were hypertension, urinary tract infection, headache, and nasopharyngitis.","There is no text provided to analyze for adverse drug event terms. ""The input is nan"" indicates that the input might not be applicable, as ""nan"" is often used as an abbreviation for ""not a number"" or signifies missing data. Without an actual excerpt from a drug label, I cannot provide a list of adverse drug event terms. Please provide the text excerpt so I can assist you with your task."
MYRBETRIQ,adverse reactions,"Table 2: Percentages of Patients with Adverse Reactions, Derived from all Adverse Events, Reported by Greater Than 2% of Patients Treated With MYRBETRIQ(r) 50 mg Once Daily in Study 4 MYRBETRIQ(r) 50 mg (%) Active Control (%) Number of Patients 812 812 Hypertension 9.2 9.6 Urinary Tract Infection 5.9 6.4 Headache 4.1 2.5 Nasopharyngitis 3.9 3.1 Back Pain 2.8 1.6 Constipation 2.8 2.7 Dry Mouth 2.8 8.6 Dizziness 2.7 2.6 Sinusitis 2.7 1.5 Influenza 2.6 3.4 Arthralgia 2.1 2.0 Cystitis 2.1 2.3 In Study 4, in patients treated with MYRBETRIQ (r) 50 mg once daily, adverse reactions leading to discontinuation reported by more than 2 patients and at a rate greater than active control included: constipation (0.9%), headache (0.6%), dizziness (0.5%), hypertension (0.5%), dry eyes (0.4%), nausea (0.4%), vision blurred (0.4%), and urinary tract infection (0.4%). Serious adverse events reported by at least 2 patients and exceeding active control included cerebrovascular accident (0.4%) and osteoarthritis (0.2%). Serum ALT/AST increased from baseline by greater than 10-fold in 2 patients (0.3%) taking MYRBETRIQ (r) 50 mg, and these markers subsequently returned to baseline while both patients continued MYRBETRIQ (r) .","neoplasm, breast cancer, lung neoplasm malignant, prostate cancer, Stevens-Johnson syndrome, increased serum ALT, increased serum AST, increased bilirubin"
MYRBETRIQ,adverse reactions,6.2 Postmarketing Experience,"angioedema of the face, lips, tongue, and larynx, urinary retention"
MYRBETRIQ,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Increases in Blood Pressure, hypertensive patients, Urinary Retention, risk of urinary retention, Angioedema, dose adjustment may be necessary"
MYRBETRIQ,warnings and precautions,5.1 Increases in Blood Pressure,"increase blood pressure, hypertensive patients, severe uncontrolled hypertension, increase in supine blood pressure, increase in systolic/diastolic blood pressure, worsening of pre-existing hypertension"
MYRBETRIQ,warnings and precautions,5.2 Urinary Retention in Patients with Bladder Outlet Obstruction and in Patients Taking Antimuscarinic Medications for OAB,Urinary retention
MYRBETRIQ,warnings and precautions,5.3 Angioedema,"Angioedema, swelling, life threatening, involve the tongue, hypopharynx, or larynx occurs, discontinue."
MYRBETRIQ,warnings and precautions,5.4 Patients Taking Drugs Metabolized by CYP2D6,"increased systemic exposure, appropriate monitoring, dose adjustment"
EDURANT,adverse reactions,6 ADVERSE REACTIONS,"Skin and Hypersensitivity Reactions, Depressive Disorders, Hepatotoxicity, depressive disorders, headache, insomnia, rash"
EDURANT,adverse reactions,6.1 Clinical Trials Experience: Adults,"adverse reaction rates, ADRs, psychiatric disorders, Rash, Common Adverse Drug Reactions, treatment-emergent laboratory abnormalities"
EDURANT,adverse reactions,"Table 1: Selected Treatment-Emergent Adverse Drug Reactions of at least Moderate IntensityIntensities are defined as follows: Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating with inability to work or do usual activity). (Grades 2-4) Occurring in at Least 2% of Antiretroviral Treatment-Naive HIV-1 Infected Adult Subjects (Week 96 Analysis) System Organ Class,Preferred Term,% Pooled Data from the Phase 3 TMC278-C209 and TMC278-C215 Trials EDURANT + BRN=686 Efavirenz + BRN=682 N = total number of subjects per treatment group; BR = background regimen Gastrointestinal Disorders Abdominal pain 2% 2% Nausea 1% 3% Vomiting 1% 2% General Disorders and Administration Site Conditions Fatigue 2% 2% Nervous System Disorders Headache 3% 4% Dizziness 1% 7% Psychiatric Disorders Depressive disorders 5% 4% Insomnia 3% 4% Abnormal dreams 2% 4% Skin and Subcutaneous Tissue Disorders Rash 3% 11% No new ADR terms were identified in adult subjects in the Phase 3 TMC278-C209 and TMC278-C215 trials between 48 weeks and 96 weeks nor in the Phase 2b TMC278-C204 trial through 240 weeks. The incidence of adverse events in the Phase 2b TMC278-C204 trial was similar to the Phase 3 trials through 96 weeks.","diarrhea, abdominal discomfort, cholecystitis, cholelithiasis, decreased appetite, somnolence, sleep disorders, anxiety, glomerulonephritis membranous, glomerulonephritis mesangioproliferative, nephrolithiasis"
EDURANT,adverse reactions,"Table 2: Selected Treatment-Emergent Changes in Laboratory Parameters (Grades 1 to 4) Observed in Antiretroviral Treatment-Naive HIV-1-Infected Adult Subjects (Week 96 Analysis) Laboratory Parameter Abnormality, (%) DAIDS Toxicity Range Pooled Data from the Phase 3 TMC278-C209 and TMC278-C215 Trials EDURANT + BRN=686 Efavirenz + BRN=682 BIOCHEMISTRY BR = background regimen; ULN = upper limit of normal N = number of subjects per treatment group Note: Percentages were calculated versus the number of subjects in ITT. Increased Creatinine Grade 1 >= 1.1-<= 1.3 * ULN 6% 1% Grade 2 > 1.3-<= 1.8 * ULN 1% 1% Grade 3 > 1.8-<= 3.4 * ULN <1% 0 Grade 4 > 3.4 * ULN 0 <1% Increased AST Grade 1 >= 1.25-<= 2.5 * ULN 16% 19% Grade 2 > 2.5-<= 5.0 * ULN 4% 7% Grade 3 > 5.0-<= 10.0 * ULN 2% 2% Grade 4 > 10.0 * ULN 1% 1% Increased ALT Grade 1 >= 1.25-<= 2.5 * ULN 18% 20% Grade 2 > 2.5-<= 5.0 * ULN 5% 7% Grade 3 > 5.0-<= 10.0 * ULN 1% 2% Grade 4 > 10.0 * ULN 1% 1% Increased Total Bilirubin Grade 1 >= 1.1-<= 1.5 * ULN 5% <1% Grade 2 > 1.5-<= 2.5 * ULN 3% 1% Grade 3 > 2.5-<= 5.0 * ULN 1% <1% Grade 4 > 5.0 * ULN 0 0 Increased Total Cholesterol (fasted) Grade 1 5.18-6.19 mmol/L200-239 mg/dL 17% 31% Grade 2 6.20-7.77 mmol/L240-300 mg/dL 7% 19% Grade 3 > 7.77 mmol/L> 300 mg/dL <1% 3% Increased LDL Cholesterol (fasted) Grade 1 3.37-4.12 mmol/L130-159 mg/dL 14% 26% Grade 2 4.13-4.90 mmol/L160-190 mg/dL 5% 13% Grade 3 >= 4.91 mmol/L>= 191 mg/dL 1% 5% Increased Triglycerides (fasted) Grade 2 5.65-8.48 mmol/L500-750 mg/dL 2% 2% Grade 3 8.49-13.56 mmol/L751-1,200 mg/dL 1% 3% Grade 4 > 13.56 mmol/L> 1,200 mg/dL 0 1% Adrenal Function","abnormal 250 micrograms ACTH stimulation test, increase in serum creatinine"
EDURANT,adverse reactions,"Table 3: Lipid Values, Mean Change from BaselineExcludes subjects who received lipid lowering agents during the treatment period Pooled Data from the Week 96 Analysisof the Phase 3 TMC278-C209 and TMC278-C215 Trials EDURANT + BR Efavirenz + BR N Baseline Week 96 N Baseline Week 96 Mean(95% CI) Mean(mg/dL) Mean(mg/dL) Mean Change(mg/dL) Mean(mg/dL) Mean(mg/dL) Mean Change(mg/dL) N = number of subjects per treatment group; BR = background regimen Total Cholesterol(fasted) 546 161 166 5 507 160 187 28 HDL-cholesterol(fasted) 545 41 46 4 505 40 51 11 LDL-cholesterol(fasted) 543 96 98 1 503 95 109 14 Triglycerides(fasted) 546 122 116 -6 507 130 141 11 Subjects co-infected with hepatitis B and/or hepatitis C virus",hepatic enzyme elevation
EDURANT,adverse reactions,6.2 Clinical Trials Experience: Pediatric Patients,"headache, depression, somnolence, nausea, dizziness, abdominal pain, vomiting, rash"
EDURANT,adverse reactions,6.3 Postmarketing Experience,"nephrotic syndrome, Severe skin and hypersensitivity reactions, DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)"
EDURANT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Torsade de Pointes, Severe skin and hypersensitivity reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), hypersensitivity, rash with systemic symptoms, elevations in hepatic serum biochemistries, Severe depressive disorders, Hepatotoxicity, redistribution/accumulation of body fat, immune reconstitution syndrome"
EDURANT,warnings and precautions,5.1 Drug Interactions,"prolong the QTc interval, Torsade de Pointes"
EDURANT,warnings and precautions,5.2 Skin and Hypersensitivity Reactions,"Severe skin reactions, hypersensitivity reactions, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), fever, organ dysfunctions, elevations in hepatic serum biochemistries, treatment-related rashes, Grade 2 severity, Grade 4 rash, Grade 1 rash, severe rash, blisters, mucosal involvement, conjunctivitis, facial edema, angioedema, hepatitis, eosinophilia."
EDURANT,warnings and precautions,5.3 Depressive Disorders,"depressive disorders, depressed mood, depression, dysphoria, major depression, mood altered, negative thoughts, suicide attempt, suicidal ideation"
EDURANT,warnings and precautions,5.4 Hepatotoxicity,"hepatic adverse events, underlying hepatitis B, hepatitis C, elevations in transaminases, worsening, development of transaminase elevations, hepatic toxicity, hepatotoxicity, liver enzyme monitoring"
EDURANT,warnings and precautions,5.5 Fat Redistribution,"central obesity, dorsocervical fat enlargement, buffalo hump, peripheral wasting, facial wasting, breast enlargement, cushingoid appearance"
EDURANT,warnings and precautions,5.6 Immune Reconstitution Syndrome,"immune reconstitution syndrome, inflammatory response, Mycobacterium avium infection, cytomegalovirus, Pneumocystis jiroveci pneumonia, tuberculosis, autoimmune disorders, Graves' disease, polymyositis, Guillain-Barre syndrome"
HARVONI,adverse reactions,6 ADVERSE REACTIONS,"fatigue, headache"
HARVONI,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction, adverse events, discontinued treatment due to adverse events, common adverse reactions, fatigue, headache"
HARVONI,adverse reactions,"Table 2 lists adverse reactions (adverse events assessed as causally related by the investigator, all grades) observed in >=5% of subjects receiving 8, 12, or 24 weeks treatment with HARVONI in clinical trials. The majority of adverse reactions presented in Table 2 occurred at severity of grade 1. The side-by-side tabulation is to simplify presentation; direct comparison across trials should not be made due to differing trial designs.","There is no text provided for me to extract adverse drug event terms from. Since you mentioned ""The input is nan,"" ""nan"" typically stands for ""not a number,"" which suggests that either there was a mistake and no information was given, or it was explicitly stated that there is no relevant drug label text to analyze. Without a given excerpt, I cannot provide a list of adverse drug event terms. Please provide the text excerpt for analysis."
HARVONI,adverse reactions,"Table 2 Adverse Reactions (All Grades) Reported in >=5% of Subjects Receiving 8, 12, or 24 Weeks of Treatment with HARVONI HARVONI8 weeks HARVONI12 weeks HARVONI24 weeks N=215 N=539 N=326 Fatigue 16% 13% 18% Headache 11% 14% 17% Nausea 6% 7% 9% Diarrhea 4% 3% 7% Insomnia 3% 5% 6% Laboratory Abnormalities","Bilirubin elevations, Lipase Elevations, Creatine Kinase elevations"
HARVONI,adverse reactions,6.2 Postmarketing Experience,serious symptomatic bradycardia
HARVONI,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Bradycardia, Serious symptomatic bradycardia, liver disease"
HARVONI,warnings and precautions,5.1 Serious Symptomatic Bradycardia When Coadministered with Amiodarone,"symptomatic bradycardia, fatal cardiac arrest, requiring pacemaker intervention, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion, memory problems"
HARVONI,warnings and precautions,5.2 Risk of Reduced Therapeutic Effect Due to P-gp Inducers,reduced therapeutic effect
HARVONI,warnings and precautions,5.3 Related Products Not Recommended,sofosbuvir (SOVALDI (r))
OSPHENA,adverse reactions,6. ADVERSE REACTIONS,"hot flush, vaginal discharge, muscle spasms, genital discharge, hyperhidrosis"
OSPHENA,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, thromboembolic stroke, hemorrhagic stroke, deep vein thrombosis (DVT)"
OSPHENA,adverse reactions,Table 1 lists adverse reactions occurring more frequently in the OSPHENA 60 mg treatment group than in placebo and at a frequency >=1%.,"If the input provided is only the word ""nan"", then it's not possible to extract any adverse drug event terms, as there's no drug label information or context to analyze. Without additional information, I cannot provide a list of terms. Please provide the relevant excerpt from the drug label."
OSPHENA,adverse reactions,"Table 1: Adverse Reactions Reported More Common in the OSPHENA Treatment Group (60 mg Once Daily) and at Frequency >=1.0% in the Double-Blind, Controlled Clinical Trials with OSPHENA vs. Placebo Ospemifene 60 mg(N=1242)% Placebo(N=958)% Vascular Disorders Hot flush 7.5 2.6 Reproductive System and Breast Disorders Vaginal discharge 3.8 0.3 Genital discharge 1.3 0.1 Musculoskeletal and Connective Tissue Disorders Muscle spasms 3.2 0.9 Skin and Subcutaneous Tissue Disorders Hyperhidrosis 1.6 0.6 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ospemifene. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.","allergic conditions, hypersensitivity, angioedema, rash, rash erythematous, rash generalized, pruritus, urticaria"
OSPHENA,boxed warnings,BOXED WARNING: WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR DISORDERS,"As you've stated that the input is ""nan"", which typically stands for ""not a number"" and indicates that there is no data provided, there are no adverse drug event terms to extract. Without the actual excerpt from the drug label, I cannot provide you with a list of terms. If you have the excerpt or any other relevant information, please provide it, and then I can assist you in identifying the adverse drug event terms."
OSPHENA,boxed warnings,WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR DISORDERS,"endometrial cancer, endometrial hyperplasia, abnormal genital bleeding, stroke, deep vein thrombosis (DVT), thromboembolic stroke, hemorrhagic stroke"
OSPHENA,boxed warnings,EXCERPT: WARNING: ENDOMETRIAL CANCER AND CARDIOVASCULAR DISORDERS,"endometrial cancer, endometrial hyperplasia, stroke, deep vein thrombosis (DVT), cerebral thromboembolic, hemorrhagic stroke"
OSPHENA,warnings and precautions,5. WARNINGS AND PRECAUTIONS,"Venous Thromboembolism, DVT, pulmonary embolism, breast cancer, Severe Hepatic Impairment"
OSPHENA,warnings and precautions,5.1 Cardiovascular Disorders,"hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, obesity, venous thromboembolism (VTE), personal history or family history of VTE, systemic lupus erythematosus, stroke, thromboembolic stroke, hemorrhagic stroke, coronary heart disease, nonfatal MI, silent MI, CHD death, myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE)"
OSPHENA,warnings and precautions,5.2 Malignant Neoplasms,"simple hyperplasia without atypia, Endometrial thickening, proliferative endometrium, Uterine polyps, increased risk of endometrial cancer, endometrial hyperplasia, increased risk of breast cancer"
OSPHENA,warnings and precautions,5.3 Severe Hepatic Impairment,severe hepatic impairment
ERIVEDGE,adverse reactions,6 ADVERSE REACTIONS,"muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, ageusia"
ERIVEDGE,adverse reactions,6.1 Clinical Trials Experience,"muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, ageusia"
ERIVEDGE,adverse reactions,Table 1: Adverse Reactions Occurring in >= 10% of Advanced BCC Patients MedDRA Preferred Term All aBCCPatients (N = 138) All Grades(%) Grade 3 (%) Grade 4 (%) Gastrointestinal disorders Nausea 42 (30.4%) 1 (0.7%) - Diarrhea 40 (29.0%) 1 (0.7%) - Constipation 29 (21.0%) - - Vomiting 19 (13.8%) - - General disorders and administration site conditions Fatigue 55 (39.9%) 7 (5.1%) 1 (0.7%) Investigations Weight loss 62 (44.9%) 10 (7.2%) - Metabolism and nutrition disorders Decreased appetite 35 (25.4%) 3 (2.2%) - Musculoskeletal and connective tissue disorders Muscle spasms 99 (71.7%) 5 (3.6%) - Arthralgias 22 (15.9%) 1 (0.7%) Nervous system disorders Dysgeusia 76 (55.1%) - - Ageusia 15 (10.9%) - - Skin and subcutaneous tissue disorders Alopecia 88 (63.8%) - - Amenorrhea:,"amenorrhea, hyponatremia, hypokalemia, azotemia"
ERIVEDGE,boxed warnings,BOXED WARNING: WARNING: EMBRYO-FETAL TOXICITY,"If the input provided is ""nan,"" which typically stands for ""not a number"" or implies that there's no actual text provided, then I cannot extract any adverse drug event terms. There is no text to analyze for terms."
ERIVEDGE,boxed warnings,WARNING: EMBRYO-FETAL TOXICITY,"embryo-fetal death, severe birth defects, embryotoxic, fetotoxic, teratogenic, severe midline defects, missing digits, irreversible malformations"
ERIVEDGE,boxed warnings,EXCERPT: WARNING: EMBRYO-FETAL TOXICITY,"embryo-fetal death, severe birth defects, embryotoxic, fetotoxic, teratogenic, severe midline defects, missing digits, irreversible malformations"
ERIVEDGE,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"This excerpt does not explicitly mention any adverse drug events; it only provides advice regarding restrictions on blood and semen donation during and after therapy with ERIVEDGE. Therefore, there are no adverse drug event terms to list from this particular text."
ERIVEDGE,warnings and precautions,5.1 Embryo-Fetal Toxicity,"embryo-fetal death, severe birth defects, embryotoxic, fetotoxic, teratogenic"
ERIVEDGE,warnings and precautions,5.2 Blood Donation,"The excerpt provided does not contain any specific adverse drug event terms. It contains instructions for patients regarding blood donation restrictions during and after the treatment with ERIVEDGE, but no terms describing adverse drug events are mentioned."
ERIVEDGE,warnings and precautions,5.3 Semen Donation,embryo-fetal harm
LATUDA,adverse reactions,6 ADVERSE REACTIONS,"Increased Mortality, Suicidal Thoughts and Behaviors, Cerebrovascular Adverse Reactions, Stroke, Neuroleptic Malignant Syndrome, Tardive Dyskinesia, Hyperglycemia, Diabetes Mellitus, Dyslipidemia, Weight Gain, Hyperprolactinemia, Leukopenia, Neutropenia, Agranulocytosis, Orthostatic Hypotension, Syncope, Seizures, Cognitive and Motor Impairment, Body Temperature Dysregulation, Suicide, Activation of Mania/Hypomania, Dysphagia, Neurological Adverse Reactions, somnolence, akathisia, extrapyramidal symptoms, nausea"
LATUDA,adverse reactions,6.1 Clinical Trials Experience,"somnolence, akathisia, extrapyramidal symptoms, nausea"
LATUDA,adverse reactions,"Table 15: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Short-term Schizophrenia Studies Note: Figures rounded to the nearest integer * Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence ** Extrapyramidal symptoms includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus Percentage of Patients Reporting Reaction LATUDA Body System or Organ Class Placebo (N=708) (%) 20 mg/day (N=71) (%) 40 mg/day (N=487) (%) 80 mg/day (N=538) (%) 120 mg/day (N=291) (%) 160 mg/day (N=121) (%) All LATUDA (N=1508) (%) Gastrointestinal Disorders Nausea 5 11 10 9 13 7 10 Vomiting 6 7 6 9 9 7 8 Dyspepsia 5 11 6 5 8 6 6 Salivary Hypersecretion <1 1 1 2 4 2 2 Musculoskeletal and Connective Tissue Disorders Back Pain 2 0 4 3 4 0 3 Nervous System Disorders Somnolence* 7 15 16 15 26 8 17 Akathisia 3 6 11 12 22 7 13 Extrapyramidal Disorder** 6 6 11 12 22 13 14 Dizziness 2 6 4 4 5 6 4 Psychiatric Disorders Insomnia 8 8 10 11 9 7 10 Agitation 4 10 7 3 6 5 5 Anxiety 4 3 6 4 7 3 5 Restlessness 1 1 3 1 3 2 2 Dose-Related Adverse Reactions in the Schizophrenia Studies","akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, anxiety"
LATUDA,adverse reactions,"Table 16: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in a Short-term Monotherapy Bipolar Depression Study Note: Figures rounded to the nearest integer *Extrapyramidal symptoms includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus ** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence Percentage of Patients Reporting Reaction Body System or Organ Class Dictionary-derived Term Placebo (N=168) (%) LATUDA 20-60 mg/day (N=164) (%) LATUDA 80-120 mg/day (N=167) (%) All LATUDA(N=331) (%) Gastrointestinal Disorders Nausea 8 10 17 14 Dry Mouth 4 6 4 5 Vomiting 2 2 6 4 Diarrhea 2 5 3 4 Infections and Infestations Nasopharyngitis 1 4 4 4 Influenza 1 <1 2 2 Urinary Tract Infection <1 2 1 2 Musculoskeletal and Connective Tissue Disorders Back Pain <1 3 <1 2 Nervous System Disorders Extrapyramidal Symptoms* 2 5 9 7 Akathisia 2 8 11 9 Somnolence** 7 7 14 11 Psychiatric Disorders Anxiety 1 4 5 4 Dose-Related Adverse Reactions in the Monotherapy Study:","nausea, somnolence, akathisia, extrapyramidal symptoms"
LATUDA,adverse reactions,"Table 17: Adverse Reactions in 2% or More of LATUDA-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Short-term Adjunctive Therapy Bipolar Depression Studies Note: Figures rounded to the nearest integer *Extrapyramidal symptoms includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus ** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence Percentage of Patients Reporting Reaction Body System or Organ Class Dictionary-derived Term Placebo (N=334) (%) LATUDA 20 to 120 mg/day (N=360) (%) Gastrointestinal Disorders Nausea 10 14 Vomiting 1 4 General Disorders Fatigue 1 3 Infections and Infestations Nasopharyngitis 2 4 Investigations Weight Increased <1 3 Metabolism and Nutrition Disorders Increased Appetite 1 3 Nervous System Disorders Extrapyramidal Symptoms* 9 14 Somnolence** 5 11 Akathisia 5 11 Psychiatric Disorders Restlessness <1 4 Extrapyramidal Symptoms","extrapyramidal symptoms, akathisia, restlessness"
LATUDA,adverse reactions,"Table 18: Incidence of EPS Compared to Placebo in Schizophrenia Studies Note: Figures rounded to the nearest integer * Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus ** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor LATUDA Adverse Event Term Placebo (N=708) (%) 20 mg/day (N=71) (%) 40 mg/day (N=487) (%) 80 mg/day (N=538) (%) 120 mg/day (N=291) (%) 160 mg/day (N=121) (%) All EPS events 9 10 21 23 39 20 All EPS events, excluding Akathisia/Restlessness 6 6 11 12 22 13 Akathisia 3 6 11 12 22 7 Dystonia* <1 0 4 5 7 2 Parkinsonism** 5 6 9 8 17 11 Restlessness 1 1 3 1 3 2 Bipolar Depression","EPS (extrapyramidal symptoms), akathisia, restlessness"
LATUDA,adverse reactions,"Table 19: Incidence of EPS Compared to Placebo in the Monotherapy Bipolar Depression Study LATUDA Adverse Event Term Placebo (N=168) (%) 20 to 60 mg/day (N=164) (%) 80 to 120 mg/day (N=167) (%) All EPS events 5 12 20 All EPS events, excluding Akathisia/Restlessness 2 5 9 Note: Figures rounded to the nearest integer * Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus ** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor Akathisia 2 8 11 Dystonia* 0 0 2 Parkinsonism** 2 5 8 Restlessness <1 0 3 Adjunctive Therapy with Lithium or Valproate","EPS, akathisia, restlessness"
LATUDA,adverse reactions,"Table 20: Incidence of EPS Compared to Placebo in the Adjunctive Therapy Bipolar Depression Studies Adverse Event Term Placebo (N=334) (%) LATUDA 20 to 120 mg/day(N=360) (%) All EPS events 13 24 All EPS events, excluding Akathisia/Restlessness 9 14 Note: Figures rounded to the nearest integer * Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus ** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor Akathisia 5 11 Dystonia* <1 1 Parkinsonism** 8 13 Restlessness <1 4 In the short-term, placebo-controlled schizophrenia and bipolar depression studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias.","abdominal pain, anemia, angina pectoris, AV block 1st degree, blurred vision, bradycardia, breast enlargement, breast pain, cerebrovascular accident, decreased appetite, diarrhea, difficulty breathing, difficulty swallowing, dismenorrhea, dysarthria, dysmenorrhea, dysuria, erectile dysfunction, galactorrhea, gastritis, hypertension, panic attack, pruritus, rash, renal failure, rhabdomyolysis, sleep disorder, spasm of the neck muscles, sudden death, tachycardia, tightness of the throat, vertigo"
LATUDA,adverse reactions,Table 21: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in Schizophrenia Studies Laboratory Parameter Placebo (N=708) LATUDA 20mg/day (N=71) LATUDA 40mg/day (N=487) LATUDA 80mg/day (N=538) LATUDA 120 mg/day (N=291) LATUDA 160mg/day (N=121) Serum Creatinine Elevated 2% 1% 2% 2% 5% 7% Bipolar Depression,"Serum Creatinine, creatinine shift from normal to high"
LATUDA,adverse reactions,Table 22: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in a Monotherapy Bipolar Depression Study Laboratory Parameter Placebo (N=168) LATUDA20 to 60 mg/day (N=164) LATUDA80 to 120 mg/day (N=167) Serum Creatinine Elevated <1% 2% 4% Adjunctive Therapy with Lithium or Valproate,"Serum Creatinine, bipolar depression, creatinine shift from normal to high"
LATUDA,adverse reactions,Table 23: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adjunctive Therapy Bipolar Depression Studies Laboratory Parameter Placebo (N=334) LATUDA 20 to 120 mg/day(N=360) Serum Creatinine Elevated 2% 4%,"If the input provided is literally ""nan"" (not a number), and you are asking for the list of adverse drug event terms from it, then there is no data to extract from since ""nan"" is commonly used to indicate a missing or undefined value. Without an actual excerpt of a drug label, it's not possible to provide a list of adverse drug event terms. Please provide the text from which you need the adverse drug event terms extracted."
LATUDA,boxed warnings,BOXED WARNING: WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS,"Given the input ""nan"" seems to indicate that the provided data is non-existent or not a number, it suggests that there is no text excerpt from a drug label to analyze. Therefore, I cannot provide a list of adverse drug event terms. If you have an actual excerpt, please provide it, and I'd be happy to assist with the identification of any adverse drug event terms."
LATUDA,boxed warnings,WARNINGS: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; AND SUICIDAL THOUGHTS AND BEHAVIORS,"increased risk of death, dementia-related psychosis, increased risk of suicidal thoughts, suicidal behavior, worsening, emergence of suicidal thoughts, emergence of suicidal behaviors"
LATUDA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"cerebrovascular adverse events, stroke, transient ischemic attack, Neuroleptic Malignant Syndrome, Tardive Dyskinesia, hyperglycemia, Diabetes Mellitus, polydipsia, polyuria, polyphagia, weakness, Dyslipidemia, Weight Gain, hyperprolactinemia, Leukopenia, Neutropenia, Agranulocytosis, Orthostatic Hypotension, Syncope, Dizziness, tachycardia, bradycardia"
LATUDA,warnings and precautions,5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis,"increased risk of death, cardiovascular (e.g., heart failure, sudden death), infectious (e.g., pneumonia)"
LATUDA,warnings and precautions,5.2 Suicidal Thoughts and Behaviors in Adolescents and Young Adults,"worsening of their depression, suicidal ideation, behavior (suicidality), unusual changes in behavior, worsening of depression, emergence of suicidality, suicidal thinking and behavior (suicidality), risk of suicidality, clinical worsening, suicidality, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania, emergence of suicidal impulses, suicidality, emergent suicidality, overdose"
LATUDA,warnings and precautions,"5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis","cerebrovascular adverse reactions, cerebrovascular accidents, transient ischemic attacks, fatalities"
LATUDA,warnings and precautions,5.4 Neuroleptic Malignant Syndrome,"Neuroleptic Malignant Syndrome (NMS), hyperpyrexia, muscle rigidity, altered mental status, irregular pulse, blood pressure changes, tachycardia, diaphoresis, cardiac dysrhythmia, elevated creatine phosphokinase, myoglobinuria, rhabdomyolysis, acute renal failure, pneumonia, systemic infection, extrapyramidal signs and symptoms (EPS), central anticholinergic toxicity, heat stroke, drug fever, primary central nervous system pathology."
LATUDA,warnings and precautions,5.5 Tardive Dyskinesia,"tardive dyskinesia, involuntary, dyskinetic movements, irreversible"
LATUDA,warnings and precautions,5.6 Metabolic Changes,"hyperglycemia, dyslipidemia, body weight gain, ketoacidosis, hyperosmolar coma, death, glucose abnormalities, diabetes mellitus, polydipsia, polyuria, polyphagia, weakness"
LATUDA,warnings and precautions,5.7 Hyperprolactinemia,"Hyperprolactinemia, galactorrhea, amenorrhea, gynecomastia, impotence, decreased bone density, mammary gland neoplasia"
LATUDA,warnings and precautions,"5.8 Leukopenia, Neutropenia and Agranulocytosis","Leukopenia, Neutropenia, Agranulocytosis, Fever, Infection, Severe neutropenia"
LATUDA,warnings and precautions,5.9 Orthostatic Hypotension and Syncope,"orthostatic hypotension, syncope, dizziness, lightheadedness, tachycardia, bradycardia"
LATUDA,warnings and precautions,5.10 Seizures,"history of seizures, seizure threshold, Alzheimer's dementia, seizures/convulsions"
LATUDA,warnings and precautions,5.11 Potential for Cognitive and Motor Impairment,"impair judgment, thinking or motor skills, somnolence, hypersomnia, hypersomnolence, sedation"
LATUDA,warnings and precautions,5.12 Body Temperature Dysregulation,"disruption of the body's ability to reduce core body temperature, elevation in core body temperature, dehydration"
LATUDA,warnings and precautions,5.13 Suicide,"suicide attempt, suicidal ideation, overdose"
LATUDA,warnings and precautions,5.14 Activation of Mania/Hypomania,"manic episode, hypomanic episode"
LATUDA,warnings and precautions,5.15 Dysphagia,"Esophageal dysmotility, aspiration, aspiration pneumonia, morbidity, mortality"
LATUDA,warnings and precautions,5.16 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies,"confusion, obtundation, postural instability, frequent falls, extrapyramidal symptoms, neuroleptic malignant syndrome"
LEXISCAN,adverse reactions,6 ADVERSE REACTIONS,"Myocardial Ischemia, Sinoatrial and Atrioventricular Nodal Block, Atrial Fibrillation/Atrial Flutter, Hypersensitivity, Anaphylaxis, Hypotension, Hypertension, Bronchoconstriction, Seizure, Cerebrovascular Accident (Stroke), dyspnea, headache, flushing, chest discomfort, dizziness, angina pectoris, chest pain, nausea"
LEXISCAN,adverse reactions,6.1 Clinical Trials Experience,"Clinical trials, adverse reaction rates, adverse reactions, headache"
LEXISCAN,adverse reactions,"Table 1 Adverse Reactions in Studies 1 and 2 Pooled (Frequency >= 5%) LexiscanN = 1,337 Adenoscan N = 678 Dyspnea 28% 26% Headache 26% 17% Flushing 16% 25% Chest Discomfort 13% 18% Angina Pectoris or ST Segment Depression 12% 18% Dizziness 8% 7% Chest Pain 7% 10% Nausea 6% 6% Abdominal Discomfort 5% 2% Dysgeusia 5% 7% Feeling Hot 5% 8% ECG Abnormalities","rhythm abnormalities, conduction abnormalities"
LEXISCAN,adverse reactions,"Table 2 Rhythm or Conduction Abnormalities12-lead ECGs were recorded before and for up to 2 hrs after dosing in Studies 1 and 2 LexiscanN / N evaluable (%) AdenoscanN / N evaluable (%) Rhythm or conduction abnormalitiesincludes rhythm abnormalities (PACs, PVCs, atrial fibrillation/flutter, wandering atrial pacemaker, supraventricular or ventricular arrhythmia) or conduction abnormalities, including AV block 332/1275 (26%) 192/645 (30%) Rhythm abnormalities 260/1275 (20%) 131/645 (20%) PACs 86/1274 (7%) 57/645 (9%) PVCs 179/1274 (14%) 79/645 (12%) First-degree AV block (PR prolongation > 220 msec) 34/1209 (3%) 43/618 (7%) Second-degree AV block 1/1209 (0.1%) 9/618 (1%) AV conduction abnormalities (other than AV blocks) 1/1209 (0.1%) 0/618 (0%) Ventricular conduction abnormalities 64/1152 (6%) 31/581 (5%) Respiratory Abnormalities","asthma, chronic obstructive pulmonary disease, respiratory adverse reactions"
LEXISCAN,adverse reactions,"Table 3 Respiratory Adverse Effects in Study 3All subjects continued the use of their respiratory medications as prescribed prior to administration of Lexiscan. Asthma Cohort COPD Cohort Lexiscan (N=356) Placebo (N=176) Lexiscan (N=316) Placebo (N=151) Overall Pre-specified Respiratory Adverse ReactionPatients may have reported more than one type of adverse reaction. Adverse reactions were collected up to 24 hours following drug administration. Pre-specified respiratory adverse reactions included dyspnea, wheezing, obstructive airway disorder, dyspnea exertional, and tachypnea. 12.9% 2.3% 19.0% 4.0% Dyspnea 10.7% 1.1% 18.0% 2.6% Wheezing 3.1% 1.1% 0.9% 0.7% FEV1 reduction >15%Change from baseline at 2 hours 1.1% 2.9% 4.2% 5.4% Renal Impairment",serious adverse events
LEXISCAN,adverse reactions,6.2 Post-Marketing Experience,"Myocardial infarction, cardiac arrest, ventricular arrhythmias, supraventricular tachyarrhythmias, atrial fibrillation with rapid ventricular response, atrial flutter, heart block, third-degree block, asystole, marked hypertension, symptomatic hypotension, transient ischemic attack, seizures, syncope, QTc prolongation, tremor, cerebrovascular accident, intracranial hemorrhage, abdominal pain, nausea, vomiting, myalgias, diarrhea, fecal incontinence, anaphylaxis, angioedema, respiratory arrest, respiratory distress, decreased oxygen saturation, throat tightness, urticaria, rashes, musculoskeletal pain, dyspnea, wheezing"
LEXISCAN,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Myocardial Ischemia, Fatal cardiac events, Unstable angina, Cardiovascular instability, First-degree AV block, Second-degree AV block, Third-degree AV block, Sinus bradycardia, Atrial Fibrillation, Atrial Flutter, Anaphylaxis, Angioedema, Cardiac arrest, Respiratory arrest, Respiratory distress, Decreased oxygen saturation, Hypotension, Throat tightness, Urticaria, Hypertension, Bronchoconstriction, Dyspnea, Seizure, Convulsive seizures, Cerebrovascular Accident (Stroke), Hemorrhagic stroke, Ischemic stroke."
LEXISCAN,warnings and precautions,5.1 Myocardial Ischemia,"Fatal myocardial infarction, nonfatal myocardial infarction, ventricular arrhythmias, cardiac arrest, acute myocardial ischemia, unstable angina, cardiovascular instability, serious cardiovascular reactions"
LEXISCAN,warnings and precautions,5.2 Sinoatrial and Atrioventricular Nodal Block,"first-degree AV block, second-degree AV block, third-degree AV block, sinus bradycardia, PR prolongation, transient second-degree AV block, dropped beat, third-degree heart block, asystole"
LEXISCAN,warnings and precautions,5.3 Atrial Fibrillation/Atrial Flutter,"new-onset atrial fibrillation, recurrent atrial fibrillation, rapid ventricular response, atrial flutter"
LEXISCAN,warnings and precautions,"5.4 Hypersensitivity, Including Anaphylaxis","Anaphylaxis, angioedema, cardiac arrest, respiratory arrest, respiratory distress, decreased oxygen saturation, hypotension, throat tightness, urticaria, rashes, hypersensitivity reactions"
LEXISCAN,warnings and precautions,5.5 Hypotension,"arterial vasodilation, hypotension, decreased systolic blood pressure, decreased diastolic blood pressure, serious hypotension, syncope, transient ischemic attacks, seizures"
LEXISCAN,warnings and precautions,5.6 Hypertension,"increases in blood pressure, hypertension"
LEXISCAN,warnings and precautions,5.7 Bronchoconstriction,"dyspnea, bronchoconstriction, respiratory compromise"
LEXISCAN,warnings and precautions,5.8 Seizure,"lower the seizure threshold, New-onset of convulsive seizures, recurrence of convulsive seizures, Some seizures are prolonged, require emergent anticonvulsive management, increase the risk of seizures"
LEXISCAN,warnings and precautions,5.9 Cerebrovascular Accident (Stroke),"hemorrhagic cerebrovascular accidents, ischemic cerebrovascular accidents, hypotension, hypertension"
BRILINTA,adverse reactions,6 ADVERSE REACTIONS,"bleeding, dyspnea"
BRILINTA,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction, Bleeding, non-CABG major bleeding event, Frequency of bleeding, Non-CABG major bleeding events"
BRILINTA,adverse reactions,"Table 1 - Non-CABG related bleeds (PLATO) BRILINTA N=9235 Clopidogrel N=9186 n (%) patients with event n (%) patients with event PLATO Major + Minor 713 (7.7) 567 (6.2) Major 362 (3.9) 306 (3.3) Fatal/Life-threatening 171 (1.9) 151 (1.6) Fatal 15 (0.2) 16 (0.2) Intracranial hemorrhage (Fatal/Life-threatening) 26 (0.3) 15 (0.2) PLATO Minor bleed: requires medical intervention to stop or treat bleeding. PLATO Major bleed: any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g., intraocular with permanent vision loss); associated with a decrease in Hb of at least 3 g/dL (or a fall in hematocrit (Hct) of at least 9%); transfusion of 2 or more units. PLATO Major bleed, fatal/life-threatening: any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units. Fatal: A bleeding event that directly led to death within 7 days. No baseline demographic factor altered the relative risk of bleeding with BRILINTA compared to clopidogrel.","bleeding, Major fatal/life-threatening bleeding, CABG-related bleeding"
BRILINTA,adverse reactions,"Table 2 - CABG-related bleeding (PLATO) BRILINTA90 mg BID N=770 Clopidogrel N=814 PLATO Total Major 626 (81.3) 666 (81.8) Fatal/Life-threatening 337 (43.8) 350 (43.0) Fatal 6 (0.8) 7 (0.9) PLATO Major bleed: any one of the following: fatal; intracranial; intrapericardial with cardiac tamponade; hypovolemic shock or severe hypotension requiring intervention; significantly disabling (e.g., intraocular with permanent vision loss); associated with a decrease in Hb of at least 3 g/dL (or a fall in hematocrit (Hct) of at least 9%); transfusion of 2 or more units. PLATO Major bleed, fatal/life-threatening: any major bleed as described above and associated with a decrease in Hb of more than 5 g/dL (or a fall in hematocrit (Hct) of at least 15%); transfusion of 4 or more units. When antiplatelet therapy was stopped 5 days before CABG, major bleeding occurred in 75% of BRILINTA treated patients and 79% on clopidogrel.","Other Adverse Reactions,PLATO,Adverse reactions,rate of 4%,Table 3"
BRILINTA,adverse reactions,Table 3 - Percentage of patients reporting non-hemorrhagic adverse reactions at least 4% or more in either group and more frequently on BRILINTA (PLATO) BRILINTAN=9235 ClopidogrelN=9186 Dyspnea 13.8 7.8 Dizziness 4.5 3.9 Nausea 4.3 3.8 Bleeding in PEGASUS (Secondary Prevention in Patients with a History of Myocardial Infarction),bleeding events
BRILINTA,adverse reactions,"Table 4 - Bleeding events (PEGASUS) BRILINTA60 mg BID + Aspirin N=6958 Aspirin Alone N=6996 n (%) patients with event Events /100 pt yrs n patients with event Events /100 pt yrs TIMI Major 115 (1.7) 0.78 54 (0.8) 0.34 Fatal 11 (0.2) 0.08 12 (0.2) 0.08 Intracranial hemorrhage 28 (0.4) 0.19 23 (0.3) 0.14 TIMI Major or Minor 168 (2.4) 1.15 72 (1.0) 0.45 TIMI Major: Fatal bleeding, OR any intracranial bleeding, OR clinically overt signs of hemorrhage associated with a drop in hemoglobin (Hgb) of >=5 g/dL, or a fall in hematocrit (Hct) of 15%. Fatal: A bleeding event that directly led to death within 7 days. TIMI Minor: Clinically apparent with 3-5 g/dL decrease in hemoglobin. The bleeding profile of BRILINTA 60 mg compared to aspirin alone was consistent across multiple pre-defined subgroups (e.g., by age, gender, weight, race, geographic region, concurrent conditions, concomitant therapy, stent, and medical history) for TIMI Major and TIMI Major or Minor bleeding events.","The excerpt provided does not contain specific adverse drug event terms, except for the indication that adverse reactions occurred at rates of 3% or more in PEGASUS. To provide a list of adverse drug event terms, the specific reactions mentioned in ""Table 5"" would be required. Since no such table is included in the input, no adverse drug event terms can be extracted from the text provided."
BRILINTA,adverse reactions,Table 5 - Non-hemorrhagic adverse reactions reported in >3.0% of patients in the ticagrelor 60 mg treatment group (PEGASUS) BRILINTA N=6958 ClopidogrelN=6996 Dyspnea 14.2 5.5 Dizziness 4.5 4.1 Diarrhea 3.3 2.5 Bradycardia,"ventricular pauses, bradycardic events, sick sinus syndrome, 2nd or 3rd degree AV block, bradycardic-related syncope, syncope, pre-syncope, loss of consciousness, serum Uric Acid increase, gout, >50% increase in serum creatinine levels, acute renal failure, chronic renal failure, toxic nephropathy, oliguria."
BRILINTA,boxed warnings,"BOXED WARNING: WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS","If the input is 'nan', it indicates that there is no excerpt provided to extract adverse drug event terms from. Therefore, there is no list to generate. If you have an actual excerpt that you would like me to analyze, please provide it and I'll gladly assist you."
BRILINTA,boxed warnings,"WARNING: (A) BLEEDING RISK, (B) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS","If the input provided is ""nan,"" which typically means ""not a number"" or is used to indicate a null or non-applicable value, and there's no actual drug label text provided to analyze for adverse drug event terms, then I am unable to extract any terms. Please provide the excerpt of the drug label for analysis."
BRILINTA,boxed warnings,A. BLEEDING RISK,"significant bleeding, fatal bleeding, active pathological bleeding, intracranial hemorrhage, urgent coronary artery bypass graft surgery"
BRILINTA,boxed warnings,BLEEDING RISK,"significant bleeding, fatal bleeding, active pathological bleeding, intracranial hemorrhage, cardiovascular events"
BRILINTA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Dyspnea, Severe Hepatic Impairment"
BRILINTA,warnings and precautions,5.1 General Risk of Bleeding,"bleeding, subsequent cardiovascular events"
BRILINTA,warnings and precautions,5.2 Concomitant Aspirin Maintenance Dose,"The task does not include any adverse drug event terms but is focused on the effectiveness of the drug in combination with aspirin. Therefore, there are no adverse drug event terms to list from the provided text."
BRILINTA,warnings and precautions,5.3 Dyspnea,dyspnea
BRILINTA,warnings and precautions,5.4 Discontinuation of BRILINTA,"myocardial infarction, stroke, death, bleeding"
BRILINTA,warnings and precautions,5.5 Severe Hepatic Impairment,"severe hepatic impairment, increase serum concentration"
KERYDIN,adverse reactions,6 ADVERSE REACTIONS,"application site exfoliation, ingrown toenail, application site erythema, application site dermatitis"
KERYDIN,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions"
KERYDIN,adverse reactions,"Table 1: Adverse Reactions Occurring in >=1% of KERYDIN Topical Solution, 5%-Treated Subjects and at a Greater Frequency than Observed with Vehicle Preferred Term KERYDINN=791 n(%) VehicleN=395 n(%) Application site exfoliation 21 (2.7%) 1 (0.3%) Ingrown toenail 20 (2.5%) 1 (0.3%) Application site erythema 13 (1.6%) 0 (0%) Application site dermatitis 10 (1.3%) 0 (0%) A cumulative irritancy study revealed the potential for KERYDIN to cause skin irritation. There was no evidence that KERYDIN causes contact sensitization.","If the input is ""nan"", which typically stands for ""not a number"" or indicates a missing or undefined value, then there is no text to extract adverse drug event terms from. Thus, I cannot provide any terms without the appropriate text excerpt from a drug label. If you can provide the actual excerpt, I'd be more than happy to assist with identifying the adverse drug event terms."
ZELBORAF,adverse reactions,6 ADVERSE REACTIONS,"New Primary Malignancies, Hypersensitivity Reactions, Dermatologic Reactions, QT Prolongation, Hepatotoxicity, Photosensitivity, Ophthalmologic Reactions, Radiation Sensitization, Radiation Recall, arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, skin papilloma."
ZELBORAF,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse drug reactions (ADRs)"
ZELBORAF,adverse reactions,"Table 1 presents adverse reactions reported in at least 10% of patients treated with ZELBORAF. The most common adverse reactions of any grade (>= 30% in either study) in ZELBORAF-treated patients were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma. The most common (>= 5%) Grade 3 adverse reactions were cuSCC and rash. The incidence of Grade 4 adverse reactions was <= 4% in both studies.","permanent discontinuation, adverse events"
ZELBORAF,adverse reactions,"Table 1 Adverse Reactions Reported in >= 10% of Patients Treated with ZELBORAFAdverse drug reactions, reported using MedDRA and graded using NCI-CTC-AE v 4.0 (NCI common toxicity criteria) for assessment of toxicity. ADRs Trial 1: Treatment Naive Patients Trial 2: Patients with Failure of at Least One Prior Systemic Therapy ZELBORAFn=336 Dacarbazinen=287 ZELBORAFn=132 All Grades (%) Grade 3(%) All Grades (%) Grade 3 (%) All Grades (%) Grade 3(%) Skin and subcutaneous tissue disorders Rash 37 8 2 0 52 7 Photosensitivity reaction 33 3 4 0 49 3 Alopecia 45 < 1 2 0 36 0 Pruritus 23 1 1 0 30 2 Hyperkeratosis 24 1 < 1 0 28 0 Rash maculo-papular 9 2 < 1 0 21 6 Actinic keratosis 8 0 3 0 17 0 Dry skin 19 0 1 0 16 0 Rash papular 5 < 1 0 0 13 0 Erythema 14 0 2 0 8 0 Musculoskeletal and connective tissue disorders Arthralgia 53 4 3 < 1 67 8 Myalgia 13 < 1 1 0 24 < 1 Pain in extremity 18 < 1 6 2 9 0 Musculoskeletal pain 8 0 4 < 1 11 0 Back pain 8 < 1 5 < 1 11 < 1 General disorders and administration site conditions Fatigue 38 2 33 2 54 4 Edema peripheral 17 < 1 5 0 23 0 Pyrexia 19 < 1 9 < 1 17 2 Asthenia 11 < 1 9 < 1 2 0 Gastrointestinal disorders Nausea 35 2 43 2 37 2 Diarrhea 28 < 1 13 < 1 29 < 1 Vomiting 18 1 26 1 26 2 Constipation 12 < 1 24 0 16 0 Nervous system disorders Headache 23 < 1 10 0 27 0 Dysgeusia 14 0 3 0 11 0 Neoplasms benign, malignant and unspecified (includes cysts and polyps) Skin papilloma 21 < 1 0 0 30 0 Cutaneous SCC 24 22 < 1 < 1 24 24 Seborrheic keratosis 10 < 1 1 0 14 0 Investigations Gamma-glutamyltransferase increased 5 3 1 0 15 6 Metabolism and nutrition disorders Decreased appetite 18 0 8 < 1 21 0 Respiratory, thoracic and mediastinal disorders Cough 8 0 7 0 12 0 Injury, poisoning and procedural complications Sunburn 10 0 0 0 14 0 Clinically relevant adverse reactions reported in < 10% of patients treated with ZELBORAF in the Phase 2 and Phase 3 studies include:","palmar-plantar erythrodysesthesia syndrome, keratosis pilaris, panniculitis, erythema nodosum, Stevens-Johnson syndrome, toxic epidermal necrolysis, arthritis, neuropathy peripheral, VIIth nerve paralysis, folliculitis, retinal vein occlusion, vasculitis, atrial fibrillation"
ZELBORAF,adverse reactions,Table 2 shows the incidence of worsening liver laboratory abnormalities in Trial 1 summarized as the proportion of patients who experienced a shift from baseline to Grade 3 or 4.,"If the input provided is ""nan"" which typically stands for ""not a number"" or simply represents nonexistent or missing information, then there are no adverse drug event terms to extract. Therefore, the output would be an empty response with no terms to list."
ZELBORAF,adverse reactions,"Table 2 Change From Baseline to Grade 3/4 Liver Laboratory AbnormalitiesFor ALT, alkaline phosphatase, and bilirubin, there were no patients with a change to Grade 4 in either treatment arm. Parameter Change From Baseline to Grade 3/4 ZELBORAF (%) Dacarbazine (%) GGT 11.5 8.6 AST 0.9 0.4 ALT 2.8 1.9 Alkaline phosphatase 2.9 0.4 Bilirubin 1.9 0 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of ZELBORAF. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.","Neoplasms benign, malignant and unspecified (incl. cysts and polyps), Progression of pre-existing chronic myelomonocytic leukemia, Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), Neutropenia, Radiation sensitization and recall, Pancreatitis."
ZELBORAF,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"New Primary Cutaneous Malignancies, New Non-Cutaneous Squamous Cell Carcinoma, Other Malignancies, Tumor Promotion in BRAF Wild-Type Melanoma, Serious Hypersensitivity Reactions, anaphylaxis, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS Syndrome), Severe Dermatologic Reactions, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, QT Prolongation, Hepatotoxicity, Photosensitivity, Serious Ophthalmologic Reactions, Embryo-Fetal Toxicity, Radiation Sensitization, Radiation Recall."
ZELBORAF,warnings and precautions,5.1 New Primary Malignancies,"cutaneous squamous cell carcinoma, keratoacanthoma, melanoma, cuSCC, non-cutaneous squamous cell carcinoma"
ZELBORAF,warnings and precautions,5.2 Tumor Promotion in BRAF Wild-Type Melanoma,"paradoxical activation of MAP-kinase signaling, increased cell proliferation"
ZELBORAF,warnings and precautions,5.3 Hypersensitivity Reactions,"Anaphylaxis, serious hypersensitivity reactions, generalized rash, erythema, hypotension, drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)"
ZELBORAF,warnings and precautions,5.4 Dermatologic Reactions,"Severe dermatologic reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis"
ZELBORAF,warnings and precautions,5.5 QT Prolongation,"QT prolongation, ventricular arrhythmias, Torsade de Pointes, electrolyte abnormalities, long QT syndrome, congestive heart failure, bradyarrhythmias"
ZELBORAF,warnings and precautions,5.6 Hepatotoxicity,"liver injury, functional hepatic impairment, coagulopathy, organ dysfunction, Grade 3 increases in transaminases, bilirubin"
ZELBORAF,warnings and precautions,5.7 Photosensitivity,photosensitivity
ZELBORAF,warnings and precautions,5.8 Ophthalmologic Reactions,"Uveitis, blurry vision, photophobia, iritis"
ZELBORAF,warnings and precautions,5.9 Embryo-Fetal Toxicity,"fetal harm, potential hazard to a fetus"
ZELBORAF,warnings and precautions,5.10 Radiation Sensitization and Radiation Recall,"Radiation sensitization, recall, cutaneous and visceral organs, severe"
FYCOMPA,adverse reactions,6 ADVERSE REACTIONS,"Serious Psychiatric and Behavioral Reactions, Suicidal Behavior and Ideation, Dizziness and Gait Disturbance, Somnolence and Fatigue, Falls, dizziness, somnolence, fatigue, irritability, nausea, weight gain, vertigo, ataxia, headache, vomiting, contusion, abdominal pain, anxiety"
FYCOMPA,adverse reactions,6.1 Clinical Trial s Experience,"dizziness, somnolence, vertigo, aggression, anger, ataxia, blurred vision, irritability, dysarthria, fatigue, falls, nausea, balance disorder, gait disturbance, weight gain"
FYCOMPA,adverse reactions,"Table 2. Adverse Reactions in Pooled Placebo-Controlled Trials in Patients with Partial-Onset Seizures (Studies 1, 2, and 3) (Reactions >= 2% of Patients in Highest FYCOMPA Dose (12 mg) Group and More Frequent than Placebo) Placebo n=442 % FYCOMPA 4 mg n=172 % 8 mg n=431 % 12 mg n=255 % Dizziness 9 16 32 43 Somnolence 7 9 16 18 Headache 11 11 11 13 Irritability 3 4 7 12 Fatigue 5 8 8 12 Falls 3 2 5 10 Ataxia 0 1 3 8 Nausea 5 3 6 8 Vertigo 1 4 3 5 Back pain 2 2 2 5 Dysarthria 0 1 3 4 Anxiety 1 2 3 4 Blurred vision 1 1 3 4 Gait disturbance 1 1 4 4 Weight gain 1 4 4 4 Cough 3 1 1 4 Upper respiratory tract infection 3 3 3 4 Vomiting 3 2 3 4 Hypersomnia 0 1 2 3 Anger <1 0 1 3 Aggression 1 1 2 3 Balance disorder 1 0 5 3 Diplopia 1 1 1 3 Head injury 1 1 1 3 Hypoaesthesia 1 0 0 3 Pain in extremity 1 0 2 3 Constipation 2 2 2 3 Myalgia 2 1 1 3 Coordination abnormal 0 1 <1 2 Euphoric mood 0 0 <1 2 Confusional state <1 1 1 2 Hyponatremia <1 0 0 2 Limb injury <1 1 1 2 Mood altered <1 1 <1 2 Arthralgia 1 0 3 2 Asthenia 1 1 2 2 Contusion 1 0 2 2 Memory impairment 1 0 1 2 Musculoskeletal pain 1 1 1 2 Oropharyngeal pain 1 2 2 2 Paraesthesia 1 0 1 2 Peripheral edema 1 1 1 2 Skin laceration 1 0 2 2 Primary Generalized Tonic- Clonic Seizures A total of 81 patients receiving FYCOMPA 8 mg once daily constituted the safety population in the placebo-controlled trial in patients with primary generalized tonic-clonic seizures (Study 4). Approximately 57% of patients were female, and the mean age was 27 years.","primary generalized tonic-clonic seizure, adverse reaction, partial-onset seizure"
FYCOMPA,adverse reactions,"Table 3 gives the incidence of adverse reactions in patients receiving FYCOMPA 8 mg (>=4% and higher than in the placebo group) in Study 4. The most common adverse reactions in patients receiving FYCOMPA (>=10% and greater than placebo) were dizziness (32%), fatigue (15%), headache (12%), somnolence (11%), and irritability (11%).","vomiting, dizziness"
FYCOMPA,adverse reactions,Table 3. Adverse Reactions in a Placebo-Controlled Trial in Patients with Primary Generalized Tonic-Clonic Seizures (Study 4) (Reactions >= 4% of Patients in FYCOMPA Group and More Frequent than Placebo) Placebo n=82 % FYCOMPA 8 mg n=81 % Dizziness 6 32 Fatigue 6 15 Headache 10 12 Somnolence 4 11 Irritability 2 11 Vertigo 2 9 Vomiting 2 9 Weight gain 4 7 Contusion 4 6 Nausea 5 6 Abdominal pain 1 5 Anxiety 4 5 Urinary tract infection 1 4 Ligament sprain 0 4 Balance disorder 1 4 Rash 1 4 Weight Gain Weight gain has occurred with FYCOMPA.,"Weight gain, Elevated triglycerides"
FYCOMPA,adverse reactions,6.2 Postmarketing Experience,"Dermatologic, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)"
FYCOMPA,boxed warnings,BOXED WARNING: WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS,"As the input provided is ""nan"", which signifies that there is no actual text from a drug label to analyze, there are no adverse drug event terms to extract. If you provide an excerpt from a drug label, I could assist you in identifying any present adverse drug event terms."
FYCOMPA,boxed warnings,WARNING: SERIOUS PSYCHIATRIC AND BEHAVIORAL REACTIONS,"aggression, hostility, irritability, anger, homicidal ideation and threats, changes in mood, behavior, or personality"
FYCOMPA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"suicidal thoughts, suicidal behavior, dizziness, gait disturbance, somnolence, fatigue, falls, injuries, increase in seizure frequency"
FYCOMPA,warnings and precautions,5.1 Serious P sychiatric and Behavioral Reactions,"hostility, aggression-related adverse reactions, irritability, aggression, anger, anxiety, belligerence, affect lability, agitation, physical assault, homicidal ideation, threat, mood worsening, paranoia, euphoric mood, mental status changes, disorientation, confusional state, disorientation, delusion"
FYCOMPA,warnings and precautions,5. 2 Suicidal Behavior and Ideation,"suicidal thoughts, suicidal behavior, depression, mood changes, suicidal thinking, suicidal ideation, suicides"
FYCOMPA,warnings and precautions,5. 3 Neurologic Effects,"Dizziness, Gait Disturbance, disturbance in gait, coordination, vertigo, ataxia, balance disorder, abnormal coordination, somnolence, fatigue, asthenia, lethargy"
FYCOMPA,warnings and precautions,5. 4 Falls,"increased risk of falls, serious injuries, head injuries, bone fracture, discontinuation"
FYCOMPA,warnings and precautions,5. 5 Withdrawal of Antiepileptic Drugs,"increased seizure frequency, seizures"
ISTODAX,adverse reactions,6 ADVERSE REACTIONS,"Myelosuppression, Infection, Electrocardiographic Changes, Tumor Lysis Syndrome, neutropenia, lymphopenia, thrombocytopenia, infections, nausea, fatigue, vomiting, anorexia, anemia, ECG T-wave changes"
ISTODAX,adverse reactions,6.1 Clinical Trials Experience,"Cutaneous T-Cell Lymphoma, Common Adverse Reactions"
ISTODAX,adverse reactions,"Table 1 summarizes the most frequent adverse reactions (> 20%) regardless of causality using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0). Due to methodological differences between the studies, the AE data are presented separately for Study 1 and Study 2. Adverse reactions are ranked by their incidence in Study 1. Laboratory abnormalities commonly reported (> 20%) as adverse reactions are included in Table 1.","As no text excerpt is provided in the input, I cannot extract any adverse drug event terms. If you provide the actual text, I'd be happy to assist with identifying the terms."
ISTODAX,adverse reactions,Table 1. Adverse Reactions Occurring in >20% of Patients in Either CTCL Study (N=185) Adverse Reactions n (%) Study 1(n=102) Study 2(n=83) All grades Grade 3 or 4 All grades Grade 3 or 4 Any adverse reaction 99 (97) 36 (35) 83 (100) 68 (82) Nausea 57 (56) 3 (3) 71 (86) 5 (6) Asthenia/Fatigue 54 (53) 8 (8) 64 (77) 12 (14) Infections 47 (46) 11 (11) 45 (54) 27 (33) Vomiting 35 (34) 1 (<1) 43 (52) 8 (10) Anorexia 23 (23) 1 (<1) 45 (54) 3 (4) Hypomagnesemia 22 (22) 1 (<1) 23 (28) 0 Diarrhea 20 (20) 1 (<1) 22 (27) 1 (1) Pyrexia 20 (20) 4 (4) 19 (23) 1 (1) Anemia 19 (19) 3 (3) 60 (72) 13 (16) Thrombocytopenia 17 (17) 0 54 (65) 12 (14) Dysgeusia 15 (15) 0 33 (40) 0 Constipation 12 (12) 2 (2) 32 (39) 1 (1) Neutropenia 11 (11) 4 (4) 47 (57) 22 (27) Hypotension 7 (7) 3 (3) 19 (23) 3 (4) Pruritus 7 (7) 0 26 (31) 5 (6) Hypokalemia 6 (6) 0 17 (20) 2 (2) Dermatitis/Exfoliative dermatitis 4 (4) 1 (<1) 22 (27) 7 (8) Hypocalcemia 4 (4) 0 43 (52) 5 (6) Leukopenia 4 (4) 0 38 (46) 18 (22) Lymphopenia 4 (4) 0 47 (57) 31 (37) Alanine aminotransferase increased 3 (3) 0 18 (22) 2 (2) Aspartate aminotransferase increased 3 (3) 0 23 (28) 3 (4) Hypoalbuminemia 3 (3) 1 (<1) 40 (48) 3 (4) Electrocardiogram ST-T wave changes 2 (2) 0 52 (63) 0 Hyperglycemia 2 (2) 2 (2) 42 (51) 1 (1) Hyponatremia 1 (<1) 1 (<1) 17 (20) 2 (2) Hypermagnesemia 0 0 22 (27) 7 (8) Hypophosphatemia 0 0 22 (27) 8 (10) Hyperuricemia 0 0 27 (33) 7 (8) Serious Adverse Reactions,"serious infection, sepsis, pyrexia, fatigue, supraventricular arrhythmia, central line infection, neutropenia, hypotension, hyperuricemia, edema, ventricular arrhythmia, thrombocytopenia, nausea, leukopenia, dehydration, aspartate aminotransferase increased, catheter related infection, hypophosphatemia, dyspnea, cardiopulmonary failure, acute renal failure, myocardial ischemia, acute respiratory distress syndrome, QT prolongation, hypomagnesemia"
ISTODAX,adverse reactions,"Table 2 summarizes the most frequent adverse reactions (>= 10%) regardless of causality, using the NCI-CTCAE, Version 3.0. The AE data are presented separately for Study 3 and Study 4. Laboratory abnormalities commonly reported (>= 10%) as adverse reactions are included in Table 2.","If the input text is ""nan,"" indicating that it may be a placeholder for missing text (such as ""not applicable"" or ""not available""), then there are no adverse drug event terms to extract. If ""nan"" is provided in error and you actually meant to submit a text excerpt from a drug label, please provide the correct text so I can assist you with finding the adverse drug event terms."
ISTODAX,adverse reactions,"Table 2. Adverse Reactions Occurring in >=10% of Patients with PTCL in Study 3 and Corresponding Incidence in Study 4 (N=178) Adverse Reactions n (%) Study 3(N=131) Study 4(N=47) All grades Grade 3 or 4 All grades Grade 3 or 4 Any adverse reactions 128 (97) 88 (67) 47 (100) 40 (85) Gastrointestinal disorders Nausea 77 (59) 3 (2) 35 (75) 3 (6) Vomiting 51 (39) 6 (5) 19 (40) 4 (9) Diarrhea 47 (36) 3 (2) 17 (36) 1 (2) Constipation 39 (30) 1 (<1) 19 (40) 1 (2) Abdominal pain 18 (14) 3 (2) 6 (13) 1 (2) Stomatitis 14 (11) 0 3 (6) 0 General disorders and administration site conditions Asthenia/Fatigue 72 (55) 11 (8) 36 (77) 9 (19) Pyrexia 46 (35) 8 (6) 22 (47) 8 (17) Chills 14 (11) 1 (<1) 8 (17) 0 Edema peripheral 13 (10) 1 (<1) 3 (6) 0 Blood and lymphatic system disorders Thrombocytopenia 53 (41) 32 (24) 34 (72) 17 (36) Neutropenia 39 (30) 26 (20) 31 (66) 22 (47) Anemia 33 (25) 14 (11) 29 (62) 13 (28) Leukopenia 16 (12) 8 (6) 26 (55) 21 (45) Metabolism and nutrition disorders Anorexia 37 (28) 2 (2) 21 (45) 1 (2) Hypokalemia 14 (11) 3 (2) 8 (17) 1 (2) Nervous system disorders Dysgeusia 27 (21) 0 13 (28) 0 Headache 19 (15) 0 16 (34) 1 (2) Respiratory, thoracic and mediastinal disorders Cough 23 (18) 0 10 (21) 0 Dyspnea 17 (13) 3 (2) 10 (21) 2 (4) Investigations Weight decreased 14 (11) 0 7 (15) 0 Cardiac disorders Tachycardia 13 (10) 0 0 0 Serious Adverse Reactions","serious infection, pyrexia, pneumonia, sepsis, vomiting, cellulitis, deep vein thrombosis, febrile neutropenia, abdominal pain, chest pain, neutropenia, pulmonary embolism, dyspnea, dehydration, aspartate aminotransferase increased, hypotension, anemia, thrombocytopenia, alanine aminotransferase increased, infection, lymphopenia, hyperbilirubinemia, hypocalcemia, hypoxia, febrile neutropenia, leukopenia, ventricular arrhythmia, vomiting, hypersensitivity, catheter related infection, hyperuricemia, hypoalbuminemia, syncope, pneumonitis, multi-organ failure/sepsis, septic shock, candida sepsis, sepsis/cardiogenic shock, aspartate aminotransferase elevation, thrombocytopenia"
ISTODAX,adverse reactions,6.2 Postmarketing Experience,No adverse drug event terms are explicitly mentioned in the provided text excerpt.
ISTODAX,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"myelosuppression, thrombocytopenia, leukopenia, neutropenia, lymphopenia, anemia, infections, fatal infections, serious infections, reactivation of DNA viruses, Epstein Barr, hepatitis B, Electrocardiographic (ECG) changes, long QT syndrome, cardiovascular disease, QT prolongation, Tumor lysis syndrome, Embryo-fetal toxicity, fetal harm"
ISTODAX,warnings and precautions,5.1 Myelosuppression,"thrombocytopenia, leukopenia, neutropenia, lymphopenia, anemia"
ISTODAX,warnings and precautions,5.2 Infections,"Fatal infections, serious infections, pneumonia, sepsis, viral reactivation, Epstein Barr viral infection, hepatitis B virus infection, life threatening infections, liver failure"
ISTODAX,warnings and precautions,5.3 Electrocardiographic Changes,"morphological changes in ECGs, T-wave changes, ST-segment changes, cardiovascular disease, QT prolongation"
ISTODAX,warnings and precautions,5.4 Tumor Lysis Syndrome,Tumor lysis syndrome
ISTODAX,warnings and precautions,5.5 Use in Pregnancy,"fetal harm, embryocidal, adverse effects on the developing fetus"
ZIOPTAN,adverse reactions,6 ADVERSE REACTIONS,conjunctival hyperemia
ZIOPTAN,adverse reactions,6.1 Clinical Studies Experience,"adverse reaction rates, conjunctival hyperemia, ocular adverse reactions, ocular stinging/irritation, ocular pruritus including allergic conjunctivitis, cataract, dry eye, ocular pain, eyelash darkening, growth of eyelashes, vision blurred, Nonocular adverse reactions, headache, common cold, cough, urinary tract infection"
ZIOPTAN,adverse reactions,6.2 Postmarketing Experience,"exacerbation of asthma, dyspnea, iritis/uveitis, periorbital and lid changes, deepening of the eyelid sulcus"
ZIOPTAN,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Pigmentation, Iris pigmentation, Eyelash Changes, increased length, thickness, number of lashes"
ZIOPTAN,warnings and precautions,5.1 Pigmentation,"increased pigmentation of the iris, periorbital tissue (eyelid) pigmentation, eyelashes pigmentation, pigment changes, iris color change"
ZIOPTAN,warnings and precautions,5.2 Eyelash Changes,"gradually change eyelashes and vellus hair, increased length, color, thickness, shape and number of lashes, Eyelash changes"
ZIOPTAN,warnings and precautions,5.3 Intraocular Inflammation,"active intraocular inflammation, iritis/uveitis, inflammation may be exacerbated"
ZIOPTAN,warnings and precautions,5.4 Macular Edema,"Macular edema, cystoid macular edema, torn posterior lens capsule"
SIGNIFOR,adverse reactions,6 ADVERSE REACTIONS,"Hypocortisolism, Hyperglycemia, Diabetes, Bradycardia, QT prolongation, Liver Test Elevations, Cholelithiasis, Pituitary Hormone Deficiency, Diarrhea, Nausea, Headache, Abdominal Pain, Fatigue, Diabetes Mellitus"
SIGNIFOR,adverse reactions,6.1 Clinical Trials Experience,"diarrhea, nausea, hyperglycemia, cholelithiasis, headache, abdominal pain, fatigue, diabetes mellitus"
SIGNIFOR,adverse reactions,Table 1 - Adverse reactions [n (%)] with an overall frequency of more than 5% in the combined dose group in the Phase III study in Cushing's disease patients SIGNIFOR0.6 mg bidN=82 SIGNIFOR0.9 mg bidN=80 OverallN=162 Diarrhea 48 (59) 46 (58) 94 (58) Nausea 38 (46) 46 (58) 84 (52) Hyperglycemia 31 (38) 34 (43) 65 (40) Cholelithiasis 25 (30) 24 (30) 49 (30) Headache 23 (28) 23 (29) 46 (28) Abdominal pain 19 (23) 20 (25) 39 (24) Fatigue 12 (15) 19(24) 31 (19) Diabetes mellitus 13 (16) 16 (20) 29 (18) Injection site reactions 14 (17) 14 (18) 28 (17) Nasopharyngitis 10 (12) 11 (14) 21 (13) Alopecia 10 (12) 10 (13) 20 (12) Asthenia 13 (16) 5 (6) 18 (11) Glycosylated hemoglobin increased 10 (12) 8 (10) 18 (11) Alanine aminotransferase increased 11 (13) 6 (8) 17 (10) Gamma-glutamyl transferase increased 10 (12) 7 (9) 17 (10) Edema peripheral 9 (11) 8 (10) 17 (10) Abdominal pain upper 10 (12) 6 (8) 16 (10) Decreased appetite 7 (9) 9 (11) 16 (10) Hypercholesterolemia 7 (9) 9 (11) 16 (10) Hypertension 8 (10) 8 (10) 16 (10) Dizziness 8 (10) 7 (9) 15 (9) Hypoglycemia 12 (15) 3 (4) 15 (9) Type 2 diabetes mellitus 10 (12) 5 (6) 15 (9) Anxiety 5 (6) 9 (11) 14 (9) Influenza 9 (11) 5 (6) 14 (9) Insomnia 3 (4) 11 (14) 14 (9) Myalgia 10 (12) 4 (5) 14 (9) Arthralgia 5 (6) 8 (10) 13 (8) Pruritus 6 (7) 7 (9) 13 (8) Lipase increased 7 (9) 5 (6) 12 (7) Constipation 7 (9) 4 (5) 11 (7) Hypotension 5 (6) 6 (8) 11 (7) Vomiting 3 (4) 8 (10) 11 (7) Back pain 4 (5) 6 (8) 10 (6) Dry skin 5 (6) 5 (6) 10 (6) Electrocardiogram QT prolonged 5 (6) 5 (6) 10 (6) Hypokalemia 6 (7) 4 (5) 10 (6) Pain in extremity 6 (7) 4 (5) 10 (6) Sinus bradycardia 8 (10) 2 (3) 10 (6) Vertigo 4 (5) 6 (8) 10 (6) Abdominal distension 4 (5) 5 (6) 9 (6) Adrenal insufficiency 4 (5) 5 (6) 9 (6) Aspartate aminotransferase increased 6 (7) 3 (4) 9 (6) Blood glucose increased 6 (7) 3 (4) 9 (6) Other notable adverse reactions which occurred with a frequency less than 5% were: anemia (4%); blood amylase increased (2%) and prothrombin time prolonged (2%).,"diarrhea, nausea, abdominal pain, vomiting, hyperglycemia, diabetes mellitus, increased HbA1c, type 2 diabetes mellitus, elevated liver tests, transient mean elevations in aminotransferase, jaundice, hypocortisolism, injection site reactions, local pain, erythema, hematoma, hemorrhage, pruritus, hypothyroidism, elevations in lipase, elevations in amylase, pancreatitis, decreases in hemoglobin, elevations in PT, elevations in PTT"
SIGNIFOR,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hypocortisolism, hyperglycemia, diabetes, bradycardia, QT prolongation, liver test elevations, cholelithiasis"
SIGNIFOR,warnings and precautions,5.1 Hypocortisolism,"weakness, fatigue, anorexia, nausea, vomiting, hypotension, hyponatremia, hypoglycemia"
SIGNIFOR,warnings and precautions,5.2 Hyperglycemia and Diabetes,"elevations in blood glucose levels, pre-diabetes, diabetes, worsening glycemia, severe hyperglycemia, ketoacidosis, hypoglycemia, uncontrolled hyperglycemia"
SIGNIFOR,warnings and precautions,5.3 Bradycardia and QT Prolongation,"Bradycardia, QT Prolongation, hypokalemia, hypomagnesemia"
SIGNIFOR,warnings and precautions,5.4 Liver Test Elevations,"ALT elevation, AST elevation, bilirubin elevation"
SIGNIFOR,warnings and precautions,5.5 Cholelithiasis,cholelithiasis
SIGNIFOR,warnings and precautions,5.6 Monitoring for Deficiency of Pituitary Hormones,"inhibition of pituitary hormones, deficiency of pituitary hormones"
SOVALDI,adverse reactions,6 ADVERSE REACTIONS,"Serious Symptomatic Bradycardia, fatigue, headache, nausea, insomnia, anemia"
SOVALDI,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions, adverse events, discontinued treatment due to adverse events, most common adverse events, fatigue, headache, nausea, insomnia, anemia"
SOVALDI,adverse reactions,"Table 2 Adverse Events (All Grades and without Regard to Causality) Reported in >=15% of Subjects with HCV in Any Treatment Arm Interferon-free Regimens Interferon-containing Regimens PBO12 weeks SOVALDI + RBV12 weeks SOVALDI + RBV24 weeks Peg-IFN alfa + RBV24 weeks SOVALDI + Peg-IFN alfa + RBV12 weeks N=71 N=650 N=250 N=243 N=327 Fatigue 24% 38% 30% 55% 59% Headache 20% 24% 30% 44% 36% Nausea 18% 22% 13% 29% 34% Insomnia 4% 15% 16% 29% 25% Pruritus 8% 11% 27% 17% 17% Anemia 0% 10% 6% 12% 21% Asthenia 3% 6% 21% 3% 5% Rash 8% 8% 9% 18% 18% Decreased Appetite 10% 6% 6% 18% 18% Chills 1% 2% 2% 18% 17% Influenza Like Illness 3% 3% 6% 18% 16% Pyrexia 0% 4% 4% 14% 18% Diarrhea 6% 9% 12% 17% 12% Neutropenia 0% <1% <1% 12% 17% Myalgia 0% 6% 9% 16% 14% Irritability 1% 10% 10% 16% 13% With the exception of anemia and neutropenia, the majority of events presented in Table 2 occurred at severity of grade 1 in SOVALDI-containing regimens.","pancytopenia, severe depression, suicidal ideation, suicide"
SOVALDI,adverse reactions,Table 3 Percentage of Subjects Reporting Selected Hematological Parameters Interferon-free Regimens Interferon-containing Regimens Hematological Parameters PBO12 weeks SOVALDI + RBV12 weeks SOVALDI + RBV24 weeks Peg-IFN + RBV24 weeks SOVALDI + Peg-IFN + RBV12 weeks N=71 N=647 N=250 N=242 N=327 Hemoglobin (g/dL) <10 0 8% 6% 14% 23% <8.5 0 1% <1% 2% 2% Neutrophils (*10 9 /L) >=0.5 - <0.75 1% <1% 0 12% 15% <0.5 0 <1% 0 2% 5% Platelets (*10 9 /L) >=25 - <50 3% <1% 1% 7% <1% <25 0 0 0 0 0 Bilirubin Elevations,"Total bilirubin elevation, Creatine Kinase Elevations, Lipase Elevations, Elevated total bilirubin"
SOVALDI,adverse reactions,6.2 Postmarketing Experience,"adverse reactions, bradycardia"
SOVALDI,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"bradycardia, symptomatic bradycardia"
SOVALDI,warnings and precautions,5.1 Serious Symptomatic Bradycardia When Coadministered with Amiodarone and Another HCV Direct Acting Antiviral,"symptomatic bradycardia, pacemaker intervention, fatal cardiac arrest, near-fainting, fainting, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pains, confusion, memory problems"
SOVALDI,warnings and precautions,5.2 Risk of Reduced Therapeutic Effect Due to Use with P-gp Inducers,"decreased sofosbuvir plasma concentrations, reduced therapeutic effect"
SOVALDI,warnings and precautions,5.3 Risks Associated with Combination Treatment,No specific adverse drug event terms are mentioned in the provided text. The excerpt advises consulting the prescribing information for additional drugs used in combination with SOVALDI for potential warnings and precautions but does not list specific adverse events.
SOVALDI,warnings and precautions,5.4 Related Products Not Recommended,"The provided text does not contain any adverse drug event terms. It only contains a recommendation against using SOVALDI in combination with other products containing sofosbuvir. An adverse drug event term typically refers to an unwanted or negative reaction experienced by a patient after taking a medication, which is not present in the text provided."
OLYSIO,adverse reactions,6 ADVERSE REACTIONS,"Serious Symptomatic Bradycardia, Hepatic Decompensation, Hepatic Failure, Photosensitivity, Rash, pruritus, nausea, fatigue, headache"
OLYSIO,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions, Grade 1 to 2 in severity, Grade 3 or 4 adverse reactions, Serious adverse reactions, discontinuation due to adverse reactions"
OLYSIO,adverse reactions,"Table 4: Adverse Reactions (all Grades) that Occurred with at Least 3% Higher Frequency Among Subjects Receiving OLYSIO 150 mg Once Daily in Combination with Peg-IFN-alfa and RBV Compared to Subjects Receiving Placebo in Combination with Peg-IFN-alfa and RBV During the First 12 Weeks of Treatment in Subjects with CHC InfectionSubjects were treatment-naive or had previously relapsed after Peg-IFN-alfa and RBV therapy. (Pooled Phase 3 TrialsPooled Phase 3 trials: QUEST 1, QUEST 2, PROMISE.) Adverse Reaction OLYSIO 150 mg + Peg-IFN-alfa+ RBVFirst 12 WeeksN=781% (n) Placebo + Peg-IFN-alfa+ RBVFirst 12 WeeksN=397% (n) Rash (including photosensitivity) 28 (218) 20 (79) Pruritus 22 (168) 15 (58) Nausea 22 (173) 18 (70) Myalgia 16 (126) 13 (53) Dyspnea 12 (92) 8 (30) Rash and Photosensitivity","rash, photosensitivity reactions, severe rash, discontinuation due to rash, photosensitivity, hospitalization due to photosensitivity reactions, dyspnea"
OLYSIO,adverse reactions,"Table 5: Laboratory Abnormalities (WHO Worst Toxicity Grades 1 to 4) Observed at a Higher Incidence in OLYSIO-Treated Subjects (Pooled Phase 3 TrialsPooled Phase 3 trials: QUEST 1, QUEST 2, PROMISE.; First 12 Weeks of Treatment) Laboratory Parameter WHO Toxicity Range OLYSIO 150 mg + Peg-IFN-alfa + RBVN=781% Placebo + Peg-IFN-alfa + RBVN=397% Chemistry Alkaline phosphatase Grade 1 > 1.25 to <= 2.50 * ULN 3 1 Grade 2 > 2.50 to <= 5.00 * ULN < 1 0 Hyperbilirubinemia Grade 1 > 1.1 to <= 1.5 * ULN 27 15 Grade 2 > 1.5 to <= 2.5 * ULN 18 9 Grade 3 > 2.5 to <= 5.0 * ULN 4 2 Grade 4 > 5.0 * ULN < 1 0 Elevations in bilirubin were predominately mild to moderate (Grade 1 or 2) in severity, and included elevation of both direct and indirect bilirubin. Elevations in bilirubin occurred early after treatment initiation, peaking by study Week 2, and were rapidly reversible upon cessation of OLYSIO. Bilirubin elevations were generally not associated with elevations in liver transaminases. The frequency of elevated bilirubin was higher in subjects with higher simeprevir exposures.","fatigue, headache, nausea, insomnia, pruritus, rash, photosensitivity, dizziness, diarrhea"
OLYSIO,adverse reactions,6.2 Postmarketing Experience,"serious symptomatic bradycardia, hepatic decompensation, hepatic failure"
OLYSIO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"serious symptomatic bradycardia, hepatic decompensation, hepatic failure, photosensitivity reactions, rash"
OLYSIO,warnings and precautions,5.1 Serious Symptomatic Bradycardia When Co-administered with Sofosbuvir and Amiodarone,"symptomatic bradycardia, pacemaker intervention, fatal cardiac arrest, heart rate, near-fainting, fainting, dizziness, lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion, memory problems"
OLYSIO,warnings and precautions,5.2 Hepatic Decompensation and Hepatic Failure,"hepatic decompensation, hepatic failure, fatal cases, increased risk for hepatic decompensation, increased risk for hepatic failure, modest increases in bilirubin levels, elevated bilirubin levels, fatigue, weakness, lack of appetite, nausea and vomiting, jaundice, discolored feces, elevation in bilirubin, liver transaminase increases, clinical signs and symptoms of hepatic decompensation, risk of serious adverse reactions"
OLYSIO,warnings and precautions,5.4 Photosensitivity,"photosensitivity reactions, serious photosensitivity reactions, burning, erythema, exudation, blistering, edema"
OLYSIO,warnings and precautions,5.5 Rash,"Rash, Severe rash, Rash requiring discontinuation of OLYSIO, Mild or moderate severity, Progression of rash, Development of mucosal signs, Oral lesions, Conjunctivitis, Systemic symptoms."
OLYSIO,warnings and precautions,5.6 Sulfa Allergy,"sulfa allergy, rash, photosensitivity reactions, adverse reactions"
OLYSIO,warnings and precautions,5.7 Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions,"reduced therapeutic effect, adverse reactions"
PLEGRIDY,adverse reactions,6 ADVERSE REACTIONS,"Hepatic Injury, Depression and Suicide, Seizures, Anaphylaxis and Other Allergic Reactions, Injection Site Reactions, Congestive Heart Failure, Decreased Peripheral Blood Counts, Autoimmune Disorders, injection site erythema, influenza-like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, arthralgia"
PLEGRIDY,adverse reactions,6.1 Clinical Trials Experience,"injection site erythema, influenza-like illness, pyrexia, headache, myalgia, chills, injection site pain, asthenia, injection site pruritus, arthralgia"
PLEGRIDY,adverse reactions,"Table 2 summarizes adverse reactions reported over 48 weeks from patients treated in the placebo-controlled phase of Study 1 who received subcutaneous PLEGRIDY 125 micrograms (n=512), or placebo (n=500), every 14 days.","If the input provided is ""nan,"" which commonly stands for 'not a number' or implies that the information is not available, there's no excerpt or text to analyze for adverse drug event terms. Therefore, it's not possible to return any terms without the actual content. If this is an error and you have a drug label excerpt to analyze, please provide the text for review."
PLEGRIDY,adverse reactions,Table 2: Adverse reactions in the 48-week placebo-controlled phase of Study 1 with an incidence 2% higher for PLEGRIDY than for placebo PLEGRIDY (N=512) % Placebo (N=500) % Nervous System Disorders Headache 44 33 Gastrointestinal Disorders Nausea 9 6 Vomiting 5 2 Musculoskeletal and Connective Tissue Disorders Myalgia 19 6 Arthralgia 11 7 General Disorders and Administration Site Conditions Injection site erythema 62 7 Influenza like illness 47 13 Pyrexia 45 15 Chills 17 5 Injection site pain 15 3 Asthenia 13 8 Injection site pruritus 13 1 Hyperthermia 4 1 Pain 5 3 Injection site edema 3 0 Injection site warmth 3 0 Injection site hematoma 3 1 Injection site rash 2 0 Investigations Body temperature increased 6 3 Alanine aminotransferase increased 6 3 Aspartate aminotransferase increased 4 2 Gamma-glutamyl-transferase increased 3 1 Skin and Subcutaneous Tissue Disorder Pruritus 4 1 Immunogenicity,"immunogenicity, neutralizing antibodies, antibodies to PEG, Flu-Like Symptoms, Influenza-like illness"
PLEGRIDY,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Hepatic injury, Depression, Suicide, Seizure, Anaphylaxis, Allergic reactions, Injection site reactions, Necrosis, Congestive heart failure, Decreased peripheral blood counts, Autoimmune disorders"
PLEGRIDY,warnings and precautions,5.1 Hepatic Injury,"Severe hepatic injury, hepatitis, autoimmune hepatitis, severe hepatic failure, Asymptomatic elevation of hepatic transaminases, Elevations in hepatic enzymes, hepatic injury, increases in hepatic transaminases, elevations of alanine aminotransferase, elevations of aspartate aminotransferase, elevated bilirubin"
PLEGRIDY,warnings and precautions,5.2 Depression and Suicide,"Depression, suicidal ideation, suicide, adverse events, serious events, psychiatric symptoms"
PLEGRIDY,warnings and precautions,5.3 Seizures,"Seizures, incidence of seizures, seizure disorder"
PLEGRIDY,warnings and precautions,5.4 Anaphylaxis and Other Allergic Reactions,"Anaphylaxis, serious allergic reactions, angioedema, urticaria."
PLEGRIDY,warnings and precautions,5.5 Injection Site Reactions,"injection site reactions, injection site necrosis, injection site erythema, pain, pruritus, edema, severe injection site reactions"
PLEGRIDY,warnings and precautions,5.6 Congestive Heart Failure,"Congestive heart failure, cardiomyopathy, cardiovascular events"
PLEGRIDY,warnings and precautions,5.7 Decreased Peripheral Blood Counts,"decreased peripheral blood counts, pancytopenia, severe thrombocytopenia, decreases in white blood cell counts, clinically significant decreases in lymphocyte counts, neutrophil counts, platelet counts, severe neutropenia, infections, bleeding, symptoms of anemia, myelosuppression"
PLEGRIDY,warnings and precautions,5.8 Autoimmune Disorders,"idiopathic thrombocytopenia, hyperthyroidism, hypothyroidism, autoimmune hepatitis"
VIBATIV,adverse reactions,6 ADVERSE REACTIONS,"Nephrotoxicity, Infusion-related reactions, Clostridium difficile-associated diarrhea, diarrhea, taste disturbance, nausea, vomiting, foamy urine."
VIBATIV,adverse reactions,6.1 Clinical Trials Experience,"renal events, respiratory events, cardiac events, infectious events, nausea, rash, pruritus, taste disturbance, vomiting, foamy urine"
VIBATIV,adverse reactions,Table 4 displays the incidence of treatment-emergent adverse drug reactions reported in >=2% of patients treated with VIBATIV possibly related to the drug.,"If the input is ""nan"", this typically indicates that the data is not applicable or is missing. ""Nan"" often stands for ""not a number."" Therefore, with this input, it's not possible to provide adverse drug event terms because there is no text provided from the drug label to examine."
VIBATIV,adverse reactions,Table 4: Incidence of Treatment-Emergent Adverse Drug Reactions Reported in >=2% of VIBATIV or Vancomycin Patients Treated in cSSSI Trial 1 and Trial 2 VIBATIV(N=929) Vancomycin(N=938) * Described as a metallic or soapy taste. Body as a Whole Rigors 4% 2% Digestive System Nausea 27% 15% Vomiting 14% 7% Diarrhea 7% 8% Metabolic and Nutritional Decreased appetite 3% 2% Nervous System Taste disturbance * 33% 7% Renal System Foamy urine 13% 3% HABP/VABP,"There do not appear to be any adverse drug event terms in the provided text. This excerpt from the drug label describes the characteristics of the clinical trials and patient demographics, but it does not mention any specific adverse events related to the use of the drug VIBATIV."
VIBATIV,adverse reactions,Table 5 summarizes deaths using Kaplan-Meier estimates at Day 28 as stratified by baseline creatinine clearance categorized into four groups. Patients with pre-existing moderate/severe renal impairment (CrCl<=50 mL/min) who were treated with VIBATIV for HABP/VABP had increased mortality observed versus vancomycin in both the trials.,N/A
VIBATIV,adverse reactions,"Table 5: 28-Day Mortality (Kaplan-Meier Estimates) Stratified by Baseline Creatinine Clearance - All-Treated Analysis Population CrCl (mL/min) Trial 1 Trial 2 VIBATIV N (%) Vancomycin N (%) Difference (95% CI) VIBATIV N (%) Vancomycin N (%) Difference (95% CI) >80 143 (12.2%) 152 (14.1%) -1.8(-9.6, 6.0) 181 (10.5%) 181 (18.7%) -8.2(-15.5, -0.9) >50-80 88 (27.4%) 88 (17.7%) 9.7(-2.7, 22.1) 96 (25.6%) 90 (27.1%) -1.5(-14.4, 11.3) 30-50 80 (34.7%) 83 (23.1%) 11.5(-2.5, 25.5) 62 (27.7%) 68 (23.7%) 4.0(-11.1, 19.1) <30 61 (44.3%) 51 (37.3%) 7.0(-11.2, 25.2) 38 (61.1%) 41 (42.1%) 19.0(-2.9, 40.8) Serious adverse events were reported in 31% of patients treated with VIBATIV and 26% of patients who received vancomycin. Treatment discontinuations due to adverse events occurred in 8% (60/751) of patients who received VIBATIV, the most common events being acute renal failure and electrocardiogram QTc interval prolonged (~1% each). Treatment discontinuations due to adverse events occurred in 5% (40/752) of vancomycin-patients, the most common events being septic shock and multi-organ failure (<1%).","If the input is ""nan"" (which typically stands for ""not a number""), there is no text provided from which to extract adverse drug event terms. Therefore, I cannot generate a list of terms without the actual content of a drug label. If you provide the excerpt of the drug label, I can assist in extracting the adverse drug event terms."
VIBATIV,adverse reactions,Table 6 displays the incidence of treatment-emergent adverse drug reactions reported in >= 5% of HABP/VABP patients treated with VIBATIV possibly related to the drug.,"I'm sorry, but there's no text provided to analyze for adverse drug event terms. If you provide the excerpt from the drug label, I can assist in identifying the terms for you."
VIBATIV,adverse reactions,Table 6: Incidence of Treatment-Emergent Adverse Drug Reactions Reported in >=5% of VIBATIV or Vancomycin Patients Treated in HABP/VABP Trial 1 and Trial 2 VIBATIV(N=751) Vancomycin(N=752) Nausea 5% 4% Vomiting 5% 4% Renal Failure Acute 5% 4% Nephrotoxicity,"increased serum creatinine, renal impairment, renal insufficiency, renal failure"
VIBATIV,adverse reactions,6.2 Postmarketing Experience,"serious hypersensitivity reactions, anaphylactic reactions"
VIBATIV,boxed warnings,BOXED WARNING: WARNINGS,"If the input text is ""nan,"" there are no adverse drug event terms to extract. The term ""nan"" itself is not an adverse drug event term. Therefore, there is no list to provide. If you meant to provide an actual excerpt and it was accidentally missed or there was a typo indicating ""nan"" instead, please provide the correct text so that I can assist you further."
VIBATIV,boxed warnings,WARNINGS,"increased mortality, Nephrotoxicity, New onset renal impairment, worsening renal impairment, Adverse developmental outcomes"
VIBATIV,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"decreased efficacy, hypersensitivity reactions, anaphylactic reactions, infusion-related reactions, Clostridium difficile-associated disease, coagulation test interference, QTc prolongation"
VIBATIV,warnings and precautions,5.1 Increased Mortality in Patients with HABP/VABP and Pre-existing Moderate to Severe Renal Impairment (CrCl<=50 mL/min),"all-cause mortality, moderate/severe renal impairment"
VIBATIV,warnings and precautions,5.2 Decreased Clinical Response in Patients with cSSSI and Pre-existing Moderate/Severe Renal Impairment (CrCl<=50 mL/min),"nephrotoxicity, renal adverse events"
VIBATIV,warnings and precautions,5.4 Pregnant Women and Women of Childbearing Potential,"adverse developmental outcomes, potential risk to the fetus"
VIBATIV,warnings and precautions,5.5 Coagulation Test Interference,"interfered with certain tests,bleeding risk"
VIBATIV,warnings and precautions,5.6 Hypersensitivity Reactions,"hypersensitivity reactions, anaphylactic reactions, skin rash, hypersensitivity"
VIBATIV,warnings and precautions,5.7 Infusion-Related Reactions,"infusion-related reactions, ""Red-man Syndrome"", flushing of the upper body, urticaria, pruritus, rash"
VIBATIV,warnings and precautions,5.8 Clostridium difficile -Associated Diarrhea,"Clostridium difficile-associated diarrhea (CDAD), mild diarrhea, fatal colitis, increased morbidity, mortality, diarrhea, refractory to antimicrobial therapy"
VIBATIV,warnings and precautions,5.9 Development of Drug-Resistant Bacteria,"development of drug-resistant bacteria, overgrowth of nonsusceptible organisms, superinfection"
VIBATIV,warnings and precautions,5.10 QTc Prolongation,"prolonged QTc interval, congenital long QT syndrome, uncompensated heart failure, severe left ventricular hypertrophy"
KIT,adverse reactions,6 ADVERSE REACTIONS,"injection site irritation, pain"
KIT,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, serious adverse reactions, Injection site irritation, pain"
KIT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hypersensitivity, reactions, signs and symptoms, resuscitation"
KIT,warnings and precautions,5.1 Hypersensitivity Reactions,"hypersensitivity reactions, Serious hypersensitivity reactions"
KIT,warnings and precautions,5.2 Radiation Risks,"cancer, excessive radiation exposure"
HETLIOZ,adverse reactions,6. ADVERSE REACTIONS,"headache, increased alanine aminotransferase, nightmares or unusual dreams, upper respiratory infection, urinary tract infection"
HETLIOZ,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse event"
HETLIOZ,adverse reactions,Table 1 shows the incidence of adverse reactions from Study 1.,"Headache, Alanine aminotransferase increased, Nightmare/abnormal dreams, Upper respiratory tract infection, Urinary tract infection"
HETLIOZ,warnings and precautions,5. WARNINGS AND PRECAUTIONS,"somnolence, impair the performance of activities requiring complete mental alertness"
HETLIOZ,warnings and precautions,5.1 Somnolence,"impaired performance, activities requiring complete mental alertness"
VOTRIENT,adverse reactions,6 ADVERSE REACTIONS,"diarrhea, hypertension, hair color changes, nausea, anorexia, vomiting, fatigue, decreased weight, decreased appetite, tumor pain, dysgeusia, headache, musculoskeletal pain, myalgia, gastrointestinal pain, dyspnea"
VOTRIENT,adverse reactions,6.1 Clinical Trials Experience,"Hepatotoxicity, QT prolongation, torsades de pointes, Cardiac dysfunction, Hemorrhagic events, Arterial and venous thromboembolic events, Thrombotic microangiopathy, Gastrointestinal perforation and fistula, Interstitial Lung Disease (ILD)/Pneumonitis, Reversible Posterior Leukoencephalopathy Syndrome (RPLS), Hypertension, Infection, Increased toxicity with other cancer therapies, diarrhea, hypertension, hair color change, nausea, fatigue, anorexia, vomiting"
VOTRIENT,adverse reactions,"Table 1. Adverse Reactions Occurring in >=10% of Patients with RCC Who Received VOTRIENT VOTRIENT Placebo (N = 290) (N = 145) All Gradesa Grade 3 Grade 4 All Gradesa Grade 3 Grade 4 Adverse Reactions % % % % % % Diarrhea 52 3 <1 9 <1 0 Hypertension 40 4 0 10 <1 0 Hair color changes 38 <1 0 3 0 0 Nausea 26 <1 0 9 0 0 Anorexia 22 2 0 10 <1 0 Vomiting 21 2 <1 8 2 0 Fatigue 19 2 0 8 1 1 Asthenia 14 3 0 8 0 0 Abdominal pain 11 2 0 1 0 0 Headache 10 0 0 5 0 0 a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.","alopecia, chest pain, dysgeusia, dyspepsia, dysphonia, facial edema, palmar-plantar erythrodysesthesia, proteinuria, rash, skin depigmentation, weight decreased, arthralgia, muscle spasms"
VOTRIENT,adverse reactions,Table 2 presents the most common laboratory abnormalities occurring in >10% of patients who received VOTRIENT and more commonly (>=5%) in patients who received VOTRIENT versus placebo.,"As the input provided is ""nan"" which typically stands for ""not a number"" and indicates that there is no data given, there are no adverse drug event terms to extract. If this is an error and there is supposed to be text provided for analysis, please provide the excerpt so that I can identify the adverse drug event terms."
VOTRIENT,adverse reactions,"Table 2. Selected Laboratory Abnormalities Occurring in >10% of Patients with RCC Who Received VOTRIENT and More Commonly (>=5%) in Patients Who Received VOTRIENT versus Placebo VOTRIENT Placebo (N = 290) (N = 145) All Gradesa Grade 3 Grade 4 All Gradesa Grade 3 Grade 4 Parameters % % % % % % Hematologic Leukopenia 37 0 0 6 0 0 Neutropenia 34 1 <1 6 0 0 Thrombocytopenia 32 <1 <1 5 0 <1 Lymphocytopenia 31 4 <1 24 1 0 Chemistry ALT increased 53 10 2 22 1 0 AST increased 53 7 <1 19 <1 0 Glucose increased 41 <1 0 33 1 0 Total bilirubin increased 36 3 <1 10 1 <1 Phosphorus decreased 34 4 0 11 0 0 Sodium decreased 31 4 1 24 4 0 Magnesium decreased 26 <1 1 14 0 0 Glucose decreased 17 0 <1 3 0 0 a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.","fatigue, diarrhea, nausea, decreased weight, hypertension, decreased appetite, vomiting, tumor pain, hair color changes, musculoskeletal pain, headache, dysgeusia, dyspnea, skin hypopigmentation"
VOTRIENT,adverse reactions,"Table 3. Adverse Reactions Occurring in >=10% of Patients with STS Who Received VOTRIENT VOTRIENT Placebo (N = 240) (N = 123) All Gradesa Grade 3 Grade 4 All Gradesa Grade 3 Grade 4 Adverse Reactions % % % % % % Fatigue 65 13 1 48 4 1 Diarrhea 59 5 0 15 1 0 Nausea 56 3 0 22 2 0 Weight decreased 48 4 0 15 0 0 Hypertension 42 7 0 6 0 0 Appetite decreased 40 6 0 19 0 0 Hair color changes 39 0 0 2 0 0 Vomiting 33 3 0 11 1 0 Tumor pain 29 8 0 21 7 2 Dysgeusia 28 0 0 3 0 0 Headache 23 1 0 8 0 0 Musculoskeletal pain 23 2 0 20 2 0 Myalgia 23 2 0 9 0 0 Gastrointestinal pain 23 3 0 9 4 0 Dyspnea 20 5 <1 17 5 1 Exfoliative rash 18 <1 0 9 0 0 Cough 17 <1 0 12 <1 0 Peripheral edema 14 2 0 9 2 0 Mucositis 12 2 0 2 0 0 Alopecia 12 0 0 1 0 0 Dizziness 11 1 0 4 0 0 Skin disorderb 11 2 0 1 0 0 Skin hypopigmentation 11 0 0 0 0 0 Stomatitis 11 <1 0 3 0 0 Chest pain 10 2 0 6 0 0 a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.","palmar-plantar erythrodysesthesia, insomnia, hypothyroidism, dysphonia, epistaxis, left ventricular dysfunction, dyspepsia, dry skin, chills, vision blurred, nail disorder"
VOTRIENT,adverse reactions,Table 4 presents the most common laboratory abnormalities occurring in >10% of patients who received VOTRIENT and more commonly (>=5%) in patients who received VOTRIENT versus placebo.,"If the input provided is ""nan"" and there is no additional context or text to analyze, it's not possible to extract any adverse drug event terms. I would need a portion of an actual drug label or text that includes information on adverse events to perform the task."
VOTRIENT,adverse reactions,"Table 4. Selected Laboratory Abnormalities Occurring in >10% of Patients with STS Who Received VOTRIENT and More Commonly (>=5%) in Patients Who Received VOTRIENT versus Placebo VOTRIENT Placebo (N = 240) (N = 123) All Gradesa Grade 3 Grade 4 All Gradesa Grade 3 Grade 4 Parameters % % % % % % Hematologic Leukopenia 44 1 0 15 0 0 Lymphocytopenia 43 10 0 36 9 2 Thrombocytopenia 36 3 1 6 0 0 Neutropenia 33 4 0 7 0 0 Chemistry AST increased 51 5 3 22 2 0 ALT increased 46 8 2 18 2 1 Glucose increased 45 <1 0 35 2 0 Albumin decreased 34 1 0 21 0 0 Alkaline phosphatase increased 32 3 0 23 1 0 Sodium decreased 31 4 0 20 3 0 Total bilirubin increased 29 1 0 7 2 0 Potassium increased 16 1 0 11 0 0 a National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.","Diarrhea, Lipase Elevations, clinical pancreatitis, Pneumothorax, Bradycardia"
VOTRIENT,adverse reactions,6.2 Postmarketing Experience,"Retinal detachment/tear, Pancreatitis"
VOTRIENT,boxed warnings,BOXED WARNING: WARNING: HEPATOTOXICITY,"As you have provided ""nan"" which stands for ""not a number"" or indicates that there is no data present, it is impossible to extract any adverse drug event terms from this input. If you have an actual excerpt from a drug label, please provide it, and I can then identify the adverse drug event terms for you."
VOTRIENT,boxed warnings,WARNING: HEPATOTOXICITY,severe and fatal hepatotoxicity
VOTRIENT,boxed warnings,EXCERPT: WARNING: HEPATOTOXICITY,"severe hepatotoxicity, fatal hepatotoxicity"
VOTRIENT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"increases in serum transaminase levels, bilirubin, severe and fatal hepatotoxicity, prolonged QT intervals, torsades de pointes, cardiac dysfunction, congestive heart failure, decreased left ventricular ejection fraction, fatal hemorrhagic events, arterial thromboembolic events, venous thromboembolic events, fatal pulmonary emboli, thrombotic microangiopathy, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, gastrointestinal perforation, fistula, fatal perforation events, interstitial lung disease, pneumonitis, reversible posterior leukoencephalopathy syndrome, hypertension, hypertensive crisis, hypothyroidism, proteinuria, infection, fetal harm"
VOTRIENT,warnings and precautions,5.1 Hepatic Toxicity and Hepatic Impairment,"hepatotoxicity, serum transaminases elevations, bilirubin increases, severe, fatal, hepatic failure, isolated ALT elevations, concurrent elevation in ALT and bilirubin, indirect hyperbilirubinemia"
VOTRIENT,warnings and precautions,5.2 QT Prolongation and Torsades de Pointes,"QT prolongation, Torsades de pointes"
VOTRIENT,warnings and precautions,5.3 Cardiac Dysfunction,"cardiac dysfunction, decreased left ventricular ejection fraction (LVEF), congestive heart failure, myocardial dysfunction, hypertension"
VOTRIENT,warnings and precautions,5.4 Hemorrhagic Events,"Fatal hemorrhage, hemorrhagic event, hematuria, epistaxis, hemoptysis, rectal hemorrhage, pulmonary hemorrhage, gastrointestinal hemorrhage, genitourinary hemorrhage, cerebral/intracranial hemorrhage, mouth hemorrhage, anal hemorrhage, Grade 4 hemorrhagic events, intracranial hemorrhage, subarachnoid hemorrhage, peritoneal hemorrhage, clinically significant gastrointestinal hemorrhage"
VOTRIENT,warnings and precautions,5.5 Arterial Thromboembolic Events,"fatal arterial thromboembolic events, myocardial infarction, ischemia, cerebrovascular accident, transient ischemic attack"
VOTRIENT,warnings and precautions,5.6 Venous Thromboembolic Events,"venous thromboembolic events, venous thrombosis, fatal pulmonary embolus, VTE, PE"
VOTRIENT,warnings and precautions,5.7 Thrombotic Microangiopathy,"Thrombotic microangiopathy (TMA), thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS)"
VOTRIENT,warnings and precautions,5.8 Gastrointestinal Perforation and Fistula,"gastrointestinal perforation, fistula, fatal perforations"
VOTRIENT,warnings and precautions,5.9 Interstitial Lung Disease (ILD)/Pneumonitis,"ILD/pneumonitis, fatal, pulmonary symptoms"
VOTRIENT,warnings and precautions,5.10 Reversible Posterior Leukoencephalopathy Syndrome,"Reversible Posterior Leukoencephalopathy Syndrome, headache, seizure, lethargy, confusion, blindness, other visual and neurologic disturbances, mild to severe hypertension"
VOTRIENT,warnings and precautions,5.11 Hypertension,"hypertension, hypertensive crisis, Grade 3 hypertension"
VOTRIENT,warnings and precautions,5.12 Wound Healing,"impair wound healing, wound dehiscence"
VOTRIENT,warnings and precautions,5.13 Hypothyroidism,Hypothyroidism
VOTRIENT,warnings and precautions,5.14 Proteinuria,"proteinuria, nephrotic syndrome"
VOTRIENT,warnings and precautions,5.15 Infection,"Serious infections, neutropenia, fatal outcome"
VOTRIENT,warnings and precautions,5.16 Increased Toxicity with Other Cancer Therapy,"pulmonary hemorrhage, gastrointestinal hemorrhage, sudden death"
VOTRIENT,warnings and precautions,5.17 Increased Toxicity in Developing Organs,"toxicity to the lungs, liver, heart, and kidney, death, serious adverse effects on organ development"
VOTRIENT,warnings and precautions,5.18 Pregnancy,"fetal harm, adverse reproductive effects, teratogenic, embryotoxic, fetotoxic, abortifacient, potential hazard to the fetus"
JAKAFI,adverse reactions,6. ADVERSE REACTIONS,"Thrombocytopenia, Anemia, Neutropenia, Risk of Infection, Symptom Exacerbation, Non-Melanoma Skin Cancer, bruising, dizziness, headache"
JAKAFI,adverse reactions,6.1 Clinical Trials Experience in Myelofibrosis,"thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache"
JAKAFI,adverse reactions,"Table 10 presents the most common adverse reactions occurring in patients who received Jakafi in the double-blind, placebo-controlled study during randomized treatment.","If the input provided is ""nan"", that usually stands for ""not applicable"" or ""not available"". With such an input, there's no actual text containing adverse drug event terms to extract. Therefore, I cannot provide a list of terms from the provided input. If you have an actual excerpt, please provide it, and I'll be happy to identify the adverse drug event terms for you."
JAKAFI,adverse reactions,"Table 10: Myelofibrosis: Adverse Reactions Occurring in Patients on Jakafi in the Double-blind, Placebo-controlled Study During Randomized Treatment a National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 b includes contusion, ecchymosis, hematoma, injection site hematoma, periorbital hematoma, vessel puncture site hematoma, increased tendency to bruise, petechiae, purpura c includes dizziness, postural dizziness, vertigo, balance disorder, Meniere's Disease, labyrinthitis d includes urinary tract infection, cystitis, urosepsis, urinary tract infection bacterial, kidney infection, pyuria, bacteria urine, bacteria urine identified, nitrite urine present e includes weight increased, abnormal weight gain f includes herpes zoster and post-herpetic neuralgia Jakafi(N=155) Placebo(N=151) Adverse Reactions AllGrades a (%) Grade 3(%) Grade 4(%) AllGrades(%) Grade 3(%) Grade 4(%) Bruising b 23 <1 0 15 0 0 Dizziness c 18 <1 0 7 0 0 Headache 15 0 0 5 0 0 Urinary Tract Infections d 9 0 0 5 <1 <1 Weight Gain e 7 <1 0 1 <1 0 Flatulence 5 0 0 <1 0 0 Herpes Zoster f 2 0 0 <1 0 0 Description of Selected Adverse Drug Reactions","anemia, thrombocytopenia, neutropenia"
JAKAFI,adverse reactions,Table 11 provides the frequency and severity of clinical hematology abnormalities reported for patients receiving treatment with Jakafi or placebo in the placebo-controlled study.,"There is no text provided to extract adverse drug event terms from. You indicated the input is ""nan"", which typically represents 'not a number' or indicates missing data. If you have an excerpt from a drug label that you wish to analyze for adverse drug events, please provide the text, and I will assist you in identifying them."
JAKAFI,adverse reactions,"Table 11: Myelofibrosis: Worst Hematology Laboratory Abnormalities in the Placebo-Controlled Studya a Presented values are worst Grade values regardless of baseline b National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 Jakafi(N=155) Placebo(N=151) Laboratory Parameter AllGrades b (%) Grade 3(%) Grade 4(%) AllGrades(%) Grade 3(%) Grade 4(%) Thrombocytopenia 70 9 4 31 1 0 Anemia 96 34 11 87 16 3 Neutropenia 19 5 2 4 <1 1 Additional Data from the Placebo-controlled Study","Grade 1 abnormalities in alanine transaminase (ALT), Grade 2 elevations, Grade 3 ALT elevations, Grade 1 abnormalities in aspartate transaminase (AST), Grade 2 AST elevations, Grade 1 elevations in cholesterol, Grade 2 cholesterol elevations"
JAKAFI,adverse reactions,6.2 Clinical Trial Experience in Polycythemia Vera,"anemia, non-hematologic treatment emergent adverse events, Discontinuation for adverse events"
JAKAFI,adverse reactions,"Table 12: Polycythemia Vera: Treatment Emergent Adverse Events Occurring in >= 6% of Patients on Jakafi in the Open-Label, Active-controlled Study up to Week 32 of Randomized Treatment a National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 b includes abdominal pain, abdominal pain lower, and abdominal pain upper c includes dizziness and vertigo d includes dyspnea and dyspnea exertional e includes edema and peripheral edema f includes herpes zoster and post-herpetic neuralgia Jakafi(N=110) Best Available Therapy(N=111) Adverse Events All Grades a (%) Grade 3-4(%) All Grades(%) Grade 3-4(%) Headache 16 <1 19 <1 Abdominal Pain b 15 <1 15 <1 Diarrhea 15 0 7 <1 Dizziness c 15 0 13 0 Fatigue 15 0 15 3 Pruritus 14 <1 23 4 Dyspnea d 13 3 4 0 Muscle Spasms 12 <1 5 0 Nasopharyngitis 9 0 8 0 Constipation 8 0 3 0 Cough 8 0 5 0 Edema e 8 0 7 0 Arthralgia 7 0 6 <1 Asthenia 7 0 11 2 Epistaxis 6 0 3 0 Herpes Zoster f 6 <1 0 0 Nausea 6 0 4 0 Other clinically important treatment emergent adverse events observed in less than 6% of patients treated with Jakafi were:","Weight gain, hypertension, urinary tract infections"
JAKAFI,adverse reactions,"Table 13: Polycythemia Vera: Selected Laboratory Abnormalities in the Open-Label, Active-controlled Study up to Week 32 of Randomized Treatmenta a Presented values are worst Grade values regardless of baseline b National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0 Jakafi(N=110) Best Available Therapy(N=111) Laboratory Parameter AllGrades b (%) Grade 3(%) Grade 4(%) AllGrades(%) Grade 3(%) Grade 4(%) Hematology Anemia 72 <1 <1 58 0 0 Thrombocytopenia 27 5 <1 24 3 <1 Neutropenia 3 0 <1 10 <1 0 Chemistry Hypercholesterolemia 35 0 0 8 0 0 Elevated ALT 25 <1 0 16 0 0 Elevated AST 23 0 0 23 <1 0 Hypertriglyceridemia 15 0 0 13 0 0","If the given input for the drug label excerpt is ""nan"", which typically means ""not applicable"" or that there is no data provided, I cannot extract any adverse drug event terms. Therefore, my response would be:

There are no terms to list."
JAKAFI,warnings and precautions,5. WARNINGS AND PRECAUTIONS,"Thrombocytopenia, Anemia, Neutropenia, Risk of Infection, Serious infections, Symptom Exacerbation, Non-Melanoma Skin Cancer"
JAKAFI,warnings and precautions,"5.1 Thrombocytopenia, Anemia and Neutropenia","thrombocytopenia, anemia, neutropenia, severe neutropenia"
JAKAFI,warnings and precautions,5.2 Risk of Infection,"serious bacterial infections, mycobacterial infections, fungal infections, viral infections, Tuberculosis, Progressive multifocal leukoencephalopathy (PML), Herpes Zoster"
JAKAFI,warnings and precautions,5.3 Symptom Exacerbation Following Interruption or Discontinuation of Treatment with Jakafi,"fever, respiratory distress, hypotension, DIC, multi-organ failure"
JAKAFI,warnings and precautions,5.4 Non-Melanoma Skin Cancer,"Non-melanoma skin cancers, basal cell, squamous cell, Merkel cell carcinoma"
AKYNZEO,adverse reactions,6 ADVERSE REACTIONS,"headache, asthenia, dyspepsia, fatigue, constipation, erythema"
AKYNZEO,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse events"
AKYNZEO,adverse reactions,Table 1: Adverse Reactions Occurring in >=3% of Cancer Patients Receiving AKYNZEO and Cisplatin Based Highly Emetogenic Chemotherapy (Cycle 1) Adverse Reactions AKYNZEO netupitant 300 mg/ palonosetron 0.5 mg (N=136) Palonosetron 0.5 mg (N=136) Dyspepsia 4% 2% Fatigue 4% 2% Constipation 3% 1 Erythema 3% 2% Anthracyclines and Cyclophosphamide Based Chemotherapy,"The provided text does not list specific adverse reaction terms; it only mentions that adverse reactions occurred at an incidence of at least 3% and with a higher rate in those receiving AKYNZEO compared to palonosetron alone. Since no specific adverse reactions are listed, I cannot provide a list of terms from this excerpt."
AKYNZEO,adverse reactions,"Table 2: Adverse Reactions Occurring in >=3% of Cancer Patients Receiving AKYNZEO and Anthracyclines and Cyclophosphamide Based Chemotherapy (Cycle 1) Adverse Reactions AKYNZEOnetupitant 300 mg/palonosetron 0.5 mg(N=725) Palonosetron 0.5 mg(N=725) Headache 9% 7% Asthenia 8% 7% Fatigue 7% 5% In addition to the adverse reactions shown above, there were reports of concomitant elevations of transaminases > 3 x ULN and total bilirubin in both arms of the two trials that compared AKYNZEO to oral palonosetron, and the frequency of these elevations was comparable between treatment groups. See Table 3.","As the input is ""nan"" which means ""not applicable"" or ""not available,"" there are no adverse drug event terms to extract. If you have an actual excerpt from a drug label, please provide that for analysis."
AKYNZEO,adverse reactions,"Table 3: Liver Function Laboratory Abnormalities Laboratory Changes AKYNZEOnetupitant 300 mg/palonosetron 0.5 mgN=861 Palonosetron 0.5 mgN=861 AST > 3 x ULN and/or ALT > 3 x ULN with Total Bilirubin > ULN 3 (0.3%) 5 (0.6%) AST > 10 x ULN and/or ALT > 10 x ULN with Total Bilirubin > ULN - 2 (0.2%) AST > 3 x ULN and/or ALT > 3 x ULN with Total Bilirubin >= 2 x ULN 1 (0.1%) 1 (0.1%) In a multi-cycle safety study of 412 patients, the safety profile of AKYNZEO (n = 308) was comparable to aprepitant and palonosetron (n = 104) in patients undergoing initial and repeat cycles (median 5 cycles, range of 1-14 cycles) of chemotherapy, including carboplatin, cisplatin, oxaliplatin, and doxorubicin regimens. There were no reports of concomitant elevations of transaminases > 3 x ULN and total bilirubin in this study in either arm.","elevations of transaminases, total bilirubin"
AKYNZEO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"hypersensitivity reactions, anaphylaxis, serotonin syndrome"
AKYNZEO,warnings and precautions,5.1 Hypersensitivity,"Hypersensitivity reactions, anaphylaxis"
AKYNZEO,warnings and precautions,5.2 Serotonin Syndrome,"serotonin syndrome, fatal, agitation, hallucinations, delirium, coma, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia, tremor, rigidity, myoclonus, hyperreflexia, incoordination, seizures, nausea, vomiting, diarrhea."
VIEKIRA,adverse reactions,6 ADVERSE REACTIONS,"fatigue, nausea, pruritus, other skin reactions, insomnia, asthenia, Increased Risk of ALT Elevations"
VIEKIRA,adverse reactions,6.1 Clinical Trials Experience,"fatigue, nausea, pruritus, other skin reactions, insomnia, asthenia, serious adverse event (SAE)"
VIEKIRA,adverse reactions,"Table 3. Adverse Reactions with >=5% Greater Frequency Reported in Subjects with Chronic HCV GT1 Infection Treated with VIEKIRA PAK in Combination with Ribavirin Compared to Placebo for 12 Weeks SAPPHIRE-I and -II VIEKIRA PAK + RBV 12 Weeks N = 770 % Placebo 12 Weeks N = 255 % Fatigue 34 26 Nausea 22 15 Pruritus* 18 7 Skin reactions $ 16 9 Insomnia 14 8 Asthenia 14 7 *Grouped term 'pruritus' included the preferred terms pruritus and pruritus generalized. $ Grouped terms: rash, erythema, eczema, rash maculo-papular, rash macular, dermatitis, rash papular, skin exfoliation, rash pruritic, rash erythematous, rash generalized, dermatitis allergic, dermatitis contact, exfoliative rash, photosensitivity reaction, psoriasis, skin reaction, ulcer, urticaria. VIEKIRA PAK with and without Ribavirin in Regimen-Controlled Trials","Pruritus, nausea, insomnia, asthenia"
VIEKIRA,adverse reactions,"Table 4. Adverse Events with >=5% Greater Frequency Reported in Subjects with Chronic HCV GT1 Infection Treated with VIEKIRA PAK in Combination with Ribavirin Compared to VIEKIRA PAK for 12 Weeks PEARL-II, -III and -IV VIEKIRA PAK + RBV 12 Weeks N = 401 % VIEKIRA PAK 12 Weeks N = 509 % Nausea 16 8 Pruritus* 13 7 Insomnia 12 5 Asthenia 9 4 *Grouped term 'pruritus' included the preferred terms pruritus and pruritus generalized. VIEKIRA PAK with Ribavirin in Subjects with Compensated Cirrhosis","Fatigue, skin reactions, dyspnea, serious adverse events (SAEs), rash-related events, skin reactions, Stevens Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), erythema multiforme (EM), drug rash with eosinophilia and systemic symptoms (DRESS), serum ALT elevations, post-baseline serum ALT levels greater than 5 times the upper limit of normal, ALT elevations, drug-related liver injury, bilirubin elevations, indirect hyperbilirubinemia, ribavirin-induced hemolysis, anemia/decreased hemoglobin, insomnia, nausea, headache, pruritus, cough, irritability, ocular icterus, jaundice, hyperbilirubinemia, median declines in CD4+ T-cell counts, diarrhea, asthenia, muscle spasms, rash"
VIEKIRA,adverse reactions,6.2 Post-Marketing Adverse Reactions,"Hypersensitivity reactions, angioedema"
VIEKIRA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"ALT elevations, loss of therapeutic effect"
VIEKIRA,warnings and precautions,5.1 Increased Risk of ALT Elevations,"ALT elevations, fatigue, weakness, lack of appetite, nausea and vomiting, jaundice, discolored feces, liver inflammation, increasing conjugated bilirubin, alkaline phosphatase, INR"
VIEKIRA,warnings and precautions,5.3 Risk of Adverse Reactions or Reduced Therapeutic Effect Due to Drug Interactions,"Loss of therapeutic effect, development of resistance, clinically significant adverse reactions"
VIEKIRA,warnings and precautions,5.4 Risk of HIV-1 Protease Inhibitor Drug Resistance in HCV/HIV-1 Co-infected Patients,"There are no specific adverse drug event terms within the provided drug label excerpt. The text discusses the potential for the selection of HIV-1 protease inhibitor resistance-associated substitutions, which is a concern for drug resistance rather than a direct adverse event. If you are looking for risks associated with the drug, the closest term in the context would be ""HIV-1 protease inhibitor drug resistance."" However, if you require typical adverse event terms such as side effects or specific conditions caused by the drug, they are not present in the provided excerpt."
PERJETA,adverse reactions,6 ADVERSE REACTIONS,"Left Ventricular Dysfunction, Embryo-Fetal Toxicity, Infusion-Related Reactions, Hypersensitivity Reactions/Anaphylaxis, diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy, vomiting, thrombocytopenia, anemia"
PERJETA,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions, adverse events, permanent discontinuation, discontinuation, diarrhea, alopecia, neutropenia, nausea, fatigue, rash, peripheral neuropathy, febrile neutropenia, leukopenia, anemia, asthenia, increased incidence of febrile neutropenia"
PERJETA,adverse reactions,"Table 1 Summary of Adverse Reactions Occurring in >= 10% of Patients on the PERJETA Treatment Arm in Study 1 Body System/Adverse Reactions PERJETA + trastuzumab + docetaxeln=407Frequency rate% Placebo + trastuzumab + docetaxeln=397Frequency rate% All Grades% Grades 3 - 4% All Grades% Grades 3 - 4% General disorders and administration site conditions Fatigue 37.6 2.2 36.8 3.3 Asthenia 26.0 2.5 30.2 1.5 Edema peripheral 23.1 0.5 30.0 0.8 Mucosal inflammation 27.8 1.5 19.9 1.0 Pyrexia 18.7 1.2 17.9 0.5 Skin and subcutaneous tissue disorders Alopecia 60.9 0.0 60.5 0.3 Rash 33.7 0.7 24.2 0.8 Nail disorder 22.9 1.2 22.9 0.3 Pruritus 14.0 0.0 10.1 0.0 Dry skin 10.6 0.0 4.3 0.0 Gastrointestinal disorders Diarrhea 66.8 7.9 46.3 5.0 Nausea 42.3 1.2 41.6 0.5 Vomiting 24.1 1.5 23.9 1.5 Constipation 15.0 0.0 24.9 1.0 Stomatitis 18.9 0.5 15.4 0.3 Blood and lymphatic system disorders Neutropenia 52.8 48.9 49.6 45.8 Anemia 23.1 2.5 18.9 3.5 Leukopenia 18.2 12.3 20.4 14.6 Febrile neutropenia 13.8 13.0 7.6 7.3 Nervous system disorders Neuropathy peripheral 32.4 3.2 33.8 2.0 Headache 20.9 1.2 16.9 0.5 Dysgeusia 18.4 0.0 15.6 0.0 Dizziness 12.5 0.5 12.1 0.0 Musculoskeletal and connective tissue disorders Myalgia 22.9 1.0 23.9 0.8 Arthralgia 15.5 0.2 16.1 0.8 Infections and infestations Upper respiratory tract infection 16.7 0.7 13.4 0.0 Nasopharyngitis 11.8 0.0 12.8 0.3 Respiratory, thoracic, and mediastinal disorders Dyspnea 14.0 1.0 15.6 2.0 Metabolism and nutrition disorders Decreased appetite 29.2 1.7 26.4 1.5 Eye disorders Lacrimation increased 14.0 0.0 13.9 0.0 Psychiatric disorders Insomnia 13.3 0.0 13.4 0.0 The following clinically relevant adverse reactions were reported in < 10% of patients in the PERJETA-treated group in Study 1:","Paronychia, Pleural effusion, Left ventricular dysfunction, Symptomatic left ventricular systolic dysfunction (CHF), Hypersensitivity, Diarrhea, Upper respiratory tract infection, Rash, Headache, Fatigue, Alopecia, Neutropenia, Nausea, Febrile neutropenia, Leukopenia"
PERJETA,adverse reactions,Table 2 Summary of Adverse Reactions Occurring in >= 10% in the Neoadjuvant Setting for Patients Receiving PERJETA in Study 2 Body System/ Adverse Reactions Trastuzumab + docetaxeln=107Frequency rate% PERJETA + trastuzumab + docetaxeln=107Frequency rate% PERJETA + trastuzumabn=108Frequency rate% PERJETA + docetaxeln=108Frequency rate% All Grades% Grades 3 - 4% All Grades% Grades 3 - 4% All Grades% Grades 3 - 4% All Grades% Grades 3 - 4% General disorders and administration site conditions Fatigue 27.1 0.0 26.2 0.9 12.0 0.0 25.5 1.1 Asthenia 17.8 0.0 20.6 1.9 2.8 0.0 16.0 2.1 Edema peripheral 10.3 0.0 2.8 0.0 0.9 0.0 5.3 0.0 Mucosal inflammation 21.5 0.0 26.2 1.9 2.8 0.0 25.5 0.0 Pyrexia 10.3 0.0 16.8 0.0 8.3 0.0 8.5 0.0 Skin and subcutaneous tissue disorders Alopecia 66.4 0.0 65.4 0.0 2.8 0.0 67.0 0.0 Rash 21.5 1.9 26.2 0.9 11.1 0.0 28.7 1.1 Gastrointestinal disorders Diarrhea 33.6 3.7 45.8 5.6 27.8 0.0 54.3 4.3 Nausea 36.4 0.0 39.3 0.0 13.9 0.0 36.2 1.1 Vomiting 12.1 0.0 13.1 0.0 4.6 0.0 16.0 2.1 Stomatitis 7.5 0.0 17.8 0.0 4.6 0.0 9.6 0.0 Blood and lymphatic system disorders Neutropenia 63.6 58.9 50.5 44.9 0.9 0.9 64.9 57.4 Leukopenia 21.5 11.2 9.3 4.7 0.0 0.0 13.8 8.5 Nervous system disorders Headache 11.2 0.0 11.2 0.0 13.9 0.0 12.8 0.0 Dysgeusia 10.3 0.0 15.0 0.0 4.6 0.0 7.4 0.0 Peripheral Sensory Neuropathy 12.1 0.9 8.4 0.9 1.9 0.0 10.6 0.0 Musculoskeletal and connective tissue disorders Myalgia 22.4 0.0 22.4 0.0 9.3 0.0 21.3 0.0 Arthralgia 8.4 0.0 10.3 0.0 4.6 0.0 9.6 0.0 Metabolism and nutrition disorders Decreased appetite 6.5 0.0 14.0 0.0 1.9 0.0 14.9 0.0 Psychiatric disorders Insomnia 11.2 0.0 8.4 0.0 3.7 0.0 8.5 0.0 The following adverse reactions were reported in < 10% of patients receiving neoadjuvant treatment and occurred more frequently in PERJETA-treated groups in Study 2: (Ptz=pertuzumab; T=trastuzumab; D=docetaxel),"Anemia, Febrile neutropenia, Hypersensitivity, Dizziness, Upper respiratory tract infection, Dyspnea, Left ventricular dysfunction, Symptomatic left ventricular dysfunction (CHF), Lacrimation increased, Diarrhea, Nausea, Alopecia, Neutropenia, Vomiting, Fatigue, Leukopenia, Thrombocytopenia, ALT increased, Hypokalemia"
PERJETA,adverse reactions,"Table 3 Summary of Adverse Reactions Occurring in >= 10% of Patients Receiving Neoadjuvant Treatment with PERJETA in Study 3 PERJETA + trastuzumab + FEC followed by PERJETA + trastuzumab + docetaxel PERJETA + trastuzumab + docetaxel following FEC PERJETA + TCH Body System/Adverse Reactions n=72Frequency rate% n=75Frequency rate% n=76Frequency rate% All Grades% Grades 3 - 4% All Grades% Grades 3 - 4% All Grades% Grades 3 - 4% FEC=5-fluorouracil, epirubicin, cyclophosphamide, TCH=docetaxel, carboplatin, trastuzumab General disorders and administration site conditions Fatigue 36.1 0.0 36.0 0.0 42.1 3.9 Asthenia 9.7 0.0 14.7 1.3 13.2 1.3 Edema peripheral 11.1 0.0 4.0 0.0 9.2 0.0 Mucosal inflammation 23.6 0.0 20.0 0.0 17.1 1.3 Pyrexia 16.7 0.0 9.3 0.0 15.8 0.0 Skin and subcutaneous tissue disorders Alopecia 48.6 0.0 52.0 0.0 55.3 0.0 Rash 19.4 0.0 10.7 0.0 21.1 1.3 Dry skin 5.6 0.0 9.3 0.0 10.5 0.0 Palmar-Plantar Erythrodysaesthesia Syndrome 6.9 0.0 10.7 0.0 7.9 0.0 Gastrointestinal disorders Diarrhea 61.1 4.2 61.3 5.3 72.4 11.8 Dyspepsia 25.0 1.4 8 0.0 22.4 0.0 Nausea 52.8 0.0 53.3 2.7 44.7 0.0 Vomiting 40.3 0.0 36.0 2.7 39.5 5.3 Constipation 18.1 0.0 22.7 0.0 15.8 0.0 Stomatitis 13.9 0.0 17.3 0.0 11.8 0.0 Blood and lymphatic system disorders Neutropenia 51.4 47.2 46.7 42.7 48.7 46.1 Anemia 19.4 1.4 9.3 4.0 38.2 17.1 Leukopenia 22.2 19.4 16.0 12.0 17.1 11.8 Febrile neutropenia 18.1 18.1 9.3 9.3 17.1 17.1 Thrombocytopenia 6.9 0.0 1.3 0.0 30.3 11.8 Immune system disorders Hypersensitivity 9.7 2.8 1.3 0.0 11.8 2.6 Nervous system disorders Neuropathy peripheral 5.6 0.0 1.3 0.0 10.5 0.0 Headache 22.2 0.0 14.7 0.0 17.1 0.0 Dysgeusia 11.1 0.0 13.3 0.0 21.1 0.0 Dizziness 8.3 0.0 8.0 1.3 15.8 0.0 Musculoskeletal and connective tissue disorders Myalgia 16.7 0.0 10.7 1.3 10.5 0.0 Arthralgia 11.1 0.0 12.0 0.0 6.6 0.0 Respiratory, thoracic, and mediastinal disorders Cough 9.7 0.0 5.3 0.0 11.8 0.0 Dyspnea 12.5 0.0 8.0 2.7 10.5 1.3 Epistaxis 11.1 0.0 10.7 0.0 15.8 1.3 Oropharyngeal pain 8.3 0.0 6.7 0.0 11.8 0.0 Metabolism and nutrition disorders Decreased appetite 20.8 0.0 10.7 0.0 21.1 0.0 Eye disorders Lacrimation increased 12.5 0.0 5.3 0.0 7.9 0.0 Psychiatric disorders Insomnia 11.1 0.0 13.3 0.0 21.1 0.0 Investigations ALT increased 6.9 0.0 2.7 0.0 10.5 3.9 The following selected adverse reactions were reported in < 10% of patients receiving neoadjuvant treatment in Study 3: (Ptz=pertuzumab; T=trastuzumab; D=docetaxel; FEC= fluorouracil, epirubicin, and cyclophosphamide; TCH=docetaxel, carboplatin, and trastuzumab)","Nail disorder, Paronychia, Pruritis, Upper respiratory tract infection, Nasopharyngitis, Pleural effusion, Left ventricular dysfunction, Symptomatic left ventricular systolic dysfunction (CHF)"
PERJETA,adverse reactions,6.2 Immunogenicity,"immune response, antibodies to PERJETA, anti-PERJETA antibodies, anaphylactic/hypersensitivity reactions, anti-therapeutic antibodies (ATA), drug interference"
PERJETA,boxed warnings,BOXED WARNING: WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY,"The text you provided (""The input is nan"") does not contain any information from which I could extract adverse drug event terms. If this was a mistake, please provide the actual excerpt from the drug label so I can assist you properly."
PERJETA,boxed warnings,WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY,"left ventricular dysfunction, embryo-fetal toxicity, cardiac failure, CHF, decreased LVEF, subclinical cardiac failure, clinical cardiac failure, embryo-fetal death, birth defects, oligohydramnios, delayed renal development"
PERJETA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Left Ventricular Dysfunction, Embryo-fetal toxicity, Infusion-Related Reactions, Hypersensitivity Reactions/Anaphylaxis"
PERJETA,warnings and precautions,5.1 Left Ventricular Dysfunction,"Decreases in LVEF, left ventricular systolic dysfunction, congestive heart failure, left ventricular dysfunction, LVEF decline, Symptomatic LVSD, uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia, CHF"
PERJETA,warnings and precautions,5.2 Embryo-Fetal Toxicity,"fetal harm, oligohydramnios, delayed fetal kidney development, embryo-fetal death, embryo-fetal death, birth defects"
PERJETA,warnings and precautions,5.3 Infusion-Related Reactions,"hypersensitivity, anaphylactic reaction, acute infusion reaction, cytokine release syndrome, pyrexia, chills, fatigue, headache, asthenia, vomiting, dysgeusia, myalgia, severe infusion reactions"
PERJETA,warnings and precautions,5.4 Hypersensitivity Reactions/Anaphylaxis,"hypersensitivity, anaphylaxis, Grade 3 - 4 hypersensitivity/anaphylaxis reactions, severe hypersensitivity"
PERJETA,warnings and precautions,5.5 HER2 Testing,"improper assay performance, sub-optimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, failure to include appropriate controls for assay validation, unreliable results"
KEYTRUDA,adverse reactions,6 ADVERSE REACTIONS,"Immune-mediated pneumonitis, Immune-mediated colitis, Immune-mediated hepatitis, Immune-mediated endocrinopathies, Renal failure, Immune-mediated nephritis, Other immune-mediated adverse reactions, Infusion-related reactions, Fatigue, Cough, Nausea, Pruritus, Rash, Decreased appetite, Constipation, Arthralgia, Diarrhea"
KEYTRUDA,adverse reactions,6.1 Clinical Trials Experience,"pneumonitis, renal failure, pain, dyspnea, pneumonia, cellulitis"
KEYTRUDA,adverse reactions,"Table 1 presents adverse reactions identified from analyses of the 89 patients with unresectable or metastatic melanoma who received KEYTRUDA 2 mg/kg every three weeks in one cohort of Trial 1. Patients had documented disease progression following treatment with ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This cohort of Trial 1 excluded patients with severe immune-related toxicity related to ipilimumab, defined as any Grade 4 toxicity requiring treatment with corticosteroids or Grade 3 toxicity requiring corticosteroid treatment (greater than 10 mg/day prednisone or equivalent dose) for greater than 12 weeks; a medical condition that required systemic corticosteroids or other immunosuppressive medication; a history of pneumonitis or interstitial lung disease; or any active infection requiring therapy, including HIV or hepatitis B or C. Of the 89 patients in this cohort, the median age was 59 years (range 18 to 88), 33% were age 65 years or older, 53% were male, 98% were white, 44% had an elevated LDH, 84% had Stage M1c disease, 8% had brain metastases, and 70% received two or more prior therapies for advanced or metastatic disease. The median duration of exposure to KEYTRUDA was 6.2 months (range 1 day to 15.3 months) with a median of nine doses (range 1 to 23). Fifty-one percent of patients were exposed to KEYTRUDA for greater than 6 months and 21% for greater than 1 year.","fatigue, cough, nausea, pruritus, rash, decreased appetite, constipation, arthralgia, diarrhea"
KEYTRUDA,adverse reactions,"Table 1: Adverse Reactions in >=10% of Patients with Unresectable or Metastatic Melanoma KEYTRUDA2 mg/kg every 3 weeksN=89 Adverse Reaction All Grades(%) Grade 3(%) General Disorders and Administration Site Conditions Fatigue 47 7 Peripheral Edema 17 1 Chills 14 0 Pyrexia 11 0 Gastrointestinal Disorders Nausea 30 0 Constipation 21 0 Diarrhea 20 0 Vomiting 16 0 Abdominal pain 12 0 Respiratory, Thoracic and Mediastinal Disorders Cough 30 1 Dyspnea 18 2 Skin and Subcutaneous Tissue Disorders Pruritus 30 0 Rash 29 0 Vitiligo 11 0 Metabolism and Nutrition Disorders Decreased appetite 26 0 Musculoskeletal and Connective Tissue Disorders Arthralgia 20 0 Pain in extremity 18 1 Myalgia 14 1 Back pain 12 1 Nervous System Disorders Headache 16 0 Dizziness 11 0 Blood and Lymphatic System Disorders Anemia 14 5 Psychiatric Disorders Insomnia 14 0 Infections and Infestations Upper respiratory tract infection 11 1 Other clinically important adverse reactions observed in up to 10% of patients treated with KEYTRUDA were:",sepsis
KEYTRUDA,adverse reactions,"Table 2: Laboratory Abnormalities Increased from Baseline in >=20% of Patients with Unresectable or Metastatic Melanoma KEYTRUDA2 mg/kg every 3 weeksN=89 Laboratory Test All Grades% Grades 3-4% Chemistry Hyperglycemia 40 2 Hyponatremia 35 9 Hypoalbuminemia 34 0 Hypertriglyceridemia 25 0 Increased Aspartate Aminotransferase 24 2 Hypocalcemia 24 1 Hematology Anemia 55 8 6.2 Immunogenicity As with all therapeutic proteins, there is the potential for immunogenicity. Because trough levels of pembrolizumab interfere with the electrochemiluminescent (ECL) assay results, a subset analysis was performed in the patients with a concentration of pembrolizumab below the drug tolerance level of the anti-product antibody assay. In this analysis, none of the 97 patients who were treated with 2 mg/kg every 3 weeks tested positive for treatment-emergent anti-pembrolizumab antibodies.","antibody formation, neutralizing antibody, underlying disease"
KEYTRUDA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"pneumonitis, colitis, hepatitis, hypophysitis, thyroid disorders, hyperthyroidism, Type 1 diabetes mellitus, hyperglycemia, nephritis, infusion-related reactions, embryofetal toxicity"
KEYTRUDA,warnings and precautions,5.1 Immune-Mediated Pneumonitis,"Pneumonitis, Grade 2 pneumonitis, Grade 3 pneumonitis"
KEYTRUDA,warnings and precautions,5.2 Immune-Mediated Colitis,"Colitis, Grade 2 colitis, Grade 3 colitis"
KEYTRUDA,warnings and precautions,5.3 Immune-Mediated Hepatitis,"Hepatitis, autoimmune hepatitis, Grade 4 hepatitis"
KEYTRUDA,warnings and precautions,5.4 Immune-Mediated Endocrinopathies,"Hypophysitis, Grade 2 hypophysitis, Grade 4 hypophysitis, hypopituitarism, adrenal insufficiency, Hyperthyroidism, Grade 2 hyperthyroidism, Grade 3 hyperthyroidism, Hypothyroidism, Grade 3 hypothyroidism, Type 1 diabetes mellitus, diabetic ketoacidosis, hyperglycemia"
KEYTRUDA,warnings and precautions,5.5 Renal Failure and Immune-Mediated Nephritis,"Nephritis, autoimmune nephritis, renal failure, interstitial nephritis, Grade 2 autoimmune nephritis, Grade 3 nephritis, Grade 4 nephritis, acute interstitial nephritis, renal function changes"
KEYTRUDA,warnings and precautions,5.6 Other Immune-Mediated Adverse Reactions,"exfoliative dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, partial seizures, severe dermatitis, bullous pemphigoid, myasthenic syndrome, optic neuritis, rhabdomyolysis"
KEYTRUDA,warnings and precautions,5.7 Infusion-Related Reactions,"infusion-related reactions, rigors, chills, wheezing, pruritis, flushing, rash, hypotension, hypoxemia, fever, severe, life-threatening"
KEYTRUDA,warnings and precautions,5.8 Embryofetal Toxicity,"fetal harm, hazard to a fetus"
MYALEPT,adverse reactions,6 ADVERSE REACTIONS,"headache, hypoglycemia, decreased weight, abdominal pain"
MYALEPT,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse reactions"
MYALEPT,adverse reactions,"Table 2: Adverse Reactions of 5% or Greater Incidence in Patients with Generalized Lipodystrophy Receiving MYALEPT in an Open-Label, Single-Arm Study All Subjects N=48 (%) 1. Hypoglycemic events were assessed as mild, moderate, severe, or life threatening based on the protocol specified definitions: Mild: Documentation of low plasma glucose values with no symptoms; Moderate: Presence of clinical symptoms requiring ingestion of glucose, self-alleviated; Severe: Presence of neuroglycopenic symptoms requiring assistance from others for alleviation; Life threatening: Loss of consciousness and/or requiring intervention by administration of intravenous glucose or intramuscular glucagon. Headache 6 (13) Hypoglycemia1 6 (13) Decreased weight 6 (13) Abdominal pain 5 (10) Arthralgia 4 (8) Dizziness 4 (8) Ear infection 4 (8) Fatigue 4 (8) Nausea 4 (8) Ovarian cyst 4 (8) Upper respiratory tract infection 4 (8) Anemia 3 (6) Back pain 3 (6) Diarrhea 3 (6) Paresthesia 3 (6) Proteinuria 3 (6) Pyrexia 3 (6) In patients with generalized lipodystrophy receiving MYALEPT in this study, less common adverse reactions included injection-site erythema and urticaria (N=2 [4%]).","hypoglycemia, pancreatitis"
MYALEPT,adverse reactions,6.2 Immunogenicity,"immunogenicity, anti-metreleptin antibodies, adverse events, severe infections, worsening of metabolic control, increases in HbA1c, increases in triglycerides, loss of endogenous leptin activity, loss of MYALEPT efficacy"
MYALEPT,boxed warnings,BOXED WARNING: WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY,"As the input provided is ""nan"" which denotes 'not a number' or is used to indicate that the data is not available or not applicable, there are no adverse drug event terms to extract. Please provide a relevant excerpt from a drug label for me to identify any potential adverse drug event terms."
MYALEPT,boxed warnings,AND RISK OF LYMPHOMA,"If the input is ""nan"", which commonly stands for ""not a number"" and indicates that there is no excerpt provided for review, I cannot extract any adverse drug event terms. If you provide an actual excerpt from a drug label, I'd be happy to identify the adverse event terms for you."
MYALEPT,boxed warnings,WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY,"If the input provided is ""nan"" indicating not applicable or not available, then there is no content to extract adverse drug event terms from. Therefore, there would be no terms to list. If this is a mistake and there is supposed to be an excerpt provided, please provide the actual text for analysis."
MYALEPT,boxed warnings,AND RISK OF LYMPHOMA,"inhibition of endogenous leptin action, loss of MYALEPT efficacy, severe infection, worsening metabolic control, T-cell lymphoma"
MYALEPT,boxed warnings,EXCERPT: WARNING: RISK OF ANTI-METRELEPTIN ANTIBODIES WITH NEUTRALIZING ACTIVITY AND RISK OF LYMPHOMA,"anti-metreleptin antibodies with neutralizing activity, inhibition of endogenous leptin action, loss of MYALEPT efficacy, worsening metabolic control, severe infection, T-cell lymphoma"
MYALEPT,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Anti-metreleptin antibodies with neutralizing activity, loss of MYALEPT efficacy, T-cell lymphoma, Hypoglycemia, Autoimmune disorder progression, Hypersensitivity reactions, Benzyl Alcohol Toxicity"
MYALEPT,warnings and precautions,5.1 Risk for Development of Antibodies that Neutralize Endogenous Leptin and/or MYALEPT,"severe infections, increases in HbA1c, increases in triglycerides, excessive weight gain, development of glucose intolerance, diabetes mellitus"
MYALEPT,warnings and precautions,5.2 Lymphoma,"T-cell lymphoma, peripheral T-cell lymphoma, severe bone marrow abnormalities, anaplastic large cell lymphoma, Lymphoproliferative disorders, malignancies, leukopenia, neutropenia, lymphadenopathy"
MYALEPT,warnings and precautions,5.3 MYALEPT REMS Program,"anti-metreleptin antibodies that neutralize endogenous leptin, lymphoma"
MYALEPT,warnings and precautions,5.4 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues,hypoglycemia
MYALEPT,warnings and precautions,5.5 Autoimmunity,"autoimmune hepatitis, membranoproliferative glomerulonephritis, massive proteinuria, renal failure"
MYALEPT,warnings and precautions,5.6 Hypersensitivity,"generalized hypersensitivity, anaphylaxis, urticaria, generalized rash"
MYALEPT,warnings and precautions,5.7 Benzyl Alcohol Toxicity,"serious adverse events, death"
TRADJENTA,adverse reactions,6 ADVERSE REACTIONS,"nasopharyngitis, Hypoglycemia"
TRADJENTA,adverse reactions,6.1 Clinical Trials Experience,"clinical trials, adverse reaction rates, safety evaluation, severe renal impairment, placebo-controlled trials, randomized, treated, exposure, follow-up, monotherapy, combination, antihyperglycemic agents, adverse reactions, incidence of adverse events"
TRADJENTA,adverse reactions,Table 1 Adverse Reactions Reported in >=2% of Patients Treated with TRADJENTA and Greater than Placebo in Placebo-Controlled Clinical Studies of TRADJENTA Monotherapy or Combination Therapy Number (%) of Patients TRADJENTA 5 mgn = 3625 Placebon = 2176 Nasopharyngitis 254 (7.0) 132 (6.1) Diarrhea 119 (3.3) 65 (3.0) Cough 76 (2.1) 30 (1.4) Rates for other adverse reactions for TRADJENTA 5 mg vs placebo when TRADJENTA was used in combination with specific anti-diabetic agents were: urinary tract infection (3.1% vs 0%) and hypertriglyceridemia (2.4% vs 0%) when TRADJENTA was used as add-on to sulfonylurea; hyperlipidemia (2.7% vs 0.8%) and weight increased (2.3% vs 0.8%) when TRADJENTA was used as add-on to pioglitazone; and constipation (2.1% vs 1%) when TRADJENTA was used as add-on to basal insulin therapy.,"back pain, arthralgia, upper respiratory tract infection, headache, cough, pain in extremity, hypersensitivity, urticaria, angioedema, localized skin exfoliation, bronchial hyperreactivity, myalgia, pancreatitis, hypoglycemia, severe hypoglycemic events"
TRADJENTA,adverse reactions,6.2 Postmarketing Experience,"Acute pancreatitis, fatal pancreatitis, Hypersensitivity reactions, anaphylaxis, angioedema, exfoliative skin conditions, Severe and disabling arthralgia, Rash, Mouth ulceration, stomatitis"
TRADJENTA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"acute pancreatitis, fatal pancreatitis, hypoglycemia, serious hypersensitivity reactions, anaphylaxis, angioedema, exfoliative skin conditions, severe and disabling arthralgia"
TRADJENTA,warnings and precautions,5.1 Pancreatitis,"acute pancreatitis, fatal pancreatitis"
TRADJENTA,warnings and precautions,5.2 Use with Medications Known to Cause Hypoglycemia,hypoglycemia
TRADJENTA,warnings and precautions,5.3 Hypersensitivity Reactions,"hypersensitivity reactions, anaphylaxis, angioedema, exfoliative skin conditions"
TRADJENTA,warnings and precautions,5.4 Severe and Disabling Arthralgia,"severe and disabling arthralgia, severe joint pain"
TRADJENTA,warnings and precautions,5.5 Macrovascular Outcomes,macrovascular risk reduction
BRINTELLIX,adverse reactions,6 ADVERSE REACTIONS,"Hypersensitivity, Clinical Worsening and Suicide Risk, Serotonin Syndrome, Abnormal Bleeding, Activation of Mania/Hypomania, Hyponatremia, nausea, constipation, vomiting"
BRINTELLIX,adverse reactions,6.1 Clinical Studies Experience,"adverse reaction rates, adverse Reactions, discontinuation of treatment, nausea, common adverse reactions, constipation, vomiting"
BRINTELLIX,adverse reactions,Table 2 shows the incidence of common adverse reactions that occurred in >=2% of MDD patients treated with any BRINTELLIX dose and at least 2% more frequently than in placebo-treated patients in the 6 to 8 week placebo-controlled studies.,"As an AI, I need an actual excerpt from a drug label to identify adverse drug event terms. If the input is ""nan"" (which typically stands for ""not a number""), there is no information for me to analyze. Please provide a relevant excerpt for me to assist with your request."
BRINTELLIX,adverse reactions,Table 2. Common Adverse Reactions Occurring in >=2% of Patients Treated with any BRINTELLIX Dose and at Least 2% Greater than the Incidence in Placebo-treated Patients System Organ Class Preferred Term BRINTELLIX5 mg/day BRINTELLIX10 mg/day BRINTELLIX15 mg/day BRINTELLIX20 mg/day Placebo N=1013% N=699% N=449% N=455% N=1621% Gastrointestinal disorders Nausea 21 26 32 32 9 Diarrhea 7 7 10 7 6 Dry mouth 7 7 6 8 6 Constipation 3 5 6 6 3 Vomiting 3 5 6 6 1 Flatulence 1 3 2 1 1 Nervous system disorders Dizziness 6 6 8 9 6 Psychiatric disorders Abnormal dreams <1 <1 2 3 1 Skin and subcutaneous tissue disorders PruritusIncludes pruritus generalized 1 2 3 3 1 Nausea,"Nausea, Sexual Dysfunction, sexual desire, sexual performance, sexual satisfaction, difficulty achieving erection, difficulty with lubrication, ease of reaching orgasm, orgasm satisfaction"
BRINTELLIX,adverse reactions,Table 3. ASEX Incidence of Treatment Emergent Sexual DysfunctionIncidence based on number of subjects with sexual dysfunction during the study / number of subjects without sexual dysfunction at baseline. Sexual dysfunction was defined as a subject scoring any of the following on the ASEX scale at two consecutive visits during the study: 1) total score >=19; 2) any single item >=5; 3) three or more items each with a score >=4 BRINTELLIX 5 mg/day N=65:67Sample size for each dose group is the number of patients (females:males) without sexual dysfunction at baseline BRINTELLIX 10 mg/day N=94:86 BRINTELLIX 15 mg/day N=57:67 BRINTELLIX 20 mg/day N=67:59 Placebo N=135:162 Females 22% 23% 33% 34% 20% Males 16% 20% 19% 29% 14% Adverse Reactions Following Abrupt Discontinuation of BRINTELLIX Treatment,"headache, muscle tension, mood swings, sudden outbursts of anger, dizziness, runny nose, hyponatremia, vertigo, dyspepsia, dysgeusia, flushing"
BRINTELLIX,boxed warnings,BOXED WARNING: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS,"If the provided input is ""nan"" and there is no other text associated with adverse drug events, then it is not possible to provide a list of adverse drug event terms. Please provide an excerpt from a drug label containing relevant information."
BRINTELLIX,boxed warnings,WARNING: SUICIDAL THOUGHTS AND BEHAVIORS,"suicidal thoughts, behavior, worsening"
BRINTELLIX,boxed warnings,EXCERPT: WARNING: SUICIDAL THOUGHTS AND BEHAVIORS,"increased risk of suicidal thinking and behavior, worsening and emergence of suicidal thoughts and behaviors"
BRINTELLIX,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Serotonin Syndrome, abnormal bleeding, Activation of Mania/Hypomania, Angle Closure Glaucoma, Hyponatremia"
BRINTELLIX,warnings and precautions,5.1 Clinical Worsening and Suicide Risk,"worsening of depression, suicidal ideation, suicidality, unusual changes in behavior, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, mania"
BRINTELLIX,warnings and precautions,5.2 Serotonin Syndrome,"life-threatening serotonin syndrome, agitation, hallucinations, delirium, coma, autonomic instability, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia, tremor, rigidity, myoclonus, hyperreflexia, incoordination, seizures, nausea, vomiting, diarrhea"
BRINTELLIX,warnings and precautions,5.3 Abnormal Bleeding,"bleeding events, gastrointestinal bleeding, ecchymosis, hematoma, epistaxis, petechiae, hemorrhages"
BRINTELLIX,warnings and precautions,5.4 Activation of Mania/Hypomania,"mania, hypomania, activation of mania/hypomania"
BRINTELLIX,warnings and precautions,5.5 Angle Closure Glaucoma,"Angle Closure Glaucoma, pupillary dilation, angle closure attack"
BRINTELLIX,warnings and precautions,5.6 Hyponatremia,"hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), headache, difficulty concentrating, memory impairment, confusion, weakness, unsteadiness, falls, hallucination, syncope, seizure, coma, respiratory arrest, death"
AUBAGIO,adverse reactions,6 ADVERSE REACTIONS,"Hepatotoxicity, Bone Marrow Effects, Immunosuppression Potential, Infections, Peripheral Neuropathy, Skin Reactions, Increased Blood Pressure, Respiratory Effects, headache, diarrhea, nausea, alopecia, increase in ALT"
AUBAGIO,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, adverse drug event"
AUBAGIO,adverse reactions,"Table 1 lists adverse reactions in placebo-controlled trials with rates that were at least 2% for AUBAGIO patients and also at least 2% above the rate in placebo patients. The most common were headache, an increase in ALT, diarrhea, alopecia, and nausea. The adverse reaction most commonly associated with discontinuation was an increase in ALT (3.3%, 2.6%, and 2.3% of all patients in the AUBAGIO 7 mg, AUBAGIO 14 mg, and placebo treatment arms, respectively).","If the input provided is ""nan"" (not a number), and there is no other context or excerpt of a drug label text provided, I cannot extract any adverse drug event terms. Please provide the necessary text containing potential adverse drug events for analysis."
AUBAGIO,adverse reactions,Table 1. Adverse Reactions in Pooled Placebo-Controlled Studies in Patients with Relapsing Forms of Multiple Sclerosis Adverse Reaction AUBAGIO 7 mg(N=1045) AUBAGIO 14 mg(N=1002) Placebo(N=997) Headache 18% 16% 15% Increase in Alanine aminotransferase 13% 15% 9% Diarrhea 13% 14% 8% Alopecia 10% 13% 5% Nausea 8% 11% 7% Paresthesia 8% 9% 7% Arthralgia 8% 6% 5% Neutropenia 4% 6% 2% Hypertension 3% 4% 2% Cardiovascular deaths,"cardiovascular deaths, sudden deaths, myocardial infarction, hyperlipidemia, hypertension, Acute Renal Failure, creatinine values increased, hyperkalemia, acute uric acid nephropathy, transient acute renal failure, Hypophosphatemia, hypophosphatemia"
AUBAGIO,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"WBC decrease, infection, peripheral neuropathy, Stevens-Johnson syndrome, toxic epidermal necrolysis, increase blood pressure"
AUBAGIO,warnings and precautions,5.1 Hepatotoxicity,"Severe liver injury, fatal liver failure, liver dysfunction, elevated serum transaminases, acute liver disease, chronic liver disease, serum alanine aminotransferase (ALT) greater than two times the upper limit of normal, severe hepatic impairment, ALT greater than three times the ULN, jaundice, hepatotoxic, hepatic dysfunction, nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine."
AUBAGIO,warnings and precautions,5.2 Use in Women of Childbearing Potential,"teratogenic effects, fetal death, serious risk to the fetus"
AUBAGIO,warnings and precautions,5.3 Procedure for Accelerated Elimination of Teriflunomide,"not well tolerated, poorly tolerated, return of disease activity"
AUBAGIO,warnings and precautions,5.4 Bone Marrow Effects/Immunosuppression Potential/Infections,"WBC count decrease, neutrophils decrease, lymphocytes decrease, platelet count decrease, neutrophil count < 1.5*10^9/L, lymphocyte count <0.8*10^9/L, pancytopenia, agranulocytosis, thrombocytopenia, infection, serious infection, klebsiella pneumonia sepsis, fatal infections, Pneumocystis jiroveci pneumonia, aspergillosis, cytomegalovirus hepatitis reactivation, tuberculosis"
AUBAGIO,warnings and precautions,5.5 Peripheral Neuropathy,"peripheral neuropathy, polyneuropathy, mononeuropathy, carpal tunnel syndrome"
AUBAGIO,warnings and precautions,5.6 Skin Reactions,"Stevens-Johnson syndrome, toxic epidermal necrolysis"
AUBAGIO,warnings and precautions,5.7 Increased Blood Pressure,"Hypertension, Elevated blood pressure"
AUBAGIO,warnings and precautions,5.8 Respiratory Effects,"Interstitial lung disease, worsening of pre-existing interstitial lung disease, cough, dyspnea, fever."
AUBAGIO,warnings and precautions,5.9 Concomitant Use with Immunosuppressive or Immunomodulating Therapies,"antineoplastic, immunosuppressive therapies, hematologic toxicity, disease activity"
POMALYST,adverse reactions,6 ADVERSE REACTIONS,"Fetal Risk, Venous and Arterial Thromboembolism, Hematologic Toxicity, Hepatotoxicity, Hypersensitivity Reactions, Dizziness, Confusional State, Neuropathy, Risk of Second Primary Malignancies, Tumor Lysis Syndrome, fatigue, asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain, pyrexia"
POMALYST,adverse reactions,6.1 Clinical Trials Experience,"adverse reactions, dose interruption, dose reduction, discontinuation rate due to adverse reactions"
POMALYST,adverse reactions,"Tables 2 and 3 summarize the adverse reactions reported in Trials 1 and 2, respectively.","If the input provided is ""nan"" and it's intended to denote not applicable or not available, it means there is no text given from which to extract adverse drug event terms. Therefore, I cannot provide a list of adverse drug event terms. If you provide an actual excerpt from a drug label, I'd be happy to help identify the adverse drug event terms."
POMALYST,adverse reactions,"Table 2: Adverse Reactions in Any POMALYST Treatment Arm in Trial 1* * Regardless of attribution of relatedness to POMALYST. a POMALYST alone arm includes all patients randomized to the POMALYST alone arm who took study drug; 61 of the 107 patients had dexamethasone added during the treatment period. b Serious adverse reactions were reported in at least 2 patients in any POMALYST treatment arm.Data cutoff: 01 March 2013 All Adverse Reactions >=10% inEither Arm Grade 3 or 4 >=5% in Either Arm System Organ Class/Preferred Term POMALYST a (N=107) POMALYST +Low-dose Dex(N=112) POMALYST(N=107) POMALYST +Low-dose Dex(N=112) Number (%) of patients with at least one adverse reaction 107 (100) 112 (100) 98 (91.6) 102 (91.1) Blood and lymphatic system disorders Neutropenia b 57 (53.3) 55 (49.1) 51 (47.7) 46 (41.1) Anemia b 41 (38.3) 47 (42.0) 25 (23.4) 24 (21.4) Thrombocytopenia b 28 (26.2) 26 (23.2) 24 (22.4) 21 (18.8) Leukopenia 14 (13.1) 22 (19.6) 7 (6.5) 11 (9.8) Febrile neutropenia b <10% <10% 6 (5.6) 3 (2.7) Lymphopenia 4 (3.7) 17 (15.2) 2 (1.9) 8 (7.1) General disorders and administration site conditions Fatigue and asthenia b 62 (57.9) 70 (62.5) 13 (12.1) 19 (17.0) Edema peripheral 27 (25.2) 19 (17.0) 0 (0.0) 0 (0.0) Pyrexia b 25 (23.4) 36 (32.1) <5% <5% Chills 11 (10.3) 14 (12.5) 0 (0.0) 0 (0.0) Gastrointestinal disorders Nausea b 39 (36.4) 27 (24.1) <5% <5% Constipation b 38 (35.5) 41 (36.6) <5% <5% Diarrhea 37 (34.6) 40 (35.7) <5% <5% Vomiting b 15 (14.0) 16 (14.3) <5% 0 (0.0) Musculoskeletal and connective tissue disorders Back pain b 37 (34.6) 36 (32.1) 15 (14.0) 11 (9.8) Musculoskeletal chest pain 25 (23.4) 22 (19.6) <5% 0 (0.0) Muscle spasms 23 (21.5) 22 (19.6) <5% <5% Arthralgia 18 (16.8) 17 (15.2) <5% <5% Muscular weakness 15 (14.0) 15 (13.4) 6 (5.6) 4 (3.6) Bone pain 13 (12.1) 8 (7.1) <5% <5% Musculoskeletal pain 13 (12.1) 19 (17.0) <5% <5% Pain in extremity 8 (7.5) 16 (14.3) 0 (0.0) <5% Infections and infestations Upper respiratory tract infection 40 (37.4) 32 (28.6) <5% <5% Pneumonia b 30 (28.0) 38 (33.9) 21 (19.6) 32 (28.6) Urinary tract infection b 11 (10.3) 19 (17.0) 2 (1.9) 10 (8.9) Sepsis b <10% <10% 6 (5.6) 5 (4.5) Metabolism and nutrition disorders Decreased appetite 25 (23.4) 21 (18.8) <5% 0 (0.0) Hypercalcemia b 23 (21.5) 13 (11.6) 11 (10.3) 1 (0.9) Hypokalemia 13 (12.1) 13 (11.6) <5% <5% Hyperglycemia 12 (11.2) 17 (15.2) <5% <5% Hyponatremia 12 (11.2) 14 (12.5) <5% <5% Dehydration b <10% <10% 5 (4.7) 6 (5.4) Hypocalcemia 6 (5.6) 13 (11.6) 0 (0.0) <5% Respiratory, thoracic and mediastinal disorders Dyspnea b 38 (35.5) 50 (44.6) 8 (7.5) 14 (12.5) Cough 18 (16.8) 25 (22.3) 0 (0.0) 0 (0.0) Epistaxis 18 (16.8) 12 (10.7) <5% 0 (0.0) Productive cough 10 (9.3) 14 (12.5) 0 (0.0) 0 (0.0) Oropharyngeal pain 6 (5.6) 12 (10.7) 0 (0.0) 0 (0.0) Nervous system disorders Dizziness 24 (22.4) 20 (17.9) <5% <5% Peripheral neuropathy 23 (21.5) 20 (17.9) 0 (0.0) 0 (0.0) Headache 16 (15.0) 15 (13.4) 0 (0.0) <5% Tremor 11 (10.3) 15 (13.4) 0 (0.0) 0 (0.0) Skin and subcutaneous tissue disorders Rash 22 (20.6) 18 (16.1) 0 (0.0) <5% Pruritus 16 (15.0) 10 (8.9) 0 (0.0) 0 (0.0) Dry skin 10 (9.3) 12 (10.7) 0 (0.0) 0 (0.0) Hyperhidrosis 8 (7.5) 18 (16.1) 0 (0.0) 0 (0.0) Night sweats 5 (4.7) 14 (12.5) 0 (0.0) 0 (0.0) Investigations Blood creatinine increased b 20 (18.7) 11 (9.8) 6 (5.6) 3 (2.7) Weight decreased 16 (15.0) 10 (8.9) 0 (0.0) 0 (0.0) Weight increased 1 (0.9) 12 (10.7) 0 (0.0) 0 (0.0) Psychiatric disorders Anxiety 14 (13.1) 8 (7.1) 0 (0.0) 0 (0.0) Confusional state b 13 (12.1) 15 (13.4) 6 (5.6) 3 (2.7) Insomnia 7 (6.5) 18 (16.1) 0 (0.0) 0 (0.0) Renal and urinary disorders Renal failure b 16 (15.0) 11 (9.8) 9 (8.4) 8 (7.1) Table 3: Adverse Reactions in Trial 2 a Percentage did not meet the criteria to be considered as an adverse reaction for POMALYST for that category of event (i.e., all adverse events or Grade 3 or 4 adverse events). b Serious adverse reactions were reported in at least 3 patients in the POM + Low-dose Dex arm, AND at least 1% higher than the High-dose-Dex arm percentage.Data cutoff: 01 March 2013 All Adverse Reactions(>=5% in POMALYST + Low-doseDex arm, and at least 2% pointhigher than the High-dose-Dex arm) Grade 3 or 4(>=1% in POMALYST + Low-dose Dexarm, and at least 1% point higher thanthe High-dose-Dex arm) System Organ Class/Preferred Term POMALYST +Low-dose Dex(N=300) High-dose Dex(N=150) POMALYST +Low-dose Dex(N=300) High-dose Dex(N=150) Number (%) of patients with at least one adverse reaction 297 (99.0) 149 (99.3) 259 (86.3) 127 (84.7) Blood and lymphatic system disorders Neutropenia b 154 (51.3) 31 (20.7) 145 (48.3) 24 (16.0) Thrombocytopenia 89 (29.7) a 44 (29.3) a 66 (22.0) a 39 (26.0) a Leukopenia 38 (12.7) 8 (5.3) 27 (9.0) 5 (3.3) Febrile neutropenia b 28 (9.3) 0 (0.0) 28 (9.3) 0 (0.0) General disorders and administration site conditions Fatigue and asthenia 140 (46.7) 64 (42.7) 26 (8.7) a 18 (12.0) a Pyrexia b 80 (26.7) 35 (23.3) 9 (3.0) a 7 (4.7) a Edema peripheral 52 (17.3) 17 (11.3) 4 (1.3) a 3 (2.0) a Pain 11 (3.7) a 3 (2.0) a 5 (1.7) 1 (0.7) Infections and infestations Upper respiratory tract infection b 93 (31.0) 19 (12.7) 9 (3.0) 1 (0.7) Pneumonia b 58 (19.3) 20 (13.3) 47 (15.7) 15 (10.0) Neutropenic sepsis b 3 (1.0) a 0 (0.0) a 3 (1.0) 0 (0.0) Gastrointestinal disorders Diarrhea 66 (22.0) 28 (18.7) 3 (1.0) a 2 (1.3) a Constipation 65 (21.7) 22 (14.7) 7 (2.3) 0 (0.0) Nausea 45 (15.0) 17 (11.3) 3 (1.0) a 2 (1.3) a Vomiting 23 (7.7) 6 (4.0) 3 (1.0) 0 (0.0) Musculoskeletal and connective tissue disorders Back pain b 59 (19.7) 24 (16.0) 15 (5.0) 6 (4.0) Bone pain b 54 (18.0) 21 (14.0) 22 (7.3) 7 (4.7) Muscle spasms 46 (15.3) 11 (7.3) 1 (0.3) a 1 (0.7) a Arthralgia 26 (8.7) 7 (4.7) 2 (0.7) a 1 (0.7) a Pain in extremity 20 (6.7) a 9 (6.0) a 6 (2.0) 0 (0.0) Respiratory, thoracic and mediastinal disorders Dyspnea b 76 (25.3) 25 (16.7) 17 (5.7) 7 (4.7) Cough 60 (20.0) 15 (10.0) 2 (0.7) a 1 (0.7) a Chronic obstructive pulmonary disease b 5 (1.7) a 0 (0.0) a 4 (1.3) 0 (0.0) Nervous system disorders Peripheral neuropathy 52 (17.3) 18 (12.0) 5 (1.7) a 2 (1.3) a Dizziness 37 (12.3) 14 (9.3) 4 (1.3) a 2 (1.3) a Headache 23 (7.7) 8 (5.3) 1 (0.3) a 0 (0.0) a Tremor 17 (5.7) 2 (1.3) 2 (0.7) a 0 (0.0) a Depressed level of consciousness 5 (1.7) a 0 (0.0) a 3 (1.0) 0 (0.0) Metabolism and nutrition disorders Decreased appetite 38 (12.7) 12 (8.0) 3 (1.0) a 2 (1.3) a Hypokalemia 28 (9.3) a 12 (8.0) a 12 (4.0) 4 (2.7) Hypocalcemia 12 (4.0) a 9 (6.0) a 5 (1.7) 1 (0.7) Skin and subcutaneous tissue disorders Rash 23 (7.7) 2 (1.3) 3 (1.0) 0 (0.0) Pruritus 22 (7.3) 5 (3.3) 0 (0.0) a 0 (0.0) a Hyperhidrosis 15 (5.0) 1 (0.7) 0 (0.0) a 0 (0.0) a Investigations Neutrophil count decreased 15 (5.0) 1 (0.7) 14 (4.7) 1 (0.7) Platelet count decreased 10 (3.3) a 3 (2.0) a 8 (2.7) 2 (1.3) White blood cell count decreased 8 (2.7) a 1 (0.7) a 8 (2.7) 0 (0.0) Alanine aminotransferase increased 7 (2.3) a 2 (1.3) a 5 (1.7) 0 (0.0) Aspartate aminotransferase increased 4 (1.3) a 2 (1.3) a 3 (1.0) 0 (0.0) Lymphocyte count decreased 3 (1.0) a 1 (0.7) a 3 (1.0) 0 (0.0) Renal and urinary disorders Renal failure 31 (10.3) a 18 (12.0) a 19 (6.3) 8 (5.3) Injury, poisoning and procedural complications Femur fracture b 5 (1.7) a 1 (0.7) a 5 (1.7) 1 (0.7) Reproductive system and breast disorders Pelvic pain 6 (2.0) a 3 (2.0) a 4 (1.3) 0 (0.0) Other Adverse Reactions Other adverse reactions of POMALYST in patients with multiple myeloma, not described above, and considered important:","Myocardial infarction, Atrial fibrillation, Angina pectoris, Cardiac failure congestive, Vertigo, Abdominal pain, General physical health deterioration, Non-cardiac chest pain, Multi-organ failure, Hyperbilirubinemia, Pneumocystis jiroveci pneumonia, Respiratory syncytial virus infection, Neutropenic sepsis, Bacteremia, Pneumonia respiratory syncytial viral, Cellulitis, Urosepsis, Septic shock, Clostridium difficile colitis, Pneumonia streptococcal, Lobar pneumonia, Viral infection, Lung infection, Alanine aminotransferase increased, Hemoglobin decreased, Fall, Compression fracture, Spinal compression fracture, Hyperkalemia, Failure to thrive, Depressed level of consciousness, Syncope, Mental status change, Urinary retention, Hyponatremia, Pelvic pain, Interstitial lung disease, Pulmonary embolism, Respiratory failure, Bronchospasm, Hypotension."
POMALYST,adverse reactions,6.2 Postmarketing Experience,"Pancytopenia, tumor lysis syndrome, allergic reactions, angioedema, urticaria, elevated liver enzymes, hepatic failure"
POMALYST,boxed warnings,EMBRYO-FETAL TOXICITY,severe life-threatening birth defects
POMALYST,boxed warnings,VENOUS AND ARTERIAL THROMBOEMBOLISM,"Deep venous thrombosis, pulmonary embolism, myocardial infarction, stroke"
POMALYST,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Neutropenia, Hematologic Toxicity, Grade 3/4 adverse event, Hepatotoxicity, Hepatic failure, Hypersensitivity Reactions, Angioedema, severe dermatologic reactions, Tumor Lysis Syndrome (TLS)."
POMALYST,warnings and precautions,5.1 Embryo-Fetal Toxicity,"severe birth defects, embryo-fetal death, teratogen"
POMALYST,warnings and precautions,5.2 POMALYST REMS Program,embryo-fetal risk
POMALYST,warnings and precautions,5.3 Venous and Arterial Thromboembolism,"Venous thromboembolic events, deep venous thrombosis, pulmonary embolism, arterial thromboembolic events, myocardial infarction, stroke, thromboembolic events, ischemic cerebrovascular conditions, ischemic heart disease."
POMALYST,warnings and precautions,5.4 Hematologic Toxicity,"neutropenia, anemia, thrombocytopenia, febrile neutropenia, hematologic toxicities"
POMALYST,warnings and precautions,5.5 Hepatotoxicity,"Hepatic failure, fatal cases, elevated levels of alanine aminotransferase, elevated levels of bilirubin, elevation of liver enzymes"
POMALYST,warnings and precautions,5.6 Hypersensitivity Reactions,"Angioedema, severe dermatologic reactions, skin exfoliation, bullae"
POMALYST,warnings and precautions,5.7 Dizziness and Confusional State,"dizziness, confusional state"
POMALYST,warnings and precautions,5.8 Neuropathy,"neuropathy, peripheral neuropathy, Grade 3 neuropathy"
POMALYST,warnings and precautions,5.9 Risk of Second Primary Malignancies,acute myelogenous leukemia
POMALYST,warnings and precautions,5.10 Tumor Lysis Syndrome,Tumor lysis syndrome
SURFAXIN,adverse reactions,6 ADVERSE REACTIONS,"endotracheal tube reflux, pallor, endotracheal tube obstruction, need for dose interruption"
SURFAXIN,adverse reactions,6.1 Clinical Trials Experience,"endotracheal tube reflux, pallor, endotracheal tube obstruction, need for dose interruption, oxygen desaturation, bradycardia"
SURFAXIN,adverse reactions,Table 2. Administration-Related Adverse Reactions in SURFAXIN Controlled Clinical Studies a,"ETT Reflux, Pallor, Dose Interruption, ETT Obstruction, Apnea, Intraventricular hemorrhage, Periventricular leukomalacia, Acquired sepsis, Patent ductus arteriosus, Retinopathy of prematurity, Necrotizing enterocolitis, Pulmonary air leak, Pulmonary interstitial emphysema, Pneumothorax, Pulmonary hemorrhage, anemia, jaundice, metabolic acidosis, oxygen desaturation, hyperglycemia, pneumonia, hyponatremia, hypotension, respiratory acidosis, bradycardia, death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia/decreased oxygen saturation, pulmonary embolism."
SURFAXIN,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"acute changes in lung compliance, bradycardia, oxygen desaturation, reflux into the endotracheal tube, airway/ETT obstruction, death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia, pneumothorax, hypotension, pulmonary embolism"
SURFAXIN,warnings and precautions,5.1 Acute Changes in Lung Compliance,"lung compliance, oxygenation"
SURFAXIN,warnings and precautions,5.2 Administration-Related Adverse Reactions,"bradycardia, oxygen desaturation, reflux of drug into the endotracheal tube, airway/ETT obstruction"
SURFAXIN,warnings and precautions,5.3 Increased Serious Adverse Reactions in Adults with ARDS,"death, multi-organ failure, sepsis, anoxic encephalopathy, renal failure, hypoxia, pneumothorax, hypotension, pulmonary embolism"
ARZERRA,adverse reactions,6 ADVERSE REACTIONS,"Infusion Reactions, Hepatitis B Virus Reactivation, Hepatitis B Virus Infection, Progressive Multifocal Leukoencephalopathy, Tumor Lysis Syndrome, Cytopenias, neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, upper respiratory tract infections, infections, sepsis"
ARZERRA,adverse reactions,6.1 Clinical Trials Experience,"adverse reaction rates, safety, adverse reactions, hematologic laboratory abnormalities"
ARZERRA,adverse reactions,"Table 3. Adverse Reactions With >=5% Incidence in Patients Receiving ARZERRA Plus Chlorambucil and Also >=2% More Than Patients Receiving Chlorambucil Adverse Reactions ARZERRA Plus Chlorambucil (N = 217) Chlorambucil (N = 227) All Grades % Grade >=3 % All Grades % Grade >=3 % Infusion reactionsa 67 10 0 0 Neutropenia 27 26 18 14 Asthenia 8 <1 5 0 Headache 7 <1 3 0 Leukopenia 6 3 2 <1 Herpes simplexb 6 0 4 <1 Lower respiratory tract infection 5 1 3 <1 Arthralgia 5 <1 3 0 Upper abdominal pain 5 0 3 0 a Includes events which occurred on the day of an infusion or within 24 hours of the end of an infusion and resulted in an interruption or discontinuation of treatment. Infusion reactions may include, but are not limited to, chills, dyspnea, flushing, hypotension, nausea, pain, pruritus, pyrexia, rash, and urticaria.","oral herpes, herpes, herpes virus infection, genital herpes, herpes simplex"
ARZERRA,adverse reactions,"Table 4. Post-baseline Hematologic Laboratory Abnormalities Occurring With >=5% Incidence in Patients Receiving ARZERRA Plus Chlorambucil and Also >=2% More Than Patients Receiving Chlorambucil ARZERRA Plus Chlorambucil (N = 217) Chlorambucil (N = 227) All Grades % Grade >=3 % All Grades % Grade >=3 % Leukopenia 67 23 28 4 Neutropenia 66 29 56 24 Lymphopenia 52 29 20 7 Infusion Reactions: Overall, 67% of patients who received ARZERRA in combination with chlorambucil experienced one or more symptoms of infusion reactions (10% were Grade 3 or greater; none were fatal). Infusion reactions that were either Grade 3 or greater, serious, or led to treatment interruption or discontinuation occurred most frequently during Cycle 1 (56% on Day 1 [6% were Grade 3 or greater] and 23% on Day 8 [3% were Grade 3 or greater]) and decreased with subsequent infusions. Infusion reactions led to discontinuation of treatment in 3% of patients. Serious adverse events of infusion reactions occurred in 2% of patients.","neutropenia, neutropenic sepsis, agranulocytosis, prolonged neutropenia, late-onset neutropenia"
ARZERRA,adverse reactions,"Table 5. Incidence of All Adverse Reactions Occurring in >=5% of Patients and in the Fludarabine- and Alemtuzumab-refractory Subset Adverse Reaction Total Population (N = 154) Fludarabine- and Alemtuzumab-refractory (N = 59) All Grades % Grade >=3 % All Grades % Grade >=3 % Pneumoniaa 23 14 25 15 Pyrexia 20 3 25 5 Cough 19 0 19 0 Diarrhea 18 0 19 0 Anemia 16 5 17 8 Fatigue 15 0 15 0 Dyspnea 14 2 19 5 Rashb 14 <1 17 2 Bronchitis 11 <1 19 2 Nausea 11 0 12 0 Upper respiratory tract infection 11 0 3 0 Edema peripheral 9 <1 8 2 Back pain 8 1 12 2 Chills 8 0 10 0 Nasopharyngitis 8 0 8 0 Sepsisc 8 8 10 10 Urticaria 8 0 5 0 Insomnia 7 0 10 0 Headache 6 0 7 0 Herpes zoster 6 1 7 2 Hyperhidrosis 5 0 5 0 Hypertension 5 0 8 0 Hypotension 5 0 3 0 Muscle spasms 5 0 3 0 Sinusitis 5 2 3 2 Tachycardia 5 <1 7 2 a Includes pneumonia, lung infection, lobar pneumonia, and bronchopneumonia.","rash, rash macular, rash vesicular, sepsis, neutropenic sepsis, bacteremia, septic shock, infusion reactions, infections, Grade 3 or greater infections, fatal infections, neutropenia, Grade 3 or greater neutropenia, Grade 4 neutropenia, new onset Grade 4 neutropenia"
ARZERRA,adverse reactions,6.2 Immunogenicity,immunogenicity
ARZERRA,adverse reactions,6.3 Postmarketing Experience,"Cardiac arrest, Stevens-Johnson syndrome, porphyria cutanea tarda"
ARZERRA,boxed warnings,BOXED WARNING: WARNING: HEPATITIS B VIRUS (HBV) REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,"If there's no excerpt provided (""The input is nan""), I cannot extract adverse drug event terms. Please provide the relevant text for analysis."
ARZERRA,boxed warnings,WARNING: HEPATITIS B VIRUS (HBV) REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,"Hepatitis B Virus Reactivation, fulminant hepatitis, hepatic failure, death, Progressive Multifocal Leukoencephalopathy (PML)"
ARZERRA,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Infusion Reactions, Tumor Lysis Syndrome, Cytopenias, Neutropenia, Anemia, Thrombocytopenia"
ARZERRA,warnings and precautions,5.1 Infusion Reactions,"bronchospasm, dyspnea, laryngeal edema, pulmonary edema, flushing, hypertension, hypotension, syncope, cardiac events, myocardial ischemia/infarction, acute coronary syndrome, arrhythmia, bradycardia, back pain, abdominal pain, pyrexia, rash, urticaria, angioedema, cytokine release syndrome, anaphylactoid/anaphylactic reactions"
ARZERRA,warnings and precautions,5.2 Hepatitis B Virus Reactivation,"Hepatitis B virus reactivation, fulminant hepatitis, hepatic failure, death, increase in transaminase levels, increase in bilirubin levels, liver failure."
ARZERRA,warnings and precautions,5.3 Hepatitis B Virus Infection,"Fatal infection, hepatitis B"
ARZERRA,warnings and precautions,5.4 Progressive Multifocal Leukoencephalopathy,"Progressive multifocal leukoencephalopathy (PML), death"
ARZERRA,warnings and precautions,5.5 Tumor Lysis Syndrome,"Tumor lysis syndrome (TLS), hospitalization, electrolyte abnormalities, renal function"
ARZERRA,warnings and precautions,5.6 Cytopenias,"Severe cytopenias, neutropenia, thrombocytopenia, anemia, Pancytopenia, agranulocytosis, fatal neutropenic sepsis, Grade 3 or 4 late-onset neutropenia, prolonged neutropenia"
ARZERRA,warnings and precautions,5.7 Immunizations,"immunization, live viral vaccines, administration of ARZERRA"
ESBRIET,adverse reactions,6 ADVERSE REACTIONS,"Liver Enzyme Elevations, Photosensitivity Reaction, Rash, Gastrointestinal Disorders, nausea, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, gastro-esophageal reflux disease, sinusitis, insomnia, weight decreased, arthralgia"
ESBRIET,adverse reactions,6.1 Clinical Trials Experience,"rash, nausea, diarrhea, photosensitivity reaction"
ESBRIET,adverse reactions,"Table 2. Adverse Reactions Occurring in >=10% of ESBRIET-Treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3 1 Includes abdominal pain, upper abdominal pain, abdominal distension, and stomach discomfort. % of Patients (0 to 118 Weeks) Adverse Reaction ESBRIET 2403 mg/day(N = 623) Placebo(N = 624) Nausea 36% 16% Rash 30% 10% Abdominal Pain 1 24% 15% Upper Respiratory Tract Infection 27% 25% Diarrhea 26% 20% Fatigue 26% 19% Headache 22% 19% Dyspepsia 19% 7% Dizziness 18% 11% Vomiting 13% 6% Anorexia 13% 5% Gastro-esophageal Reflux Disease 11% 7% Sinusitis 11% 10% Insomnia 10% 7% Weight Decreased 10% 5% Arthralgia 10% 7% Adverse reactions occurring in >=5 to <10% of ESBRIET-treated patients and more commonly than placebo are photosensitivity reaction (9% vs. 1%), decreased appetite (8% vs. 3%), pruritus (8% vs. 5%), asthenia (6% vs. 4%), dysgeusia (6% vs. 2%), and non-cardiac chest pain (5% vs. 4%).","If the input text is ""nan"", it signifies that there is not any actual text provided for analysis. Assuming ""nan"" stands for ""not applicable"" or ""not available,"" there are no drug label contents given, hence there are no adverse drug event terms to identify. If you require analysis of a specific text or drug label, please provide the relevant content."
ESBRIET,adverse reactions,6.2 Postmarketing Experience,"Agranulocytosis, Angioedema, Bilirubin increased, ALT increases, AST increases"
ESBRIET,warnings and precautions,5 WARNINGS AND PRECAUTIONS,"Elevated liver enzymes, ALT and AST elevations, bilirubin elevations, photosensitivity, rash, nausea, vomiting, diarrhea, dyspepsia, gastro-esophageal reflux disease, abdominal pain"
ESBRIET,warnings and precautions,5.1 Elevated Liver Enzymes,"Increases in ALT, Increases in AST, Elevations in ALT, Elevations in AST, Elevated bilirubin, Severe liver injury, Liver enzyme elevations"
ESBRIET,warnings and precautions,5.2 Photosensitivity Reaction or Rash,"photosensitivity reactions, rash"
ESBRIET,warnings and precautions,5.3 Gastrointestinal Disorders,"nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, abdominal pain"
